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Abstract	
Neuroimmune	interactions	are	important	in	the	pathophysiology	of	many	chronic	inflammatory	diseases,	particularly	those	associated	with	alterations	in	sensory	processing	and	pain	(Grace	et	al.,	2014).	Much	of	our	understanding	of	these	interactions	comes	from	studies	on	mast	cell-	sensory	neuron	interactions	in	diseases	such	as	irritable	bowel	syndrome	(IBS)	(Barbara	et	al.,	2004)	.	Mast	cells	and	neurons	are	connected	to	each	other	both	functionally	and	structurally.	Cell	adhesion	molecule	1	(CADM1)	has	been	identified	as	an	adhesion	molecule	between	mast	cells	and	sensory	neurons	(Ito	et	al.,	2008).	However,	it	remains	to	be	unclear	if	CADM1	is	essential	in	mast	cell-neuron	functional	cross-talk.	
The	aim	of	this	study	is	to	investigate	the	role	of	CADM1-	mediated	adhesion	between	
mast	cell	and	neuron	on	IgE-	mediated	mast	cell	signalling	and	pro-inflammatory	
mediator	secretion.	Using	the	in	vitro	co-culture	system	of	mouse	bone	marrow	mast	cells	(BMMC)	with	sensory	neurons	isolated	from	dorsal	root	ganglions	(DRG),	expression	and	cellular	distribution	of	CADM1	was	determined.	The	adhesion	between	BMMC	and	sensory	neurons	was	quantified	using	a	fluorescent	assay.	Application	of	a	CADM1	blocking	peptide	or	knockdown	CADM1	in	BMMCs	were	found	to	significantly	decrease	both	the	BMMC	attachment	to	sensory	neurites,	as	well	as,	the	enhancement	of	IgE-mediated	BMMC	degranulation	in	the	presence	of	neurons.	Furthermore,	CADM1	Knockdown	attenuates	the	enhancement	of	IL-6	release	from	BMMC	in	co-culture.	Importantly,	this	study	also	showed	that	the	CADM1-dependent	enhancement	of	IgE-mediated	mast	cell	response	is	specific	for	neurons.	It	is	suggested	that	neurons	may	mediate	mast	cell	enhancement	through	action	potential	(AP)-independent	neuropeptide	release.	
In	conclusion,	my	data	have	been	revealed	for	first	time	the	direct	role	of	CADM1	in	functional	mast	cell-sensory	neuron	cross-talk.	Elucidating	the	precise	mechanisms	of	
CADM1	in	IgE	signaling	is	imperative	for	understanding	many	disease	processes.	The	results	of	this	study	would	contribute	to	the	available	knowledge	about	role	of	CADM1	in	neuroimmune	interactions	and	hold	promise	as	a	therapeutic	target	in	various	diseases	such	as	IBS.		
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Chapter	1:	Introduction		
1.1	Mast	cell	biology	and	relevance	Mast	cells	are	long-lived,	highly	granulated	immune	cells.	They	are	best	acknowledged	for	their	major	role	in	defence	against	pathogens	and	responses	to	allergens.	Mast	cells	are	considered	as	both	sensory	cells	and	effector	cells	because	they	are	activated	by	various	stimuli,	and	release	a	plethora	of	potent	mediators.		
1.1.1	Mast	cell	development	and	the	importance	of	microenvironment	In	contrast	to	other	hematopoietically-derived	cells,	mast	cells	depart	the	bone	marrow	as	immature	progenitor	cells	that	complete	their	maturation	within	tissues.	Mast	cells	originate	from	multipotential	CD34+	stem	cells	in	bone	marrow	(Kirshenbaum	et	al.,	1991)	and	circulate	as	immature	mast	cells	progenitors	(MCp)	expressing	CD34+,	Kit+and	FceRI-		(Agis	et	al.,	1993)	(Chen	et	al.,	2005).		MCp	migrate	into	various	tissues	under	a	regulating	process	of	locally-produced	cytokines.	Within	tissues,	they	remain	as	a	homeostatic	pool	or	differentiate	into	mature	mast	cells	under	the	influence	of	specific	micro-environmental	signals	and	growth	factors	(Galli,	1990).		Although	mast	cells	can	be	found	in	various	organs,	their	distribution	and	density	are	highest	at	the	surfaces	exposed	to	the	environment	like	mucosal	surfaces	in	the	airways	and	gastrointestinal	tracts	(Abraham	and	St	John,	2010).	Moreover,	they	ultimately	dwell	in	close	to	nerves,	blood	vessels,	and	smooth	muscle	cells	(Galli	and	Tsai,	2008).		Mature	mast	cells	are	long-lived	cells	(Padawer,	1974).	Indeed,	they	have	the	ability	to	re-granulate	in	response	to	additional	stimuli	after	recovery	from	initial	degranulation	(Xiang	et	al.,	2001).		Mast	cell	development,	survival,	maturation,	and	functional	responses	are	influenced	by	locally	tissue-derived	growth	factors.	The	most	critical	factor	to	control	mast	cell	
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differentiation	from	MCp	is	interleukine-3	(IL-3)	.	IL-3	induces	differentiation	of	MCp	into	mucosal-like	mast	cells	(MMC)	(Razin	et	al.,	1984).	However,	it	may	also	act	synergistically	with	other	factors	like	IL-4	to	induce	differentiation	into	connective	tissue	-like	mast	cells	(CTMC)	(Schmitt	et	al.,	1987).	Other	interleukins	such	as	IL-9	or	IL-10	enhance	mast	cell	proliferation	only	when	used	synergistically	with	IL-3	(Hültner	et	al.,	1990)		(Rennick	et	al.,	1995).	Furthermore,	nerve	growth	factor	(NGF)	has	a	synergistic	effect	with	IL-3	on	the	development	of	CTMC-like	cells	(Matsuda	et	al.,	1991).	Therefore,	the	effect	of	IL-3,	alone	or	in	combination	with	other	micro-environmental	factors	plays	a	crucial	role	in	determining	the	final	phenotype	of	mast	cells	in	a	particular	tissue	(Hu	et	al.,	2007).		The	other	important	factor	for	mast	cell	migration	and	growth	is	stem	cell	factor	(SCF)	(Galli	et	al.,	1993).	In	vivo,	SCF	is	released	from	stromal	cells	(Galli	et	al.,	1993)	like	fibroblasts	(Hogaboam	et	al.,	1998),	and	endothelial	cells	(Mierke	et	al.,	2000).	It	is	either	expressed	on	the	cell	surface	or	released	as	a	soluble	protein.	In	both	ways,	it	binds	receptor	tyrosine	kinase	(c-Kit)	on	mast	cells.	c-Kit	receptor	belongs	to	immunoglobulin	(Ig)-superfamily	of	proteins.	It	has	five	(Ig)-like	motifs	in	its	extracellular	ligand-binding	domain,	a	single	transmembrane	domain	and	a	cytoplasmic	domain	(Galli	et	al.,	1994).	SCF	promotes	mast	cells	migration	by	two	mechanisms.	Serum	SCF	recruits	MCp	from	bone	marrow	to	blood	(Okumura	et	al.,	1996)	while	tissue-derived	SCF	acts	as	chemotactic	for	MCp	(Nilsson	et	al.,	1994).	Although	mast	cells	in	vitro	can	be	cultured	without	SCF,	they	can’t	be	in	vivo.	KitSI/KitSI-d	mice	and	KitW/KitWv	mice	that	lack	SCF	and	functional	c-kit,	respectively,	lack	mast	cells	in	their	tissues	(Kitamura	et	al.,	1978)	(Kitamura	and	Go,	1979).	More	interestingly,	SCF	doesn’t	only	influence	MCp	but	also	influences	mast	cell	function	after	complete	maturation.	SCF	can	augment	IgE-dependent	mast	cell	degranulation	and	cytokine	release	(Hundley	et	al.,	2004).	In	addition,	SCF	increase	mast	cells	adhesion	to	fibronectin,	and	integrin	(Kinashi	and	Springer,	1994).			
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Indeed	extracellular	matrix	(ECM)	proteins	also	have	a	vital	role	in	regulating	mast	cell	biology	like	differentiation	and	maturation.	In	vivo,	mast	cell	progenitors	migrate	from	circulation	into	tissues	to	complete	their	development.	This	process	requires	them	to	physically	interact	with	ECM	proteins	and	other	cells.	Mature	mast	cells	are	always	found	within	tissues	attached	to	other	structures	or	ECM.	Thus,	mast	cell	adhesion	molecules	have	a	vital	role	in	their	development	and	functions.	In	order	to	facilitate	the	migration	of	mast	cell	progenitors		into	tissues	where	they	mature	and	residence,		mast	cells	express	a	diversity	of	adhesion	receptors.	These	include	several	members	of	integrins	(Sperr	et	al.,	1992),		cell	adhesion	molecule-1	(CADM1)	(Ito	et	al.,	2003),	and	N-cadherin	(Suzuki	et	al.,	2004).	These	molecules	are	discussed	in	greater	detail	below	(Section	1.4).		
1.1.2		Mast	cell	activation		A	fundamental	feature	of	mast	cells	is	their	ability	to	secrete	and	produce	mediators	in	response	to	certain	stimulants.	Mature	mast	cells	can	be	stimulated	by	two	primary	mechanisms.	IgE-dependent	or	IgE-independent	mechanisms.	In	the	former,	mast	cell	activation	is	initiated	by	antigen	(Ag).	While	in	the	later,	mast	cell	activation	is	initiated	by	exposure	to	complement	factors,	bacterial	components,	and	neuropeptides	(Figure	1.2)			
1.1.2.1	IgE-dependent	mast	cell	activation	Mast	cell	expresses	high-affinity	IgE	receptors	(FceRI)	on	their	cell	surfaces.	FceRI	is	a	tetrameric	protein	complex	comprising	of	the	IgE	binding	a-	chain,	the	membrane-tetraspanning		b	chain	and	two	disulphide-linked		g	chains	(Blank	et	al.,	1989).	IgE-dependent	activation	is	initiated	upon	binding	of	Ag	to	specific	IgE	that	binds	to	FceRI	a	chain	on	mast	cells	via	its	Fc	portion	(Hakimi	et	al.,	1990)	(Metcalfe,	2008).	The	crosslinking	of	surface-bound	IgE	by	specific	antigens	leads	to	aggregation	of	FceRI.	This	results	in	a	sequence	of	phosphorylation	events	that	recruit	and	activate	specific	signaling	molecules	(Figure	1.1)	(Metcalfe	et	al.,	1997).	As	reviewed	by	(Gilfillan	and	
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Rivera,	2009),	aggregation	of	FcεRI	receptor	stimulates	Src	(sarcoma)	tyrosine	kinase	(Lyn)	that	bound	to	β	subunit.	Lyn	trans-phosphorylates	the	immunoreceptor	tyrosine-based	activation	motifs	(ITAMs)	on	γ	chains	of	the	FcεRI	which	act	as	major	docking	sites	for	other	Src	tyrosine	kinase	(Syk).	Activated	Syk	phosphorylates	the	adaptor	molecule	LAT1	(linker	for	activation	of	T	cell-	1)	and	recruits	adaptor	molecules	such	as	Gab2	and	Grb2	to	assemble	a	signaling	complex	(Rivera	and	Olivera,	2007).		This	complex	phosphorylates	phospholipase	Cγ	(PLCγ)	that	hydrolyze	phosphatidylinositol-4,5-bisphosphate	(PIP2)	to	procedure	soluble	inositol-1,4,5-triphosphate	(IP3).	By	binding	to	its	receptor	IP3R	on	endoplasmic	reticulum	membrane,	IP3	induces	the	release	of	the	“first	wave”	intracellular	calcium	stores.	Once	endoplasmic	calcium	stores	are	emptied,	the	calcium	sensor	on	endoplasmic	reticulum	called	stromal	interaction	molecule	1	(STIM1)	interacts	with	Orai1	channels	(the	store-	operated	calcium	channel)	on	plasma	membrane	to	facilitate	“the	second	wave”	of	calcium	influx	from	the	extracellular	space.	Increased	intracellular	calcium	activates	protein	kinase	C	(PKC)	and,	eventually,	initiate	degranulation	(Wu,	2011).	Also,	the	increase	in	intracellular	calcium	dephosphorylates	the	nuclear	factor	for	T	cell	activation	(NFAT)	to	cross	nucleus	membrane	and	regulates	several	cytokine	genes	transcription	including	TNFa	(Klein	et	al.,	2006).		In	addition,		Syk-	LAT1	complex	activates	MAPK	(mitogen-activated	protein	kinase)	and		phospholipase	A2	(PLA2).	PLA2	releases	arachidonic	acid	from	cell	membrane	to	generate	arachidonic	acid	mediators	.		A	parallel	pathway,	aggregation	of	FcεR1	receptor	phosphorylates	other	Src	tyrosine	kinase	(Fyn).	Fyn	activates	and	recruits	adaptor	proteins	such	as	linker	for	activation	of	T	cell-2	(LAT2),		and	Gab2	that	form	signaling	complex	(Rivera	and	Olivera,	2007).	This	results	in	activates	the	signaling	enzyme	phosphoinositide	3-kinase	(PI3K)	that	phosphorylates	PIP2	to	IP3	and	mediate	degranulation.	PI3K	also	induces	nuclear	translocation	of	the	transcription	factor	(NFκB)	by	degrading	its	inhibitor	IκB	that	bind	to	it.	In	addition,	Fyn-	LAT2	activation	results	in	formation	of	phosphotyrosine	-induced	STAT5	dimers	that	transfer	into	the	nucleus	and	stimulate	cytokine	production	(Pullen	et	al.,	2012).	MAPK/STAT	(Akira,	1997)	and	NFκB	(Kalesnikoff	et	al.,	2002)	are	
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important	in	IL-6	production.		Fyn	also	induces	calcium	influx	through	transient	receptor	potential	canonical	channels	(TRPC-1)	channel	(Gilfillan	et	al.,	2009).		
	
Figure.	1.1	FcεRI	signalling	in	mast	cells	Upon	FcεRI	 cross	 linking	 by	 IgE,	 the	 Src-family	 kinases	 Lyn,	 Syk	 and	Fyn	 induce	 downstream	 signaling	cascade	that	activate	PLCγ	and	ultimately	gives	rise	to	large	increases	in	cytosolic	Ca2+	and	degranulation.	The	production	of	eicosanoids	occurs	following	activation	of	the	mitogen-activated	protein	kinase	(MAPK)	pathway.	Nuclear	factor	activation	lead	to	cytokines	generation.		
1.1.2.2	IgE-independent	mast	cell	activation	The	other	primary	mast	cells	activating	pathway	is	IgE-	independent	and	achieved	by	activating	G-protein	coupled	receptors	(GPCRs).	Mast	cells	express	various	GPCRs	.	Among	many,	polybasic	secretagogue	of	mast	cells	compounds	such	as	the	pan-mast	cell	activator	compound	48/80	(C48/80)	(Shefler	et	al.,	1999).	C48/80	interacts	with	membrane	proteins	to	directly	activate	GPCRs	through	PI3-kinase	(Byrne	et	al.,	2007).	
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In	addition,	neuropeptides	such	as	substance	P	(SubP)	can	induce	histamine	release	from	mast	cells	(Ebertz	et	al.,	1987),	as	well	as,	calcitonin	gene-related	peptide	(CGRP)	(Bauer	and	Razin,	2000).	These	mediators	will	be	covered	in	detail	in	an	upcoming	section	(Section	1.2.2)	of	this	thesis.			The	extracellular	adenosine	5'-triphosphate	(ATP)	can	also	activate	mast	cells	by	binding	to	purinoceptors	(P2).	Two	subtypes	of	P2	are	expressed	by	mast	cells;	the	ligand-gated	ion	receptors	(P2X),	and	(P2Y)	which	is	GPCR.		Mast	cells	phenotype	and	anatomical	source	determine	the	subtype	expression	of	P2.	Similarly,	the	mast	cell	responses	to	ATP	are	distinct	between	different	species	(Bulanova	and	Bulfone-Paus,	2010).	For	example,	It	has	been	reported	that	ATP	induces	histamine	and	prostaglandin	(PG)	release	from	rat	peritoneal	mast	cells	through	P2X	and	P2Y	receptors.	This	effect	is	mediated	by	PKC	downstream	signaling	(Jaffar	and	Pearce,	1990).	Contrary,	HLMCs	don’t	degranulate	in	response	to	ATP,	but	enhances	IgE-mediated	histamine	release	(Schulman	et	al.,	1999).		Apart	from	activating	mast	cells	by	means	of	GPCRs,	mast	cells	can	also	be	directly	activated	by	diverse	array	of	reagents.	Calcium	ionophores	(ionomycin)	activate	mast	cells	by	increasing	intracellular	calcium	release	and	extracellular	influx	(Morgan	and	Jacob,	1994).	Pathogens	can	also	directly	activate	mast	cells	by	binding	Toll-like	receptors	(TLRs).	Among	11	different	TLRs,	mast	cells	known	to	express	TLR2,	TLR3,	TLR4,	TLR6	and	TLR8	(Sandig	and	Bulfone-Paus,	2012).	Each	receptor	has	a	district	effect	on	mast	cell	function	and	mediator	release	(Varadaradjalou	et	al.,	2003).	C3a	and	C5a	anaphylatoxins	which	are	complement	components	also	induce	calcium	mobilization	and	mediators	production	in	mast	cells	(Venkatesha	et	al.,	2005).		Mast	cells	express	C3aR	and	C5aR	that	couple	to	the	Gαi	family	of	heterotrimeric	GPCRs	(Nilsson	et	al.,	1996).			In	conclusion,	the	sensitivity	of	mast	cells	to	wide	range	of	distinct	stimuli	reflects	the	variety	of	mast	cells	roles	in	vivo.	
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1.1.3	Mast	cell	mediators	Upon	activation,	mast	cells	release	and	synthesize	a	diverse	array	of	mediators	that	have	diverse	biological	functions	as	shown	in	(Figure	1.2).	They	are	categorized	into	three	major	categories	(Metcalfe	et	al.,	1997):	(1)	preformed	active	mediators	that	are	stored	in	the	cytoplasmic	granules,	(2)	de	novo	synthesized	lipid	mediators,	and	(3)	de	novo	synthesized	cytokines,	chemokines	and	growth	factors. Table	1.1	lists	mast	cell	mediators	and	their	biological	functions.	However,	it	is	not	necessary	mediators	from	all	three	categories	are	released	together	or	happen	always	as	some	mast	cell	activation	can	cause	release	of	certain	cytokines	without	preceding	with	degranulation.	In	addition	to	the	fact	that	mast	cell	mediators	induce	a	broad	range	of	biological	effects,	the	mediators	overlap	in	their	biological	effects	and	sometimes	opposite	their	effects.	Therefore,	mast	cell	effects	are	stimulant-specific,	mediator-specific,	and	tissue-specific.												 		
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Figure.1.2	Mast	cell	activation	and	mediator	release.			Mast	cells	express	a	diversity	of	cell	surface	receptors.	Mast	cells	can	be	activated	either	by	IgE-dependent	or	IgE-independent	mechanisms	which	results	in	synthesize	and	release	of	a	diverse	array	of	mediators.	
Ag,	Antigen;	FceRI,	high	affinity	IgE	receptor;	TLR,	Toll-like	receptor;	c48/80,	compound	48/80;	CGRP,	calcitonin	gene-related	peptide;	SubP,	substance	P;	NK-1,	neurokinin	1;	GPCR,	G-protein	coupled	receptor;	TNF-a,	tumor	necrosis	factor	a;	ATP,	Adenosine	5'-triphosphate;	LT,	leukotrienes;	PAF,	platelet-	activating	factor;	PGD2,	prostaglandin	D2;	IL,	interleukine;	NGF,	nerve	growth	factor;	VEGF,	vascular	endothelium	growth	factor;	and	CSF,	colony-	stimulating	factor.	
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1.1.3.1	Preformed	granule-	stored	mediators	The	largest	category	of	mast	cells	mediators	are	the	preformed	granule-stored	mediators.		These	mediators	include	biogenic	amines,	protease	enzymes,	proteoglycans,	and	preformed	cytokines	like	tumor	necrosis	factor-a	(TNFa).	Within	minutes	after	activation,	they	are	released	from	cytoplasmic	granules	through	a	process	of	degranulation.	Increased	Ca2+	influx	after	activation	mediates	granule	movement	and	fusion	to	the	cell	membrane.	Selective	release	of	only	certain	mediators	from	the	granules	by	exocytosis	is	called	piecemeal	degranulation	(Dvorak	and	Morgan,	1997)	while	the	classic	granule	extrusion	is	called	anaphylactic	degranulation	(Dvorak	et	al.,	1991).		The	most	well-known	biogenic	amine	in	mast	cells	is	histamine.	It	is	formed	from	decarboxylation	of	histidine	in	the	Golgi	apparatus	of	mast	cells	(Metcalfe	et	al.,	1997).	Although	it	is	released	from	different	cells	such	as	basophils	(Ishizaka	et	al.,	1972),	its	major	source	is	mast	cell	(RILEY	and	WEST,	1952).	Histamine	exerts	its	biological	function	by	binding	to	its	G-protein	coupled	receptors	called	histamine	receptors	(H1-H4)	(MacGlashan,	2003).	Histamine	receptors	are	widely	expressed	by	different	cell	types.	The	fast	release	of	histamine	and	wide-spread	expression	of	its	receptors	explain	the	paracrine	effect	of	histamine.	Therefore,	it	promotes	many	physiological	functions	including	increased	vascular	permeability	and	systematic	vasodilation	(Bachert,	2002).	Serotonin	is	also	present	in	mast	cell	granules		(Kushnir-Sukhov	et	al.,	2007).	The	major	biological	functions	of	serotonin	are	vasoconstriction	and	pain	(Theoharides	et	al.,	2007).		The	second	group	of	preformed	granule-associated	mediators	are	the	protease	enzymes	such	as	tryptase,	chymases,	and		carboxypeptidase	A.	The	effects	of	tryptase	on	other	cell	types	have		been	extensively	investigated,	with	a	specific	focus	on	epithelium,	smooth	muscle	cells	and	fibroblasts	(Gruber	et	al.,	1997).	It	mediates	its	effects	by	activating	protease-activated	receptor	2	(PAR-2)	(Akers	et	al.,	2000).	Tryptase	is	found	in	MCC	and	CTMC	while,	chymase	is	specific	for	CTMC	(Metcalfe	et	al.,	1997).		Unlike	
	
10	
phenotype-specific	tryptase	and	chymases,	hexosaminidase	is	known	to	be	found	in	lysosomes	of	all	mast	cell	subpopulations.	Therefore,	it	is	frequently	used	in	in	vitro	studies	to	quantify	degranulation	(Lundequist	and	Pejler,	2011).	Mast	cells	also	release	granule	ATP	upon	Ag	stimulation	(Marquardt	et	al.,	1984)	(Suzuki	et	al.,	2007).	Because	extracellular	ATP	is	quickly	degraded	by	ecto-nucleotidases	enzymes	(Colgan	et	al.,	2006),	ATP	mediates	autocrine	or	paracrine	signaling	in	mast	cells	and	nearby	cells,	respectively,	by	binding	to	P2	(Abbracchio	and	Burnstock,	1998)	(Novak,	2003).	As	mentioned	above	(section	1.1.2.2	),	It	produces	a	diverse	array	of	biological	effects	depending	on	which	P2	receptor	subtype	binds	to	(Bulanova	and	Bulfone-Paus,	2010).			Another	group	of	preformed	granule-associated	mediators	is	the	proteoglycans.	They	have	a	unique	molecular	structure	consisting	of	a	central	protein	core	of	repeating	serine	and	glycine	residues	connected	to	glycosaminoglycans	which	are	unbranched	carbohydrate	side	chains	(Metcalfe	et	al.,	1997).	This	structure	gives	proteoglycans	the	ability	to	regulate	and	stabilize	other	preformed	secretory	granule	mediators.	The	most	commonly	found	mediators	in	mast	cells	are	heparin	and	chondroitin	sulphate	E.	(Metcalfe	et	al.,	1997).	Heparin	is	known	for	its	ability	to	inhibit	blood	coagulation.		
1.1.3.2	de	novo	synthesized	lipid	mediators	Beside	their	ability	to	exocytose	preformed	granule-derived	mediators,	activated	mast	cells	also	respond	to	stimuli	by	synthesizing	and	releasing	lipid-derived	substances	like	PGs	and	leukotrienes	(LT).	Membrane	phospholipids	are	broken	down	to	arachidonic	acid	by	phospholipase	A2	enzyme.	Then,	arachidonic	acid	is	metabolized	by	either	cyclooxygenase	to	generate	PGs	and	thromboxanes,	or	by	lipoxygenase	to	generate	leukotrienes	(Metcalfe	et	al.,	1997).	Because	gene	transcription	is	not	required	to	synthesize	lipid	mediators,	they	are	released	from	mast	cells	within	5-30	minutes	of	activation.				
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1.1.3.3	de	novo	synthesized	cytokines	mediators	Mast	cells	may	also	respond	to	activation	by	induction	of	gene	transcription	and	production	of	a	wide-range	of	cytokines,	chemokines	and	growth	factors.	Which	of	these	factors	are	synthesized	is	dependent	upon	the	mast	cells’	microenvironment	and	phenotype		(Bradding	et	al.,	1995),	and	the	kinetics	of	second	messenger	signaling	cascades	evoked	as	a	result	of	receptor	activation	(Gilfillan	and	Tkaczyk,	2006).	In	contrast	to	lipid	mediators,	cytokine	release	from	mast	cells	occurs	hours	after	activation.	In	general,	cytokines	and	chemokines	regulate	recruitment	and	function	of	local	immune	cells	(Metcalfe	et	al.,	1997).	Major	cytokines	expressed	and	released	by	activated	mast	cells	include	IL-3,	IL-6,	IL-10	and	TNFα	(Kobayashi	et	al.,	2000).																			
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Class	 Mediators	 Main	biological	function	
Pr
ef
or
m
ed
	m
ed
ia
to
rs
	
Biogenic	amines:	 	Histamine	 Vasodilation,	increase	vascular	permeability	and	pain	Serotonin	 Vasoconstriction	and	pain	
Enzymes:		 Remodel	tissue	matrix	Tryptase	 Degradation	of	fibrinogen,	pro-inflammatory,	pain	Chymase	 Degradation	of	basal	membrane	substance,	conversion	of	Angiotensin	Carboxypeptidase	A	 Peptide	processing	
Proteoglycan:		 	Heparin	 Angiogenesis,	NGF	stabilization	Chrondroitin	sulfate	 Cartilage	synthesis,	anti-inflammatory	action		 Others:	ATP	 Extracellular	signaling	by	binding	to	purinergic	receptor	
Li
pi
d	
m
ed
ia
to
rs
	 Chemokines:		 	Leukotriene	B4	 Leukocyte	chemotaxis	Leukotriene	C4		 Vasoconstriction,	pain	
Platelet-activating	factor	 Platelet	activation,	vasodilation	
Prostaglandins	D2	 vasodilation,	pain	
Cy
to
ki
ne
s	
Interleukins		 	(IL-1,	IL-2,	IL-3,	IL-4,	IL-5,	IL-6,	IL-9,	IL-10,	IL-13,	and	IL-16)	 Pro-inflammatory,	leukocyte	migration,	pain	
Tumor	necrosis	factor	a	 Pro-inflammatory,	vascular	adhesion	molecule	expression	
Growth	Factors	 	Nerve	growth	factor	(NGF)	 Peripheral	sensitization	Vascular	endothelial	growth	factor	(VEGF)	 Neovascularization,	vasodilation	Colony	stimulating	factor	(CSF)	 Promote	eosinophil	production	
Table	1.1.	Mast	cell	as	an	effector	cell		“adapted	from	(Theoharides,	2002)”		
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1.1.4	Heterogeneity	of	mast	cell	phenotypes	As	mentioned	above	(section	1.1.1),	MCp	arise	from	the	bone	marrow	and	are	recruited	to	different	tissues	to	mature	under	the	control	of	micro-environmental	factors.	In	vivo,	mature	mast	cells	exist	as	a	heterogeneous	population	depending	on	their	anatomic	location,	function	and	biochemical	properties	(Moon	et	al.,	2010).	The	heterogeneity	of	mast	cells	was	first	reported	when	mouse	mast	cells	from	mucosal	tissues	were	found	to	histochemicaly	differ	from	mast	cells	in	connective	tissues.	Since	then,	mouse	mast	cells	have	been	classified	into	two	major	subpopulations	based	on	their	anatomical	locations	(Table	1.2):	MMC	are	found	beneath	the	mucosal	surface	of	the	respiratory	and	gastrointestinal	tract	while,	CTMC	mostly	localize	in	the	submucosa	of	the	gastrointestinal	tract	(GIT),	peritoneum,	and	in	the	skin.			Mast	cell	subpopulations	differ	not	only	in	their	immunohistochemical	properties,	but	also	in	the	mediators	they	release	in	response	to	stimuli	and	in	their	responses	to	inhibitory	drugs.	Immunohistochemical	studies	have	revealed	that	MMC	are	immunoreactive	to	chymase	and	CTMC	are	immunoreactive	to	both	tryptase	and	chymase	(Xing	et	al.,	2011).	Alcian	blue/safranin	histochemical	staining	can	also	be	used	to	distinguish	between	MMC	and	CTMC	(Kitamura,	1989).	MMC	stain	blue	with	Alcian	blue,	while	CTMC	stain	red	with	safranin.	CTMC	produce	more	histamine	in	response	to	activation	than	MMC	(Purcell	et	al.,	1989).	On	the	other	hand,	MMC	synthesize	higher	amounts	of	all	arachidonic	acid	metabolites	except	PGD2,	compared	to	CTMC	(Levi-Schaffer	et	al.,	1987).	Regards	their	responsiveness	to	different	stimuli,	CTMC	respond	robustly	to	c48/80	by	releasing	more	histamine	than	MMC	(Galli,	1990),	but	CTMC	respond	better	to	the	stabilizing	effect	of	Na-	cromolyn	(Pearce	et	al.,	1989).		In	contrast	to	mice	mast	cell	phenotypes,	human	mast	cells	from	different	anatomical	sites	strongly	express	tryptase,	but	not	all	of	them	express	chymase.	Therefore,	human	mast	cells	are	classified	into	two	subpopulations	based	on	their	granular	proteases	(Irani	et	al.,	1986)	as	tryptase	(MCT	),	or	tryptase	and	chymase	(MCTC)	positive.	This	classification	is	believed	to	be	equivalent	to	mice	mucosal	and	connective	tissue	
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phenotypes.	However,	these	are	no	distinct	anatomical	localizations	for	these	subpopulations	in	vivo.	Human	mast	cells	from	the	same	site	may	differ	in	their	phenotype.	For	example,	human	mast	cells	in	GIT	mucosa	are	mainly	MCT,	but	some	of	the	mast	cells	are	MCTC	phenotype	(Irani	et	al.,	1989).	Interestingly,	mast	cell	phenotypes	show	a	high	level	of	plasticity	in	vivo	and	in	vitro.		Changing	the	surrounding	tissue	environment	may	change	mast	cell	phenotype.	Thus,	the	model	of	mast	cells	used	in	experiments	must	be	considered	when	studying	mast	cell	functions	(Kitamura,	1989).		
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	 MMC	 CTMC	 References	
Tissue	localization	
Mucosa	of	respiratory	and	GI	tracts	 Submucosa	of	respiratory	and	GI	tracts,	Skin,	and	peritoneum	 (Galli,	1990)	
T-cell	dependent	in	
development	
No	 Yes	 (Razin	et	al.,	1984)	
Staining	
Formaldehyde	fixation	 Sensitive	 Resistant	 (Craig	et	al.,	1988)	
Alcian/blue/Sarfanin	
O	
Blue	 Red	 (Kitamura,	1989)	
Berberine	sulphate	 -	 +	 (Kitamura,	1989)	
Mediators	
Histamine	 <1	pg/	cell	 1-30	pg/cell	 (Purcell	et	al.,	1989)	
Proteoglycan	 Condroitin	sulphate	 Heparin,	chondroitin	sulphate	E	 (Razin	et	al.,	1982b)	
Protease	Tryptase	
Chymase	
carboxypeptidase	
-	
MCP-1	and	-2	-	
MCP-6,	and	-7	
MCP-4,	and	-5	+	
(Xing	et	al.,	2011)	
LTC4	 >25	ng/105	cells	 n.d	 (Razin	et	al.,	1982a)	
LTB4	 3-12	ng/105	cells	 n.d	 (Levi-Schaffer	et	al.,	1987)	
PGD2	 1-5	ng/105cells	 n.d	 (Levi-Schaffer	et	al.,	1987)	
Response	to	secrtagouges	
IgE/Ag	 +	 +	 (Kitamura,	1989)	(Galli,	1990)	
Substance	P	 +	 +	 (Kitamura,	1989)	(Galli,	1990)	
Compound	48/80	 -	 +	 (Kitamura,	1989)	(Galli,	1990)	
Inhibited	by	Na	
Chromoglycerate	
No	 Yes	 (Pearce	et	al.,	1989)	
Table	1.2.	Mast	cell	heterogeneity	in	mouse.	
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1.1.5	Mast	cell	functions	in	health	and	diseases		Although	mast	cells	are	best	recognized	for	their	major	contribution	in	allergies,	a	growing	body	of	literature	has	highlighted	the	contribution	of	mast	cells	in	homeostasis	and	promoting	the	pathology	of	different	diseases	(Moon	et	al.,	2010)	(Weller	et	al.,	2011).	Understanding	mast	cells’	strategic	distribution,	response	to	various	stimuli,	variety	of	mediators,	and	plasticity	leads	to	better	appreciation	of	mast	cells	in	biology	and	pathology.		
1.1.5.1	Mast	cell	functions	in	health		
1.1.5.1.1	Mast	cells	in	homeostasis	The	fact	that	no	living	human	being	can	exist	lacking	mast	cells	(Weller	et	al.,	2011)	reflects	the	important	role	of	mast	cells	in	maintaining	health.	Since	mast	cells	are	potent	inflammatory	cells,	and	inflammation	is	a	homeostatic	response	in	principle	then	it	is	acceptable	to	consider	mast	cells	as	players	in	homeostasis.	By	using	mast	cell-deficient	(MC	−	/	−	)	mice,	the	physiological	functions	of	mast	cells	have	been	defined	(Wershil,	2000).	Mast	cells	contribute	to	hair	growth,	bone	remodeling	and	wound	healing	as	MC	−	/	−		mice	have	impaired	hair	follicle	cycling	(Maurer	et	al.,	1997),	osteopenia	(Silberstein	et	al.,	1991)	and	significant	delay	wound	healing	(Noli	and	Miolo,	2001).	The	effect	of	mast	cells	on	bone	remodeling	is	mediated	by	release	of	osteopontin	(Nagasaka	et	al.,	2008),	IL-1	and	histamine	which	act	to	promote	osteoclast	development	(Chiappetta	and	Gruber,	2006).	Similarly,	mast	cells	promote	epithelial	cell	and	fibroblast	proliferation	by	producing	of	many	growth	factors	such	as	NGF,	platelet-derived	growth	factor,	and	fibroblast	growth	factors	(Noli	and	Miolo,	2001).	In	the	gut,	mast	cells	and	their	mediators	are	important	for	gut	homeostasis.	Mast-	cell-chymase-	deficient	mice	showed	alteration	in	chloride	and	water	transport,	mucous	section	from	epithelial	cells,	vascular	permeability	and	intestinal	motility	(Groschwitz	et	al.,	2009).			
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1.1.5.1.2	Mast	cells	in	host	defence	The	strategic	position	of	mast	cells	near	to	surfaces	exposed	to	external	environment	makes	them	the	first	“defense-barrier”	to	recognize	the	invading	microbes	(Echtenacher	et	al.,	1996).	Pathogens	activate	TLR	receptors	expressed	on	mast	cells	leading	to	release	of	a	diversity	of	mediators	including	chymase	(Knight	et	al.,	2000)	and	tryptase	(Huang	et	al.,	2001),	TNFa,	LTB4	and	other	mediators	that	recruit	neutrophils	(von	Köckritz-Blickwede	et	al.,	2008).	By	using	mast	cell-deficient	(MC	−	/	−	)	mice,	mast	cells	were	shown	to	play	a	critical	contribution	to	host	defense	against	different	pathogens	including	parasites	(Knight	et	al.,	2000)	(Maurer	et	al.,	2006,	Sasaki	et	al.,	2005)	and	bacteria	(Xu	et	al.,	2006).	Indeed,	it	has	been	shown	in	a	mouse	cecal	ligation	model	that	mast	cell-	derived	TNFa	is	necessary	to	survive	acute	septic	peritonitis	(Echtenacher	et	al.,	1996).			
1.1.5.2	Mast	cells	in	disease	In	principal,	mast	cells	mediate	the	same	functions	in	physiological	and	pathological	conditions.	However,	mast	cell	functions	can	become	harmful	when	they	respond	to	innocuous	stimuli	or	when	their	response	is	prolonged,	as	is	the	case	in	allergy	and	chronic	inflammation,	respectively.	The	increase	in	mast	cell	numbers	within	tissues	is	reported	in	many	pathophysiological	conditions	such	as	asthma	(Brightling	et	al.,	2002),	multiple	sclerosis,	(Ibrahim	et	al.,	1996)	rheumatoid	arthritis,	(Huang	et	al.,	2002),	irritable	bowel	disease	(O'Sullivan	et	al.,	2000)	(Park	et	al.,	2003)	(Barbara	et	al.,	2004),	congestive	heart	failure	(Hara	et	al.,	2002),	and	cancer	(Terada	and	Matsunaga,	2000)	(Molin	et	al.,	2002).	For	the	purpose	of	this	thesis,	it	is	useful	to	focus	on	the	contribution	of	mast	cell	in	allergy	and	pain-related	diseases.					
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1.1.5.2.1	Asthma	and	allergy	The	role	of	mast	cells	in	allergic	diseases	is	well-defined	(Bradding	et	al.,	2006).	The	number	of	mast	cells	has	been	reported	to	be	significantly	increased	in	allergic	lesions.	In	lungs	of	asthmatic	patients,	number	of	mast	cells	that	settle	in	direct	contact	with	key	anatomical	structures	for	asthma	such	as	airway	smooth	muscle,	mucus	glands	and	epithelium	is	remarkably	increased	(Carroll	et	al.,	2002).	Mast	cells’	location	close	to	external	environment	helps	in	them	becoming	sensitized	with	IgE	against	specific	antigens.	Mast	cell-derived	mediators	contribute	in	pathogenesis	of		the	chronic	inflammation	of	asthma	either	directly	or	by	promoting	tissue	remodeling.	The	acute	allergic	symptoms	that	range	from	a	runny	nose	to	lethal	anaphylactic	shock	are	due	to	the	rapid	release	of	preformed	mediators	such	as	histamine,	tryptase,	PGD2,	and	LTC4	from	activated	mast	cells.	As	I	mentioned	earlier	(section	1.1.3),	these	mediators	act	on	neighbor	cells	and	induce	vasodilation,	bronchoconstriction	and	mucus	secretion.	Mast	cell	derived	mediators	also	account	for	late-phase	reactions	by	producing	de	novo	synthesized	cytokines	like	IL-4,	IL-5,	and	IL-13	that	control	leucocyte	recruitment	(Yu	et	al.,	2006).			
1.1.5.2.2	Functional	gastrointestinal	disorder	and	IBS	The	contribution	of	mast	cells	in	the	pathophysiology	of	irritable	bowel	syndrome	(IBS)	has	recently	been	reviewed	(Wouters	et	al.,	2016).	IBS	is	the	most	prevalent	diagnosis	among	the	functional	gastrointestinal	disorders.	It	is	presented	clinically	with	bloating,	changes	in	bowel	habits	and	recurrent	abdominal	cramp	or	pain	which	underlies	visceral	hypersensitivity	(Longstreth	et	al.,	2006).	Many	researchers	have	reported	the	same	observation	of	increased	mast	cells	numbers	in	the	GIT	mucosa	of	IBS	patients	(Weston	et	al.,	1993)	(O'Sullivan	et	al.,	2000)	(Guilarte	et	al.,	2007)	(Wang	et	al.,	2007)	(Goral	et	al.,	2010),	with	an	apparent	preferred	association	with	nerve	fibers	(Park	et	al.,	2003).	Moreover,	it	has	been	observed	by	electron	microcopy	that	the	number	of	degranulated	mast	cells	in	close	contact	with	nerves	is	also	increased	in	biopsies	of	IBS	patients	(Barbara	et	al.,	2004).	This	number	correlates	to	abdominal	pain	severity	in	IBS	(Park	et	al.,	2006)	(Di	Nardo	et	al.,	2014).	This	strongly	implicates	a	crucial	role	of	mast	cells	in	the	pathophysiology	of	visceral	hypersensitivity	in	IBS	(Ohman	and	Simrén,	
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2010).	Mast	cells	in	mucosal	biopsies	of	IBS	patients	showed	not	only	increases	in	their	number	but	also	increases	in	their	mediator	content	(Guilarte	et	al.,	2007).	Supernatants	of	mucosal	biopsies	and	stool	samples	of	IBS	patients	have	increased	levels	of	mast	cell	mediators	like	tryptase,	histamine,	serotonin,	PGE2	and	IL-6	(Barbara	et	al.,	2007)	(Liebregts	et	al.,	2007)	(Buhner	et	al.,	2009,	Annaházi	et	al.,	2009).	These	mediators	may	sensitize	neurons.		Indeed,	supernatants	isolated	from	mucosal	biopsies	of	IBS	patients	evoked	spike	discharge	in	human	submucosal	neurons	(Buhner	et	al.,	2009)	and	rat	DRG	(Barbara	et	al.,	2007).		Pre-incubation	with	histamine	and	serotonin	receptor	antagonists	or	protease	inhibitor	block	IBS	supernatants-	mediated	response.	IL-6	also	plays	a	role	in	visceral	hypersensitivity	(O'Malley	et	al.,	2011).	Supernatant	from	colon	of	maternal	separation	rat	as	an	animal	model	for	IBS	evoked	calcium	response	in	submucosal	neurons.	Pre-	incubation	with	anti-	IL-6	antibody	blocked	this	response	(O'Malley	et	al.,	2011).		Interestingly,	IBS	patients	with	atopic	background	have	more	increase	in	intestinal	permeability	compared	to	non-atopic	IBS	patients	(Lillestøl	et	al.,	2010).	Furthermore,	atopic	IBS	patients	show	significantly	increased	numbers	of	IgE-coupled	mast	cells	(Lillestøl	et	al.,	2010)	as	well	as	the	higher	serum	IgE	level	correlates	with	GIT	complain	severity	(Vara	et	al.,	2016).	All	together,	these	data	suggest	that	mast	cell-IgE-	mediated	
signaling	could	be	a	major	player	in	the	pathophysiology	of	IBS.	Understanding	the	key	
role	of	mast	cells	in	IBS	is	likely	to	reveal	potential	therapeutic	targets.			
1.1.5.2.3	Migraine	Migraine	is	a	chronic	disorder	that	is	characterized	by	recurrent	episodes	of	moderate	to	severe	headache	associated	with	visual	and	sensory	symptoms.	Although	the	precise	pathophysiology	of	migraine	remains	incompletely	understood,	it	is	highly	accepted	that	neuro-sensitization	and	cerebral	vaso-dilation	have	the	primary	roles	(Spierings,	2003).	Remarkably,	mast	cell	mediators	have	been	suggested	to	contribute	in	the	both	effects	(Theoharides	et	al.,	2005).	It	has	been	shown	that	systematic	administration	of	c48/80	into	rats	resulted	not	only	in	dural	mast	cells	degranulation	but	also	sensitization	of	
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meningeal	nociceptors	(Levy	et	al.,	2007).	Further	studies	identified	mast	cell	mediators	involved	in	sensitization	of	meningeal	nociceptors	namely:	ATP	(Giniatullin	et	al.,	2008)	PG,	tryptase,	TNFa	and	IL-6	(Aich	et	al.,	2015).		
1.1.5.2.4	Autoimmune	diseases	It	has	been	shown	that	mast	cells	contribute	in	the	pathogenesis	of	many	autoimmune	diseases.	The	observation	of	increased	mast	cell	number	with	increase	their	mediator	secretion	at	sites	of	inflammation	is	common	in	many	autoimmune	diseases	such	as	rheumatoid	arthritis.		It	is	an	autoimmune,	chronic	joint	disease	that	characterized	by	leukocyte	–mediated	cartilage	and	bone	destruction.	Mast	cells	accumulate	in	synovial	fluids	of	affected	joints	(Tetlow	and	Woolley,	1995).	Mast	cell-	deficient	mice	are	resistant	to	the	development	of	rheumatoid	arthritis	(Lee	et	al.,	2002).	Mast	cell-derived	IL-1	is	a	key	mediator	in	initiation	of	autoantibody-mediated	arthritis	(Nigrovic	et	al.,	2007).		In	conclusion,	the	ability	of	mast	cells	to	migrate	to	different	tissues,	and	the	potent	mediators	can	be	released	from	them	reflect	the	diversity	of	mast	cells	functions.	Mast	cells	responses	are	essential	in	homeostasis,	but	also	contribute	in	the	pathogenesis	of	a	diverse	array	of	diseases.	Controlling	mast	cell	roles	in	these	diseases	is	an	attractive	therapeutic	target.	Interestingly,	the	role	of	mast	cells	in	different	diseases	is,	in	part,	indirect	through	their	continuous	communication	with	various	cells	and	the	surrounding	environment.	Understanding	these	intercellular	communications	is	essential	
to	advance	the	science	of	mast	cell-directed	therapies.		
1.1.6	Models	for	studying	mast	cells	in	vitro		Unlike	other	immune	cells	that	are	found	in	peripheral	blood,	mature	mast	cells	can	be	only	isolated	from	tissues	(Metcalfe	et	al.,	1997).	Thus,	it	is	challenging	to	isolate	pure	primary	mast	cells	from	either	humans	or	rodents.	Despite	this	limitation,	available	human	and	mouse	models	for	primary	mast	cells	have	been	developed	for	in	vitro	
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studies	(Table	1.3).	Because	mast	cells	display	a	strong	species	and	organ-specific	heterogeneity	even	after	maturation,	one	should	keep	in	mind	that	the	biochemical	properties	and	functional	responses	of	mast	cells	are	critically	dependent	on	the	micro-environmental	culturing	conditions.	Thus	when	studying	mast	cell	functions	in	vitro,	cell	source	and	culturing	conditions	must	be	carefully	considered	(Bischoff,	2007)	(Moon	et	al.,	2010).			
1.1.6.1	Primary	mast	cells	
Primary	Mouse	mast	cells	Primary	mouse	mast	cells	can	be	generated	either	as	bone	marrow-derived	mast	cells	(BMMCs)	or	mouse	peritoneal	cell-derived	mast	cells	(mPCMC).	BMMCs	are	the	most	widely	used	model.	BMMCs	are	considered	to	be	phenotypically	equivalent	to	MMC	mast	cells	(Razin	et	al.,	1984).	BMMCs	are	cultured	from	bone	marrow-derived	progenitors	till	maturation,	with	support	of	IL-3.	After	4	weeks,	generated	cultures	have	>98%	pure	FceRI+	Kit+	mast	cells	that	can	survive	in	culture	for	6	weeks	(Razin	et	al.,	1982b).	BMMCs	are	the	most	extensively	used	primary	mast	cells	because	their	isolation	protocol	is	relatively	easy	and	it	generates	large	quantities	of	mast	cells.	More	importantly,	they	have	the	advantage	that	they	can	be	successfully	used	in	reconstitution	experiments	in	mast	cell-	deficient	mice	and	they	are	relatively	easy	to	transfect	(Otsu	et	al.,	1987).	This	allows	researchers	to	expand	work	from	basic	in	vitro	cell	biology	and	investigate	specific	mast	cell	function	in	complex	in	vivo	settings.	A	limitation	though,	is	that	BMMCs	represent	only	one	phenotype	that	is	MMC.	Because	different	mast	cell	phenotypes	response	differently,	another	model	is	required	when	CTMC	responses	in	particular	are	under	investigation.	mPCMC	are	isolated	as	mature	CTMC	from	mouse	peritoneum	and	cultured	in	the	presence	of	SCF	only	for	two	weeks.	This	method	can	generate	cultures	have	>98%	pure	FceRI+Kitlow	mast	cells	that	can	survive	for	more	than	two	months	(Czarnetzki	and	Behrendt,	1981).	However,	only	5%	of	recovered	peritoneal	cells	are	mast	cells,	and	thus	quantities	recovered	may	be	insufficient	for	some	types	of	experiments.	A	disadvantage	of	mPCMC	is	that	they	have	no	equivalent	in	humans,	who	don’t	have		peritoneal	mast	cells	in	physiological	
	
22	
condition	(Bischoff,	2007).Thus,	translation	of	findings	from	mPCMC	to	human	biology	is	questionable.		
	Primary	Human	mast	cells 		Mature	human	mast	cells	are	difficult	to	be	isolated	in	large	number	because	they	are	not	found	in	blood.	However,	they	can	be	cultured	either	as	mast	cell	progenitors	from	blood	or	as	mature	mast	cells	from	solid	tissues.	Mast	cell	progenitors	can	be	obtained	from	peripheral	blood	or	umbilical	cord	blood	(CBMC)	(Saito	et	al.,	1995)	and	must	be	cultured	in	the	presence	of	SCF	for	6-12	weeks	while	they	mature.	Thy	are	depend	on	SCF	for	their	survival	which	can	make	working	with	them	cost	intensive,	however,	they	can	be	produced	in	large	quantities.	After	maturation,	peripheral	blood	mast	cells	are	tryptase+	chymase+	(Rottem	et	al.,	1994)	while	CBMCs	are	tryptase+chymase.-	CBMCs	express	less	FceRI	that	upregulated	after	incubate	them	with	IgE	and	IL-4	(Yamaguchi	et	al.,	1999).			Primary	human	mast	cells	can	also	be	obtained	from	solid	tissues	such	as	lung	(Schulman	et	al.,	1982),	intestine	(Lorentz	et	al.,	2015)	and	skin	(Gibbs	et	al.,	2001).	Isolated	mast	cells	keep	the	phenotype	of	their	tissue	of	origin.	Although	tissue-derived	mast	cells	are	mature	mast	cells	and	can	be	used	immediately,	they	are	limited	in	number	and	need	multiple	steps	for	purification.	The	lack	of	availability	of	large	quantities	of	fresh	human	tissues,	usually	obtained	from	surgical	specimens,	is	the	most	common	reason	for	abandoning	their	use.		
1.1.6.2	Mast-	cell	lines:	Because	the	low	yield	and	the	time	constraints	and	cost	factors	for	primary	cultures,	transformed	mast	cell	lines	have	been	considerably	used	as	an	alternative.	They	can	be	of	either	human	or	murine	origin.	Currently,	there	are	4	human	cell	lines:	the	human	leukemic	mast	cell	line-1	(HMC-1),	laboratory	of	allergic	diseases	cell	line	(LAD1-2),	cell	line	(LUVA)	and	mast	cell	progenitor	Vienna	(MCPV-1).	HMC-1	has	been	established	
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from	peripheral	blood	of	a	patient	suffering	from	mast	cell	leukemia	(Butterfield	et	al.,	1988)	.	Mast	cells	from	HMC-1	are	fast	growing,	and	SCF-independent	because	Kit	is	permanently	phosphorylated.	However,	they	are	immature	mast	cells	and	don’t	express	FceRI	on	their	surface	even	after	incubation	with	IgE,	which	makes	them	not	suitable	for	studying	allergic	responses	(Moon	et	al.,	2010)	.	In	contrast,	LAD2	cells	are	FCeRI+	and	more	mature.	They	respond	to	Ag	and	release	b-hexosaminidase,	histamine,	tryptase	and	chymase.	Although	LAD2	is	established	from	the	bone	marrow	of	a	patient	suffering	from	mast	cell	sarcoma	with	a	KIT	mutation,	mast	cells	derived	from	LAD2	have	normal	KIT	(Kirshenbaum	et	al.,	2003)	.	Thus,	they	depend	on	SCF	for	survival	as	do		primary	human	mast	cells.	The	major	disadvantage	of	this	cell	line	is	its	long	doubling	time	(15-20	days).	Another	cell	line	(LUVA)	was	established	from	CD34+		purified	peripheral	blood	cells	of	a	donor	suffering	from	aspirin-exacerbated	respiratory	disease	but	without	clinical	symptoms	of	mastocytosis	or	leukemia	(Laidlaw	et	al.,	2011).	Despite	their	normal	KIT	expression,	they	are	SCF-independent.	Initially,	they	express	FCeRI	and	respond	to	Ag	by	release	of		b-hexosaminidase,	protease	and	cytokines.	However,	they	lose	FCeRI	expression	after	long-term	culture.	Recently,	MCPV-1	cell	line	was	designated	by	lentiviral	immortalization	of	cord	blood-derived	mast	cell	progenitors	(Hoermann	et	al.,	2014).	The	aim	of	this	cell	line	was	to	generate	a	cell	line	reflecting	systemic	mastocytosis	in	vitro.	Thus,	MCPV-1	express	CD52,	the	molecular	target	in	systemic	mastocytosis.		Regarding	murine	mast	cell	lines,	the	most	extensively	used	one,	is	the	rat	basophilic	leukemia-2H3	cells	(RBL-2H3).	This	cell	line	was	established	from	chemically-induced	leukemia	in	rat,	then	modified	to	secrete	histamine.	Because	of	RBL-2H3	–derived	mast	cells	express	FceRI,	they	are	extensively	used	to	answer	questions	related	to	FceRI	signaling	pathways	and	related	degranulation.	However,	they	share	typical	characteristics	of	basophils	which	could	influence	the	interpretation	of	the	results	(Passante	et	al.,	2009).	MC/9	is	another	murine	mast	cell	line.	Unlike	RBL-2H3	mast	cells,	MC/9	mast	cells	are	IL-3	dependent.	Both	of	these	cell	lines	can	respond	to	different	stimulants	such	as	Ag/IgE,	calcium	ionophore	and	other	secretagogues	(Musch	
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and	Siegel,	1986).	They	can	be	easily	grown	in	large	numbers.	However,	as	transformed	cells	their	normal	cell	functions	may	be	altered.	Another	less	known	murine	mast	cell	line	is	IC-2.	This	cell	line	is	established	from	mouse	BMMCs.	It	depends	on	IL-3	only	on	their	survival	and	doesn’t	express	Kit	(Koyasu	et	al.,	1985).		In	a	conclusion,	there	is	no	perfect	model	to	represent	mast	cell	functions	in	human.	The	most	suitable	mast	cell-model	to	be	used	in	a	study	must	be	decided	according	to	the	research	question	and	available	facilities.		
Model	 Murine	 Human	 Limitations	
Primary	
cultures	of	
mast	cells	from	
progenitor	cells	
• BMMC	 • Cord-blood-derived	mast	cell	
• Peripheral-blood-derived	mast	cell	
• Long-lasting	process;	development	of	mast	cells	requires	progenitor	cell	cultures	for	6-12	weeks	,	and	addition	of	a	cocktail	of	cytokines	
• It	is	currently	questionable	whether	full	mast-cell	maturation	can	be	achieved	by	this	means	
Primary	
cultures	of	
tissue	mast	
cells	
• Peritoneal	mast	cells	
• Isolated	mucosal	or	skin	mast	cells	are	more	difficult	to	obtain	(small	amounts	of	tissue	and	low	mast-cell	densities)	
• HLMC	
• Human	skin	mast	cells		
• Murine	peritoneal	mast	cells	might	differ	from	tissue	mast	cells	in	the	peritoneal	cavity	in	humans	under	normal	conditions	
• Murine	mucosal	mast	cells	occur	only	at	small	numbers	in	normal	mucosa	(mouse<rat<human)	
• Human	tissue	mast	cells	are	limited	cell	yield	(	~104	-105	mast	cells	per	gram	of	tissue),	cumbersome	isolation	procedures	and	purification	techniques	
Transformed	
mast-cell	lines	
RBL	and	IC-2	 HMC-1,LAD-1,	LAD-2,		LUVA,		and	MCPV-1.	 • Transformation	substantially	alters	normal	cell	function	(e.g	KIT	is	permanently	phosphorylated	in	HMC-1	cells,	which	therefore	become	independent	of	SCF	;	by	contrast,	LAD	cells	require	SCF	for	survival	and	therefore	might	be	more	appropriate	as	a	human	mast-cell	model)	
Table	1.3.	Models	for	studying	mast	cell	in-vitro		“adapted	from	(Bischoff,	2007)”		BMMC,	bone	marrow	mast	cell;	HLMC,	human	lung	mast	cell;	RBL,	Rat	basophilic	leukemia;	HMC-1,	human	leukemic	mast	cell	line-1;	LAD1,	Laboratory	of	allergic	diseases	cell	line;	and	MCPV-1,	mast	cell	progenitor	Vienna.	
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1.2	Sensory	neurons	
1.2.1	Pain	and	nociception		Pain	is	defined	by	the	international	association	for	the	study	of	pain	(IASP)	as	“an	unpleasant	sensory	and	emotional	experience	associated	with	actual	or	potential	tissue	damage,	or	described	in	terms	of	such	damage”,	and	nociception	as	“the	neural	process	of	encoding	noxious	stimuli”	(www.iasp-pain.org).	Three	different	types	of	noxious	stimuli,	mechanical,	thermal	and	chemical,	could	initiate	nociception	at	the	terminals	of	nociceptive	sensory	neurons.	Their	cell	bodies	lie	within	dorsal	root	ganglia	(DRG)	and	trigeminal	ganglia	(TG)	(Woolf	and	Ma,	2007).	DRG	contain	3	subtypes	of	sensory	neurons:	Aβ-fibers,	Aδ-	fibers	and	C-	fibers.	These	fibers	are	classified	based	on	their	conduction	velocity	which	positively	correlates	with	the	diameter	and	degree	of	myelination.	Aβ-fibers	with	a	large	diameter	and	thick	myelination	have	the	fastest	conduction	velocity.	They	respond	only	to	innocuous	stimuli	such	as	light	touch.	Therefore,	they	are	classified	as	non-nociceptive	neurons.	While	c-fibers,	and	Aδ-	fibers	are	nociceptive	neurons.	Aδ-	fibers	with	medium-diameter	and	thinly-myelinated	have	faster	conduction	velocity	than	c-fibers	with	small	and	unmyelinated	axons	(Hunt	and	Mantyh,	2001)	(Basbaum	et	al.,	2009).	Nociceptors	can	further	be	divided	based	on	their	neuropeptide	expression.	Peptidergic	nociceptors	express	and	release	subP	or	CGRP.	In	contrast,	non-peptidergic	nociceptors	don’t	express	neuropeptides	but	bind	to	their	specific	marker	isolectin	IB4	(Carlton,	2014).		Painful	stimuli	usually	activate	first	Aδ-	fibers	that	are	responsible	for	the	immediate	sharp	pain	(Bishop,	1958).	When	stimulus	strength	increases,	c-fibers	are	activated	and	mediate		slower	diffuse	pain.	As	shown	in	Figure	1.3,	two	physiological	consequences	follow	nociceptor	activation,	first,	activated	nociceptors	generate	action	potentials	(AP)	that	synapse	in	the	dorsal	horn	of	the	spinal	cord.	APs	are	transmitted	to	second	order	nociceptive	neurons	via	the	excitatory	neurotransmitter	glutamate	(Petrenko	et	al.,	2003).	Then,	nociceptive	signals	ascend	contra-laterally	in	the	spino-thalamic	and	spino-reticulothalamic	tracts	to	the	somatosensory	cortex	where	nociceptive	signals	are	processed	in	cognitive,	emotional	and	motivational	ways	(Garland,	2012).	In	addition,	
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nociceptors’	cell	bodies	within	DRG	synthesize	and	release	several	neuropeptides	and	inflammatory	mediators	upon	activation.	These	include	SubP,	CGRP,	serotonin	and	ATP.	Released	mediators	at	the	nerve	terminals	result	in	neurochemical	changes	in	the	local	environment	that	activate	nociceptors	or	lowers	their	activation	threshold,	and	eventually	leads	to	peripheral	sensitization.		
	
Figure.1.3	The	nociceptive	pain	pathway	and	neurogenic	inflammation	
(1)	Activation	of	nociceptors	by	noxious	stimuli	generates	orthodomic	and	antidromic	signals.	(2)	Orthodromic	signals	travel	to	the	dorsal	root	ganglion	(DRG).	(3)	Then,	action	potential	(AP)	synapses	in	dorsal	horn	of	the	spinal	cord.	(4)	From	the	dorsal	horn,	the	signals	are	carried	along	the	ascending	pain	pathway	or	the	spinothalamic	tract	to	the	thalamus	and	the	cortex.	(5)	Antidromic	signals	induce	neuropeptide	release.	Neuropeptides	cause	recruitment	of	inflammatory	cells,	vasodilatation	and	mast	cell	activation	(neurogenic	inflammation)(6).			
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1.2.2	Neuropeptides:	Within	DRG,	cell	bodies	of	activated	peptidergic	nociceptors	synthesize	several	neuropeptides	including	subP,	and	CGRP	(Ebersberger	et	al.,	1999)	and	other	peptides	such	as	vasoactive	intestinal	peptide.	Besides	their	role	in	nociception,	sub	P,	and	CGRP	act	as	pro-inflammatory	mediators	.		The	most	extensively	studied	neuropeptide	is	subP.	It	is	found	mainly	in	nociceptor	neurons	that	have	their	cell	bodies	in	the	DRG	and	TG	(Severini	et	al.,	2002).	However,	it	is	also	found	in	some	immune	cells,	including	macrophages	(Pascual	and	Bost,	1990),	and	eosinophils	(Aliakbari	et	al.,	1987)	which	reflects	its	inflammatory	functions	(Black,	1994).	It	is	involved	in	development	of	inflammation	either	directly	or	by	activating	other	inflammatory	cells	like	mast	cells.	It	binds	to	neurokinin	(NK)-1		receptor	on	endothelial	cells	and	induces	vasodilation	(Bhatia,	2010).	It	promotes	leucocyte	recruitment	to	sites	of	inflammation	and	facilitates	leukocytes	adhesion	to	endothelium	(Maggi,	1997).	It	activates	mast	cells	and	induces	degranulation	(Suzuki	et	al.,	1999).				Another	neuropeptide	released	from	activated	nociceptors	is	CGRP	(Maggi,	1995).	CGRP	mediates	its	effects	by	binding	to	its	receptor	that	has	two	components.	One	component	is	GPCR	called	calcitonin	receptor-like	that	is	a	seven	transmembrane	protein.	The	other	component	is	a	member	of	receptor	activity-modifying	protein-1	(McLatchie	et	al.,	1998).	Like	subP,	CGRP	is	involved	in	inflammation	(Brain	and	Williams,	1985).	It	is	a	potent	vasodilator	neuropeptide	by	activating	its	receptor	on	endothelial	cells	(Brain	et	al.,	1985).	Although	CGRP	doesn't	affect	vascular	permeability,	it	enhances	the	effect	induced	by	SubP	when	both	neuropeptides	are	released	concomitantly	(Maggi,	1995).	However,	CGRP	has	more	long-acting	effects	than	SubP	(Ebersberger	et	al.,	1999).	CGRP	is	important	in	regulating	hypertension	because	it	has	a	positive	inotropic	and	chronotropic	effect	on	the	heart,	besides	its	vasodilation	effect	(Deng	and	Li,	2005).	CGRP	also	induces	secretion	of	pro-inflammatory	cytokines	like	IL-1,	IL-6,	and	TNFa	from	mononuclear	cells	(Cuesta	et	al.,	2002)	and	mast	cells	(Ottosson	and	Edvinsson,	1997).	
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1.2.3	Neurogenic	inflammation	Sensory	neurons	are	highly	complicated	structures	(Carlton,	2014).	They	are	best	known	as	an	afferent	for	noxious	stimuli.	However,	because	they	are	able	to	synthesize	and	release	neuropeptides	that	induce	biological	effects,	they	could	be	considered	as	efferent	as	well	(Maggi	and	Meli,	1988).	This	efferent	function	is	known	as	dorsal	root	reflexes	(DRR)	which	is	thought	to	contribute	to	disease	pathology	(Carlton,	2014).	As	shown	in	Figure	1.3,	the	anti-dromic	activity	of	nociceptors	results	in	release	of	their	neuropeptides:	subP	and	CGRP	(Maggi,	1995).	Neuropeptides	mediate	vasodilation	that	results	in	redness,	hotness	and	increased	vascular	permeability	that	causes	swelling.	Collectively,	these	are	signs	of	inflammation.	Since	this	inflammation	is	evoked	by	activation	of	nociceptors,	it	is	defined	as	neurogenic	inflammation	(Schmelz	and	Petersen,	2001).	The	subpopulation	of	nociceptors	that	specifically	mediate	neurogenic	inflammation	are	capsaicin-sensitive	nociceptors	(Holzer,	1988)	which	are	a	subtype	of	c-peptidergic	fibers	(Weng	and	Dougherty,	2005).	Indeed,	destruction	of	these	nociceptors	suppresses	neurogenic	inflammation.	Although,	the	nociceptors	are	the	major	players	in	neurogenic	inflammation,	other	immune	cells	that	are	activated	by	neuropeptides	such	as	mast	cells	are	important	to	feedback	and	prolong	the	inflammation	(Schmelz	and	Petersen,	2001).		It	has	been	suggested	that	neurogenic	inflammation	has	a	potential	role	in	the	pathophysiology	of	neuroimmune	diseases	such	as	migraine	(Malhotra,	2016)	asthma	(Pisi	et	al.,	2009),	allergic	rhinitis	(Klimek	and	Pfaar,	2011),	and	inflammatory	bowel	disease	(Renzi	et	al.,	2000)			
1.2.4	Sensory	neuron	in	vitro	model	(DRG	culture)	DRG	cultures	have	been	widely	used	to	study	cellular	and	molecular	mechanisms	involved	in	pain	signaling,	and	pathogenesis	of	the	peripheral	neuropathy	disorders.	Moreover,	they	provide	a	valuable	tool	to	identify	and	validate	new	potential	analgesic	drugs.	
	
29	
		Different	types	of	sensory	neuron	cultures	have	been	developed	and	proved	as	a	powerful	tool	(Melli	and	Höke,	2009).	However,	the	research	design	is	the	most	important	factor	to	determine	the	best	type	to	answer	the	research	questions.	Sensory	neuronal	cell	cultures	could	be	either	primary	or	cell	lines.		
1.2.4.1	Primary	DRG	The	most	important	advantage	of	primary	DRG	cultures	over	neuronal	cell	lines	are	that	they	are	more	likely	to	reflect	the	in	vivo	biology.	Primary	sensory	neurons	are	easily	isolated	from	DRG	of	various	animals	(Melli	and	Höke,	2009).	Rodent	DRG	cultures	have	been	extensively	used	to	study	sensory	nerve	development,	function,	neuronal	survival,	electrical	signaling	(Harper	and	Lawson,	1985a),	and	neurite	outgrowth	(Gavazzi	et	al.,	1999).	They	are	also	used	as	an	in	vitro	model	of	peripheral	neuropathies	disorders,	such	as	diabetic	neuropathy	(Vincent	et	al.,	2007)	and	inflammatory	pain	(Kallenborn-Gerhardt	and	Schmidtko,	2011).			Different	protocols	can	be	used	to	culture	sensory	neurons	from	mouse	DRG.	They	can	be	isolated	from	embryonic	(Horie	and	Kim,	1984)	or	adult	(Scott,	1977)	mice	and	they	can	be	either	dissociated	by	enzymatic	trypsinization	or	seeded	as	explants.	Two	advantages	are	unique	for	embryonic	DRG	culture	(Melli	and	Höke,	2009).	The	high	yield	of	cells	make	embryonic	DRG	an	ideal	model	for	neuroprotective	drug	screening	(Melli	et	al.,	2006a)	(Melli	et	al.,	2008).	The	second	advantage	is	that	the	growth	of	neurites	is	highly	dependent	on	NGF,	and	they	undergo	degeneration	by	withdrawing	NGF	(Unsain	et	al.,	2014).		This	feature	makes	embryonic	DRG	an	ideal	model	for	studying	axonal	degeneration	in	diseases	such	as	diabetes	(Taiana	et	al.,	2014)	and	HIV	(Melli	et	al.,	2006b).	Furthermore,	embryonic	DRG	sensory	neurons	are	suitable	to	be	used	with	Campenot	chambers	to	study	axon	development.	Campenot	chambers	are	compartmentalized	so	that	axons	can	extend	separately	and	grow	away	from	cell	bodies	and	be	examined	independently	(Campenot,	1977).	However,	NGF-dependent	neurite	
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survival	limits	the	use	of	embryonic	DRG	cultures	in	experiments	when	the	effect	of	other	chemical	factors	is	investigated.			In	contrast,	adult	DRG	can	survive	independently	of	NGF	and	serum,	as	well.	Therefore,	they	can	be	used	in	experiments	with	defined	media	(Melli	et	al.,	2006a).	In	addition,	adult	DRG	cultures	provide	a	model	of	completely	developed	sensory	neurons	that	more	closely	reflect	their	biology	in	vivo.	Adult	DRG	cultures	are	commonly	used	in	studying	the	effect	of	inflammatory	mediators	on	nociceptive	signaling	(Lin	et	al.,	2006).			The	main	difficulty	with	primary	DRG	cultures,	in	general,	is	the	heterogeneity	of	the	population	due	to	the	presence	of	different	neuronal	subtypes	as	well	as	non-neuronal	cells	(Petruska	et	al.,	2000).	A	recent	single-cell,	RNA	sequencing	experiment	showed	that	one	DRG	could	represent	potentially	11	functionally	distinct	neuronal	subtypes	(Usoskin	et	al.,	2015).		
1.2.4.2	DRG	cell	lines	The	limited	cell	numbers	of	primary	neuronal	cultures	make	them	unsuitable	for	a	high-throughput	screening	of	analgesic	drugs.	Therefore,	sensory	neuronal	lines	are	used.	50B11	is	a	cell	line	derived	from	embryonic	rat	DRG	(Chen	et	al.,	2007).	Neurons	from	this	cell	line	can	be	differentiated	and	produce	high	cell	numbers.	They	have	typical	characteristic	receptors	for	nociceptive	sensory	neurons.	They	express	DRG	neuronal	markers	such	as	transient	receptor	potential	vanilloid	(TRPV1)	and	receptors	for	NGF.	However,	data	generated	from	this	cell	line	must	be	validated	in	primary	DRG	cultures.	Another	cell	line	derived	from	Mouse	Embryonic	DRG	is	MED17.11(Doran	et	al.,	2015).	They	differentiate	quickly,	and	neurite	outgrowth	can	be	detected	within	hours.	Although	the	cells	express	sodium-voltage	channel	1.7	(NaV1.7)	and	respond	to	nociceptor	stimulants	such	as	capsaicin	and	veratridine,	they	fail	to	express	NaV1.8.	Their	unique	advantage	is	that	they	don't	form	aggregates	like	other	cell	lines	making	them	an	excellent	model	for	high-throughput	drug	screening.	
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1.3.	Mast	cell-	neuron	interactions	Mast	cells	and	neurons	are	found	to	communicate	with	each	other	both	functionally	and	structurally	(Forsythe	and	Bienenstock,	2012).	They	are	found	in	close	association	with	each	other,	where	activation	of	one	cell	type	influences	the	other	activities	(Figure	1.4).	These	mast	cell-neuron	cross-talk	has	been	demonstrated	in	diverse	tissues	like	GIT,	respiratory	system,	skin,	and	brain	in	health	and	disease.			
1.3.1	Mast	cell-	nerve	functional	interactions	The	functional	connection	between	mast	cells	and	neurons	has	been	studied	extensively	and	reveals	that	there	is	bi-directional	communication	between	these	cells	(van	Diest	et	al.,	2012).	Activated	mast	cells	release	mediators	that	feed	back	onto	the	activating	neurons.	Activated	neurons	release	neuropeptides	that	could	further	activate	mast	cells.	This	functional	crosstalk	is	important	in	the	regulation	of	normal	homeostasis	and	pathophysiological	conditions.											
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Figure.1.4.	Mast	cell-	nerve	interaction.		Mast	cell-nerve	proximity	is	mediated	by	adhesion	molecules:	cell	adhesion	molecule-1	(CADM1)	and	N-cadherins.	 This	 proximity	 facilities	 the	 functional	 bidirectional	 communication.	 Mast	 cell	 releases	 or	synthesizes	mediators,	which	act	on	the	relevant	receptors	expressed	by	sensory	neurons.	Sensory	neuron	responses	by	release	neuropeptides	that	activate	mast	cells.	Encircles	numbers	represent	references.	(1)	(Linden	et	al.,	2001);	(2)	(Amadesi	et	al.,	2004);	(3)	(Leon	et	al.,	1994);	(4)	(Lindsay	and	Harmar,	1989);	
(5)	(Kakurai	et	al.,	2006);	(6)	(Hensellek	et	al.,	2007)	(van	Diest	et	al.,	2012)	(7)	(Kakurai	et	al.,	2006);	(8)	(Suzuki	et	al.,	2007);	(9)	(Maggi,	1997)	(Suzuki	et	al.,	1999)	(10)	(Mori	et	al.,	2002);	(11)	(Suzuki	et	al.,	2004);	 (12)	 (Furuno	 et	 al.,	 2005)	 (Hagiyama	 et	 al.,	 2011)	 (Furuno	 et	 al.,	 2012).	 Ag,	 antigen;	 IgE,	immunogloubulin	E;	PAR2,	Protease	activated	receptor	2;	NGF,	nerve	growth	factor;	trkA	 ,	high-affinity	tropomyosin	 kinase	 receptor	 A;	 TNF-a,	 tumour	 necrosis	 factor	 -a	 ;	 TNFR1,	 tumour	 necrosis	 factor	receptor	 1;	 ATP,	 adenosine	 tri-phosphate;	 P2X,	 purinergic	 2X	 receptor;	 SubP,	 substance	 P;	 NK-1,	neurokinin	1;	TRPV1,	transient	receptor	potential	vanilloid	;AP,	action	potential.			
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1.3.1.1	Mast	cell	signaling	to	neurons		Mast	cells	synthesize,	store	and	release	a	diversity	of	mediators	that	induce	direct	functional	responses	in	neurons	or	sensitize	nociceptors	indirectly	through	activation	of	co-expressed	receptors	(van	Diest	et	al.,	2012).	These	mediators	include	all	classes	of	mast	cell	mediators.	Preformed	mediators	like	tryptase,	histamine,	serotonin	and	ATP.	Synthesized	lipid	mediators	such	as	PGs	and	cytokines	such	as	NGF,	and	TNFa.		As	shown	in	Figure	1.4,	mast	cells	secrete	tryptase	upon	stimulation.	Tryptase	cleaves	and	activates	PAR2	expressed	on	sensory	neurons	(Linden	et	al.,	2001)	and	sensitizes	TRPV1,	the	most	studied	receptor	involved	in	sensory	pain	perception	(Amadesi	et	al.,	2004).		As	a	result,	neuropeptides	subP	and	CGRP	are	released	from	neurons	causing	hyperalgesia	(Amadesi	et	al.,	2004)	and	neurogenic	inflammation	(Cenac	et	al.,	2003).	Likewise,	other	preformed	mast	cell	mediators	have	been	reported	to	modulate	TRPV	channels	as	well.	Histamine	and	serotonin	sensitize	TRPV1	and	TRPV4	by	binding	to	their	receptors	on	nociceptors	(Van	Steenwinckel	et	al.,	2009).	Pre-incubation	of	DRG	with	histamine	and	serotonin	enhance	calcium	response	induced	by	TRPV	agonist	in	
vitro.	On	the	same	way,	they	enhance	the	visceral	hypersensitivity	induced	by	colorectal	distension	in	rat	(Cenac	et	al.,	2010).	Excitingly,	systematic	administration	of	histamine	H1	receptor	antagonist	effectively	reduces		visceral	hypersensitivity	in	maternal	separation	model	for	IBS	in	comparable	to	other	analgesic	drugs	(Stanisor	et	al.,	2013).		Mast	cells	synthesize	and	release	cytokines	and	growth	factors	that	influence	neuronal	activation.	Mast	cell-derived	IL-1β	and	IL-6	cytokines	evoke	neuronal	excitatory	responses	of	small	intestinal	submucosal	neuron	of	guinea	pig	(Xia	et	al.,	1999).	Moreover,	mast	cells	synthesize,	store,	and	release	NGF	(Leon	et	al.,	1994).	In	addition	to	the	vital	role	of	NGF	on	survival	and	differentiation	neurons	(Matsushima	and	Bogenmann,	1990),	it	has	been	reported	that	local	injection	of	NGF	lowers	the	threshold	of	sensory	neurons	and	induces	long-lasting	hypersensitivity	in	human	(Rukwied	et	al.,	2010)	and	rat	(Mills	et	al.,	2013).	This	effect	may	be	due	to	its	ability	to	up-regulate	SubP	and	CGRP	expression	in	DRG	(Lindsay	and	Harmar,	1989).		Interestingly,	NGF	has	
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autocrine	effect	on	mast	cells.	It	activates	high-affinity	tropomyosin	kinase	receptor	A	(TrkA)	expressed	by	mast	cells	(Tam	et	al.,	1997)	and	induces	CTMC	degranulation	(Stempelj	et	al.,	2003)	and	IL-6	and	PGE2	production	in	vitro,	in	rat	(Marshall	et	al.,	1999).	In	addition,	NGF	promotes	mast	cell	migration	in	vitro	(Sawada	et	al.,	2000).	TNFa	is	also	secreted	from	activated	mast	cells	and	acts	on	sensory	neurons	either	directly	or	indirectly.	Mast	cell-	derived	TNFa	can	bind	directly	to	TNFR1	on	sensory	neurons	that	leads	to	nerve	elongation.	In	an	animal	model	of	contact	hypersensitivity,	oxazolone	failed	to	induce	cutaneous	nerve	elongation	in	TNF-deficient	mice	(Kakurai	et	al.,	2006).	It	doesn't	only	promote	nerve	elongation:	one	interesting	finding	in	Kakurai’s	work	is	that	mast	cell-	derived	TNFa	enhances	the	close	proximity	between	mast	cells	and	nerve	fibers	(Kakurai	et	al.,	2006).	TNFa	also	increases	nerve	susceptibility	to	excitatory	stimuli	such	as	capsaicin	(van	Houwelingen	et	al.,	2002).	Conversely,	mast	cell-	derived	TNFa	can	act	on	neurons	indirectly	via	activation	of	TNFR1	on	fibroblasts,	which	leads	to	fibroblast	production	of	NGF	that	in	turn	acts	on	sensory	neurons.	Both	TNFa,	and	NGF	are	involved	in	sensitization	and	up-regulation	of	TRPV1	nociceptors	in	sensory	neurons	(Winston	et	al.,	2001)	(Hensellek	et	al.,	2007).	Moreover,	ATP	secreted	from	Ag-	activated	mast	cells	induces	calcium	signal	in	sensory	neuron	in	co-culture	and	applying	ATP	antagonist	(apyrase)reduces	this	effect	(Suzuki	et	al.,	2007).	Sensory	neurons	express	P2X	and	P2Y	purinergic	receptors	(Ruan	and	Burnstock,	2003),	and	purinergic	signaling	plays	a	role	in	pain	transmission	pathways	(Burnstock,	2009).		P2X	signaling	contributes	in	pain	pathway	by	provoking	glutamate	release	from	nociceptors	which	leads	to	fast	synaptic	transmission	(Gu	and	MacDermott,	1997).		While,	P2Y	contributes	in	pain	transmission	by	its	interaction	with	TRPV1	(Moriyama	et	al.,	2003).		
1.3.1.2	Neuron	signalling	to	mast	cells		As	explained	in	(section	1.2.3),	sensory	neurons	can	influence	mast	cell	activation	through	DDR-	related	mechanism.	Upon	electrical	stimulation	of	rat	vagus	nerve,	the	amount	of	intestinal	mast	cell-derived	histamine	is	increased	(Gottwald	et	al.,	1995).	Indeed,	capsaicin	–	activated	c-fiber	neurons	also	showed	the	same	effect.	This	suggests	that	noxious	stimuli	activate	c-fiber	neurons	that	response	as	efferent	by	releasing	
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neuropeptides	that	activate	mast	cells	(Suzuki	et	al.,	1999)	(Mori	et	al.,	2002).	Mori	examined	the	effect	of	subP	at	the	site	of	mast	cell	contact	with	neurons.	He	found	that	stimulation	of	the	neurons	leads	to	the	release	of	subP	which	then	causes	mast	cell	membrane	ruffling	and	granule	movement	(Mori	et	al.,	2002).		In	this	regard,	subP	is	the	most	extensively	investigated	neuropeptide.	SubP	induces	mast	cell-	derived	mediators	like	histamine	(Ottosson	and	Edvinsson,	1997)	and	cytokines	such	as:IL-1	(Laurenzi	et	al.,	1990),	IL-6	(Gagari	et	al.,	1997),	IL-10,	TNF-α	(Lee	et	al.,	1994)	and	NGF	(Maggi	et	al.,	1997)	(Cuesta	et	al.,	2002).	Interestingly,	NK1	receptor-deficient	mice	failed	to	develop	stress-induce	asthma	(Pavlovic	et	al.,	2008).	In	a	model	of	stress-induced	atopic	dermatitis,	there	was	increased	number	of	degranulated	mast	cells	in	contact	to	subP-	positive	nerves	in	the	skin	of	mice	(Peters	et	al.,	2005).	Collectively,	this	is	proposing	the	important	role	of	subP	in	mast	cell-mediated	inflammation.		Several	lines	of	evidence	indicate	that	subP	is	a	functional	messenger	between	neurons	and	mast	cells	and	has	a	major	function	in	the	pathogenesis	of	pain,	neurogenic	inflammation	and	stress-induced	diseases.	This	has	been	proven	using	mast	cell-	neuron	co-culture	system.	Activated	neurons	release	subP	that	causes	either	piecemeal-	or	classic	degranulation	of	mast	cells	(Maggi,	1997).	Scorpion	venom-	induced	neuronal	activation	increases		calcium	mobilization	in	mast	cells	in	co-culture.	This	effect	is	abolished	by	subP	antibody	or	NK-1	receptor	antagonist	(Suzuki	et	al.,	1999).	SubP	activates	mast	cells	via	both	NK1	receptor-dependent	and	a	receptor-independent	pathway.	NK1	expression	in	mast	cells	seems	to	depend	on	microenvironment	factors.	Human	intestinal	mast	cells	don’t	express	NK	receptors	in	physiological	conditions,	but	they	are	upregulated	after	IgE-mediated	mast	cell	activation	(Bischoff	et	al.,	2004).	Furthermore,	IL-3	dependent	BMMC	don’t	express	NK1	that	is	upregulated	when	BMMCs	are	co-cultured	with	pro-inflammatory	cytokines	IL-4	and	SCF		(van	der	Kleij	et	al.,	2003)	(Okabe	et	al.,	2006),	and	as	a	result	these	mast	cells	acquire	the	sensitivity	to	subP	(Karimi	et	al.,	2000).	This	suggests	that	mast	cells	don’t	express	NK	receptor	in	normal	physiological	conditions,	which	is	why	higher	concentrations	of	substance	P	is	needed	to	activate	mast	cells	through	receptor-independent	pathway.	By	contrast,	lower	concentrations	of	subP	can	activate	mast	cells	directly	through	NK1	receptors	that	are	expressed	during	inflammation	(van	der	Kleij	et	al.,	2003).		
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	It	has	been	suggested	that	a	picomolar	concentration	of	subP	that	does	not	induce	mast	cell	degranulation	in	physiology	could	increase	the	sensitivity	of	mast	cells	to	subsequent	stimuli	(Suzuki	et	al.,	1999).	In	contrary	to	this	suggestion,	small	dose	of	subP	has	been	reported	to	downregulate	FcɛRI	expression	in	human	primary	mast	cells	and	LAD2	cell	line	(McCary	et	al.,	2010).	However,	pre-senstized	mast	cells	with	IgE	have	been	shown	to	prevent	subP-	induced	FcɛRI	downregulation.	This	is	of	great	interest	clinically	because	it	suggests	that	SubP-mediated	FcɛRI	downregulation	is	a	physiological	process	to	protect	mast	cells	from	further	activation.	However,	this	downregulation	is	not	happened	in	allergic	patients	with	IgE-	sensitized	mast	cells.	That	could	explain	the	increased	incidence	of	neurogenic	inflammation	disorders	in	atopic	patients	(Jones	et	al.,	2014).	More	importantly,	this	proposes	that	nerve	cell-derived	
neuropeptides	not	just	activate	mast	cells,	but	they	regulate	their	functions	in	health	and	
diseases.			In	contrast	to	subP,	little	data	are	available	regarding	the	effect	of	CGRP	on	mast	cells,	and	there	is	discrepancy	whether	CGRP	could	induce	mast	cell	degranulation.	Although	CGRP	evokes	an	increase	in	Ca2+	signaling	in	BMMCs	(De	Jonge	et	al.,	2004),	it	produces	only	small	amount	of	mMCP-1	without	affecting	degranulation	(Rychter	et	al.,	2011).	CGRP	also	can’t	induce	degranulation	in	LAD2	(Kulka	et	al.,	2008).	On	the	other	hand,	CGRP	was	shown	to	increase	histamine	release	from	dura	mater	mast	cells	in	rat,	although	it	doesn’t	induce	peritoneal	mast	cells	degranulation	in	rats	(Ottosson	and	Edvinsson,	1997).	The	histamine	released	from	CGRP-activated	dura	mater	mast	cells	is	blocked	by	CGRP	receptor	antagonist	suggesting	receptor	mediated	mechanism.	However,	more	works	needs	to	be	done	to	explore	the	role	of	CGRP	in	mast	cell-	neuron	cross-talk.		
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1.3.2	Mast	cell-	nerve	structural	interactions	Many	studies	are	providing	conclusive	evidence	for	the	juxtaposition	of	mast	cells	and	nerves	in	vivo.	Indeed,	mast	cells	have	shown	preference	to	attach	to	subP	and	CGRP-	positive	sensory	neurons	in	human	and	rat	intestine	(Stead	et	al.,	1987),	respiratory	tract	(Alving	et	al.,	1991)	dura	matter	(Rozniecki	et	al.,	1999),	and	other	tissues	(Spanos	et	al.,	1997).	By	electron	microscopy,	it	has	been	shown	that	the	gap	between	mast	cells	and	nerves	is	not	larger	than	20nm	(Stead	et	al.,	1987).	Moreover,	it	is	reported	that	the	number	of	contacts	between	mast	cells	and	neurons	is	increased	during	infection	(Stead	et	al.,	1987),	allergic	conditions	(El-Nour	et	al.,	2005),	and	inflammatory	conditions	such	as	irritable	bowel	syndrome	(Barbara	et	al.,	2004).			
In	vitro	co-culture,	superior	cervical	ganglion	(SCG)	with	RBL	cell	line	showed	that	mast	cells	attach	to	neurites	although	they	don’t	form	typical	characteristics	of	synapses	(Blennerhassett	et	al.,	1991)	(Furuno	et	al.,	2005).	Although	many	studies	showed	the	mast	cell-	neuron	bi-directional	communications,	few	studies	examined	the	effect	of	intimate	attachment	of	mast	cells	to	neurites	on	their	communications.	Apart	from	one	study	showed	that	the	movement	of	mast	cells	granules	and	membrane	ruffling	were	restricted	at	the	point	of	contact	between	mast	cell	and	neuron	as	seen	by	electron	microscopy	(Mori	et	al.,	2002),	one	study	clearly	compared	the	response	between	attached	and	non-attached	mast	cells	to	neurites	(Suzuki	et	al.,	2005).	After	IgE-activation	of	mast	cells,	both	Ca+2	responses	and	FcεRI	expression	were	increased	significantly	in	mast	cells	attached	to	neurites	compared	to	non-attached	mast	cells	in	the	same	co-culture.	These	data	indicate	that	physical	contact	between	mast	cells	and	
neurons	may	augment	mast	cell	responses	to	antigen.	However,	this	attractive	suggestion	
needs	to	be	scientifically	investigated	to	explore	the	novel	subsequent	event	for	mast	cell-
neuron	cross-talk.				
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1.4	Cell	adhesion	molecules	(CAMs)	Localization	and	function	of	different	cells	are	controlled	by	cell-cell	or	ECM-cell	adhesions	that	mediated	by	CAMs.	Cell	adhesion	is	a	fundamental	process	for	normal	tissue	architecture	and	intercellular	communication.	In	some	cases,	the	cytoplasmic	domain	of	CAMs	interact	with	protein	kinases	to	induce	intracellular	signaling	which	involves	cell	functions	such	as	cell	growth,	degranulation,	and	chemotaxis	(Hynes,	1992).	CAMs	can	mediate	either	homotypic	adhesion,		in	which	the	same	CAMs	bind	to	each	other	in	both	cells,	and	heterotypic	adhesion,		in	which	CAM	from	one	class	bind	CAM	from	different	class	on	the	surface	of	another	cell	(Figure	1.5).	Here,	I	will	review	some	examples	for	CAMs	involved	in	protein-protein	interactions			
	
	
Figure.1.5	Main	families	of	cell	adhesion	molecules		General	 structural	 characteristics	 for:	 Selectins,	 Integrins,	 Cadherins	 and	 Immunoglobulin	 superfamily	 adhesion	molecules	(IgSF-CAM)	are	shown.	Selectin,	integrins	and	cadherins	are	calcium	(Ca2+)-	dependent	CAMs,	while	IgSF-CAMs	are	calcium-independent.	Unlike	cadherins,	selectins	and	integrins	can	mediate	heterotypic	cell	adhesion.	IgSF-CAMs	mediate	both	homo-and	heterotypic	cell	adhesion.	EGF=	epidermal	growth	factor.			
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1.4.1	CAM	families		
1.4.1.1	The	selectins		Structurally,	selectins	have	an	extracellular	domain	that	consists	of	an	N-terminal,	lectin-like	subunit	(C-type),	and	an	epidermal	growth	factor	(EGF)-like	subunit,	followed	by	a	transmembrane	domain,	and	a	cytoplasmic	tail	(Figure.	1.5)	(St	Hill,	2011).	The	selectins	have	three	members	E-,	L-,	and	P-selectins	which	named	after	the	cell-type	expressed	on	endothelial	cells,	leukocytes	and	platelets;	respectively.	They	are	important	in	leukocytes	homing	in	sites	of	tissue	inflammation.	Thus,	they	are	implicated	in	the	pathogenesis	of	cancer	and	inflammatory	diseases	like	asthma	and	arthritis	(Kelly	et	al.,	2007).		
1.4.1.2	The	Integrins		The	integrins	have	a	unique	structure	among	CAMs.	They	present	as	heterodimers	of	non-	covalently	linked	a	and	b	transmembrane	subunits	with	globular	extracellular	domain	(Figure.	1.5)	(Hynes,	2002).	They	mediate	cell-ECM	interactions,	as	well	as,	heterotypic	cell-cell	interactions.	Intriguingly,	integrins	also	induce	intracellular	signaling	upon	binding	to	ECM.	This	signaling	regulate	cell	growth,	and	proliferation(Hynes,	2002)	and	impaired	signaling	can	contribute	in	the	pathogenesis	of	thrombotic	disorders	and	cancer	(Guo	and	Giancotti,	2004)	(Avraamides	et	al.,	2008).			
1.4.1.3	The	Cadherin	Cadherins	are	transmembrane	calcium-dependent	homotypic	CAM.	Their	extracellular	domain	has	five	repeated	subdomains,	EC1	to	EC5	(Figure.	1.5)	(Takeichi,	1995).	The	classic	cadherins	are	named	after	the	first	cell-type	identified	to	express	prominently	in,	although	it	is	not	exclusive.	For	example,	E-cadherin	is	mostly	present	in	epithelial	cells,	N-cadherin	in	the	nervous	system,	P-cadherin	in	placenta	cells	and	VE-cadherin	is	specific	for	the	vascular	endothelial	cells	(Gumbiner,	2005).	Cadherins	form	cis	homodimers	of	alike	molecules	that	trans	interact	to	counter-receptors	on	other	cells	in	zipper-	
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in	selective	adhesion	between	embryonic	cells(Tepass	et	al.,	2002).	Furthermore,	cadherins	can	induce	intracellular	signaling	(Gumbiner,	2005).	Loss	of	cadherins	can	lead	to	increase	metastatic	potential	in	malignancies.	Thus,	it	is	used	as	a	prognostic	biomarker	in	solid	cancers	(Richardson	et	al.,	2012).		
1.4.1.4	Immunoglobulin	superfamily	of	cell	adhesion	molecules	(IgSF-CAMs)		The	IgSF-CAM	superfamily	is	the	largest	group	with	a	distinct	range	of	cell	adhesion	molecule	subfamilies.	Members	of	this	family	are	characterized	by	the	presence	of	one	or	more	Ig-like	extracellular	domains	with	single	transmembrane	glycoproteins	(Figure.	1.5).	For	example,	Intercellular	adhesion	molecule	1	(ICAM1)	has	five	Ig-	like	domains,	ICAM2	has	only	two	Ig-	like	domains,	while	CADMs	and	nectins	have	three	Ig-	like	domains.	IgSF-CAMs	interact	in	trans	both	homotypically	and	heterotypically	with	other	IgSF-CAMs	members,	as	well	as,	other	CAMs	classes	including	integrins,	cadherins	and	tyrosine	kinase	receptors.	They	mediate	Ca2+-independent	cellular	adhesion	(Cavallaro	and	Christofori,	2004).		An	example	for	IgSF-CAM	subfamily	is	the	nectins.	Nectins	colocalize	with	N-cadherin	in	synapses	of	the	developing	nervous	system	(Mizoguchi	et	al.,	2002)	(Okabe	et	al.,	2004).	Although	the	number	of	synapses	in	the	hippocampus	is	decreased	in	nectin-deficient	mice,	no	change	in	in	the	properties	of	synaptic	transmission	is	detected	in	those	mice.	Therefore,	it	seems	that	formation	of	synapses	is	not	entirely	dependent	on	nectins	(Honda	et	al.,	2006).		Among	IgSF-CAM	molecules,	I	found	CADM1	is	interesting.	CADM1	is	multifunctional	immunoglobulin	adhesion	receptor.	It	participates	in	mast	cell	adhesion	to	fibroblasts	(Ito	et	al.,	2003)	(Moiseeva	et	al.,	2013b),	airway	smooth	muscle	cells	(ASM)	(Yang	et	al.,	2006)	(Hollins	et	al.,	2008)	(Moiseeva	et	al.,	2013b)	and	nerves	(Furuno	et	al.,	2005)	(Hagiyama	et	al.,	2011).		
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1.4.2	Cell	adhesion	molecule	1	(CADM1)	The	CADM1	is	a	member	of	IgSF-CAMs	subfamily	which	has	four	members:	CADM1,	CADM2,	CADM3,	and	CADM4	(Biederer,	2006).	All	of	them	have	three	Ig-like	domains	of	the	V-,	C1-,	and	I-set	subclasses,	a	transmembrane	domain	and	a	cytoplasmic	tail	that	is	highly	conserved	among	them.	However,	their	protein	structures	are	different	in	the	presence	or	absence	of	O-and	N-	glycosylation	sites	in	the	extracellular	domain.	In	addition,	the	CADM	genes	are	remarkably	different	in	size	(Biederer,	2006).			
1.4.2.1	CADM1	expression,	function	and	alternative	nomenclature	Extraordinarily,	CADM1	is	known	in	literature	with	different	nomenclatures	due	to	the	parallel	identification	of	the	same	molecule	by	various	research	groups	with	different	research	goals.	Table	1.4	lists	of	alternative	nomenclatures	for	the	CADM1.	Eventually,	its	nomenclature	was	standardized	to	CADM1	by	the	HUGO	gene	nomenclature	committee	(Koma	et	al.,	2008),	the	name	that	has	been	used	in	this	thesis.	Therefore,	CADM1	has	been	cross-referenced	in	literature.			The	diversity	of	nomenclatures	for	CADM1	reflect	the	numerous	cell	types	that	express	it	and	its	broad	range	of	functions	(As	shown	in	table	1.4).	Interestingly,		CADM1	expression	in	BMMC	has	been	confirmed	to	be	regulated	by	the	microphthalmia	transcriptional	factor	(MITF)	(Ito	et	al.,	2003),	a	member	of	the	basic-helix-loop-helix-leucine	zipper	family	that	involve	in	signaling	pathways	required	for	mast	cell	survival	(Hodgkinson	et	al.,	1993).			 	CADM1	has	been	reported	to	express	in	several	cell	types	including	nerves	(Biederer	et	al.,	2002),	mast	cells.	(Ito	et	al.,	2003),	spermatogonia	(Wakayama	et	al.,	2001),	pancreatic	secretory	(Koma	et	al.,	2008)	and	pulmonary	alveolar	cells	(Pletcher	et	al.,	2001).				
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Name	 Protein	function	 Reference	
Synaptic	cell	adhesion	molecule1	(SynCAM)		
synaptic	adhesion	molecule	that	expressed	throughout	the	brain		It	drives	assembly	of	synaptic	cleft		Involved	in	CNS	formation	and	development		
	(Biederer	et	al.,	2002)	
Tumor	suppressor	in	lung	cancer-1	(TSLC1)		
Tumor	suppressor	gene	in	lung	cancer		 (Masuda	et	al.,	2002)	(Pletcher	et	al.,	2001)	
Spermatogenic	immunoglobulin	superfamily		(SgIGSF)		
spermatogenesis,	Male	sexual	development		Bile	duct/ductule	formation	in	the	pancreas 	
Mast	cell	adhesion	protein	
(Wakayama	et	al.,	2001)	(Ito	et	al.,	2003)		
IgSF4		 Synapsis	formation		 (Watabe	et	al.,	2003)	
Nectin-like	molecule-2(Necl-2)	 Localization	of	transmembrane	proteins	in	epithelial	cells		 	(Shingai	et	al.,	2003)	
CADM1		 Tumor	suppression	Apoptosis 	Nerve-islet	cell	interactions		 (Koma	et	al.,	2008)	
Table	1.4:	Alternative	nomenclature	for	the	CADM1	molecule	
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1.4.2.2	CADM1	structure	and	isoforms	As	other	CADMs,	CADM1	has	three	extracellular	Ig-like	domains,	a	single	transmembrane	region,	and	a	short	cytoplasmic	domain	(Ito,	2010).	CADM1	is	a	442	amino	acid	protein.	The	extracellular	domain	comprises	of	373	amino	acids;	the	transmembrane	domain	comprises	of	23	amino	acids,	and	the	cytoplasmic	domain	has	46	amino	acids.	CADM1	undergoes	O-linked	glycosylation	on	the	extracellular	domain.		Its	intracellular	domain	has	protein	4.1	and	PDZ-binding	motifs	that	act	as	a	molecular	scaffold	for	cytoskeleton	and	CASK,	syntenin,	and	focal	adhesion	kinase	(FAK),	respectively	(Watabe	et	al.,	2003)	(Figure	1.6).		
	Figure.1.6	Structure	of	cell	adhesion	molecule1	(CADM1)		CADM1	has	three	extracellular	Ig-like	domains,	a	single	transmembrane	region,	and	a	short	cytoplasmic	domain	with	protein	4.1	and	PDZ	motif.	As	a	result	of	mRNA	alternative	splicing,	four	CADM1	isoforms	(a-d)	are	generated.		
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Depending	on	the	type	of	the	cell	expressing	CADM1	and	binding	partner	on	attached	cells,	cis	homodimers	of	CADM1	can	trans	bind	either	homotypically	or	heterotypically	in	zipper-	like	manner	(Ito,	2010)	(Figure	1.5).	The	binding	that	occurs	among	neuronal	cells	is	an	example	of	homotypical	binding		(Biederer	et	al.,	2002),	while	the	heterotypic	adhesion	is	between	mast	cells	and	fibroblasts	(Ito	et	al.,	2003)	and	between	spermatogenic	and	Sertoli	cells	(Wakayama	et	al.,	2001).	The	adhesion	partners	could	be	CADM1	itself,	CADM2,	CADM3,	nectin3	and	CRTAM	(Ito,	2010)				CADM1	gene	is	mapped	on	chromosome	9	in	mouse	and	11	in	human.	It	consists	of	12	exons	in	mouse	(Biederer,	2006).		As	a	result	of	alternative	mRNA	splicing	between	exons	7	and	11,	CADM1	has	four	isoforms	(CADM1a-CADM1d).	Those	isoforms	differ	in	the	juxtamembranous	extracellular	region,	that	is,	downstream	of	the	exon	encoding	the	third	Ig-like	loop	and	upstream	of	the	exon	encoding	the	transmembrane	region	(Biederer,	2006)	(Figure	1.6).				
1.4.2.3	CADM1	in	diseases	CADM1	is	essential	for	health	and	development.	However,	modulation	of	its	expression	has	been	implicated	in	several	diseases.	CADM1-	knockout	mice	developed	lymphoma	and	leukaemia,	in	addition	to,	some	solid	tumours	such	as	lung,	stomach	and	hepatocellular	carcinomas	(van	der	Weyden	et	al.,	2012).	Clinically,	It	has	been	recommended	to	use	CADM1	as	diagnostic	and	prognostic	markers	for	osteosarcoma	(Inoue	et	al.,	2013)	and	colon	cancer	(Zhang	et	al.,	2012),	respectively.	Furthermore,	its	expression	is	reduced	in	pathogenesis	in	autism	(Zhiling	et	al.,	2008)	and	venous	thrombosis	(Hasstedt	et	al.,	2009),	while	is	increased	in	the	neurodevelopmental	disorder	Rett	syndrome	(Nectoux	et	al.,	2010).			
1.4.2.4	Adhesion	molecules	in	mast	cell-neuron	contact	Remarkably,	little	is	known	regarding	the	molecular	mechanisms	involved	in	the	close	anatomical	relationship	between	mast	cells	and	neurons.	As	a	result	of	the	success	of	in-
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vitro	co-culture	system	of	mast	cells	and	neurons,	efforts	were	spent	to	investigate	the	molecules	involved	in	this	functional	unit	(Forsythe	and	Bienenstock,	2012).	Tow	adhesion	molecules	have	been	proposed	to	be	the	responsible	of	mast	cell-	neuron	interaction.			CADM1	was	recently	shown	to	be	expressed	by	both	mast	cells	(Ito	et	al.,	2003)	and	neurons	(Biederer	et	al.,	2002).	CADM1	was	found	to	mediate	the	attachment	of	mast	cells	to	fibroblasts	(Ito	et	al.,	2003,	Moiseeva	et	al.,	2013b)	and	mast	cells	to	airway	smooth	muscle	cells	(ASMCs)	(Yang	et	al.,	2006)	(Moiseeva	et	al.,	2013b).	CADM1	is	also	expressed	in	the	adhesion	site	of	mast	cells	to	neurons	(Furuno	et	al.,	2005)	(Hagiyama	et	al.,	2011)	and	blocking	CADM1	by	peptide	disrupts	adhesion	between	BMMC	and	SCG	neurons	in	a	dose-dependent	manner	(Furuno	et	al.,	2005).			Interestingly,	it	is	proposed	that	CADM1	doesn’t	promote	only	the	adhesion	but	also	enhances	the	functional	crosstalk	between	mast	cells	and	sensory	neurons	(Ito	et	al.,	2008).	This	suggestion	was	based	on	the	observation	that	the	mast	cells	lines	(IC-2)	that	express	all	other	adhesion	molecules	except	CADM1	response	less	efficiently	to	neuronal	activation	compared	to	BMMCs,	which	express	endogenous	CADM1	(Furuno	et	al.,	2005).	Indeed,	ectopic	expression	of	IC-2	cells	with	CADM1	normalized	their	response.	Consistent	with	this	observation,	the	number	of	degranulated	mast	cells	in	mice	mesentery	after	nerve	stimulation	is	decreased	in	CADM1-deficient	mice	compared	to	wild	type	(Ito	et	al.,	2007).	All	these	evidence	suggest	the	crucial	role	of	CADM1	in	upgrading	the	level	of	functional	communication	between	mast	cells	and	sensory	neurons.	However,	further	investigations	are	needed	to	validate	this	hypothesis.		Furthermore,	when	CADM1	molecules	were	blocked	with	pretreatment	with	anti-CADM1,	there	was	a	small	but	appreciable	number	of	mast	cells	attached	to	neurons.	This	observation	suggests	that,	in	addition	to	the	major	role	of	CADM1	in	mediating	the	intercellular	attachment	between	mast	cells	and	neurites,	other	adhesion	molecules	are	also	involved	in	this	communication.	Since	N-cadherins	are	expressed	by	mast	cells	and	
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neurites,	it	is	proposed	that	N-cadherins	are	accountable	for	the	residual	adhesion	of	mast	cells	to	neurites	(Furuno	et	al.,	2005).	N-cadherins	are	homophilic,	calcium-dependent	adhesion	proteins	which	are	known	to	have	a	role	in	neural	synapse	formation	(Goda,	2002)	(This	molecule	will	be	covered	in	detail	below).	In	BMMC	monoculture,	N-cadherins	are	expressed	as	an	intracellular	protein.	However,	they	traffic	to	the	plasma	membrane	after	co-culture	BMMC	with	SCG	(Suzuki	et	al.,	2004).	This	suggests	that	N-cadherins	are	involved	in	contact	between	mast	cells	and	neurons.	However,	mast	cells	from	IC-2	cell	lines	and	BMMC	from	microphthalmia	transcription	factor	(MITF)	mutant	mice	are	lacking	endogenous	CADM1	but	express	a	normal	level	of	all	other	adhesion	molecules	including	N-cadherins	(Ito	et	al.,	2003).	Because	these	mast	cells	without	CADM1	attach	less	to	neurites,	compared	to	wild-type	BMMC	and	because	there	is	no	evidence	of	the	involvement	of	N-cadherin	in	mast	cell-neuron	functional	interaction,	CADM1	apparently	play	a	key	role	in	mast	cell-	neuron	interaction	and	the	role	of	N-cadherin	is	less	critical.	This	speculation	needs	to	be	carefully	investigated.													
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1.5	Thesis	aims	and	outlines:	The	role	of	expression,	function	and	interactions	of	cell	adhesion	molecules	in	normal	development	and	pathogenesis	is	a	rapidly	advancing	research	area	(Mandai	et	al.,	2015).	However,	it	remains	unclear	if	adhesion	is	essential	in	mast	cell-neuron	cross-talk.	Therefore,	we	tested	the	hypothesis	that	the	functional	cross	talk	between	mast	cells	
and	sensory	neurons	is	modulated	by	CADM1	by	up-regulating	their	mediators	and/or	
receptors	involved	in	this	intercellular	communication.			Thus,	the	objectives	of	this	thesis	were:		
1. To	characterise	and	optimize	the	BMMC	and	DRG	cultures	as	models	for	primary	
mast	cells	and	sensory	neurons,	respectively,	are	described	in	in	chapter	3	and	4.	
2. 	To	investigate	the	impact	of	neurons	on	IgE-mediated	mast	cell	signalling	using	in	
vitro	co-culture	system	(chapter	4).		
3. To	identify	and	characterise	CADM1	expression	in	primary	murine	mast	cells	and	
sensory	neurons	and	verify	its	involvement	in	mast	cell-sensory	neuron	adhesion	
(chapter	5).		
4. To	examine	the	effect	of	CADM1	adhesion	on	IgE-	mediated	mast	cell	signalling	and	
pro-inflammatory	mediator	secretion	in	the	presence	of	neurons	(chapter	5).	
5. To	explore	the	potential	mechanisms	of	adhesion-mediated	neuronal	effect	on	mast	
cell	functions	(chapter	6).		Final	conclusions	and	how	my	results	could	be	transferred	into	human	health	and	diseases	are	summarized	in	chapter	7.				
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Chapter	2.	Material	and	Methods	
	
2.1	Primary	cell	cultures	and	co-culture	
2.1.1	Bone	Marrow	Derived	Mast	Cells	(BMMC)	Isolation	and	Culturing	Mouse	bone	marrow-derived	mast	cells	(BMMCs)	are	a	valuable	model	to	investigate	the	function	of	mucosal-	type	mast	cells	(Razin	et	al.,	1982b).	BMMCs	were	isolated	from	8-12	week-old	C57BL6	wild	type	mice	(Suzuki,	2004)		
2.1.1.1	Preparation	and	isolation	of	mouse	BMMCs	After	scarifying	the	mouse,	its	fur	was	wet	with	70%	ethanol	and	its	intact	femur	and	tibia	were	removed.	Then,	all	the	tissue	was	scraped	away.	The	remaining	steps	were	carried	out	under	sterile	condition	in	tissue	culture	hood.	The	epiphysis	of	femur	and	tibia	were	cut	off	to	expose	the	bone	marrow.	Then,	bone	marrow	cells	were	extracted	by	repeatedly	flushing	the	femur	and	tibia	using	a	27-G	needle	and	10	ml	syringe	filled	with	calcium	and	magnesium	free	phosphate	buffer	solution	(PBS,	PAN	Biotech	GmbH,	Cat	no.	P04-53500).	The	cells	thus	obtained	were	washed	by	centrifuging	at	340xg	for	10	min	at	4°C.	Then,	red	blood	cells	were	lysed	using	lysis	buffer	(Ery-lyse-buffer,	0.83%	ammonium	chloride	4.15g/500ml	0.168%	Na	carbonate	0.84g/500ml	1mM	ethylene-diaminetera	acetic	acid	(EDTA)	(1ml	of	0.5	M	stock)/500	ml	pH	7.3	filtered	sterile)	for	10	min	at	room	temperature.	To	stop	the	reaction,	10	ml	of	complete	Iscove's	Modified	Dulbecco's	Media	(IMDM)	medium	was	added.	Table	2.1	shows	contents	of	complete	IMDM	medium.	Then,	cell	suspension	was	centrifuged	at	340xg	for	10	min	at	4°C.	After	discarding	the	supernatant,	cell	pellet	was	re-suspended	in	5	ml	of	complete	medium.	Then,	the	cells	were	collected	by	passage	through	20µM	mesh	filter	(Falcon)	into	a	50	ml	tube.	Then,	5	ng/ml	mouse	recombinant	IL-3	with	or	without	10	ng/ml	recombinant	mouse	stem	cell	factor	(rmSCF)	were	added.	These	cells	were	collected	in	a	75cm2	tissue	culture	flask	and	cultured	at	the	density	of	0.5x106	-1x106	cells/ml	in	7.5%	CO2	at	37	°C	
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for	4	weeks	until	they	differentiated	into	BMMCs.	At	this	stage,	BMMC	purity	was	confirmed	with	flow	cytometry	(FACS)	(see	below).			
Complete	IMDM	Reagent	 Amount	 Concentration	 Supplier	
IMDM	with	HEPES,	without	L-
glutamine	
50	ml	 	 Lonza12-726F	
Heat	inactivated	fetal	bovine	
serum	(FBS)	
5	ml	 10%	 Gibco	10500-064	Lot	07F2645K	
L-Glutamine	with	
Penicillin/Streptomycin	100X	
500	μl	 100	u/ml	 PAA	Laboratories	P11-01	
MEM	Vitamin	100X	 500	μl	 1%	 Gibco	11120-037	
2-mercaptoethanol	 50	μl	 50	μM	 Gibco	31350-010	
Sodium	pyruvate	100	mM	 500	μl	 1%	 Gibco	11360-039	
Non-essential	amino	acid	X100	 500	μl	 1%	 Gibco	11140-035		
Growth	Factors	Reagent	 Amount	 Concentration	 Supplier	
Mouse	SCF	10	μg/ml	 25	μl	 10	ng/ml	 R&D	systems	455-MC-010	
Mouse	IL-3	10	μg/ml	 12.5	μl	 5	ng/ml	 R&D	systems	403-ML-010	
	Table	2.1.	Contents	of	BMMC	medium		
2.1.1.2	maintenance	of	BMMC	culture.	Every	week,	non-	adherent	cells	were	transferred	to	50	ml	falcon	tube	and	spun	X340xg	for	10	min	at	4°C.	Then,	supernatant	was	discarded	and	cell	pellet	was	re-suspended	with	fresh	complete	IMDM	medium	supplemented	with	5	ng/ml	rmIL-3	with	or	without	
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10	ng/ml	rmSCF.	Cells	were	retained	for	further	culturing	in	new	culture	flask	while	adherent	cells	were	discarded.		
2.1.1.3	Cell	Counting	Because	specific	cell	numbers	were	needed	for	each	experiment,	cells	were	counted	using	a	haemocytometer.	100	μl	of	a	cell	suspension	was	diluted	with	400	of	medium	(1:4).	Then,	45	μl	of	Trypan	Blue	solution	(Gibco,	Invitrogen)	was	added	to	determine	viable	and	non-viable	cells.	10	μl	of	this	solution	was	pipetted	under	each	end	of	the	haemocytometer’s	coverslip	to	fill	the	chamber	by	capillary	action.	Using	a	light	microscope	at	x10	magnification,	the	number	of	cells	present	was	counted	in	each	of	the	four	divided	corners	of	haemocytometer.	The	following	equation	was	used	to	determine	the	total	viable	cell	number:	
Cell	number/	ml	=	(four	chamber	viable	cell	number/4)	x	(dilution	factor)	x	104	To	work	out	the	required	volume	for	a	particular	number	of	cells:	
Volume	of	cell	suspension	for	required	cell	number	(ml)	=	(required	cell	number/actual	
total	cell	number)	x	volume	of	actual	total	cell	suspension	Figure	2.1	shows	BMMC	growth	curve	for	24-hour	after	maturation.	
	
Figure.	2.1.	BMMC	growth	rate	after	maturation		After	4	weeks	of	culturing	in	complete	medium,	BMMCs	were	counted	at	different	time	points	(2-6-12-24	hour)	to	estimate	BMMC	growth	rate	after	maturation.	
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2.1.2	Dorsal	Root	Ganglion	(DRG)	culturing	Adult	mouse	DRG	neurons	cultures	were	used	as	a	model	to	study	sensory	neurons	functions.	(Melli	and	Höke,	2009)	(Sleigh	et	al.,	2016)		
2.1.2.1	Preparation	of	Matrigel-coated	well	Matrigel	(growth	factor	reduced,	phenol	red	free,	BD,	356231)	is	a	solubilized	basemembrane	preparation,	extracted	from	the	Engelbreth-Holm-Swarm	mouse	sarcoma.	Its	major	components	include	laminin	and	collagen	IV.	Depending	on	the	experiment;	wells	with	glass	coverslip	or	without	were	coated	with	matrigel	(thin	gel	method)	before	seeding	DRG.	50μl	aliquot	of	matrigel	slowly	thawed	on	ice	(at	least	2	hours).	Glass	coverslips	were	placed	in	a	24-well	plate	and	cooled	in	fridge	with	box	of	tips.	By	using	cold	tips,	50	μL	of	defrost	matrigel	was	diluted	in	450	μl	of	cold	medium	(1:9)	and	mix.	50	μl	of	diluted	matrigel	was	added	to	the	middle	of	each	well.	Then,	it	removed	quickly	by	cold	pipette.		Plate	was	incubated	at	37°C	for	20-25	minutes	and	cells	were	immediately	seeded	onto	the	middle	of	coverslips.	Wells	were	flooded	after	1	hour	and	cultured	overnight	prior	to	subsequent	experiments.		
2.1.2.2	DRG	isolation	and	culturing	Adult	(from	8-	12	weeks)	C57BL	male	mouse	was	used	for	DRG	isolation.	After	killing	the	animal	with	cervical	dislocation,	the	spinal	column	was	isolated	from	the	back	of	the	mouse	and	cut	longitudinally	by	scalp	to	identical	two	halves.	Then	the	spinal	cord	and	meninges	were	removed.	Under	stereomicrosope,	around	30	DRGs	were	collected	in	small	petri	dish	(35mm,	Nunc,	thermo	scientific)	filled	with	PBS	on	ice.	Then	quickly	DRGs	were	trimmed	off	all	attached	fibers	(Sleigh	et	al.,	2016).	After	that,	DRGs	were	transferred	to	1ml	of	PBS	with	0.06μg/ml	collagenase	XI	(Sigma)	and	0.1	μg/ml	Dispase	for	enzymatically	digestion.	DRGs	were	incubated	for	1	hour	in	37°C,	7.5%	CO2.	After	a	time,	DRGs	were	gently	triturated	by	pipetting	with	narrow	tip	pipette	until	cloudy	and	all	DRGs	were	dissociated.	For	selective	isolation	of	neurons,	gradient	centrifuge	technique	with	15%	bovine	serum	albumin	(BSA)	in	medium	was	used.	Cells	were	
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carefully	added	to	the	top	layer	of	15%	BSA	solution.	Cells	were	then	spun	at	450xg	(1900rpm)	for	eight	minutes	without	deceleration.	After	collecting	the	neurons	from	15%	BSA	solution;	neurons	were	washed	with	complete	Neurobasal	A	medium	(NBA,	Gibco)	containing	2%	B-27	supplement	(Gibco),	2mM	Glutamax	(Gibco),	1%	penicillin	/streptomycin	(Gibco).		Finally,	neurons	were	resuspended	in	small	amount	of	complete	NBA	medium	(50	μl/	well)	and	seeded	on	16	mm	matrigel	(BD)	-	coated	glass	coverslips	(see	above).	Wells	were	incubated	in	37°C,	7.5%	CO2.	After	1hour,	cells	were	flooded	with	complete	NBA	medium	supplemented	with	10ng/ml	NGF	(sigma)	and	1	μM	Cytosineβ-D-arabinofuranoside	(Ara-C,	Sigma)	and	incubated	for	one	day	before	using	in	co-culture.	NGF	and	Ara-C	were	used	only	for	first	day	of	DRG	culture.	Ara-C	is	anti-	mitotic	agent	that	used	to	control	the	number	of	proliferating	non-neuronal	cells	and	improve	the	purity	of	DRG	culture	without	effect	neuronal	viability	(Schwieger	et	al.,	2016).		
Complete	NBA	Reagent		 Amount	 Concentration	 Supplier	
NBA	 10	ml	 	 Gibco	10888-022	
B-27	 200	μl	 2%	 Gibco	17504044	
Glutamax	200mM	 100	μl	 2	mM	 Gibco	35050-061	
Penicillin/Streptomycin	 100	μl	 1	%	 PAA	P11-013	
Ara-C	(1mM)	 10	μl	 1	μM	 Sigma	C1768		
Growth	Factors	Reagent		 Amount	 Concentration	 Supplier	
Mouse	NGF	(10	μg/ml)	 10	μl	 10	ng/ml	 Sigma	N2513	
Table	2.2.	Contents	of	NBA	media		
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2.1.3	BMMC-DRG	Co-culture	BMMC	were	isolated	as	mentioned	above	(section	2.1.1).	After	4	weeks,	the	purity	of	BMMCs	were	assessed	by	flow	cytometry	(see	below)	and	were	used	only	if	the	purity	>95%.		On	the	other	hand,	DRGs	were	isolated	as	mentioned	in	(section	2.1.2)	and	seeded	on	matrigel-coated	wells.	After	1	day	of	DRG	cultured	in	complete	NBA	medium,	DRG	media	were	removed	and	(1-3X105/50µl/well	depend	on	the	experiment)	BMMCs	suspensed	in	co-culture	medium	was	added	to	DRG.	Co-cultures	were	incubated	in	37oC	with	presence	of	IL-3	(5ng/ml)	for	different	time	points.	For	separation	experiment	(Figure	4.5),	transwells	(Costar;	Corning)	with	a	0.4-μm	insert	were	used.	DRG	were	cultured	in	the	lower	chamber,	while	BMMCs	were	added	in	the	insert.	Supernatants	were	collected	and	analyzed	for	mediators’	release.																
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50%	of	Complete	IMDM	
Reagent	
Amount	 Concentration	
IMMD	 10	ml	 50%	
FCS	 1	ml	 10%	
L-Glutamine	with	
Penicillin/Streptomycin	100X	
100	μl	 100	u/ml	
MEM	Vitamin	100X	 100	μl	 1%	
2-mercaptoethanol	 10	μl	 50	μM	
Sodium	pyruvate	100	mM	 100	μl	 1%	
Non-essential	amino	acid	
X100	
100	μl	 1%	
	
50%	Complete	NBA	Reagent		 Amount	 Concentration	
NBA	 10	ml	 50%	
B-27	 200	μl	 2%	
Glutamax	200mM	 100	μl	 2	mM	
Penicillin/Streptomycin	 100	μl	 1	%		
Growth	Factors	Reagent	 Amount	 Concentration	
Mouse	IL-3	10	μg/ml	 10	μl	 5	ng/ml	
Table	2.3.	Contents	of	BMMC-DRG	co-culture	medium	
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2.2	HEK	293	cell	line		
2.2.1	Maintenance	of	HEK	293	cells	Human	embryonic	kidney	(HEK)	293	cells	were	maintained	in	Dulbecco’s	Modified	Eagle’s	Medium	(DMEM,	Sigma	D5796)	supplemented	with	10%	heat-	inactivated	FBS,	1mM	sodium	pyruvate	and	100	μg/ml	streptomycin,	and	100	units/ml	penicillin	at	37°C,	5%	CO2	with	humidity	control.		
2.2.2	Sub-culturing	of	HEK	293	cells	When	HEK	293	cell	monolayer	reached	around	75%	confluence,	flasks	were	sub-cultured.	Confluent	cells	were	washed	with	5	ml	pre-warmed	DMEM	(for	T-25	flasks).	Then,	cells	were	treated	with	1	ml	trypsin-EDTA	(Sigma,	T4049)	for	one	min	at	37°C.	4	ml	pre-warmed	complete	medium	was	added	to	the	flask	to	stop	trypsinization.	The	detached	cells	were	collected	into	15-ml	Falcon	tube.	Cells	were	centrifuged	1000	rpm	for	5	minutes	at	room	temperature.	Pellet	was	resuspended	in	10	ml	DMEM,	and	then	seeded	into	T-25	flasks	at	the	desired	density.	HEK	293	cell	cultures	were	sub-cultured	eight	to	ten	times	before	being	discarded	and	a	new	cryopreserved	cell	aliquot	thawed.		
2.2.3	BMMC-	HEK	co-culture	HEK	cells	were	plated	in	96-well	plate	in	their	medium.	When	HEK	cells	reach	75%-80%	confluence,	media	were	removed	and	mature	BMMCs	were	added	and	co-cultured	in	the	same	way	as	for	BMMC-DRG	co-culture	(see	section	2.1.3).		
2.3	Mediators	secretion	assays	After	co-culturing	BMMC	and	DRG	for	various	time	points,	cells	were	stimulated	either	in	IgE-	dependent	or	IgE	independent	pathways.	After	stimulation,	specific	assay	was	used	for	each	mediator.	
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1. Preformed	mediator	release	and	degranulation:	b-hexosamindase.	2. Newly	transcript	cytokines:	TNFa	and	IL-6	using	enzyme-linked	immunosorbent	assay	(ELISA)	commercial	kits.		
2.3.1	BMMC	stimulation	Two	major	pathways	can	activate	exocytosis	in	mast	cells.	Antigen	(Ag)-	activated	and	non	Ag-activated	pathways.				
2.3.1.1	Ag-activated	BMMC	stimulation	Ag	stimulates	mast	cells	by	aggregation	of	the	high	affinity	receptor	for	IgE	(FcεRΙ).		Thus,	BMMCs	were	incubated	at	1X106	cells/	ml	in	their	complete	culture	medium	with	0.5	μg/ml	of	murine	anti-dinitrophenol	(DNP)	IgE	(Sigma,	D8406,	clone	SPE-7)	at	37°C	and	7.5%	CO2	overnight.	Next	day,	cells	were	transferred	to	15-ml	falcon	tube,	centrifuged	340xg	for	5	min	and	washed	twice	with	complete	IMDM	or	co-culture	medium,	depend	on	the	experiment,	to	wash	excess	IgE.	After	last	wash,	cells	were	resuspended	with	90	μl/	well	and	added	to	96	well-plate	and	allowed	to	equilibrate	at	37oC	before	stimulation.		In	case	of	studying	BMMC	activation	in	co-culture,	BMMC	added	to	1-day-old	DRG	culture	and	co-cultured	for	specific	time	2,	6,	or	24	hours.	To	stimulate	BMMC	with	DNP	Ag	(Sigma,	A6661),	10μl	of	10X	DNP	Ag	diluted	in	same	culture	medium	was	added.	Final	concentration	of	DNP	was	from	(0-10-30-100-300	ng/ml).	To	measure	spontaneous	release	(which	will	be	referred	by	constitutive/	Ag-independent	degranulation	throughout	this	thesis),	10μl	of	only	medium	was	added	to	control	wells.	Cells	were	challenged	for	various	period	of	time	in	37°C	depend	on	mediators	wanted	to	measure.		
2.3.1.2	Non-Ag-	activated	BMMC	stimulation	As	mentioned	in	introduction	(section	1.1.2.2),	some	compounds	trigger	mast	cell	exocytosis	by	directly	act	on	G	proteins	such	as	amine	compound	48/80	(c48/80).	
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Compound	48/80	BMMCs	were	challenged	with	different	concentration	of	c48/80	ranging	from	(10-100	μg/ml)	for	30	minutes	at	37°C	before	collecting	supernatants.	Supernatants	were	used	to	measure	β-Hexonaminidase	(β-Hex)	(See	2.3.3.1).	The	dose	response	curve	(Figure	2.2)	showed	that	EC50	was	30μg/ml.	Thus,	we	used	this	submaxium	concentration	in	subsequent	experiments.		
	 	
Figure.	2.2.	Log	dose-response	curve	of	Compound	48/80.	Percentage	of	BMMC	degranulation	upon	stimulation	with	different	concentration	of	c48/80	(10,	30	and	100	μg/ml).	
2.3.2	DRG	stimulation		For	mediator	secretion	assay,	nociceptive	neurons	in	coculture	were	stimulated	with	1	
µM	of		capsaicin	(Sigma,	12084).			
2.3.3	Measuring	of	mast	cell	degranulation	by	β-hexosaminidase	release	
assay		β-Hexonaminidase	(β-Hex)	is	lysosomal	associated	enzyme	that	is	secreted	into	cell	supernatants	upon	mast	cell	degranulation.	β-Hex	enzyme	activity	can	be	monitored	by	using	4-Nitrophenyl	N-acetyl-β-D-glucosaminide	as	substrate.	β-Hex	convert	4-Nitrophenyl	N-acetyl-β-D-glucosaminide	to	4-nitrophenol	that	can	measured	at	absorbance	of	405nm	using	spectroscopy	(Wendeler	and	Sandhoff,	2009).	
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	For	optimization	β-Hex	assay	in	respect	of	BMMCs	cell	numbers,	the	absorbance	reading	from	lysates	of	different	cell	number	of	BMMCs	were	compared	(Figure	2.3).	On	my	hand,	the	assay	was	unable	to	detect	B-Hex	amount	from	cell	culture	with	less	than	1X105	BMMCs.	Thu,	2.5X105	BMMCs/	well	were	used	for	all	subsequent	β-Hex	experiments.		2.5X105	BMMCs/well	were	stimulated	with	indicated	agonists	(or	medium	for	spontaneous	release)	for	30	minute	in	37°C.	Then,	plate	was	centrifuged	at	340xg	for	5	min	at	4ºC	and	50μL	of	supernatant	were	transferred	to	a	96-	well	plate	and	incubated	with	50μl	of	2mM	of	substrate	solution	4-Nitrophenyl	N-acetyl-β-D-glucosaminide	(Sigma,	N-9376)	diluted	in	0.2	M	citrate	buffer	(PH	4.5)	(Table	2.4)	for	2	hours	at	37	°C.	The	total	β-Hex	value	was	determined	by	lysis	the	cell	pellet	(from	each	well)	with	0.5%	triton-	X	100	in	medium	for	10	minutes	at	room	temperature.	Then,	the	plate	spun	again	and	50μL	of	lysate	was	transferred	to	another	substrate	plate	and	incubate	for	2	hours	as	the	same	manner	as	supernatant	plate.	The	reaction	was	stopped	by	adding	90μl	of	1M	Trizma-HCl	(sigma,	T3253)	buffer	(pH	9.0).	The	absorbance	of	the	mixture	was	measured	at	405	nm	using	a	microplate	reader	(Optima).		Background	absorbance	readings	(b)	were	determined	from	wells	containing	all	buffers	except	supernatant.	Experiments	were	carried	out	in	duplicate	in	a	single	experiment	and	each	experiment	was	repeated	at	least	with	3	cultures.		The	β-Hex	activity	was	calculated	using	the	following	formula:	degranulation	(%)	=	
((supernatant	-b)/(Total-b))	x100.		
Fold	change	of	enhancement	in	degranulation	was	calculated	by	dividing	the	percentage	of	
degranulation	in	tested	condition	to	the	percentage	of	degranulation	in	control	condition.	Results	are	displayed	as	mean	±SEM.	Significance	was	assessed	using	paired	two-tailed	
t-test.			
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Reagent		 Amount	 Concentration	 Supplier	
Citric	acid	 2.34g	 0.2M	 Sigma,	C1909	
Na	Citrate	 2.588g	 0.2M	 BDH	301284C	
Autoclaved	ddH2O	 100	ml	 	 	
pH	 4.5	 	 	
Store	at	room	temperature	
Table	2.4.	Recipe	of	citrate	buffer	
	
Figure.	2.3.	Correlation	between	B-hex	absorbance	and	number	of	BMMCs.		For	optimization	of	B-Hex	assay,	different	cell	number	of	BMMCs	were	lysed	with	0.5%	tritonX100	and	supernatants	were	collected.			
2.3.4	Measuring	cytokines	release	by	ELISA	(IL-6,	and	TNFα)	IL-6,	 and	 TNFα	 are	 cytokines	 important	 for	 both	 homeostatic	 and	 inflammatory	functions	 of	 mast	 cells.	 To	 prepare	 lysate	 for	 the	 assay,	 1X105	 BMMCs/well	 were	stimulated	with	DNP	for	6	hours	in	37°C.	Then,	cell	suspension	was	transferred	to	1.5	ml	
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Eppendorf	 tubes	 and	 spun	 at	 5000xg	 for	 2	 min	 at	 4ºC.	 Supernatants	 were	 carefully	collected	 and	 transferred	 to	 new	 tubes	 and	 stored	 at	 -20	 ºC.	 Then	 ELISAs	 were	performed	 according	 to	 the	 manufacturerʼs	 protocol	 (see	 Table	 2.5	 for	 kit	 numbers).	Briefly,	50μl	of	assay	diluent	was	added	to	required	number	of	pre-coated	wells.	Then,	50μl	 of	 the	 samples	 and	 standards	 was	 added	 and	 incubated	 for	 2	 hours	 at	 room	temperature.	After	5	times	washing,	100	μl	of	specific	conjugate	was	added	to	each	well	and	incubated	for	2	hours	at	room	temperature.	After	another	5	times	washing,	100	μl	of	substrate	 solution	was	 added	 to	 each	well	 and	 incubated	 for	 30	minutes	 (in	 dark)	 at	room	 temperature.	 Finally,	 reaction	was	 stopped	 by	 adding	 100μl	 of	 stop	 solution	 to	each	well	 and	 absorbances	 determined	 using	OPTIMA	 plate	 reader	 set	 to	 450nm	 and	corrected	wavelength	540nm.			Sample	 concentrations	 were	 determined	 from	 the	 standard	 curve.	 Samples	 and	standards	were	performed	in	duplicate	and	each	experiment	was	repeated	3	times.	The	serial	dilutions	from	the	standard	were	prepared	from	1000pg/ml	to	7.8pg/ml,	then	the		standard	 curve	 was	 constructed.	 The	 mean	 absorbance	 for	 each	 standard	 against	concentration	 were	 plotted	 on	 the	 y-axis	 and	 x-axis,	 respectively.	 Then,	 sample	concentration		could	be	detriments	from	the	curve.	Results	are	displayed	as	mean	±SEM.	Significance	was	assessed	using	two-tailed	paired	t-test.			
Cytokine	 Supplier	 Cat.no.	
IL-6	 R&D	 M6000B	
TNFα	 R&D	 MTA00B	
Table	2.5.	Cytokines	ELISA	kits		
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2.4	Flurometric	Calcein-	adhesion	assay	Calcein-AM	(Vybrant	Cell	Adhesion	Assay	Kit	(V13181),	Invitrogen,	Life	Technologies)	is	nonfluorescent	lipophilic	dye.	Once	entered	into	cells,	it	is	cleaved	by	endogenous	esterases	to	calcein,	a	highly	green	fluorescent	and	well-retained	dye.	It	is	considered	as	a	viability	maker	because	it	is	quenched	upon	loss	of	cell	viability	(Lichtenfels	et	al.,	1994).		
2.4.1	BMMCs	labelling	with	Calcein-AM	1X106	BMMCs/	ml	of	serum-free	medium	were	labelled	with	5µM	Calcein-AM	for	30	minutes	at	37	°C	and	carefully	washed	three	times	with	pre-warmed	medium.	After	washing,	cell	pellet	was	resuspend	at	density	of	1X105	BMMCs/	100µl/	well	and	used	for	subsequent	experiments.			
2.4.2	BMMC	–DRG	adhesion	assay	BMMC	–DRG	adhesion	assays	were	performed	as	shown	in	(Figure	2.4).	DRG	culture	was	seeded	at	density	of	1.5X103	cells/	well	in	matrigel-coated	96-well	plates	and	incubated	for	1	day.	Next	day,	1X106	BMMCs/	ml	of	serum-free	medium	/	well	were	labelled	with	5µM	Calcein-AM	(Invitrogen,	Life	Technologies)	for	30	minutes	at	37	°C	and	carefully	washed	three	times	with	pre-wormed	medium.	Subsequently,	calcein-	labelled	BMMCs	were	resuspended	with	co-culture	medium	at	density	of	1X105	BMMCs/	100µl/	well	and	co-culture	with	DRG	for	2	hours.	Unattached	BMMCs	were	washed	out	by	spinning	the	plate	upside	down	at	20xg	for	2	minutes.	Wells	were	filled	up	with	co-culture	medium	again.	The	fluorescent	signal	was	measured	by	plate	reader	before	and	after	washing	step	for	total	and	attached	readings,	respectively.	Calcein	excitation	wavelength	used	is	485	nm	and	emission	wavelength	is	520	nm.	experiments	were	run	in	duplication.	Background	fluorescence	from	DRG	only	wells	was	subtracted.	Adhesion	was	presented	as	percentages	of	adherent	BMMCs	to	total.	For	comparison	control,	calcein-labeled	
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BMMCs	were	seeded	on	1-day	old	matrigel	coated	wells	in	same	co-culture	medium	and	for	the	same	time	like	the	ones	with	DRG	co-culture.		When	CADM1	blocking	peptide	was	used,	calcein	labeled	BMMCs	or	DRG	were	pre-incubated	for	30	minutes	prior	to	co-culture	with	1-30	µg/ml	of	recommended	protein	against	extracellular	domain	of	CADM1.This	functional	blocker	is	fused	with	human	IgG	FC	(9D2,	Medical	&	Biological	Laboratories).	Peptide	incubation	period	is	followed	by	co-culture	step	without	washing	the	peptide.	All	experiments	were	repeated	at	least	three	times.	
		
Figure.	2.4.	calcein	adhesion	assay.			Calcein-labeled	BMMCs	were	co-culture	with	1-day	old	DRG	for	2	hours.	un-attached	BMMCs	were	removed	by	spinning	plate	upside	down	(20xg)	for	2	minutes.	Calcein	fluorescence	was	detected	with	excitation	wavelength	of	485	nm	and	emission	wavelength	520	nm	by	plate	reader.	
By	spinning	plate	upside	down	
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2.4.3	BMMC	–HEK	adhesion	assay	BMMC	–HEK	adhesion	assay	was	performed	in	the	same	way	as	for	BMMC-DRG	adhesion	assay	except	for	the	step	of	removal	of	non-adherent	BMMCs.	Because	HEK	cells	are	more	delicate	than	neurons,	using	spinning	method	to	remove	non-attached	BMMCs	results	in	removing	HEK	cells	as	well.	Thus,	we	removed	non-attached	BMMCs	from	BMMC-HEK	cells	co-culture	by	gently	washing	with	200	µl	of	PBS	and	filliping	the	plate	for	3	times.			
2.5	Techniques	to	study	protein	expression	
2.5.1	Flowcytometry		BMMC	surface	protein	expression	was	examined	using	flow	cytometry.	1X106	BMMCs/	sample	were	used.	BMMCs	were	washed	two	times	with	cold	PBS,	at	340g	for	5	min.	Cells	were	resuspended	in	cold	FACS	buffer	in	concentration	of	1X106	cells	/	100	μl/	sample.	All	following	procedures	were	carried	out	on	ice	and	all	antibodies	were	diluted	in	FACS	buffer	(2	mMol	EDTA	in	PBS	with	2%	FBS).	BMMCs	were	blocked	with	1:100	of	Fc	Block	(CD16/32)	(eBioscience)	for	15	minutes	on	ice	to	prevent	non-specific	binding	of	antibodies.	After	washing	with	FACS	buffer	twice,	BMMCs	were	incubated	with	the	optimal	concentrations	of	conjugated	antibodies	for	20	minutes	on	ice	(Table	2.6	for	list	of	antibodies).	Next,	BMMCs	were	washed	with	0.5	ml	of	FACS	buffer	twice	and	spun	at	340xg	for	2	minutes	at	4°C	in	between.	After	spinning,	cell	pellet	was	resuspended	with	300	μl	of	FACS	buffer/	tube.	Fluorescence	was	detected	with	FACSCalibur	(BD	Biosciences)	at	emission	wavelengths	of	488	nm	for	Alexa	Fluor®	488	labeled	samples,	660	nm	for	APC	labeled	samples	or	585	nm	for	PE	labeled	samples.	For	analysis,	the	viability	was	first	gated	based	on	side	scatter	and	electronic	volume	from	unstained	sample.	Only	viable	cells	from	gated	population	were	included	in	fluorescence	measurements.			
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For	CADM1	intracellular	expression,	BMMCs	were	fixed	and	permeablized	before	staining	with	antibodies.	To	do	so,	cells	were	fixed	in	4%	paraformaldehyde	(PFA)	in	PBS	(pH	7.4)	for	20	minutes	at	4oC.	Then,	permeablized	with	0.1%	tritonX100	for	10	minutes.			All	antibodies	used	for	flow	cytometry	experiments	were	conjugated	except	CADM1.	Thus,	indirect	immunofluorescence	staining	was	performed.	Alexa	flour	@488	anti-rabbit	(Invetrogen)	is	used	as	secondary	antibody.	For	all	experiments,	two	markers	were	measured	simultaneously	in	the	same	samples.	One	of	them	was	c-kit	as	a	specific	marker	for	BMMCs.	All	experiments	were	repeated	3	times.		
FACS	antibodies	 Dilution	 Supplier	
APC-anti-	mouse	c-Kit	(CD117)	 1:100	 eBioscience	(17-1171)	
PE-	anti-mouse	FCeRI	 1:100	 eBioscience	(12-5898)	
Rabbit	anti-CADM1	
Polyclonal	IgG	(H-300)	
1:100	 Santa	Cruz	sc-33198	lot	F0407	
Alexa	Fluor@	488	donkey	anti-rabbit	 1:1000	 Invitrogen	A-21206	
Table	2.6.	FACS	antibodies		
2.5.2	Immunocytochemistry	
2.5.2.1	BMMC	seeding	BMMC	were	seeded	on	matrigel-coated	glass	coverslip	16mm	(see	2.1.2.1	for	matrigel	coating).		But,	because	BMMCs	are	difficult	to	adherent	to	glass	coveslip,	the	dilution	of	matrigel	used	for	BMMC	seeding	was	(1:3).	After	coating	the	well	with	matrigel,	BMMC	cultured	for	4-6	weeks	were	counted	(2X	103	cells/	well),	washed	and	resuspended	in	50μl/	well	of	complete	IMDM.	50μl	of	BMMCs	were	loaded	in	the	middle	of	each	well.	
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Plate	was	incubated	for	30	min	then	wells	were	flooded	with	complete	IMDM	and	incubated	for	further	1-2	hours	to	ensure	BMMC	were	well	attached.		
2.5.2.2	BMMC,	DRG	and	co-culture	immunocytochemical	staining	Seeded	BMMC	and	DRG	on	wells	were	washed	with	PBS	twice.	Then,	fixed	with	4%	PFA	for	10	minutes.	To	enhance	the	permeability,	cells	were	incubated	with	0.1%	tritonX100	in	PBS	for	10	minutes.	Then,	incubate	for	1	hour	with	blocking	buffer	(2%	normal	donkey	serum	(sigma),	0.2%	Fish	serum	gelatine	(FSG)	Sigma,	G7765)	and	0.01%	TritonX100)	in	PBS).	After	that,	cells	were	stained	with	primary	antibodies	with	specific	concentration	(see	table	2.7	for	complete	list	of	primary	antibodies)	and	incubated	for	overnight	at	4°C.	On	next	day,	dishes	were	washed	3	times	with	blocking	buffer.	Each	time	for	5	minutes.	Then,	cells	were	stained	with	secondary	antibodies	with	specific	concentration	(see	table	2.7	for	complete	list	of	secondary	antibodies)	for	2	hours	in	dark	at	room	temperature.	After	time,	dishes	were	washed	3	times	(each	time	5	minutes)	with	PBS	and	one	time	with	dH2O.	Glass	coverslips	were	mounted	onto	microscope	slides	using	mounding	medium	(Vectashield	Hard	set	H1500,	Vector)	with	4',6-diamidino-2-phenylindole	(DAPI)	to	stain	the	nucleus.	For	negative	control,	some	wells	were	stained	with	only	secondary	antibodies.		
For	surface	staining:	After	washing	cells	with	cold	PBS,	primary	antibody	was	added	slowly	to	the	living	cells	in	cold	PBS,	and	incubated	for	30	minutes	at	4	oC	to	prevent	endocytosis	of	any	added	antibody.	Then,	dishes	were	washed	3	times	with	cold	blocking	buffer	(without	tritonX100).	Each	time	for	5	min.	Then,	cells	were	stained	with	secondary	antibodies	for	2	hours	in	dark	at	room	temperature	on	ice.	After	washing	the	wells	3	times	with	cold	PBS,	cells	were	fixed	with	4%	PFA	at	room	temperature	for	15	minutes.	After	that,	coverslips	were	mounted	as	above.				
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Primary	Antibodies	 Dilution	 Supplier	
Rabbit	anti-periphrin	 1:1000	 Sigma	P5117	
Guinea	pig	anti-SubP	 1:100	 Abcam	ab10353	
Mouse	anti-CGRP	 1:100	 Abcam	Ab81887	
Mouse	anti-B	III	Tubulin	monoclonal	IgG	 1:1000	 R&D	MAB1195	clone	TuJ-1	lot	HGQ0113121	
Rabbit	Anti-CADM1	
Polyclonal	IgG	(H-300)	
1:300	 Santa	Cruz	sc-33198	lot	F0407	
Mouse	anti-Tryptase	 1:300	 Abcam	ab2378	
Goat	anti	FcεRIγ	
(A-18)	polyclonal	IgG	
1:300	 Santa	Cruz	(sc-33496	lot:	I2811)	
Alexa	Fluor@	488	anti-mouse		c-Kit	 1:100	 Biolegend	(6861)		
Secondary	Antibodies		 Dilution	 Supplier	
Alexa	Fluor®	488	donkey	anti-rabbit	 1:1000	 Invitrogen	A-21206	
Alexa	Fluor®	594	donkey	anti-mouse		 1:1000	 Invitrogen	A-21203	
FITC-donkey	anti-guinea	pig		 1:100	 Millipore		
Alexa	Flour®	647	chicken	anti-goat	IgG	 1:500	 Invitrogen	A21449	lot	1700331	
Table	2.7	Antibodies	List			
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2.5.2.3	Fluorescence	and	Confocal	microscopy		Images	were	viewed	using	a	40X	and	60X	oil	objective	(N.A.	1.42)	on	Nikon	A1	TIRF	confocal	microscope.	Samples	were	illuminated	at	the	required	wavelength	using	405nm,	488nm,	561nm	lasers.		Stacks	of	0.5	µm	thickness	(z	–	axis)	were	collected	for	each	cell	studied.		
2.5.2.4	Image	Analysis	3	coverslips	were	prepared	for	each	condition.	At	least	4	fields	with	X20	or	X40	magnification	from	each	coverslip	were	captured.	Experiments	were	repeated	at	least	three	times	using	cultures	prepared	from	different	animals.	Each	experiment	was	designated	as	an	“N”	of	one	and	“n”	represents	number	of	total	cells.	Images	were	analyzed	using	Fiji-Image	J	(Schneider	et	al.,	2012).			
Neurons	subtype	quantifications:		Specific	subtype	immunoreactive	cells	were	counted	manually	using	cell	counter	plugin.	Only	neurons	with	a	visible	nucleus	that	were	not	touching	the	edge	of	the	image	were	counted.		
Neuronal	morphology:		To	calculate	soma	diameter,	area	and	neurite	length,	DRG	cultures	were	stained	with	anti-b	III	Tubulin	antibody	to	identified	neurons	and	neurites.	Soma	diameter	was	calculated	by	measuring	the	largest	axes	containing	the	nucleus.	Soma	area	was	calculated	by	measuring	the	area	of	region	of	interest	that	was	selected	using	the	freehand	selections	tool	around	the	edge	of	each	soma.	Neurite	length	was	defined	as	the	length	of	neurites	that	are	initiated	from	one	neuron.	To	quantified	neurite	length,	first	neurites	were	traced	by	simple	neurite	tracer	plugin	(Image	J)	for	all	neurons	in	the	field	to	generate	total	neurite	length	(in	µm).	Then,	total	neurites	length	was	divided	over	the	number	of	neurons	in	the	field	(Longair	et	al.,	2011).	Neurites	complexity	was	assessed	using	Sholl	analysis	plugin	(Fiji-ImageJ)	that	calculated	number	of	neurite	crossing	points	of	a	concentric	circle	set	with	radii	increasing	by	20μm	(Stanko	et	al.,	2015).	
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Fluorescence	intensities	plots	were	generated	in	Fiji	using	RGB	profiler	plugin.	(http://rsb.info.nih.gov/ij/plugins/rgb-profiler.html).	After	merging	of	two	different	channel	images,	line	was	drawn	across	cell	of	interest.	Then,	RGB	profiler	plugin	was	lunched.	
For	co-localization	quantification,	Coloc	2	plugin	(Fiji)	was	used.	After	select	region	of	interest	(ROI)	from	2	color	channel	images,	Coloc	2	plugin	was	lunched.	Colocalization	significance	was	judged	based	on	calculated	Pearson’s	R	coefficients.	R=1	indicates	a	perfect	colocalization	and	R=0	a	complete	exclusion.	
To	calculate	surface	FceRI	mean	fluoresce	intensities	(MFI),	particle	analysis	function	from	Fiji	software	was	used.	First,	background	was	subtracted	and	threshold	was	adjusted	before	MFI	plugin	was	used.			
2.5.3	Western	blot	One	way	of	protein	detection	in	cells	is	by	western	blotting.	It	consists	of	gel	electrophoresis,	a	way	to	separate	proteins	based	on	their	molecular	sizes.	Then,	proteins	are	transferred	onto	a	membrane	and	incubated	with	antibodies	to	allow	the	protein	detection.	Finally,	protein	detection	is	visualized	using	chemiluminescent	or	fluorescent	techniques.	All	immunoblots	presented	throughout	this	thesis	have	been	repeated	at	least	3	times.	Representative	examples	are	shown	in	figures.		
2.5.3.1	Preparing	cell	lysis	For	BMMCs	and	HEK	cells,	1X106	of	4-	week	old	BMMCs	and	80%	confluent	HEK	cells	were	washed	twice	with	2	ml	of	cold	PBS	then	resuspended	with	200	µl	of	cold	lysis	buffer	(50mM	Tris-HCl,	150mM	NaCl,	0.3%	TritonX100,	PH	8)	with	1%	of	protease	inhibitor	cocktail	III	(PIC	)	(Fisher	Scientific).	Whereas,	DRGs	were	isolated	and	all	cells	were	cultured	in	one	well	for	24	hours	to	allow	for	neurite	outgrowth.	Next	day,	cultures	were	washed	twice	with	cold	PBS.	Then	100	µl	of	cold	in	lysis	buffer	and	PIC		added	and	adherent	cells	were	scalped	by	cold	plastic	cells	scraper.	Then	cell	suspension	was	collected	into	0.5ml-eppendorf	tube.	Lysates	from	BMMC,	HEK	cells	and	DRG	were	
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incubated	with	lysis	buffer	and	PIC	for	one	hour	at	4oC	with	rotation.	The	insoluble	debris	was	removed	by	spinning	at	14,000	g	for	20	minutes	at	4oC.	Supernatants	were	aliquot	in	new	tubes	(10	µl	each)	and	stored	at	-80oC	or	proceed	to	Bradford	assay.			
	
2.5.3.2	Determination	of	protein	concentration		The	protein	concentration	of	each	lysate	was	measured	before	use	it	to	obtain	the	same	amount	of	each	sample.	To	do	so,	Bradford	protein	assay	was	used.	The	color	of	Bradford	dye	is	changed	differently	in	response	to	varying	protein	concentrations.	Protein	concentrations	for	samples	were	calculated	from	a	standard	curve	based	on		bovine	serum	albumin	(BSA)	standard	(Sigma).	Eight	serial	dilutions	of	BSA	(1mg/ml)	were	prepared.	5	μl	of	diluted	lysate	or	BSA	was	added	to	the	middle	of	96	well	plate.	Then	250	µl	Bradford	reagents	(Sigma)	was	added.	the	absorbance	measured	at	595	nm	with	plate	reader.	BSA	standard	absorbance	values	were	exported	into	Prism	Graphpad	and	plotted	against	its	different	concentration.	Samples	concentrations	were	calculated	from	the	curve	then	multiply	by	its	dilution	factor	to	give	the	protein	concentration	in	mg/ml.			
2.5.3.3	Sodium	dodecyl	sulphate-polyacrylamide	gel	electrophoresis	(SDS-PAGE)		The	resolving	and	stacking	acrylamide	gels	(Proto	gel,	National	diagnostic)	were	made	as	described	in	(Table	2.8	and	2.9),	respectively.	For	separation	of	CADM1	protein,	10%	resolving	gel	was	used.	After	cleaning	the	glass	plates	with	ethanol	and	assembly,	the	resolving	gel	was	loaded	between	the	glass	plates.	Water	was	added	to	top	of	the	gel	to	flatten	the	gel.	Once	the	resolving	gel	set,	water	was	removed	and	the	stacking	gel	was	added	with	the	comb	in	place.	Once	the	stacking	gel	set,	the	glass	plates	were	transferred	to	running	unit	(Biorad)	and	ensure	its	assembly	with	the	smaller	plate	inside.	Then,	the	comb	was	removed	carefully	and	the	running	buffer	(Table	2.10)	was	added	slowly.	5-7	
µl	of	Pre-Stained	ladder	marker	(Fisher	Scientific)	was	loaded	into	the	first	well.	Equal	amount	of	protein	(5-10	µg/lane)	was	added	to	4X	Lameli	loading	buffer	(Sigma)	and	boiled	for	5	minutes	at	95oC	to	denature	the	proteins.	Then,	samples	were	carefully	loaded	into	the	wells	of	the	stacking	gel	using	loading	tips.	The	gel	was	run	at	a	constant	
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voltage	of	75V	till	the	ladder	was	showed	up	then	the	voltage	increased	to	100V	for	2	hours	at	room	temperature.				
Resolving	Gel	 10%	Water	 4.1	ml	Tris	pH	8.8	 2.5	ml	30%	Acrylamide	 3.3	ml	10%	sodium	dodecyl	sulphate	(SDS)	 100	µl	10%		Ammonium	Persulfate	(APS)	 50	µl	Tetramethylethylenediamine	(TEMED)	 10	µl	
Table	2.8	Resolving	gel		
Stacking	Gel	 4%	Water	 6.1	ml	Tris	pH	6.8	 2.5	ml	Acrylamide	 1.3	ml	10%	sodium	dodecyl	sulphate	(SDS)	 100	µl	10%		Ammonium	Persulfate	(APS)	 50	µl	Tetramethylethylenediamine	(TEMED)	 10	µl	
Table	2.9	Stacking	gel				
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10X	Running	Buffer	 Final	Concentration	 Calculated	weight	
Tris	 250mM	 30.3g	
Glycine	 2M	 144g	
sodium	dodecyl	sulphate	(SDS)	 0.1%	 10g	
Water	 	 1L	
	 pH	8.3	store	@4oC	 	
To	make	1L	of	1X:	100ml	of	10X	was	topped	up	to	1	L	with	water	
Table	2.10.	Running	buffer		
2.5.3.4	Electroblotting		Before	the	running	is	finished,	1L	of	1X	transfer	buffer	was	prepared	(Table	2.11).	Nitrocellulose	transfer	membrane	(Biorad)	was	soaked	in	transfer	buffer	along	with	sponges	and	filter	papers.	Once	the	transfer	had	finished,	the	gel	was	removed	carefully	from	the	glass	and	rinsed	in	transfer	buffer.	Transfer	holder	was	placed	black	side	on	the	bench	and	transfer	sandwich	was	constructed	in	following	order	downside	up:	sponge-filter	paper-gel-membrane-filter	paper-sponge	attention	was	taken	to	minimize	air	bubbles	in	each	layer.	the	holder	was	then	secured	and	inserted	(black	side	of	the	holder	to	the	black	side	of	the	tank)	into	the	transfer	tank	with	ice	block.	The	tank	then	topped	up	slowly	with	transfer	buffer.	Transfer	was	performed	at	85V	for	90	minutes	at	4oC	(protein	of	interest	110kDa).			
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10X	Transfer	Buffer	 Final	Concentration	 Calculated	weight	
Tris	 250mM	 30.3g	
Glycine	 2M	 144	g	
Water	 	 1L	
To	make	1L	of	1X:	100ml	of	10X	and	100ml	of	methanol	were	topped	up		to	1	L	with	water	
Table	2.11	transfer	buffer		Meanwhile,	5%	milk	blocking	buffer	in	TBST	(Table	2.12)	was	prepared.	Complete	dissolving	of	milk	was	ensured.	After	finishing	the	transfer,	the	membrane	was	incubated	for	1	hour	with	5%	milk	blocking	buffer	on	an	orbital	shaker.	Then,	the	membrane	was	transferred	to	plastic	wallet.	The	appropriate	concentration	of	primary	antibodies	were	prepared	in	milk	blocking	buffer	(see	table	2.13	for	list	of	antibodies).	2ml	of	diluted	primary	antibodies	was	pipetted	into	the	wallet	and	the	wallet	was	sealed.	The	membrane	was	incubated	with	primary	antibodies	overnight	at	4oC	on	an	orbital	shaker.	The	following	day,	the	membrane	was	washed	with	TBST	for	3	times.	Each	time	was	for	10	minutes	on	orbital	shaker.	Then,	the	membrane	transferred	to	plastic	wallet	again	and	incubated	with	diluted	secondary	antibodies	in	5%	milk	for	2	hours	(see	table	2.13	for	list	of	antibodies).	In	case	of	using	Li-cor	system,	the	following	steps	were	carried	out	in	dark.	The	membrane	washed	again	with	TBST	in	the	same	way	like	for	primary	Abs.	For	Licor	system,	the	membrane	was	allowed	to	dry	then	the	fluorescent	signals	were	detected	immediately.	For	chemiluminescent,	the	membrane	was	wrapped	in	cling	film	in	cassette.	ECL	Western	Blotting	Detection	Reagents	(ThermoScientific)	was	used	for	1-3	minutes	to	develop	the	membrane.	Then,	it	exposed	to	X-ray	films	(Fuji)	and	developed	using	x-ray	developer.		
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10X	TBS	Buffer	 Final	Concentration	 Calculated	weight	
Tris	 200mM	 24.3g	
NaCl	 1.37M	 80g	
Water	 	 1L	
	 pH	7.4	 	
To	make	1L	of	1X:	100ml	of	10X	was	topped	up	to	1	L	with	water.		then,	0.1%	tween	20	was	added	
Table	2.12	TBST	buffer		
Table2.13.	List	of	Antibodies	used	in	western	blot	
	
	
Antibody	 Concentration	 Supplier	
Mouse	anti-mouse	GAPDH	 1:5000	 Fisher	Thermo	
Mouse	anti-mouse	a-Tubulin	 1:5000	 Sigma	
Rabbit	anti-mouse	CADM1	 1:300	 Santa	Cruz	
HRP-	conjugated	Goat-	anti	Rabbit	IgG	 1:2000	 Sigma	
HRP-	conjugated	Goat	anti-mouse	IgG	 1:2000	 Sigma	
Goat	IRDye	800	anti-Rabbit	 1:5000	 Licor	
Goat	IRDye	700	anti-Mouse	 1:5000	 Licor	
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2.6	Calcium	imaging	Fluorescent	calcium	imaging	was	used	to	quantify	changes	in	intracellular	calcium	after	activation.	In	this	study,	Fura-2	AM	was	used	as	a	ratiometric	calcium	indicators.	The	excited	advantage	of	ratiometric	indicators	is	that	they	reduce	the	problems	of	photobleaching,	uneven	dye	loading	(Paredes	et	al.,	2008).	The	peak	absorbance	of	not	bounded	Fura-2	is	380nm.	When	it	bounds	to	Ca+2,	its	absorbance	shifts	to	340nm.	This	shift	can	be	observed	by	measuring	emission	at	510nm.	Therefore,	using	the	ratio	of	340/380	provides	an	accurate	measurement	of	intracellular	calcium	regardless	to	the	concentration	of	Fura-2	inside	the	cell.	Moreover,	to	prevent	the	leakage	commonly	associated	with	fluorescent	indicators,	Fura-2	AM	(acetoxy-methyl)	was	used.	Form	with	AM	group	is	membrane	permeable.	This	allows	for	the	fluorescent	dye	to	enter	and	trapped	into	the	cells.	The	intracellular	non-specific	esterases	cleave	off	the	acetoxy-methyl	groups	(AM)	and	convert	the	dye	to	the	free	lipophobic	pentacarboxylic	Fura-2	form	that	is	membrane	impermeable.	All	together	allows	accurate	measurement	of	intracellular	calcium.		
2.6.1	Loading	of	cells	with	Fura-2	AM	Cultures	were	seeded	on	16-mm	glass	coverslips.	Coverslips	were	incubated	with	2.5	µM	Fura-2AM	(frozen	aliquotes	of	1mM	made	up	in	Dimethyl	sulphoxide	(DMSO))	(Invitrogen)	in	medium	for	45	minutes	in	7.5%	CO2	at	37oC.	Then	the	cells	were	washed	with	medium	for	15	minutes	in	7.5%	CO2	at	37oC,	followed	by	15-minute	wash	with	external	solution	at	room	temperature.	Coverslips	were	protected	from	light	at	all	stages.				
2.6.2	Experimental	set	up	and	image	acquisition		Coverslips	were	placed	into	a	recording	chamber	(bath	dimensions	(LxWxH)	24x13x4.1mm,	volume	by	depth	133µl/mm)	(RC-25F,	Warner	instruments).	Coverslips	were	mounted	onto	an	inverted	fluorescent	microscope	(Axiovert	S100	TV,	Zeiss)	and	
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viewed	using	a	40X	oil	immersion	objective	(NA	1.3,	Zeiss).	The	external	solution	was	perfused	to	recording	chamber	from	a	reservoir	bottle	at	constant	rate.	Syringes	on	a	perfusion	rack	were	used	to	apply	drugs	when	required.	The	outflow	from	the	recording	chamber	was	connected	to	a	length	of	silicone	tubing,	with	a	suction	pump	(Watson	Marlow	SciQ	323)	to	draw	the	fluid	into	a	waste	bottle.	To	ensure	carrying	out	the	experiments	at	37oC,	tubes	containing	solutions	were	passed	through	a	heating	block	before	application	to	cells,	and	a	thermometer	was	placed	in	the	perfusion	chamber	to	check	bath	temperature.			Labeled	cells	were	alternately	illuminated	at	340	and	380nm	using	a	monochromator	(Polychrome	IV,	TILL	Photonice	LPS-150).	The	emitted	light	was	passed	through	a	510	nm	filter	and	detected	by	CCD	camera	(Roper	scientific,	Photometrics).	Images	were	analysed	by	regions	of	interest	being	placed	around	individual	cells	and	acquired	using	Metamorph®	software	(Meta	Imaging).	The	data	were	further	analysed	and	graphed	using	Prism	(GraphPAD	software).	The	background	fluorescence	was	subtracted	from	the	fluorescence	value	for	each	wavelength.	Then,	the	ratio	of	(340/380)	was	calculated	using	Microsoft	excel.	Dchange	was	also	calculated	using	this	formula	(The	maximum	of	ratio	340/380	in	the	presence	of	stimulant)	–	(the	mean	of	5	frames	of	ratio	340/380	prior	to	stimulant	application).			In	DRG	silence	experiments	(Section	6.2.4),	different	system	was	used.	Experiments	were	carried	on	using	an	inverted	microscope	(Olympus,	IMT-2)	and	a	40X	oil	immersion	objective	(Olympus,	160/-,	DPlanApo40UVPL).		All	recordings	were	performed	at	room	temperature	and	a	thermometer	was	placed	next	to	the	recording	rig	to	monitor	the	room	temperature	at	all	times.	Cells	were	alternately	illuminated	at	2	second	intervals	at	350	and	380nm	using	a	Cairn	Dual	OptoLED	light	source.	Images	were	acquired	using	Simple	PCI	6	software.	The	ratio	of	(350/380)	was	also	calculated	by	the	software.		
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2.6.3	Imaging	solution	10mM	Hepes	(pH	7.4),	142mM	NaCl,	5mM	NaHCO3,	16mM	Glucose,	2mM	KCl,	1mM	MgCl2	and	2mM	CaCl2,	0.1%	BSA.		
2.6.4	Stimulants	used	for	calcium	imaging	Pre-sensitized	BMMCs	were	stimulated	with	100	ng/ml	DNP	(Sigma,	A6661).	While,	neurons	were	stimulated	with	either	capsaicin	(Sigma,	12084)	or	high-potassium	solution	(85mM	NaCl,	5mM	NaHCO3,	62mM	KCl,	1mM	MgCl2,	10mM	glucose,	10mM	HEPES,	2.5mM	CaCl2,	pH	7.4).			In	DRG	silence	experiments	(Section	6.2.4),	toxin	cocktail	(CTX)	compose	of	1µm	from	each	tetrodotoxin	(TTX)	(Almone	labs,	T-500),	w–conotoxin	MVIIC	(Almone	labs,	C-150)	and	w–conotoxin	GVIA	(Almone	labs,	C-300)	was	used.	To	examine	the	effectiveness	of	CTX	to	block	AP	in	neurons,	DRG	cultures	were	stimulated	by	KCl.	It	has	been	reported	that	there	is	no	significant	difference	in	calcium	signals	from	sequential	KCl	stimulations	of	neurons	(up	to	3	stimulations	)	(Unpublished	data,	Zainab	Mohammed	and	Mohammed	Nassar,	2015).				
2.7	Amaxa	nucleofection	of	BMMC	Transfection	is	a	process	of	introducing	exogenous	nucleic	acids	into	cells.	It	is	a	powerful	tool	to	study	gene	function	and	intracellular	signaling	pathways	by	modifying	protein	production.	Nucleofection	is	a	new	efficient	non-	viral	transfection	method	for	primary	and	hard–to–transfect	cells.	Comparing	with	other	non-viral	transfection	methods,	nucleofection	has	shown	better	transfection	efficiency	than	other	chemical	techniques	as	lipofection	(Jacobsen	et	al.,	2006)	and	higher	cell	viability	than	other	physical	techniques	as	electroporation.		
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The	exciting	advantage	of	nucleofection	technique	is	its	ability	to	deliver	the	negatively	charged	exogenous	material	straight	to	the	nucleus	by	using	both	the	chemical	and	physical	transfection	principals.	The	chemical	principal	is	by	bounding	the	exogenous	molecule	to	a	nuclear-localization	signal	protein	to	form	a	complex	in	a	cell–type	specific	solution.	On	the	other	hand,	the	physical	principle	is	by	using	specific	electrical	shocks	to	form	small	pores	on	the	cell	membrane.	These	pores	allow	the	molecule–protein	complex	to	transfer	into	the	cells.	Another	advantage	of	nucleofection	is	that	it	is	independent	on	cell	division	because	the	exogenous	material	is	introduced	straight	into	the	nucleus.	All	together	make	nucleofection	is	good	choice	for	non-divided	and	hard–to–transfect	cells	(Hagemann	et	al.,	2006).	BMMCs	are	difficult	to	transfect	most	likely	due	to	their	low	proliferative	rate.	Therefore,	nucleofection	by	Nucleofector	II	(Amaxa,	Lonza)	was	used	in	this	study.	ShRNA’s	used	in	nucleofection	are	listed	in	(Table	2.14).	3	unique	constructs	of	CADM1	ShRNA	plasmids	and	non-targeting	scramble	control	(Figure	2.5)	from	(Genecopoeia)	were	used.	The	important	of	scramble	control	ShRNA	is	to	test	the	possibility	of	non-specific	effect	of	transfection.			
	
Figure.	2.5	Plasmid	used	for	shRNA	knockdown	experiments	http://www.genecopoeia.com/wp-content/uploads/oldpdfs/product/shrna/psi-U6.pdf	
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CAT	
NUMBER	
PROMOTER	
SELECTING	
MARKER	
REPORTER	 VECTOR	
TARGET	SEQUENCE	
CADM1-	ShRNA1	 MSH031688-31	
U6	 Puromycin	 eGFP	 psi-U6	
ggacagaatctgtttactaaa	
CADM1-	ShRNA2	 MSH031688-32	 cctccacgtaacttgatgatc	
CADM1-	ShRNA3	 MSH031688-33	 ggagattgaagtcaactgtac	
Scramble-	ShRNA	 CSHCTR001	 	
Table	2.14.	List	of	CADM11	ShRNA	plasmid	constructs	
	
2.7.1	Transfection	optimization	and	Efficiency	analysis	The	nucleofection	was	conducted	in	accordance	to	the	manufacturer's	instructions.	Basic	Fibroblasts	nucleofector	kit	(VPI-1002,	90279050)	and	recommended	programs	(X-001	or	T-016)	were	suggested	by	a	representative	from	Lonza	to	use	for	BMMC.	To	choose	the	correct	program,	we	transfected	BMMCs	first	with	2μg	pMax-green	fluorescent	protein	(pmaxGFP)	control	plasmid	provided	with	Nucleofector	Kit.	After	48	hours,	the	transfection	efficacy	was	judged	by	counting	GFP	positive	BMMC	using	fluorescent	microscope	at	488	nm	wavelength	(Figure	2.6).	Three	positions	of	each	well	of	each	transfection	were	captured	and	pmaxGFP	positive	BMMC	were	counted	manually	using	Image	J.	Transfection	efficacy	for	both	programs	was	almost	the	same	58.2%	and	53.75%	for	X-001	and	T-016,	respectively.	Moreover,	the	viability	of	cells	from	both	programs	that	evaluated	by	0.4%	trypan	blue	was	70%.		However,	cells	from	T-016	program	look	smaller.	Based	on	this	results,	X-001program	was	chosen	for	subsequent	transfections.			
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	For	more	accurate	evaluation	for	transfection	efficiency,	FACS	was	also	conducted	using	a	488-nm	laser	(Beckman).	Viability	was	gated	based	on	side	scatter.	only	viable	cells	were	included	in	fluorescence	measurements.	Transfection	efficiency	was	measured	by	the	percent	of	total	population	that	is	expressing	pmaxGFP	(Figure	2.6).	Results	of	FACS	also	supported	the	effectiveness	of	Amaxa	nucleofection	with	more	than	50%	transfection.	
	
Figure	2.6:	Optimization	of	Amaxa	nucleotransfection	in	BMMC.		BMMCs	were	transfected	with	maxGFP-labeled	plasmid	at	a	concentration	of	2	µg	using	program	T-016	(A)	or	X-001	(B).	48	hours	after	transfection,	the	cells	were	washed	and	analyzed	visually	by	fluorescence	microscopy.	Representative	images	of	GFP	(left),	brightfield	(BF)	(middle)	and	merged	(right).	Scale	bar	represents	30	µm.	Also,	transfection	was	quantified	by	FACS.	Histograms	show	measured	cell	count	(y	axis)	against	level	of	GFP	florescence	(x	axis).	GFP-transfected	cells	are	expressed	as	percentage	of	the	total	cells.			
2.7.2	Amaxa	nucleofection	for	BMMC	(optimized	protocol)	On	brief,	4-5×106	BMMCs	/	reaction	were	washed	twice	with	IMDM	and	spun	at	380xg	for	5	min.	After	discarding	the	supernatant,	cell	pellet	was	resuspended	with	82μl	and	18μl	of	the	cell	specific	Nucleofector	solution	and	supplement	(provided	with	kit),	respectively.	2μg	of	CADM1	ShRNA	plasmid	was	added	and	mixed.	cell	suspension	was	transferred	into	the	Nucleocuvette	(provided	with	kit)	and	ran	in	the	Amaxa	
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Nucleofector	II	(Amaxa)	using	the	optimized	Nucleofector	program	(X-001).	Transfected	cells	were	pipetted	out	into	6-well	plates.	Cells	were	flooded	with	2-ml	of	complete	culture	media	with	cytokines	and	incubated	for	6	hours	at	37oC	and	7.5%	CO2	to	allow	cell	recovery.	Then,	cells	were	washed	with	complete	media	to	totally	get	rid	of	the	transfection	reagents.	After	48	hours,	cells	were	sorted	using	fluorescence	activated	cell	sorting	(FACS).		Only	the	GFP	expressing	cells	were	carried	out	for	subsequent	experiments.			3	unique	constructs	of	CADM1	ShRNA	plasmids	and	scramble	control	were	tested	separately	to	identify	the	most	efficiently	transfected	construct.	48	hours	post	transfection,	cells	were	sorted	by	FACS	and	lysed.	Knockdown	efficacy	was	judged	by	western	blot	(Method	was	described	in	section	2.5.3).	ShRNA	constructs	number	2	and	3	showed	100%	knockdown	(Figure	2.7).	Thus,	1	μg	of	each	constructs	was	used	simultaneously	for	subsequent	knockdown	experiments,	as	recommended	from	the	company.	
	
Figure.	2.7	CADM1	ShRNA	constructs	knockdown	efficacy.	BMMCs	cells	were	transfected	with	3	ShRNA	constructs	using	the	Amaxa	nucleotransfection.	48	hours	post	transfection	cells	were	lysed	and	CADM1	expression	determined	by	western	blot.	GAPDH	was	used	as	loading	control.	Representative	examples	of	three	experiments	performed	
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2.8	Statistical	analysis		The	results	are	expressed	in	the	figures	as	the	means	±	standard	error	of	the	mean	(SEM)	of	at	least	3	independent	experiments;	unless	otherwise	stated.	Statistical	comparisons	with	the	appropriate	controls	of	data	from	adhesion	assay	experiment	with	blocking	peptide	and	all	knockdown	experiments	were	performed	using	one-way	repeated	measures	(ANOVA)	followed	by	Tukry’s	post-test.	Data	from	other	experiments	were	analyzed	using	paired	t-test	.	Probability	values	(P)	<	0.05	were	considered	statistically	significant.	All	data	handling,	statistical	analysis	and	graphs	were	performed	using	Graphpad	Prism		(version	6.Oh).																			
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Chapter	3:	Characterization	of	bone-
marrow	mast	cells	(BMMC)	culture		
	
3.1	Introduction		Unlike	other	hematopoietically-derived	cells,	MCp	originate	from	pluripotent	bone	marrow-derived	stem	cells	(Kirshenbaum	et	al.,	1992)	(Chen	et	al.,	2005),	and	circulate	immature	MCp	in	the	blood	(Metcalfe	et	al.,	1997).	MCp	then	migrate	to	target	tissues	where	they	differentiate	into	their	mature	phenotype	under	the	control	of	tissue-specific	micro-environmental	factors	(Galli,	1990).	The	major	factors	found	to	support	mast	cell	differentiation	and	maturation	are	IL-3	(Razin	et	al.,	1984)	and	SCF	(Tsai	et	al.,	1991)	(Irani	et	al.,	1992)	(Mitsui	et	al.,	1993).	Mature	mast	cells	are	recognized	by	the	expression	of	high	levels	of	surface	FceRI	and	Kit,	and	functional	response	to	IgE-mediated	crosslinking	and	activation.	Because	mature	mast	cells	are	usually	found	only	as	a	minor	population	within	healthy	tissues,	it	is	problematic	to	isolate	sufficient	numbers	of	primary	mast	cells	for	research	(as	mentioned	in	section	1.1.6).	Therefore,	in	
vitro	differentiation	of	bone	marrow	stem	cells	to	mast	cells	is	an	alternative	approach	for	generating	a	large	number	of	mast	cells	(Razin	et	al.,	1982b),	and	BMMC	have	been	extensively	used	to	study	mast	cell	activation	and	signaling	(Bischoff,	2007).		In	order	to	use	BMMCs	and	DRG	co-culture	as	a	model	to	investigate	the	bidirectional	communications	between	the	immune	and	sensory	nervous	systems,	it	was	first	necessary	to	optimize	BMMC	culture	conditions.	One	of	the	important	issues	regarding	BMMC	culture	is	whether	to	culture	BMMC	with	or	without	SCF.	SCF	is	a	cytokine	which	plays	a	major	role	in	hematopoiesis	by	binding	to	c-kit	receptors	(receptor	tyrosine	
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kinase	or	CD117).	All	hematopoietic	progenitor	cells	express	c-kit	receptors,	but	with	the	notable	exception	of	mast	cells,	they	then	downregulate	c-kit	expression	as	they	mature.	Mast	cells	are	the	only	mature	hematopoietic	cells	that	express	c-kit	receptors	(Okayama	and	Kawakami,	2006).	Although	mice	with	c-kit	(KitW/Wv	)or	SCF	(KitSI/SId	)	mutation	show	profoundly	decrease	in	tissue	mast	cells	numbers	(Kitamura	et	al.,	1978)	(Kitamura	and	Go,	1979),	mouse	BMMC	can	be	successfully	differentiated	and	survive	till	maturation	with	IL-3	alone	in	the	absence	of	SCF	in	vitro	(Razin	et	al.,	1984).			In	addition	to	acting	as	a	growth	factor	for	mast	cells,	SCF	is	also	reported	to	modulate	IgE-	mediated	mast	cell	activation.	While	synergistic	administration	of	SCF	and	Ag	enhance	IgE	mediated	activation	(Bischoff	and	Dahinden,	1992)	(Hundley	et	al.,	2004)	(Tkaczyk	et	al.,	2004),	it	has	been	reported	that	chronic	exposure	to	SCF	(for	4-week-	culturing	duration)	attenuates	IgE-	mediated	activation	in	BMMC	(Ito	et	al.,	2012).	Given	the	complexity	of	SCF	signaling	in	BMMCs,	I	first	investigated	in	depth	the	role	of	SCF	in	growth	and	function	of	BMMCs	compared	their	properties	when	cultured	in	the	presence	of	IL-3,	or	a	combination	of	IL-3	and	SCF.													
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3.2	Results	
3.2.1	Effects	of	culturing	BMMC	with	SCF	on	cell	growth	The	effect	of	SCF	on	BMMC	growth	was	evaluated	by	comparing	the	total	cell	number	of	BMMCs	in		cultures	with	and	without	addition	of	SCF.	Each	BMMC	preparation	from	one	mouse	was	divided	equally	into	two	groups.	One	was	cultured	with	IL-3	(5ng/ml)	in	the	presence	of	SCF	(10ng/ml)	for	6	weeks	termed	chronic	SCF-cultured	(cSCF-BMMCs).	The	other	was	cultured	with	IL-3	alone	for	the	same	period	(BMMC).	Live	cells	were	counted	once	per	week	by	hemocytometer	with	trypan-blue	staining.	After	4	weeks	of	culture,	the	cell	suspension	of	both	(cSCF-BMMCs)	and	(BMMC)	showed	identical	cell	morphological	characteristics,	consisting	of	non-adherent,	uniformly	sized	spherical	cells.	However,	BMMC	cultured	with	a	combination	of	IL-3	and	SCF	showed	higher	cell	count	at	every	time	point	(Figure	3.1).	Cell	counts	from	both	BMMCs	culture	conditions	reached	their	maximum	point	at	week	4	and	the	total	cell	number	of	BMMC	cultured	in	the	presence	of	SCF	was	significantly	(P=0.04)	higher	(25.6	±	3.8	x106	BMMC/	prep)	than	the	total	cell	number	of	BMMC	cultured	with	IL-3	alone	(15.6	±1.8	x106	BMMC/	prep).	After	reaching	their	maximum	point	at	week	4,	BMMCs	from	(cSCF-BMMCs)	culture	decreased	slightly	in	number	around	week	5	(22.55	±	1.6	x106	BMMC/	prep)	before	apparently	reaching	a	steady	state	level	(22	±	1.6	x106	BMMC/	prep)	at	week	6	(end	point).	In	contrast,	BMMCs	from	(BMMC)	cultures	gradually	diminished	in	number	from	week	4	until	returning	almost	to	their	starting	level	(9.15	±	0.15	x106	BMMC/	prep)	after	6	weeks.									
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Figure.3.1	SCF	enhances	and	prolongs	BMMC	growth		BMMCs	were	cultured	with	IL-3	(5ng/ml)	in	the	presence	(cSCF-BMMCs)	or	absence	(BMMC)	of	10ng/ml	SCF	for	6	weeks.	The	data	shown	are	the	mean	±	SEM	of	3	independent	experiments,	each	performed	in	duplicate.	Data	were	analyzed	using	multiple	t-test	followed	by	Holm-Sidak	method.	*p<0.05						
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3.2.2	Effects	of	culturing	BMMC	with	SCF	on	maturation	and	purity	In	order	to	investigate	the	role	of	SCF	in	the	maturation	of	BMMCs,	cells	from	each	preparation	were	analyzed	for	surface	expression	of	the	high-affinity	IgE	receptor	(FcεRI)	and	SCF	receptor	(c-kit),	the	classic	mast	cell	markers,	by	flow	cytometry.	BMMCs	were	cultured	with	IL-3	with	the	presence	(cSCF-BMMCs)	or	absence	(BMMC)	of	SCF	for	4	weeks.	Then,	BMMCs	were	stained	with	antibodies	against	FcεRI,	and	c-kit.	Forward	scatter	and	side	scatter	of	the	cells	were	used	to	determine	viable	cells	for	subsequent	analysis	of	fluorescent-labeled	antibodies	in	the	BMMC	population	(Figure	3.2).		(cSCF-BMMCs)	and	(BMMC)	cultures	showed	the	same	high	expression	level	of	c-kit	and	FcεRI	(99.3%	and	99.1%,	respectively).	In	agreement	with	previous	reports,	both	preparations	successfully	generate	a	homogeneous	population	of	typical	phenotypic	characteristics	of	mast	cells	(Ito	et	al.,	2012).	
	
Figure	3.2	The	maturation	and	purity	of	BMMCs	were	confirmed	by	flow	cytometry.	Flow	cytometric	analysis	of	cell	surface	expression	of	FCεRI	versus	c-Kit	in	BMMCs.	1X106	BMMCs	per	test	were	cultured	for	4	weeks	in	the	presence	of	SCF	(10ng/ml)	and	IL-3	(5ng/ml)	(cSCF-BMMCs)	(A)	or	IL-3	alone	(BMMC)	(B)	Numbers	in	dot	plots	indicate	the	percentage	of	cells	in	the	indicated	gate.	Representative	examples	of	3	independent	experiments.		
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3.2.3	Effects	of	SCF	on	IgE-mediated	mast	cell	degranulation	To	investigate	the	role	of	chronic	culturing	BMMC	with	SCF	on	IgE-mediated	responses,	BMMC	degranulation	from	(cSCF-BMMCs)	or	(BMMC)	cultures	were	compared	using	b-hexaminidase	(b-Hex)	assay	(see	method,	section	2.3.3)	.	Pre-sensitized	BMMCs	were	stimulated	with	varying	concentration	of	the	antigen	DNP,	0-600	ng/ml,		for	30	minutes	(see	method,	section	2.3.1.1).	Both	culture	conditions	showed	concentration-dependent	degranulation	by	DNP	(Figure	3.3).	There	was	no	significant	difference	in	the	percentage	of	BMMC	degranulation	between	both	cultures	at	all	concentrations	of	DNP	tested.	The	highest	DNP	concentration	(600ng/ml)	induced	the	maximum	degranulation,	measured	as	43.2	±	0.93%	and	42.5	±	1.1	%	from	(cSCF-BMMCs)	and	(BMMC)	cultures,	respectively.	These	data	indicate	that	chronic	exposure	of	BMMCs	to	SCF	(10ng/ml)	doesn’t	affect	IgE-mediated	BMMC	degranulation	within	the	time	frame	and	culture	conditions	used	in	the	present	study.		
	
Figure	 3.3.	 In	 the	 short	 term,	 culturing	 BMMCs	 with	 SCF	 does	 not	 alter	 antigen-induced	
degranulation.	BMMCs	were	cultured	in	IL-3	in	the	presence	(cSCF-BMMC)	or	absence	of	SCF	(BMMC)	for	4	weeks.	The	cells	were	then	sensitized	with	IgE	overnight,	before	being	challenged	with	the	indicated	concentrations	of	Ag	(DNP)	for	30	minutes	and	b-hex	released	into	the	extracellular	medium	determined	and	expressed	as	a	percentage	of	the	total	cellular	content	of	b-hex.	Data	shown	are	mean	±	SEM	of	3	independent	experiments,	each	performed	in	duplicate.	Data	were	analyzed	using	two-tailed	paired	t-test.		
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Next,	I	examined	the	acute	effect	of	SCF	on	IgE-mediated	BMMC	degranulation.	BMMCs	were	cultured	in	medium	supplemented	with	IL-3	in	the	presence	of	SCF	for	4	weeks	(cSCF-BMMCs).	Then,	BMMCs	were	synergistically	stimulated	with	SCF	(10	and	100ng/ml)	and	DNP	(100ng/ml)	for	30	minutes.		Results	showed	that	there	were	no	noticeable	differences	in	percentage	of	b-Hex	release	in	the	absence	(19.8	±	1.2	%)	or	presence	(20.3		±	0.83%)	of	10	ng/ml	of	SCF	(Figure	3.4).	However,	at	the	higher	concentration	of	SCF	tested	(100ng/ml),	a	significant	(P=	0.024)	enhancement	of	IgE-	mediated	b-Hex	release	(25.4	±	1.8	%)	was	observed.	This	data	demonstrates	that	co-stimulation	of	SCF	enhances	IgE	receptor-dependent	mediator	release	in	BMMCs.			
	
Figure.	3.4.	Co-stimulation	of	BMMCs	with	SCF	enhances	IgE-mediated	degranulation.	BMMCs	were	cultured	in	IL-3	in	the	presence	of	SCF	(cSCF-BMMC)	for	4	weeks.	The	cells	were	then	sensitized	with	IgE	overnight	before	being	stimulated	with	Ag	(100ng/ml	DNP)	and	SCF	(10	and	100ng/ml)	for	30	minutes,	and	degranulation	(β-hex)	determined.	Data	shown	are	mean	±	SEM	of	3	independent	experiments,	each	performed	in	duplicate.	*	indicates	p<0.05	compared	to	DNP-only	stimulated	BMMCs.	ns=	non-significant.	Data	were	analyzed	using	one-way	ANOVA	test	with	Turkey’s	multiple	comparison	post-test.		
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3.3	Discussion	Before	going	on	to	establish	an	in	vitro	model	for	studying	mast	cell-sensory	neuron	interactions,	it	was	necessary	to	find	the	optimum	protocol	for	generating	mature,	functional	mast	cells.	Mast	cells	develop	different	phenotypical	and	pharmacological	characteristics	depending	on	local	micro-environmental	factors.	Those	factors	include,	but	are	not	limited	to,	various	cytokines,	and	inflammatory	mediators	(Galli,	1990)	(Moon	et	al.,	2010).	These	factors,	in	combination	or	alone,	influence	gene	expression	in	mast	cells	and	phenotypic	alteration	and	tissue-specific	mast	cell	heterogeneity.	As	mentioned	in	section	1.1.4,	mast	cell		heterogeneity	determines	and	regulates	mediator	production	to	different	stimuli	(Metcalfe	et	al.,	1997).	Moreover,	mast	cell	heterogeneity	is	observed	not	only	between	species	but	also	between	organs	and	even	within	the	same	organ	(Moon	et	al.,	2010).	This	makes	it	difficult	to	isolate	large	numbers	of	mature	mast	cells	with	identical	characteristics	directly	from	tissue.	As	an	alternative,	in	vitro	culture	systems	from	mast	cell	progenitors,	such	as	BMMC,	have	been	established	to	produce	large	numbers	of	homogenous	mast	cells	(Moon	et	al.,	2010).	BMMC	can	be	successfully	differentiated	and	survive	for	a	limited	period	with	IL-3	alone	without	SCF	(Razin	et	al.,	1984).	However,	SCF/c-Kit	interaction	has	been	identified	as	a	necessary	factor	for	mast	cell	production	in	vivo.	Because	of	these	conflicting	observation,	it	was	crucial	to	study	the	
effect	of	SCF	on	BMMC	proliferation,	maturity,	and	pharmacological	responsiveness.		I	compared	two	different	in	vitro	BMMC	culture	conditions.	Although	IL-3	alone	supported	BMMC	growth,	addition	of	SCF	significantly	enhanced	mast	cells	proliferation	and	prolonged	their	survival.	These	results	are	in	the	line	with	previous	reports	(Haig	et	al.,	1994)	(Ito	et	al.,	2012).	Similar	synergistic	effects	of	SCF	with	IL-3	have	also	been	observed	with	peritoneal	mast	cells	(Haig	et	al.,	1994).	The	SCF	enhancement	effect	is	thought	to	result	from	its	ability	to	prevent	apoptosis	(Iemura	et	al.,	1994).	Removing	SCF	from	BMMC	cultures	for	6	hours,	already	induces	a	decrease	in	cell	numbers,	concomitant	with		condensation	of	nuclear	chromatin	and	nuclear	pyknosis	which	are	characteristic	morphological	features	associated	with	apoptosis.			
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In	addition	to	supporting	mast	cell	growth,	SCF	may	also	impact	on	mast	cell	maturity	and	FceIR	expression.		Consistent	with	previous	studies	(Ito	et	al.,	2012),	I	found	that	the	presence	or	absence	of	SCF	didn’t	change	BMMC	purity	in	term	of	c-kit	and	FcεRI	expression,	nor	did	chronic	exposure	to	low	levels	of		SCF	significantly	alter	mast	cell	degranulation	in	response	to	Ag.	This	observation	contrasts	with	that	of	Tomonobu	Ito	(Ito	et	al.,	2012)	who	argue	that	chronic	exposure	to	SCF	results	in	a	hypo-responsiveness	phenotype	to	Ag		caused	by	cytoskeletal	reorganization.	The	time	of	exposure	to	SCF	may	be	important	for	observing	this	hypo-responsiveness	as	another	study	reported	there	is	no	difference	in	BMMC	response	to	IgE	stimulation	when	cultured	with	100ng/ml	of	SCF	for	12	days,	if	the	exposure	is	extended	beyond	12	days	then	a	significant	decrease	in	degranulation	is	observed	(Takano	et	al.,	2008).		SCF	concentrations	used	in	these	previous	studies	(Ito	et	al.,	2012)	(Takano	et	al.,	2008)	were	notably	10-times	higher	than	used	here	.	I	decided	to	use	the	physiological	concentration	of	SCF	in	tissue.	The	normal	level	of	SCF	in	serum	of	257	healthy	subjects	measured	using	ELISA	was	3-8	ng/mL	(Langley	et	al.,	1993).	In	peritoneal	fluid	of	32	healthy	females,	the	average	SCF	concentration	was	reported	to	be	2.84	ng/ml	(Osuga	et	al.,	2000).	At	these	low	concentrations,	SCF	may	support	mast	cells	proliferation	and	chemotactic	migration	but	do	not	cause	activation.			In	contrast	to	the	effect	of	chronic	SCF	on	IgE-mediated	degranulation,	acute	stimulation	of	BMMCs	with	SCF	concomitantly	with	antigen	enhanced	IgE-mediated	degranulation.	This	observation	is	reported	by	many	authors	and	is	a	common	finding	with	mast	cells	isolated	from	different	tissues	and	species	(Bischoff	and	Dahinden,	1992,	Hundley	et	al.,	2004)	(Tkaczyk	et	al.,	2004)	(Hill	et	al.,	1996).	While	SCF	by	itself	does	not	induce	degranulation	or	cytokine	production,	it	synergizes	with	Ag	to	enhance	B-hex	in	rat	BMMC	(Hill	et	al.,	1996)	and	human	mast	cells	(Hundley	et	al.,	2004)	(Tkaczyk	et	al.,	2004)	and	histamine	release	and	cytokine	productions	(Bischoff	and	Dahinden,	1992).		SCF	enhances	IgE-	mediated	activation	by	interact	with	its	signaling	pathway	(Figure	3.5).	As	discussed	in	(section	1.1.2.1),		IgE	crosslinking	results	in	a	sequence	of	
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phosphorylation	events.	IgE	and	c-kit	share	many	downstream	signaling	molecules	such	as	PLCγ,	PI3K	and	cytosolic	adapter	molecules	Grb2	(Tkaczyk	et	al.,	2004).	In	addition,	both	pathways	activate	MAPK/STAT	and	NFκB	pathways	that	is	important	for	some	of	cytokine	production	such	as	IL-6	(Akira,	1997)	(Kalesnikoff	et	al.,	2002).	However,	unlike	IgE	that	activates	Src	kinase	to	phosphorylate	the	transmembrane	adapter	molecules	LAT1	and	LAT2,	c-Kit	directly	phosphorylates	only	LAT2	by	its	intrinsic	tyrosine	kinase	(Tkaczyk	et	al.,	2004).	Inability	of	c-kit	to	activate	LAT1	and	NFAT	pathways	could	explain	its	inability	to	mediate	degranulation	and		some	of	cytokine	production,	respectively,		in	the	absence	of	Ag	(Gilfillan	et	al.,	2009)	(Klein	et	al.,	2006).		
	
Figure.	3.5	Integration	of	mast	cells	signalling	pathways	mediated	by	FcεRI	and	c-kit.	Upon	cross	linking	of	FcεRI	by	IgE	and	SCF	binding	to	c-kit,	a	series	of	phosphorylation	and	recruitment	of	intracellular	 molecules,	 leads	 to	 a	 large	 increases	 in	 intracellular	 calcium	 ultimately	 results	 in	degranulation	and	cytokine	production.	The	Figure	is	modified	from	Figure	1.1				
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My	data	showed	in	general	that,	except	for	cell	growth,	chronic	exposure	of	BMMCs	to	low	concentrations	of	SCF	has	no	significant	effect	on	maturation	or	IgE-mediated	activation.	Indeed,	BMMC	can	be	cultured	and	survive	with	IL-3	alone	in	vitro.	However,	there	is	one	crucial	reason	why	supplementing	the	culture	media	with	SCF	is	desirable,	and	that	is	the	fact	that	mast	cells	can’t	survive	in	vivo	without	SCF.	Mutations	at	the	W	locus	that	encodes	c-kit	or	at	the	S1	locus	that	encodes	SCF	result	in	mast	cell	deficiency	in	mice	(Kitamura	et	al.,	1978)	(Kitamura	et	al.,	1987).	Even	in	vivo,	mature	mast	cells	within	tissues	are	continuously	exposed	to	soluble	or	transmembrane	SCF	from	neighboring	cells	such	as	fibroblasts,	smooth	muscle	cells	and	endothelial	cell	(Metcalfe	et	al.,	1997).	Indeed,	IgE-mediated	mast	cell	activation,	in	vivo,	likely	occurs	in	a	background	of	SCF	and	SCF-c-kit	signaling.	To	mirror	this	in	vitro,	BMMCs	were	cultured	with	10ng/ml	SCF	for	4	weeks	for	all	subsequent	BMMC	preparations	till	maturation.	Then,	BMMC	were	cocultured	with	DRG	without	SCF,	as	well	as,	all	IgE-mediated	mast	cell	activation	experiments	reported	in	this	thesis	were	carried	out	without	the	presence	of	SCF	to	eliminate	the	possible	enhancement	effect	of	SCF	on	IgE-mediated	mast	cells	activation.			The	present	study	has	characterized	BMMCs	in	culture	supplemented	with	IL-3	and	SCF	for	4	weeks.	BMMCs	have	a	phenotypic	character	of	mature	mast	cells	as	judged	by	their	morphology,	>99%	pure	FceRI+	Kit+	cells,	and	their	degranulation	in	response	to	IgE-mediated	stimulation.	Although	mouse	mast	cells	can	differentiate	and	survive	in	culture	supported	with	IL-3	only,	culturing	BMMC	in	the	presence	of	SCF	enhances	the	growth	and	survival	of	mast	cells.	These	results	emphasize	that	mast	cell	phenotypic	and	functional	characteristics	are	influenced	by	micro-environmental	factors.	
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Chapter	4.	The	Impact	of	sensory	
neurons	on	mast	cells	function	
	
4.1	Introduction	The	increased	number	of	mast	cells	and	mast	cell-nerve	associations	have	been	described	in	many	neurogenic	inflammatory	disorders	like	irritable	bowel	syndrome	(Barbara	et	al.,	2004,	Park	et	al.,	2003),	and	fibromyalgia	(Blanco	et	al.,	2010).	Based	on	these	observations	in	vivo,	the	functional	bi-directional	crosstalk	between	mast	cells	and	neurons	was	studied	in	vitro.	The	majority	of	those	in	vitro	studies	used	co-culture	model	of	mast	cells	and	neurons	(Furuno	and	Nakanishi,	2011).		This	model	is	very	informative	regarding	the	molecular	and	structural	formation	of	this	neuroimmune	synapse.	It	provides	a	useful	system	to	study	the	mechanism	of	direct	mast	cell	crosstalk	to		neurons	without	the	influence	of	other	intermediary	cells.	However,	many	different	protocols	have	been	developed	to	co-culture	mast	cell	and	neurons	in	vitro.	The	first	effort	to	establish	mast	cell-neuron	co-culture	was	by	using	RBL	cell	line,	which	are	widely	used	as	model	mast	cells	(Passante	et	al.,	2009),		and	neurons	isolated	from	murine	SCG	(Blennerhassett	and	Bienenstock,	1990)	(Blennerhassett	et	al.,	1991).	But	since	RBL	is	a	cancerous	cell	line	and	transformation	can	alert	normal	cell	functions	(See	introduction	section	1.1.6.2	and	Table	1.3),	the	co-culture	model	was	improved	to	use	murine	bone	marrow-derived	mast	cells	(BMMC)	as	a	model	for	mucosal	mast	cells	instead	of	RBL.	Along	the	same	line,	sympathetic	SCG	is	replaced	by	adult	murine	DRG.	DRG	cultures	have	been	widely	accepted	as	standard	model	for	peripheral	sensory	neurons	to	study	pain	mechanism	in	vitro	(Melli	and	Höke,	2009)	(See	section	1.2.4).		The	success	of	BMMC-DRG	co-culture	model	attracted	much	interest	to	study	mast	cell-nerve	interactions	in	vitro.	However,	most	of	these	studies	investigated	the	crosstalk	in	
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this	functional	unit	by	activation	of	either	neurons	or	mast	cells	and	then	look	for	other	cell	type	response	(Section	1.3.1).	It	has	shown	that	the	electrical	or	chemical	stimulation	of	nerves	activate	mast	cells,	and	that	mast	cell-derived	mediators	can	evoke	neuronal	response	(Janiszewski	et	al.,	1990)	(Blennerhassett	et	al.,	1991)	(Suzuki	et	al.,	1999)	(Suzuki	et	al.,	2001)	(Mori	et	al.,	2002)	(De	Jonge	et	al.,	2004)	(Furuno	et	al.,	2004)	(Nakanishi	and	Furuno,	2008).	However,	the	effect	of	close	contact	between	these	two	cells	on	mast	cells	functions,	in	particular	their	response	to	Ag,	is	still	unknown.	Here	in	this	chapter,	I	describe	the	results	of	experiments	I	performed	to	investigate	the	effect	of	sensory	neuron	interactions	on	the	biological	function	of	mast	cells,	in	particular,	how	this	interaction	may	modify	IgE-mediated	activation.	I	also	examined	how	activation	of	sensory	neurons	impacts	mast	cell	activation,	with	a	view	to	gaining	a	better	understanding	of	how	mast-cell-sensory	neuron	crosstalk	may	be	altered	in	pain	.	Finally,	I	examined	the	specific	adhesion	of	mast	cells	to	neurites.	But	before	all	that,	I	characterized	my	DRG	culture.	Then,	I	investigated	the	effect	of	co-culturing	BMMC	on	DRG	culture	morphology.													
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4.2	Results	
4.2.1	Characterization	of	primary	DRG	culture	There	are	many	different	protocols	to	culture	primary	DRG	neurons.	Because	I	aimed	to	study	the	direct	communication	between	mast	cells	and	sensory	neurons	without	the	influence	of	other	intermediary	cells,	and	because	typical	dissociated	primary	DRG	culture	is	heterogeneous	with	mixture	of	neurons	and	non-	neuronal	cells,	the	neuronal	purity	of	DRG	culture	was	my	primary	concern	in	evaluating	the	best	dissociation	and	culture	conditions	to	use	in	my	research.	As	described	in	methods	(Section	2.1.2.2),	to	limit	the	proliferation	of	non-neuronal	cells	in	DRG	cultures,	I	used	B-27	supplement	instead	of	serum	and	anti-mitotic	reagent	Cytosine	β-	D	-arabinofuranoside	(Ara-C)	that	slows	glial	cell	division.(Liu	et	al.,	2013).	Although	DRG	can	be	cultured	from	neonatal	or	adult	animals,	I	decided	to	isolate	DRG	from	adult	mice	(8-12	weeks)	for	3	reasons	(Melli	and	Höke,	2009):	1)	cultures	prepared	from	isolated	adult	DRG	offer	a	model	more	similar	to	in	vivo	DRG	neurons	because	they	provide	completely	developed	and	mature	neurons,	2)	survival	of	adult	DRG	neurons	is	not	dependent	upon	serum	so	they	can	be	cultured	in	defined	media,	without	serum	the	density	of	non-neuronal	cells	can	be	more	easily	controlled.	3)	I	am	interested	in	studying	BMMC-DRG	co-culture	as	a	model	of	neurogenic	inflammatory	diseases	that	are	more	common	in	adulthood.		To	examine	the	purity	of	my	neuronal	cultures,	I	first	isolated	DRG	from	8-12	week	old	male	mice,	and	cultured	the	cells	recovered	following	enzymatic	digestion	either	in	serum-free	medium	supplemented	with	1	µM	Ara-C	(serum-	free	culture)	or	with	10%	heat	inactivated	FBS	and	without	Ara-C	(culture	with	serum	)	for	72hr	(the	detailed	protocol	is	in	section	2.1.2.2).	The	purity	of	neurons	in	the	cultures	was	quantified	by	immunocytochemistry	and	expressed	as	the	percentage	of	anti-b	III	Tubulin	positively	stained	cells	relative	to	the	total	number	of	DAPI	positively	stained	cells.		Bright-field	images	of	cultures	prepared	with	both	protocols	(Figure	4.1	A1-2)	revealed	a	heterogeneous	population	of	bright	round	soma	of	different	sizes	with	extensive	outgrowth	of	neurites	which	formed	networks	(asterisks).	In	both	cultures,	a	thin	layer	
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of	glia	growing	beneath	the	neurons	was	identified	as	small,	dark	and	spindle-shaped	cells	(arrows).	All	these	observations	were	reported	in	previous	studies	(Liu	et	al.,	2013).	Under	bright-field	microscopy,	neuronal	and	glial	populations	can	be	distinguished	by	their	morphologies.	Analysis	of	fluorescent	images	(Figure	4.1	B1-2),	showed	that	growing	cells	in	serum	free	defined	media	yielded	a	culture	consisting	of	30%	b	III	tubulin	-positive	neurons,	this	was	decreased	to	7%	in	cultures	grown	with	serum	(Figure	4.1	C).	Thus,	the	purity	of	neuronal	cells	in	serum-	free	culture	is	significantly	higher	than	culture	with	serum	by	4-fold	(P=0.0145)	.	
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Figure.	 4.1.	 Effect	 of	 Ara-C	 and	 serum-free	medium	 in	 controlling	 proliferation	 of	 non-neuronal	
cells	in	cultures	of	primary	DRG.		(Figure	 of	 the	 previous	 page)	 Isolated	DRG	 cultured	with	 1	 µM	Ara-C	 and	 serum	 free	medium	 or	with	serum	for	72hr.	Bright-field	images	from	culture	with	serum	(A-1)	and	serum	free	culture		(A-2)	showing	that	 the	primary	culture	of	DRG	consists	of	a	heterogeneous	population	of	neurons	with	different	 soma	size	 and	 they	 exhibit	 a	 network	 of	 neurites.	 The	 arrows	 indicate	 non-neuronal	 cells	 while	 asterisks	indicate	 somas.	 (B-1)	 (B-2)	 Showing	b-Tubulin	 III	 immunocytochemistry	 staining	 for	DRG	culture	 from	culture	 with	 serum	 and	 serum	 free	 culture,	 respectively.	 The	 purity	 of	 DRG	 culture	 was	 expressed	 as	percentage	of	b-Tubulin	 III	 immunoreactive	cells	 to	 total	 cells	 in	control	 culture	with	serum	and	serum	free	cultures	(C)	*	denotes	P<0.05	paired	students	t-test	(N=4).	Scale	bar	represents	25µm		To	characterize	neurons	based	on	their	function,	I	examined	the	proportion	of	nociceptive	and	mechanoreceptive	neurons	in	my	protocol.	The	simplest	method	to	define	neurons	to	nociceptive	and	mechanoreceptive	is	by	measuring	their	soma	size	(Yoshida	and	Matsuda,	1979)	(Harper	and	Lawson,	1985b)	.	Soma	size	can	be	expressed	as	diameter	or	area.	As	defined	previously	by	Scoggs	and	Fox	(1992)	,	small	neurons	(diameter:	<	30	μm	and	area:	<600	μm2)	are	considered	to	be	nociceptive	while	medium	(diameter:	30-40	μm	and	area:	600-1200	μm2)	and	large	neurons	(diameter:	>	40	μm	and	area:	>1200	μm2)	are	mechanoreceptive	(Scroggs	and	Fox,	1992).	The	soma	size	distribution	of	neurons	from	my	protocol	was	unimodal	with	more	than	60%	of	the	population	were	small-sized	nociceptive	neurons	(Figure	4-2A).	To	confirm	this	result,	cells	were	stained	with	peripherin,	a	neurofilament	protein	expressed	selectively	in	nociceptive	neurons	(Goldstein	et	al.,	1991).	To	provide	the	total	number	of	neurons	in	DRG	culture,	cells	were	also	stained	with	anti-b	III	Tubulin	(Figure	4-2	B).	Data	are	expressed	as	the	mean	±	SEM.	The	result	shows	that	66	±	5	%	of	b	III	Tubulin-immunoreactive	neurons	are	positive	for	peripherin	(Figure	4-2	C).	Taken	together,	the	data	confirms	that	my	protocol	generates	neuronal	cultures	enriched	for	nociceptors.		
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	Nociceptors	can	be	further	categorized	into	peptidergic	and	non-peptidergic	subsets.	Peptidergic	neurons	contain	subP	and	CGRP,	while	non-peptidergic	do	not.	To	further	complete	the	picture,	neurons	were	stained	with	antibodies	to	subP	and	CGRP	(Figure	4-2	D-E).	Then,	cells	were	quantified	as	the	percentage	of	total	b	III	Tubulin-immunoreactive	neurons(Figure	4-2	C).	Results	showed	that	32	±	8	%	and	28	±	4	%of	b	III	Tubulin-immunoreactive	neurons	were	positive	for	subP	and	CGRP,	respectively.	Collectively,	my	protocol	produces	neuronal	culture	with	at	least	60%	nociceptors	and	50%	of	the	nociceptors	are	peptidergic.	
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Figure.	4.2.	Characterization	of	DRG	culture.		(Figure	of	 the	previous	page)	 Isolated	DRG	cultured	with	1	µM	Ara-C	and	serum	 free	medium	 for	72hr.	Soma	size	distribution	based	on	soma	diameter	(A-1)	and	area	(A-2)	showing	that	my	DRG	preparation	is	enriched	 for	 small-	nociceptors	<30	μm	 in	diameter.	 (B)	 Immunocytochemistry	visualizing	β-III	 tubulin	and	nociceptor	marker	peripherin.	(C)	Percentage	of	cells	positive	for	peipherin,	substance	P	(SubP)	and	calcitonin	 gene-related	 peptide	 (CGRP)	 as	 divided	 by	 number	 of	 β-III	 tubulin	 immunoreactive	 neurons	(N=3).	 	 (D)	 Immunocytochemistry	 is	 visualizing	 β-III	 tubulin	 and	 SubP.	 (E)	 Immunocytochemistry	 is	visualizing	β-III	tubulin	and	CGRP.	Scale	bar	represents	25µm		
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4.2.2	Effect	of	co-culture	of	BMMC	with	DRG	on	neuronal	morphology	It	has	been	reported	that	the	length	of	SubP-	immunoreactive	nerve	fibers	is	increased	in	airway	of	allergic	conditions	such	as	asthma	(Ollerenshaw	et	al.,	1991).	In	addition,	activated	mast	cell	produce	NGF	and	TNFa	that	could	enhance	neuronal	outgrowth	(Leon	et	al.,	1994)	(Kakurai	et	al.,	2006).		Thus,	I	aim	here	to	study	the	effect	of	co-culturing	BMMC	on	neuronal	morphology,	I	measured	total	neurite	length	and	complexity	(number	of	neurite	crossing	points	of	a	concentric	circle	set	with	radii	increasing	by	20μm)	in	BMMC-DRG	co-culture	(detailed	method	is	in	section	2.5.2.4).	To	control	for	the	effects	of	BMMC	media	on	neuronal	morphology,	parallel	experiments	were	performed	with	DRG	alone	treated	with	complete	co-culture	medium	and	IL-3	for	24	hours.	The	neurites	and	BMMCs	were	detected	by	immunocytochemistry	staining	for	
bIII-tubulin	and	c-kit,	respectively	(Figure	4-3	A-B).		Culturing	BMMCs	with	DRG	showed	no	significant	difference	in	total	neurite	length	(Figure	4-3	C)	from	DRG	monoculture	(	2997µm	and	2530µm),	respectively	(P=0.35).		Co-culturing	BMMC	with	DRG	showed	some	enhancement	in	neurite	complexity	compared	to	DRG	monoculture	(Figure	4-3	D)	but	this	did	not	achieve	statistical	significance.		In	the	case	of	DRG	monoculture,	the	mean	number	of	crossings	reached	a	maximum	of	19	around	60	μm	from	the	soma	while	in	co-culture	a	maximum	of	22	crossings	were	measured	at	the	same	distance.	Taken	together,	the	data	indicate	that	co-culturing	BMMC	with	DRG	does	not	alter	neuronal	morphology.	
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Figure.	4.3.	Effect	of	BMMC	co-culture	with	DRG	on	neuronal	morphology.		(A1-B1)	 Representative	 schematic	 tracings	 of	 the	 neurites	 from	 DRG	 culture	 alone	 or	 BMMC-DRG	 co-culture,	respectively.		Soma	and	neurites	were	visualized	with	β-III	tubulin	and	c-kit	in	DRG	(A2)	and	co-culture(B2).	 (C)	 Shows	 quantitative	 analysis	 of	 total	 neurites	 length	 in	DRG	 alone	 and	 co-culture	 using	unpaired	 t-test.	 (D)	Shows	plot	of	 sholl	 analysis	of	 the	neurites.	Each	bar	 represents	 the	mean	±SEM	of	number	of	crossing	neurites	found	in	each	given	distance	from	the	soma.	Statistical	analysis	using	multiple	T-test.		N=3.	Scale	bar	represents	10µm	
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4.2.3	Neurons	enhance	IgE-mediated	mast	cell	degranulation	in	vitro	 	The	observation	of	significant	increases	in	the	number	of	degranulated	mast	cells	in	proximity	of	mucosal	innervation	in	biopsies	from	IBS	patients	with	respect	to	controls	(Park	et	al.,	2003)	(Barbara	et	al.,	2004)	raises	the	interesting	possibility	that	neurons	could	influence	mast	cell	degranulation.	To	investigate	this	possibility,	I	co-cultured	IgE-sensitized	BMMC	with	DRG	for	24	hours.	I	then	stimulated	BMMC	cultured	alone	or	co-culture	with	DRG	with	the	antigen	(Ag)	DNP,	and	I	measured	the	percentage	of	β-hexosaminidase	(β-hex)	release	in	Ag-independent	(Ag-Indep)	BMMC	and	Ag-activated	BMMC	(the	detailed	protocol	is	in	section	2.3.1	and	2.3.3)	.	Initially,	the	percentage	of	β-hex	release	was	measured	from	supernatant	collected	at	several	time	points	(2-6-24	hours)	following	BMMC	co-cultured	with	DRG.	I	found	that	the	percentage	of	β-hex	released	from	BMMC	in	co-culture	increased	slightly	with	time	(Figure	4.4	A).	In	contrast,	the	percentage	of	β-hex	release	from	BMMC	alone	stayed	approximately	the	same	across	the	three	time	points	investigated.	The	percentage	of	Ag-activated	degranulation	from	BMMC	co-cultured	with	neurons	for	2	hours	was	28	±	1	%	(N=3,	each	performed	in	duplicate	)	while	co-culture	for	24	hours	increased	the	percentage	of	Ag-activated	degranulation	up	to	33	±	2	%	.	Similarly,	the	percentage	of	antigen-independent	degranulation	from	BMMC	in	co-culture	increased	from	6	±2%	following	2	hours	co-culture	to	9±	0.6%		after	24	hours	of	co-culture.	However,	the	maximum	of	Ag-independent	and	Ag-activated	degranulation	from	BMMC	in	co-culture	at	24	hours	was	2.5-fold,	and	1.6	fold	increased,	respectively,	compared	to	degranulation	in	BMMC	alone	(Figure	4.4	B).	These	results	indicate	that	neuronal	co-culture	with	mast	cells	not	only	activate	mast	cell	but	also	enhance	their	response	to	Ag.	Interestingly,	both	effects	are	increased	with	the	time.		Next,	I	investigated	the	kinetics	of	the	effect	of	sensory	neuron	co-culture	on	the	enhancement	of	Ag-activated	BMMC	degranulation.	I	compared	the	degranulation	from	BMMC	alone	or	in	co-culture	at	each	time	point.	At	the	2-hour	time	point,	the	presence	of	neurons	did	not	significantly	change	Ag-independent	nor	Ag-activated	degranulation	(P=0.084	and	P=0.16,	respectively)	(Figure	4.4	C1,	D1).	In	sharp	contrast,	after	6	hours	
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of	co-culture	of	BMMC	with	neurons,	both	Ag-independent	and	Ag-activated	BMMC	degranulation	was	significantly	enhanced	(P=0.007	and	P=0.046,	respectively)	(Figure	4.4	C2,	D2).	In	the	same	way,	co-culture	of	neurons	with	BMMC	for	24	hours	caused	a	significant	augementation	of	both	Ag-independent	and	Ag-activated	BMMC	degranulation	(P=0.0091	and	P=0.0002,	respectively)	(Figure	4.4	C3,	D3).	These	findings	suggested	that	the	mechanism	of	neuronal-enhancement	of	mast	cell	degranulation	is	relatively	slow	with	significant	onset	after	6	hours	and	increasing	over	24	hours	of	co-culture.				
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Figure.	4.4.	Kinetics	of	the	effect	of	sensory	neuron	co-culture	on	the	enhancement	of	Ag-activated	
BMMC	degranulation.		(A)	 Pre-sensitized	 BMMCs	 were	 cultured	 alone	 or	 with	 DRG	 for	 various	 times	 as	 indicated.	 Then,	 β-hexosaminidase	(β-hex)	release	was	measured	in	resting	condition	or	after	DNP	stimulation.	Total	β-hex	measured	from	BMMC	lysed	with	0.5%	Triton	Xl00.	(B)	Shows	the	fold-change	in	the	percentage	of	β-hex	release	 from	BMMC	in	co-culture	to	BMMC	alone	at	different	time	points.	(C1-3)	Shows	the	effect	of	co-culture	of	BMMC	with	DRG	on	constitutive	degranulation	at	each	time	point.	(D1-3)	Shows	the	effect	of	co-culture	of	BMMC	with	DRG	on	Ag-activated	degranulation	at	each	time	point.	Data	shown	are	mean	±	SEM	in	 (A	 -	 B)	 and	 SD	 in	 (C-D)	 of	N=3,	 each	 performed	 in	 duplicate.	 *	p<	0.05,	 **	 p<	0.01	 and	 ***	 p<	 0.001	compared	to	BMMC	alone.	Data	were	analyzed	using	two-tailed	paired	t-test.	
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To	examine	the	possibility	that	mediators	released	from	neurons	in	co-culture	could	be	accountable	for	the	enhancement	of	mast	cell	degranulation	in	co-culture,	I	incubated	BMMC	for	24	hours	with	supernatant	from	BMMC-DRG	co-culture.	Then,	I	measured	β-hex	at	resting	condition	or	after	DNP	stimulation.	As	shown	in	(figure	4.5	A),	in	contrast	to	BMMC-DRG	co-culture,	supernatant	from	co-culture	alone	had	no	effect	on	constitutive	(P=0.59)	or	Ag-activated	(P=0.69)	mast	cell	degranulation.	Next,	I	examined	whether	neuronal	enhancement	of	Ag-activated	mast	cell	degranulation	requires	cell-to-cell	contact	or	soluble	factors	only.	I	cultured	BMMCs	in	the	upper	chamber	of	Transwell	inserts,	0.4-	m	pore	size	(Costar)	and	DRG	in	the	lower	chamber.	I	found	that	co-culturing	BMMC	with	DRG	using	a	transwell	system	did	not	enhance	either	constitutive	(P=0.73)	or	Ag-activated	(P=0.49)	BMMC	degranulation	(Figure	4.5	B).	Collectively,	my	data	indicate	that	neurons	enhance	mast	cell	degranulation	in	a	cell–cell	contact-dependent	manner.			
	
110	
		
Figure.	4.5.	Effect	of	BMMC-DRG	co-culture	supernatant	on	BMMC	degranulation.		(A)	 Pre-sensitized	BMMCs	were	 cultured	 alone	 or	with	 supernatant	 from	BMMC-DRG	 co-culture	 for	 24	hours.	 Then,	 β-hexosaminidase	 (β-hex)	 release	 was	 measured	 in	 resting	 condition	 or	 after	 DNP	stimulation.	Total	 β-hex	measured	 from	BMMC	 lysed	with	0.5%	Triton	Xl00.	 (B)	 Pre-sensitized	BMMCs	were	cultured	alone	or	on	the	top	of	DRG	cultured	using	a	transwell	system	for	24	hours.	Data	shown	are	mean	±	SEM	of	N=3	in	A	an	N=2	in	B,	each	performed	in	duplicate.	Data	were	analyzed	using	two-tailed	paired	t-test.	
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4.2.4	Neurons	enhance	IgE-mediated	mast	cell	IL-6,	but	not	TNFα	
production.	To	further	confirm	the	influence	of	neurons	on	mast	cells	function,	I	measured	Ag-induced	production	of	pro-inflammatory	cytokines	from	mast	cells,	like	IL-6	and	TNFα.	I	co-cultured	BMMC	with	DRG	or	separately	for	24	hours,	then	I	stimulated	BMMC	with	Ag	(DNP)	for	6	hours	in	media,	collected	the	supernatant,	and	measured	cytokines	by	ELISA.	I	found	that	upon	Ag-induced	stimulation,	there	was	a	significant	increase	in	IL-6	released	from	BMMC	in	co-culture	(772	±69	pg/ml)	compared	to	BMMC	cultured	alone	(309	±	21pg/ml;	equivalent	to	a	2.5-fold	increase,	P=	0.035)	(Fig	4.6	A).	There	was	also	a	slight	increase,	though	not	significant	(P=0.07)	in	IL-6	release	from	unstimulated	BMMC.	In	contrast,	the	amount	of	TNFα	released	from	BMMCs	was	not	affected	by	co-culture	with	DRG	(Figure	4.6	B).	As	a	control,	I	measured	the	concentration	of	IL-6	and	TNFα	cytokines	in	supernatant	collected	from	DRG	monoculture.	However,	a	negligible	amount	of	both	cytokines	was	detected.	These	results	indicated	that	neurons	enhance	IL-6	production	by	mast	cells	without	affecting	TNFα	production.													
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Figure.	4.6.	Effect	of	sensory	neurons	on	IgE-mediated	cytokine	production	from	mast	cells	
	Pre-sensitized	BMMCs	were	cultured	alone	or	with	DRG	for	24	hours.	Then,	IL-6	(A)	and	TNFα	(B)	production	were	measured	in	resting	condition	or	after	DNP	stimulation	for	6	hours.	Data	shown	are	mean	±	SEM	of	N=3,	each	performed	in	duplicate.	*	p<	0.05	compared	to	stimulated	BMMC	alone.	Data	were	analyzed	using	two-tailed	paired	t-test.		
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4.2.5	Evaluation	of	BMMC-DRG	crosstalk.	Having	shown	that	neurons	promote	mast	cell	degranulation	when	in	co-culture,	I	next	looked	for	evidence	of	intercellular	communication	between	mast	cells	and	neurons	and	whether	this	communication	results	in	cellular	activation.	Cell	activation	could	be	studied	indirectly	at	a	single	cell	level	by	monitoring	intracellular	calcium.		To	do	so,	I	co-cultured	BMMC	with	DRG	for	24	hours.	Then	I	loaded	the	co-culture	with	2.5µM	Fura-2AM,	a	fluorescent	calcium	indicator,	and	measured	the	change	in	fluorescence	in	both	cell	types	after	activation.	First,	I	activated	pre-sensitized	BMMCs	alone	(Figure	4.7A)	and	in	co-culture	(Figure	4.7B)	with	100ng/ml	DNP	(Ag).	As	expected,	BMMC	in	both	conditions	showed	a	response	within	a	minute	of	antigen	application.	Surprisingly,	nearby	neurons	also	showed	an	increase	in	fluorescence	10	seconds	after	the	BMMCs	(Figure	4.7B).	However,	applying	100ng/ml	DNP	to	DRG	monoculture	didn’t	produce	any	response	in	all	cells	(Figure	4.7C).	This	indicated	that	the	response	shown	in	neurons	in	co-culture	is	a	result	of	Ag-induced	BMMC	activation.	Another	important	observation,	co-culture	BMMC	with	DRG	increased	the	change	in	fluorescence	from	0.041	in	monoculture	to	0.275	in	co-culture.	This	suggests	that	neurons	modulate	FcɛRI-stimulated	calcium	signaling.		Next,	1µM	of	capsaicin	was	applied	to	DRG	monoculture,	and	as	expected	from	mixed	DRG	culture	(figure	4.2),		only	2	nociceptor	out	of	6	neurons	responded	(Figure	4.7C).	62	mM	KCl	was	applied	to	test	neuronal	response	in	general,	all	cells	except	one	(non-neuronal	cell)	responded.				Next,	I	activated	nociceptors	in	co-culture	by	1µM	of	capsaicin.	Nociceptors	showed	increase	in	fluorescence	within	one	minute	of	drug	application	followed	by	activation	of	some	of	BMMCs,	as	indicated	by	increased	fluorescence	(Figure	4.7	D).	Taken	together,	these	results	confirm	direct	crosstalk	between	mast	cells	and	sensory	neurons	in	co-culture.	
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Figure.	4.7.	Bidirectional	activation	of	BMMCs	and	neurons	in	co-culture	(Figure	of	the	previous	page)	.A1,	change	in	calcium	signaling,	as	reported	by	Fura-2,		of	individual	BMMC	in	 response	 to	100ng/ml	DNP	 (n	=	39)	 and	mean	 response	±	 SEM	 (A2).	 (A3),	 Image	of	BMMCs	 loaded	with	 1µM	 Fura-2AM.	 (B1),	 Example	 trace	 of	 the	 change	 in	 calcium	 in	 a	 neuron	 following	 Ag-induced	activation	 of	 BMMCs	 kept	 in	 	 co-culture	with	 neurons	 for	 24	 hours	 	 (B2)	 Brightfield	 and	 fluorescence	images	 of	 Fura-2	 loaded	 co-culture.	 (C1),	 sample	 control	 trace	 for	DRG	 after	 activation	with	 100ng/ml	DNP	then	1µM	of	capsaicin	and	62mM	KCl	(n=7).	(C2),	Brightfield	and	fluorescence	images	of	Fura-2AM	loaded	 DRG	 culture.	 (D1),	 example	 trace	 of	 the	 change	 in	 calcium	 in	 BMMCs	 kept	 in	 co-culture	 for	 24	hours	and	 following	stimulation	of	neurons	with	capsaicin.	 (D2),	Brightfield	and	 fluorescence	 images	of	Fura-2AM	loaded	co-culture.	 		Since	I	showed	before	that	co-culturing	sensory	neurons	with	mast	cells	induced	constitutive	degranulation	at	rest,	I	also	examined	the	effects	of	simply	adding	BMMC	to	calcium	signals	measured	in	‘resting’	neurons.	I	loaded	DRG	with	Fura-2AM	and	monitored	baseline	calcium	levels		before	adding	BMMCs	and	monitoring	the	fluorescence	for	a	further	10	minutes.	Addition	of	BMMCs	did	not	produce	any	immediate	significant	increase	in	intracellular	calcium	in	neurons.	Moreover,	activation	of	BMMCs	with	antigen	after	10	minutes	of	co-culture	didn’t	produce	a	measurable	effect	on	neuronal	intracellular	calcium	as	seen	in	established	co-cultures	(Figure	4.8).	This	suggests	that	mast	cells	may	need	to	settle	for	some	time	on	DRG	before	effective	communication	is	established.						
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Figure.	4.8.	The	immediate	response	of	neurons	to	BMMCs.		(A),	Example	traces	of	the	immediate	effect	of	adding	BMMCs	on	intracellular	calcium	levels	of	neurons	and	following	Ag-induced	BMMCs	activation(n=9).	(B),	brightfield	and	fluorescence	images	of	2.5µM	Fura-2AM	loaded	DRG	culture	after	adding	BMMCs.		
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4.2.6	Effect	of	sensory	neurons	activation	on	mast	cells	degranulation.	As	shown	in	the	previous	section	and	reported	by	others	(Suzuki	et	al.,	1999)	(Mori	et	al.,	2002)	(Furuno	et	al.,	2004)	(Suzuki	et	al.,	2007)	(Hagiyama	et	al.,	2011),	stimulation	of	sensory	neurons	induces	calcium	signal	in	mast	cells	in	co-culture	but	classic	degranulation	is	not	investigated	.	Because	many	of	the	symptoms	of	neuroinflammatory	disorders	are	a	result	of	mediators	released	from	activated	mast	cells,	I	attempted	to	complete	the	picture	by	examining	the	effect	of	activated	sensory	neurons	on	mast	cell	degranulation	in	co-culture.	Sensory	neurons	in	1-day	old	co-culture	with	BMMCs	were	activated	with	1µm	of	Capsaicin	for	20	minutes	at	37oC.	Then,	the	percentage	of	β-Hex	release	in	the	supernatant	from	co-culture	was	measured.	As	shown	in	(Figure	4.9	A),	the	percentage	of	β	-hex	release	from	BMMC	after	capsaicin-	mediated	sensory	neuron	activation	was	significantly	higher	than	β-hex	release	in	co-culture	in	rest	(17	±0.73%	and	10.1	±0.54%,	respectively	P=0.02).	As	a	negative	control,	β-hex	release	was	also	measured	from	DRG	alone	and	capsaicin-	activated	DRG	to	rule	out	the	possibility	of	having	β-hex	release	from	DRG	culture.	Moreover,	β-hex	release	was	also	measured	from	BMMC	alone	and	capsaicin-	activated	BMMC	to	rule	out	the	possibility	of	non-specific	activation	of	BMMC	by	capsaicin.	All	together	the	results	from	these	experiments	indicate	that	sensory	neuron	activation	results	in	mast	cells	degranulation	and	release	of	mediators.			To	examine	the	possibility	that	the	mediator	released	from	activated	sensory	neurons	could	be	responsible	for	the	increased	mast	cell	degranulation	in	co-culture,	I	incubated	BMMCs	for	20	minutes	with	supernatant	from	capsaicin-activated	DRG	culture.	The	percentage	of	β-hex	release	in	both	groups	was	almost	the	same	5.4	±0.78%	(figure	4.9	B).	This	suggests	that	the	soluble	factors	from	activated	sensory	neurons	alone	are	not	enough	to	cause	mast	cell	degranulation,	and	cell-cell	contact	is	required	for	this	phenomenon.		
	
118	
Because	I	showed	before	that	sensory	neurons	enhance	Ag-activated	mast	cell	degranulation	(section	4.2.3),	I	aimed	to	investigate	if	the	mediators	released	from	activated	sensory	neurons	are	responsible	for	this	enhancement.	For	this,	I	cultured	BMMC	with	supernatant	from	capsaicin-activated	DRG	for	20	minutes	then	I	activated	BMMC	with	DNP	(Ag)	for	30	minutes.	Unexpectedly,	the	percentage	of	β-hex	released	from	BMMC	with	capsaicin-activated	DRG	supernatant	after	Ag	stimulation	was	significantly	lower	than	the	control	(16.5	±1.9%	and	11.7	±	0.8%,	respectively)	(P=0.042)	(Figure	4.9	C).	However,	the	lack	of	increase	in	Ag-activated	mast	cells	degranulation	with	supernatant	from	activated	sensory	neurons	confirms	again	that	the	crosstalk	between	mast	cells	and	sensory	neurons	depends	on	direct	contract	between	the	two	cell	types.				
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Figure.	4.9.	Effect	of	capsaicin-activated	sensory	neurons	on	BMMC	degranulation.		(A)	 Sensory	 neurons	 maintained	 for	 1-day	 in	 co-culture	 with	 BMMCs	 were	 activated	 with	 1µm	 of	Capsaicin	 for	 20	 minutes	 at	 37oC.	 Then,	 the	 percentage	 of	 β-hexosaminidase	 (β-Hex)	 release	 was	measured.	For	control,	β-Hex	release	was	also	measured	 from	DRG,	BMMC	and	capsaicin-activated	DRG	and	 BMMC	 (B)	 BMMCs	were	 cultured	 alone	 or	with	 supernatant	 from	 capsaicin-	 activated	 DRG	 for	 20	minutes.	 Then,	 β-hex	 release	 was	 measured.	 (C)	 Pre-sensitized	 BMMCs	 were	 cultured	 alone	 or	 with	supernatant	from	capsaicin	(Cap)-	activated	DRG	for	20	minutes.	Then,	β-hex	release	was	measured	after	activation	with	100ng/ml	DNP	for	30	minutes.	Total	β-hex	measured	from	BMMC	lysed	with	0.5%	Triton	X	l00.	Data	shown	are	mean	±	SEM	of	N=3,	each	performed	in	duplicate.	For	(A),	Data	were	analyzed	using	one-way	 ANOVA	 followed	 by	 Turkey’s	 multiple	 comparison	 post-test,	 while	 for	 (B	 and	 C)	 two-tailed	paired	t-test.	*	p<	0.05	and	**	p<	0.01	compared	to	appropriate	controls.	
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4.2.7	Adhesion	of	mast	cells	to	neurites	in	co-culture	model.	Because	the	sensory	neurons’	enhancement	of	mast	cell	activation	required	cell-cell	contact,	I	next	assessed	the	intercellular	adhesion	between	mast	cells	and	neurons.	In	order	to	obtain	a	quantitative	measurement,	I	used	Calcein-AM	flurometric	adhesion	assay.	To	optimize	this	assay,	I	first	quantified	the	lifetime	of	Calcein	in	mast	cells	by	measuring	the	fluorescent	signal	from	Calcein-labeled	BMMCs	at	different	time	points	(30	minutes,	1	hour,	2	hours,	3	hours,	6	hours,	and	24	hours).	Then,	I	calculated	relative	intensity	compared	to	the	reading	at	0	point.	Calcein	signals	in	BMMCs	were	found	to	be	stable	for	3	hours	after	loading.	After	24	hours	(end	of	experiment),	the	relative	intensity	of	Calcein	signal	was	however	decreased	to	0.27	(Figure	4.10).		Based	on	this	result,	I	set	up	the	optimum	time	for	adhesion	assay	to	be	done	after	2	hours	of	co-culture.			I	performed	adhesion	assay	as	shown	in	material	and	method	(Section	2.4);	DRG	were	first	seeded	on	Matrigel-coated	wells	and	cultured	for	1	day	in	order	to	establish	an	extensive	network	of	neurites.	The	next	day,	Calcein-	labeled	BMMCs	were	added	to	DRG	for	2	hours.	Non-adherent	cells	were	washed	away	by	spinning	the	plate	upside-down.	To	control	for	non-specific	adhesion	of	BMMCs	to	Matrigel,	some	Calcein–labeled	BMMCs	were	cultured	on	1	day-old	Matrigel-coated	wells	in	the	same	way	as	the	ones	in	co-cultures.	Even	after	vigorous	spinning	(Figure	4.10	B),	a	high	proportion	of	BMMCs	remained	attached	to	the	neurites	compared	to	wells	with	BMMC	cultures	alone	(Figure	4.10	C),	and	moreover	the	adherent	BMMCs	appeared	to	preferably	contact	to	neurites	over	cell	bodies	(Figure	4.10	B).		To	quantify	the	adhesion	between	mast	cells	and	neurons,	I	measured	the	fluorescent	from	Calcein-labeled	BMMCs	before	(for	total)	and	after	spinning	(for	adherent)	by	plate	reader.	I	expressed	the	results	as	percentage	of	the	adherent	to	the		total.	Without	the	presence	of	DRG,	only	a	few	percentages	of	BMMCs	(6±0.7%)	adhered	to	the	plate	(Figure	4.10	E).	In	the	presence	of	DRG,	the	number	of	adherent	BMMCs	increased	to	(28	
±1	%).			
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These	results	suggested	that	mast	cells	significantly	attached	to	neurons	in	vitro	(P=0.003).		This	morphological	attachment	may	influence	mast	cell	signaling.		
	
Figure.	4.10.	Adhesion	of	BMMC	to	neurons.		
(A)	Kinetics	of	calcein	labeling	of	BMMCs.	(B)	Superimposed	bright-field	and	fluorescent	image	showing	Calcein-labeled	 BMMCs	 (green)	 were	 co-cultured	 with	 DRG	 for	 2	 hours.	 Non-attached	 BMMCs	 were	removed.	 Then,	 images	 of	 live	 cells	were	 captured	 by	 inverted	 fluorescent	microscopy.	 (C)	 Fluorescent	image	 of	 non-specific	 attachment	 of	 calcein	 labeled-BMMCs	 to	 a	matrigel-coated	well.	 (D)	 DRG	 culture	alone.	 (E)	 BMMCs	 adhesion	 to	 DRG	 quantified	 as	 percentage	 of	 adherent	 BMMC	 to	 total	 BMMC	 before	washing.	Data	are	shown	as	mean	±	SEM	from	N=3.	Each	done	in	duplicate.	Data	were	analyzed	two-tailed	paired	t-test	**p<0.01	compared	to	BMMC	culture	alone.	Scale	bar	represents	10µm	
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4.3	Discussion	The	close	contact	and	interaction	between	mast	cells	and	neurons	are	increased	in	many	neurogenic	inflammatory	disorders	(Barbara	et	al.,	2004)	(Park	et	al.,	2003).	Indeed,	mast	cells	attached	to	neurons	in	IBS	biopsies	show	evidence	of	degranulation,	consistent	with	the	view	that	neurons	may	lead	to	increased	mast	cell	activity	(Park	et	al.,	2003)	(Barbara	et	al.,	2004).	Sensory	neurons	are	a	potential	source	of	potent	mast	cell	activators,	including	subP	(Karimi	et	al.,	2000)	(Okabe	et	al.,	2006)	and	CGRP	(Forsythe	et	al.,	2000)	(Rychter	et	al.,	2011).	In	neurogenic	inflammatory	disorders,	sensory	neurons	increase	neuropeptide	production	(Mayer	et	al.,	1988)	(Baluk,	1997).	The	close	association	of	mast	cells	to	sensory	neurons	may	thus	expose	mast	cells	to	these	neuropeptides	and	may	result	in	altered	mast	cell	function.	On	the	other	hand,	a	growing	body	of	evidence	suggests	that	mast	cells	and	their	mediators	may	also	participate	in	sensory	neuronal	signaling	(van	Houwelingen	et	al.,	2002)	(Kakurai	et	al.,	2006).	Collectively,	these	studies	offered	substantial	evidence	for	the	functional	bi-directional	crosstalk	between	mast	cells	and	sensory	neurons.	However,	the	role	of	cell-cell	contact	in	modulating	this	crosstalk	remains	unresolved.	In	this	chapter,	I	aimed	to	investigate	the	effect	of	direct	contact	between	sensory	neurons	and	mast	cells	on	their	biological	activity	by	using	BMMC-DRG	co-culture	methods.	The	in	vitro	method	used	in	this	study	has	great	potentials	for	conducting	detailed	investigations	on	neuro-immune	interactions	in	general	and	sensory	neuron-mast	cell	interactions	in	particular.		To	characterize	functional	interactions	established	in	DRG-BMMC	co-cultures,	I	examined		neuronal	morphology.	Addition	of	BMMCs	to	DRG	culture	for	1	day	did	not	affect	either	total	neurite	length	or	neurite	complexity.	Although	it	is	reported	that	activated	mast	cells	produce	NGF	and	TNF-a,	which	enhance	neuronal	outgrowth	and	plasticity	(Leon	et	al.,	1994)	(Kakurai	et	al.,	2006),	in	my	co-culture	system,	the	former,	at	least	was	not	apparent.		Key	methodological	differences	that	could	account	for	the	lack	of	morphological	changes	in	my	co-culture	system	could	be	due	to	the	use	of	adult	versus	embryonic	DRG	culture	(Leon	et	al.	1994)	.	It	is	well	known	that	embryonic	DRG	cultures	are	dependent	on	NGF	for	their	survival	(Melli	and	Höke,	2009),	while	adult	
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DRG	cultures	that	are	not	dependent	on	NGF	for	their	survival	despite	its	receptors	expression.	Indeed,	the	role	of	NGF	in	adults	shifts	away	from	the	neurotrophic	effect	to	a	pro-inflammatory	effect	that	regulates	neuronal	function	and	plasticity	(Sofroniew	et	al.,	2001).	Kakurai	et	al.,	2006	proposed	that	mast	cell-	derived	TNFa	promotes	sensory	neuron	elongation	in	vivo	in	a	contact	hypersensitivity	model	in	mice.		The	evidence	for	mast	cells	being	the	source	of	TNF-a		relies	on	comparisons	made	between	wild	type	and	c-kit	mutant	mice,	which	are	known	to	be	deficient	in	mature	mast	cells.	However,		because	the	full	extent	of	the	loss	of	c-kit	signaling	is	not	yet	completely	understood,	some	of	these	differences	may	be	due	to	changes	in	neuronal	development	and/or	function.	Interestingly,	one	study	showed	that	co-culture	of	activated	peritoneal	mast	cells	with	4-day-old	myenteric	neurons	for	2	days	significantly	reduces	neuronal	survival	(Sand	et	al.,	2009).	This	neuronal	loss	was	shown	to	be	dependent	on	mast	cell	degranulation	and	release	of	PG	and	IL-6.	Peritoneal	mast	cells	are	classified	as	CTMC	(Chen	and	Enerbäck,	1999)	while	myenteric	neurons	are	referred	as	the	motor	neuron	of	the	unique	enteric	nervous	plexus	(Furness	et	al.,	2014).	Mast	cell	and	neuron	heterogeneity	is	an	important	issue	because	it	may	lead	to	different	response	to	the	same	stimulus.	Moreover,	it	is	well	known	that	in	vitro	some	mediators	that	cause	persistent	firing	of	primary	DRG	can	induce	neuronal	apoptosis	(Dodd,	2002);	of	note	is	that	in	my	study	the	period	of	mast	cell	activation	was	limited	to	30	minutes	and	thus	any	pro-apoptotic	effects	of	mast	cell	derived	mediators	were	unlikely	to	have	been	activated.			Because	mast	cells	mature	only	within	tissues	(Galli,	2000)	when	they	are	in	proximity	to	other	cell	types,	one	can	speculate	that	mast	cell	interactions	with	other	cells	may	regulate	mast	cell	function.	To	test	this	idea,	the	influence	of	DRG	neurons	on	mast	cell	degranulation	was	quantified	and	compared	with	data	from	BMMCs	alone.		Interestingly,	I	found	that	co-culture	mast	cells	with	neurons	enhances	not	only	constitutive	(antigen-independent)	mast	cell	degranulation	but	also	Ag-activated	mast	cell	degranulation.	In	both	conditions,	the	development	of	this	enhancement	is	time-depended,	with	a	significant	effect	only	measurable	after	6	hours	of	co-culture	and	then	increasing	over	
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the	ensuing	24	hours.	Besides,	I	showed	that	sensory	neurons-mediated	mast	cell	degranulation	is	a	contact-dependent	as	compared	to	results	from	co-cultures	in	a	transwell	and		supernatant	from	co-culture	failed	to	enhance	mast	cells	degranulation.				The	observation	that	mast	cell	degranulation	may	be	modulated	by	communication	with		other	cells,	even	in	the	absence	of	external	stimulation,	has	been	reported	previously.		co-culture	HLMC	with	ASM	show	increased	constitutive	histamine	release	(Hollins	et	al.,	2008)	which	starts	after	16	hours	of	co-culture	(Lewis	et	al.,	2016).	Also	activated	T-cells	enhance	constitutive	histamine	release	from	BMMC	when	direct	co-cultured	for	16	hours	(Inamura	et	al.,	1998).	Co-culture	LAD2	with	tumor	cells,	like	pancreatic	ductal	adenocarcinoma	for	24	hours		also	show	enhanced	constitutive	tryptase	release	(Ma	et	al.,	2013).	However,	IgE-mediated	mast	cell	degranulation	is	influenced	differently	by	communication	with	other	cells.	ASM	(Hollins	et	al.,	2008)	and	bone-marrow	stromal	cells	(Brown	et	al.,	2011)	significantly	decrease	IgE-	mediated	histamine	and	B-hex	release,	respectively.		In	contrast,	co-culture	mast	cells	with	activated	T-cells	results	in	enhancing	Ag-activated	mast	cells	degranulation	(Inamura	et	al.,	1998).			Mast	cells,	upon	activation,	not	only	release	stored	mediators	by	degranulation	but	also	synthesize	de	novo	cytokines	(See	section	1.1.3.3).	Different	cytokines	have	different	functions	in	health	and	diseases.	Some	of	these	cytokines	are	reported	to	influence	pain	perception	and	are	likely	involved	in	sensory	neuron	activation	.	For	example,	IL-6	and	TNFα	are	both	known	to	sensitize	nociceptors	(Hughes	et	al.,	2013).	Thus,	I	measured	the	production	of	these	cytokines	in	BMMC-DRG	co-culture.	My	results	showed	that	neurons	enhanced	mast	cells	derived-IL-6	secretion	in	co-culture,	but	this	effect	was	significant	only	after	Ag	stimulation.	Conversely,	TNFα	production	by	mast	cells	in	co-culture	did	not	change	with	the	presence	of	neurons	even	after	Ag-	stimulation.	These	data	indicate	that	cross-talk	with	neurons	initiates	or	facilitates	a	stimulatory	signal	in	mast	cells	that	enhances	degranulation	and	Ag-induced	IL-6	production.	This	is	in	agreement	with	what	has	been	reported	in	vivo,	namely	that	mast	cells	of	IBS	patients	
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secrete	greater	amounts	of	the	IL-6	(Liebregts	et	al.,	2007)	by	influences	enteric	neuronal	hyperexcitability	(O'Malley	et	al.,	2011).	IL-6	has	a	pivotal	role	in	the	pathology	of	inflammatory	neuropathy.	In	vivo,	IL-6	has	been	found	to	induce	mechanical	nociceptive	plasticity	(Melemedjian	et	al.,	2010)	(Hughes	et	al.,	2013)	that	evokes	allodynia	(Oka	et	al.,	1995)	(Dina	et	al.,	2008).	Therefore,	pain-related	disorders	may	involve	an	increase	in	IL-6	levels.	Moreover,	the	role	of	IL-6	in	development	of	neurogenic	inflammation	depends	also	appears	to	involve	its	effects	on	sensory	neurons	because	selectively	blocking	IL-6	receptors	in	neurons	reduces	inflammation	in	an	Ag-induced	arthritis	model	(Ebbinghaus	et	al.,	2015).	Indeed,	anti-IL-6	receptor	antibodies	show	promising	therapeutic	potential	in	controlling	pain	in	rheumatoid	arthritis	(Nishimoto	et	al.,	2009).			It	has	been	shown	that	co-culture	mast	cells	with	fibroblasts	(Fitzgerald	et	al.,	2004),	and	immune	cells	like	regulatory	T-cells	(Ganeshan	and	Bryce,	2012)	also	lead	to	enhanced	IL-6	production	from	mast	cells.	In	contrary	to	my	result,	enhancement	of	TNFa	production	by	mast	cells	has	been	reported	following	co-culture	mast	cells	with	other	cell	types	such	as	pancreatic	ductal	adenocarcinoma	(Ma	et	al.,	2013)..	TNF-α	has	also	been	reported	to	cause	a	pronounced	sensitization	in	colonic	sensory	afferents	(Hughes	et	al.,	2013),	but,	at	least	in	my	model,	it	seems	sensory	neurons	don’t	influence	TNF-a	synthesis	by	mast	cells	in	response	to	Ag.	Remarkably,	the	selective	enhancement	in	certain	mast	cells’	mediators	(but	not	all	mediators)	may	underlie	the	mechanism	of	sensory	neuron-mast	cell	cross	talk.	The	pathways	of	IgE-	mediated	IL-6	and	TNFa	transcription	in	mast	cell	are	different	(Section	1.1.2.1).	IgE-	mediated	TNFa	production	is	dependent	on	PKC/NFAT	signaling	pathway,	but	this	pathway	doesn’t	contribute	in	IL-6	production	(Klein	et	al.,	2006)	(Figure	1.1).	This	suggests	that	the	neuronal	enhancement	of	IgE-	mediated	mast	cells	function	most	likely	doesn’t	involve	PKC/NFAT	pathway.		
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With	respect	to	neuroimmune	and	neuronal-mast	cell	interaction,	my	study	is	the	first	to	
show	that	direct	contact	with	sensory	neurons	enhances	IgE-	activated	mast	cell	mediator	
secretion.	However,	the	vital	role	of	nociceptive	neurons	on	IgE-mediated	activation	has	been	hinted	at	previous	in	in	vivo	experiments.	Neonatal	capsaicin	treatment	to	denervate	nociceptors	abolishes	IgE-mediated	dermatitis	in	mice	(Nakano	et	al.,	2008)	and	IgE-induced	inflammation	in	rats’	lungs	(Sestini	et	al.,	1989).		A	number	of	different	mechanisms	may	underlie	the	enhancing	role	of	IgE-mediated	mast	cell	function	following	co-culture	with	sensory	neurons.	It	could	either	reflect	an	increased	proliferation	and	survival	of	mast	cells	or	an	increase	in	signaling	/	activation	of	mast	cells.	I	tested	the	first	hypothesis	because	previous	reports	have	found	that	other	cells	types	induce	mast	cells	proliferation	like	human	umbilical	vein	endothelial	cells	(HUVEC)	(Mierke	et	al.,	2000),	fibroblasts	(Sellge	et	al.,	2004),	epithelial	cells	(Hsieh	et	al.,	2005)	and	airway	smooth	muscle	(Hollins	et	al.,	2008).	However,	the	cell	growth	rate	of	BMMCs	after	maturation	doesn’t	go	with	this	possibility	(Figure	2.1)	because	it	is	known	that	mast	cells	stop	proliferation	after	maturation	.	Moreover,	the	standard	curve	of	total	B-Hex	absorbance	from	different	BMMC	cell	count	(Figure	2.2)	shows	that	more	than	300	x103	BMMCs	are	needed	to	get	the	20%	enhancement	of	B-Hex	absorbance	as	seen	in	co-culture.	Thus,	it	seems	nonsensible	that	BMMC	could	extensively	proliferate	that	much	in	co-culture	to	produce	this	significant	high	amount	of	B-Hex.	However,		
further	experiments	needs	to	be	done	to	assess	the	possibility	of	neuronal	effect	on	BMMC	
proliferation	in	chronic	co-culture.	Suggested	methods	like	tetrazolium	salts	(MTT)	with	colorimetric	detection	are	recommended.			Another	possible	enhancement	of	mast	cell	function	in	the	presence	of	neurons	is	due	to	chemical	intercellular	crosstalk.	Thus,	I	reproduced	previously	published	data	regarding	mast	cell-neuron	positive	feedback	loop.	Consistent	with	what	has	been	reported,	I	confirmed	the	intercellular	communication	between	mast	cells	and	neurons	by	monitoring	calcium	signaling	in	both	cell	types	(Suzuki	et	al.,	1999)	(Suzuki	et	al.,	2001)	
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(Suzuki	et	al.,	2005).	Ag-induced	mast	cells	activation	was	followed	by	neuronal	activation,	while	Capsaicin-	induced	nociceptor	activation	was	followed	by	mast	cell	activation.	The	lag	time	between	activation	of	the	cells	,	likely	arising	from	the	time	needed	for	chemical	communication	by	release	mediators	such	as	SubP	(Suzuki	et	al.,	1999)	to	generate	signals	in	the	contacted	cell.	I	did	not	seek	to		identify	the	specific	mediators	involved	in	this	communication	as	it	was	beyond	the	scope	of	my	study	and	this	has	already	been	the	topic	of	intensive	investigation	(See	introduction	section	1.3.1).	However,	it	is	worth	noting	that	in	previous	studies	of	intercellular	communication	between	mast	cells	and	neurons,		after	stabilizing	the	co-culture	for	2	days	(Suzuki	et	al.),	while	I	found	that	neurons	could	induce	mast	cell	degranulation	at	rest	within	as	minimum	as	6	hours,	indicating	that	mast	cell	attachment	to	sensory	neurons	is	rapid	and	capable	of	activating	mast	cells	independent	of	external	stimulants.	To	test	this	hypothesis,	I	measured	calcium	signals	in	neurons	immediately	after	addition	of	mast	cells,	however	no	obvious	response	from	neurons	was	recorded.	Moreover,	neurons	didn’t	response	even	after	stimulating	mast	cells	with	Ag	for	10	minute.	This	suggests	that	mast	cells	may	need	to	establish	good	structural	interaction	with	neurons	before	effective	communication	is	established,	and	that’s	seems	to	needs	some	time	(more	than	10	minutes).	Collectively,	these	findings	support	the	critical	role	of	cell-cell	contact	between	mast	cells	and	neurons	for	their	effective	communication.		Thus,	my	next	aim	was	to	examine	the	adhesion	between	neurons	and	mast	cells.			The	mechanism	of	the	increased	mast	cell	activation	in	the	presence	of	sensory	neurons	could	be	explained	due	to	the	mediators	released	from	activated	neurons	that	could	induce	calcium	signaling	(Figure	4.7)	and,	more	importantly,	degranulation	(Figure	4.9)	in	mast	cells	in	a	contact-dependent	mechanism.	This	has	been	suggested	by	other	authors	(Janiszewski	et	al.,	1994)	(Mori	et	al.,	2002)	(Suzuki	et	al.,	1999)	(Suzuki	et	al.).	But,	the	fact	that	physical	separation	of	mast	cells	from	neurons	and/or	incubation	of		mast	cells	with	supernatant	collected	from	neuronal	cultures	did	no	reproduce	the	enhancement	effect	of	sensory	neurons	seen	in	co-culture	suggests	that	this	communication	may	depend	on	more	than	just	the	soluble	factors.		Indeed,	direct	cell-cell	contact	between	mast	cells	and	neurons	appears	vital	in	this	crosstalk.	As	reported	
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by	other	authors	using	co-culture	methods	(Ohshiro	et	al.,	2000)	(Suzuki	et	al.,	2001)	(Suzuki	et	al.,	2004),	I	subsequently	showed	that	mast	cells	firmly	adhere	to	neurons.	Although	the	adhesion	kinetics	were	not	studied	in	detail	in	this	study	because	of	the	short	lifespan	of	calcein	fluorimetric	stain,	2	hours	of	co-culture	was	sufficient	time	to	get	more	than	20%	of	mast	cells	attached	to	neurons.	This	percentage	is	in	agreement	with	that	reported	previously	using	a	more	subjective	method	for	quantifying	mast	cell	adhesion	by	counting	mast	cell	in	co-culture	under	light	microscope	(Furuno	et	al.,	2005).	However,	the	percentage	of	mast	cells	adhered	to	neurons	was	low	compared	to	that	reported	for	human	lung	mast	cells	adherent	to	fibroblast	(Trautmann	et	al.,	1997),	ASM	(Yang	et	al.,	2006)	or	bronchial	epithelium	(Sanmugalingam	et	al.,	2000)	when	quantified	using	histamine-based	adhesion	assay.		In	this	assay,	total	histamine	from	co-culture	are	measured.	Knowing	that	fibroblast	ASM	and	epithelium	cells	don’t	contain	histamine,	the	total	amount	of	histamine	in	co-culture	will	correlate	to	number	of	adherent	mat	cell.	However,	the	fact	that	other	cells	may	influence	histamine	release	and	content	in	mast	cells	could	questioning	the	validation	of	this	method.	This	difference	in	adhesion	percentages	could	be	contributed	to	mast	cell	heterogeneity	between	BMMC	and	lung	mast	cells,	different	cell	type	partners,	different	adhesion	molecules	involved	and/or	different	methods	to	quantify	the	adhesion.				Mast	cell	tendency	to	attach	to	other	cells	supports	the	theory	that	adhesion	is	required	for	them	to	perform	their	function	normally.	Indeed,	mast	cells	are	not	found	in	blood,	but	mature	within	tissues	following	contact	with	other	cells	or	matrix.	Therefore,	in	vivo	mature	mast	cells’	phenotype	is	regulated	by	other	cells.	This	has	led	to	the	speculation	that	studying	the	pharmacological	regulation	of	mediator	release	from	mast	cells	in	suspension	does	not	reflect	the	mast	cell	phenotype	in	vivo.	Cell	adhesion	may	influence	intracellular	signaling	and	the	response	to	different	agonists.	Thus,	I	hypothesize	that	mast	cells’	attachment	to	neurons	enhances	mast	cell	function.	Interestingly,	the	kinetics	of	the	increase	in	mast	cell	degranulation	following	co-culture	with	neurons	closely	paralleled	the	kinetics	of	adhesion	.	Although	the	exact	molecular	mechanism	of	how	attachment	of	mast	cells	to	neurons	enhances	mast	cell	function	needs	further	
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investigation,	a	number	of	mechanisms	can	be	proposed.	(1)	The	close	apposition	of	mast	cells	to	nociceptor	neurons	may	form	a	kind	of	synapse.	This	structural	arrangement	could	expose	mast	cells	directly	to	undiluted	neuronal	mediators	as	sub	P	and	CGRP	that	activate	and	induce	mast	cells	degranulation	(Suzuki	et	al.,	1999)	(Forsythe	et	al.,	2000)	(De	Jonge	et	al.)	(Rychter	et	al.,	2011),	and	their	effects	are	additive	with	IgE	–mediated	activations.	(2)	Adhesion	of	mast	cells	to	neurons	and	exposure	to	neuronal	mediators	could	alter	mast	cells	phenotype	and	may	result	in	enhancing	their	IgE-mediated	response	(Blennerhassett	and	Bienenstock,	1998).	As	mentioned	in	introduction	(Section	1.1.4),	changing	mast	cell	microenvironment	could	influence	their	heterogeneity	and	response	to	different	stimuli	by	inducing	different	gene	expression	(Metcalfe	et	al.,	1997).		(3)	Mast	cell	attachment	results	in	cytoskeletal	changes	and	redistribution	of	secretory	granules	to	the	cell	periphery	and	enhanced	IgE-mediated	degranulation	(Hamawy	et	al.,	1994).	(4)	Mast	cell	adhesion	to	neurons	helps	to	stabilize	FceRI	at	the	membrane	and	‘signaling	complexes’	through	anchoring	of	adaptor	proteins.	IgE-mediated	activation	in	fibronectin-adherent	mast	cells	markedly	enhances	FceRI	tyrosine	phosphorylation	compare	to	non-adherent	cells	(Hamawy	et	al.,	1993).	In	support	of	the	latter,	it	has	previously	been	shown	that	co-culture	BMMC	with	fibroblasts	or	SCG	for	3	days	results	in	increased	FceRI	surface	expression	and	enhanced	Ag-induced	calcium	signaling	(Katz	et	al.,	1992)	(Suzuki	et	al.,	2005).			Among	other	adhesion	molecules,	recent	studies	identified	CADM1	as	an	adhesion	molecule	expressed	on	mast	cells	that	may	mediate	homotypic	adhesion	to	neurons	(Furuno	et	al.,	2005)	(Hagiyama	et	al.,	2011).	However,	the	contribution	of	this	adhesion	
molecule	in	functional	crosstalk	has	not	been	studied	before,	and	subsequently	became	the	
focus	of	my	studies.		In	conclusion,	the	results	reported	in	this	chapter	add	to	existing	evidence	for	a	positive	feedback	loop	between	mast	cells	and	sensory	neurons.		Moreover	I	showed	for	the	first	time	that	sensory	neurons	have	the	ability	to	enhance	IgE-mediated	mast	cell	activation.	
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My	data	indicates	that	this	effect	is	dependent	on	cell-cell	contact.	Identifying	the	
adhesion	molecules	involved	in	this	crosstalk	and	understanding	the	signaling	pathways	
behind	this	are	important	future	goals.																							
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Chapter	5:	Investigating	the	involvement	
of	CADM1	in	mast	cell	–neuron	crosstalk		
	
5.1	Introduction	Cell-cell	adhesion	is	a	fundamental	process	for	intercellular	communication.	It	ensures	tight	contacts	between	neighbouring	cells,	which	are	necessary	not	for	maintaining	tissue	integrity	but	also	for	regulating	specific	cell-cell	signalling.	With	respect	to	mast	cells,	mast	cells	in	vivo	mature	only	after	they	migrate	to	tissues	and	adhere	to	ECM	or	other	cells	such	as	fibroblasts,	muscle	cells	and	neurons	(Hamawy	et	al.,	1994).	In	the	preceding	chapter,	I	showed	that	mast	cells	attach	directly	to	sensory	neurons	in	culture	and	that	there	are	significant	bi-directional	consequences	of	this	attachment.	I	demonstrated	that	structural	contact	of	mast	cells	to	neurons	induces	mast	cell	activation	and	production	of	pro-inflammatory	mediators.	More	remarkably,	neurons	enhanced	IgE-mediated	mast	cell	activation	in	cell–cell	contact-dependent	manner.	
However,	the	identify	and	role	of	adhesion	molecules	involved	in	this	crosstalk	is	unknown.		As	mentioned	in	introduction	(section	1.1.1.1),	mast	cells	express	a	variety	of	adhesion	molecules,	including	integrins	(Sperr	et	al.,	1992),	E-	and	N-cadherins	(Nishida	et	al.,	2003)	(Suzuki	et	al.,	2004),	ICAM1	(Toru	et	al.,	1997),	and	cell	adhesion	molecule-1	(CADM1)	(Ito	et	al.,	2003)	(Yang	et	al.,	2006)	(Moiseeva	et	al.,	2013a).	Among	all	these	molecules,	I	chose	to	focus	on	CADM1,	because	as	mentioned	in	Section	1.3.2.1,	it	had	previously	been	proposed	to	participates	in	mast	cell	adhesion	to	other	types	of	peripheral	neurons	(Furuno	et	al.,	2005)	(Hagiyama	et	al.,	2011).	More	importantly,	it	is	suggested	that	CADM1	enhance	neuronal	to	mast	cell	crosstalk.	This	suggestion	was	based	on	the	observation	that	calcium	signal	of	mast	cell	lines	like	IC-2	that	express	all	other	adhesion	molecules	except	CADM1	do	not	show	an	increase	in	response	to	
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scorpion	venom-activated	superior	cervical	ganglion	neurons	in	co-culture	compared	to	BMMCs,	which	express	endogenous	CADM1	(Furuno	et	al.,	2005).	Indeed,	transfection	of	IC-2	cells	with	CADM1	normalized	their	response	to	activated	neurons	in	co-culture.	However,	the	contribution	of	CADM1	in	neuronal	enhancement	of	IgE-signalling	in	mast	cells	was	not	investigated	yet.																						
	
133	
5.2	Results	
5.2.1	CADM1	expression	and	distribution	in	mast	cells	and	neurons	First,	I	investigated	CADM1	protein	expression	in	BMMC	and	DRG	cultures.	Lysates	were	prepared	from	each	culture	separately	then	probed	for	CADM1.	GAPDH	and	a-Tubulin	were	used	as	loading	controls	for	chemiluminescent	and	Li-cor	WB	techniques,	respectively.	My	results	showed	that	both	cell	types	express	CADM1	(Figure	5.1)	but	of	different	molecular	weights.	BMMC	expressed	CADM1	as	a	protein	with	molecular	weight	of	∼100	kDa,	while	in	DRG	the	protein	was	∼75	kDa.	Notably,	the	band	from	DRG	lysate	was	more	intense	compared	to	that	from	BMMCs.	As	a	positive	control,	CADM1	expression	was	also	investigated	in	lung	tissue	(Masuda	et	al.,	2002)	where	I	observed	it	as	a	single	band	of	∼75	kDa	(Figure	5.1a).	Furthermore,	because	it	is	reported	that	mouse	fibroblasts	don’t	express	CADM1	(Ito	et	al.,	2003),	I	used	NIH/3T3	lysate	as	a	negative	control	to	validate	CADM1	antibody	specificity.	As	expected,	no	bands	were	detected	at	any	known	size	of	CADM1	isoforms	(Figure	5.1a).														
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Figure.	5.1.	Protein	expression	of	CADM1	in	BMMC	and	DRG.	Immunoblot	of	lysates	prepared	from	NIH/3T3,	Lung,	DRG	and	BMMC	cultures,.		The	blots	were	probed	with	anti-CADM1.	Bands	were	detected	using	chemiluminescent	(A)	or	Li-cor	(B)	methods.		The	blots	were	probed	again	with	anti-GAPDH	and	anti-a-Tubulin	to	indicate	the	total	amount	of	proteins	loaded	per	lane.	The	m.w.	scale	is	shown	to	the	right	of	the	blot.	The	expected	sizes	of	the	different	CADM1	isoforms	(a-d)	are	shown	on	the	left.	Lysate	from	lung	tissue	and	NIH/3T3	were	used	as	positive	and	negative	controls,	respectively.	Representative	examples	of	three	experiments	performed	on	each	cell	type.				
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				Next,	I	examined	the	subcellular	distribution	of	CADM1	in	BMMCs	and	neurons.	BMMCs	cultures	were	double	stained	with	Abs	against	CADM1	and	the	mast	cell	marker	c-Kit.	All	BMMCs	showed	strong	expression	of	CADM1.	As	shown	in	(Figure	5.2	A),	CADM1	staining	was	concentrated	mainly	at	the	cell	membrane	of	BMMCs	as	was	c-Kit.	CADM1	showed	a	punctate	distribution,	compared	to	c-Kit.	Fluorescence	intensities	of	CADM1	and	c-Kit	were	plotted	across	the	cell	(Figure	5.2	A2),		fluorescence	intensities	of	both	Abs	significantly	decreased	in	cytoplasm	compared	to	the	membrane.	This	confirms	that	CADM1	and	c-Kit	are	located	in	the	peripheral	margin	of	mast	cells.	2-day	old	DRG	cultures	were	also	double	stained	with	Abs	against	CADM1	and	the	neuronal	marker	b-tubulin.	All	different	sizes	of	soma	showed	strong	expression	of	CADM1.	In	contrast	to	BMMCs,	CADM1	distributed	homogeneously	within	the	soma	(Figure	5.2	B).	However,	CADM1	stained	some	of	neurites	(white	arrows),	mainly	the	ones	with	big	diameter	(Figure	5.2C)	but	not	along	their	whole	length.	Remarkably,	CADM1	was	expressed	only	in	b-tubulin	immunoreactive	neurons	but	not	any	of	the	non-neuronal	cells	(arrowheads).	Neurites	and	soma	showed	the	same	pattern	of	CADM1	distribution	as	shown	in	fluorescence	intensities	plot	(Figure	5.2B	2-3);	in	both	structures	CADM1	showed	diffuse	distribution.									
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Figure.5.2	Immunocytochemistry	expression	of	CADM1	by	BMMCs	and	neurons.		
(A-1),	Confocal	immunofluorescence	images	of	c-Kit	(red)	and	CADM1(green)	in	BMMC.	Scale	bar	represents	10µm.	(A-2),	The	plot	shows	the	variation	in	fluorescence	intensity	along	the	yellow	arrow.	Notably,	the	cell	membrane	is	the	most	intensely	fluorescent.	(B-1)	immunofluorescence	images	of	b-Tubulin	(red)	and	CADM1(green)	in	DRG	culture.	White	arrows	indicate	CADM1	immunoreactive	neurites.	Note	that	non-neuronal	cells	are	negative	for	CADM1	(arrowheads).	Scale	bar	represents	20µm.	(B-2)	and	
(B-3)	plots	show	the	variation	in	fluorescence	intensity	along	the	yellow	arrows	in	neurite	and	soma,	respectively.	(C),	Confocal	immunofluorescence	images	of	b-tubulin	(red)	and	CADM1(green)	in	DRG	cultures	(bottom).	Scale	bar,	20	µm.	Representative	examples	of	three	experiments	performed	on	each	cell	type.			
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Because	immunocytochemistry	analysis	suggested	that	CADM1	is	concentrated	at	the	cell	surface	of	BMMCs,	FACS	was	performed	to	measure	CADM1	surface	and	total	expression	in	BMMCs.	1X106/reaction	of	non-	permeabilized	and	TritonX100-permeablized	BMMCs	were	double	labelled	with	conjugated	c-Kit	and	CADM1	Abs.	Then,	CADM1	expression	was	measured	by	FACS	from	both	groups.	Results	from	FACS	analysis	revealed	that	almost	all	BMMCs	expressed	pronounced	surface	CADM1	at	level	comparable	to	total	expression	(Figure	5.3).	However,	BMMCs	expressed	surface	CADM1	as	two	distinct	population	subsets.	The	majority	(88.3%)	of	BMMCs	expressed	surface	CADM1	with	medium	fluorescence	intensity	and	only	(9.5%)	was	with	high	fluorescence	intensity.	In	contrast,	BMMCs	expressed	total	CADM1	as	single	population	with	high	fluorescence	intensity.			
	
Figure.5.3	Flow	cytometric	analysis	of	surface	and	total	CADM1	expression	by	BMMCs.		1X106	BMMC/reaction	of	non-	permeablized	(A)	and	TritonX100-permeablized	(B)	BMMCs	were	double	labelled	with	conjugated	c-Kit	and	CADM1	Abs	and	analysed	by	flow	cytometry.	BMMCs	were	gated	as	c-kit+	CADM1high	cell	subset	and	c-kit+	CADM1medium	cell	subset.	Numbers	in	plots	are	the	percentages	of	cells	in	the	indicated	gate.	Representative	examples	of	two	experiments.				
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As	I	showed	above,	CADM1	was	highly	expressed	on	BMMCs	and	DRG	neurons.	Next,	I	investigated	the	localization	of	this	adhesion	molecule	in	BMMCs-neuron	co-culture	by	immunocytochemistry.	BMMCs	were	co-cultured	with	DRG	culture	for	24hours.	After	removal	of	non-adherent	BMMCs,	co-cultures	were	stained	with	the	Abs	to	CADM1	,	FceRI	and	b-tubulin	to	identify	mast	cells	and	neurons,	respectively.	Representative	fluorescence	images	are	shown	in	(Figure	5.4).	CADM1	clearly	stained	almost	all	BMMCs	and	neuron	soma	but	not	the	whole	length	of	neurites	(Figure	5.4B).	Interestingly,	CADM1	appeared	intense	at	the	site	of	neurites	where	BMMCs	attached.	Fluorescence	intensities	plot	of	the	site	of	BMMC-neuron	attachment	showed	that	CADM1	intensity	increased	in	the	periphery	of	BMMCs,	but,	in	addition,	it	extended	to	area	of	b-tubulin	fluorescence	signal	with	no	discontinuation	of	its	signal	(Figure	5.4C),	consistent	with	the	notion	that	CADM1	may	mediate	BMMC	attachment	to	neurons.				
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Figure	5.4	A	representative	fluorescence	images	of	the	co-culture	of	BMMC	and	DRG	neurons.		BMMCs	were	co-cultured	with	DRG	for	24	hours.	After	removal	of	nonadherent	BMMCs.	Co-cultures	were	stained	with	CADM1	and	b-Tubulin	to	label	neurons.	(A)	Confocal	image	for	co-culture	with	BMMC	labelled	with	FceRI.	(B-C1)	showing	that	CADM1labeled	all	BMMCs	and	part	of	neurites	where	BMMCs	attached	(White	Arrow).	(C-2)	Fluorescence	intensities	plot	of	the	site	of	BMMC-	neurite	attachment	(yellow	arrow)	scale	bar	represents	10	μm.	Representative	examples	of	three	experiment.	
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5.2.2	BMMCs	adhesion	to	neurons	is	mediated	mainly	by	CADM1	Having	shown	that	both	BMMCs	and	neurons	strongly	express	CADM1	when	analyzed	by	both	confocal	immunofluorescence	and	western	blot,	I	next	wished	to	determine	whether	CADM1	is	required	for	BMMC-	Neuron	adhesion.	Calcein-labeled	BMMCs	were	incubated	with	different	concentration	of	CADM1	peptide	(0,	1,	3,	10	and	30	μg/ml)	for	30	minutes	at	37oC	before	co-culture	them	with	DRG.	After	2	hours,	non-adherent	BMMCs	were	removed,	and	the	percentage	of	adherent	BMMC	was	calculated.	My	results	showed	that	blocking	CADM1	on	BMMCs	inhibited	the	adhesion	of	BMMC	to	neurons	in	a	concentration-dependent	manner	(Figure	5.5	A)	and	was	almost	abolished	(3.1	±	2	%)	at	the	maximum	concentration	of	blocking	peptide	tested	(30μg/ml)	when	compared	to	percentage	of	BMMC	adhered	to	neurons	in	the	absence	of	blocking	peptide	(37.1	±	1.26%).	In	contrast,	incubating	DRG	cultures	with	CADM1	peptide	before	co-culture	did	not	significantly	reduce	adhesion	of	BMMC	except	at	the	maximum	concentration	of	blocking	peptide	(30μg/ml)	where	some	attenuation	in	percentage	of	BMMC	adhesion	to	neurons	could	be	seen,	but	this	did	not	achieve	significance	(P=0.062)	(Figure	5.5	B).	Unfortunately,	higher	concentrations	of	the	blocking	peptide	could	not	be	tested	for	technical	reasons.		None	the	less,	these	results	indicate	that	CADM1	on	mast	cells	mediates	up	to	90%	of	the	adhesion	between	mast	cells	and	neurons.								
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Figure	5.5	Attenuation	of	BMMC-	neurons	adhesion	by	CADM1	blocking	peptide.		BMMCs(A)	or	DRG	cultures	(B)	were	incubated	with	different	concentration	of	CADM1	blocking	peptide	for	30	minutes	at	37oC	before	co-culture.	Percentage	of	adherent	BMMC	was	calculated	using	the	calcein	adhesion	assay.	Each	condition	was	done	in	duplication.	N=3.	Each	point	represents	the	mean	±SEM.	One-way	ANOVA	followed	by	Turkey’s	multiple	comparison	post-test	was	performed.	*	denotes	p<	0.05,	**	p<	0.01	and	***	p<	0.001	compared	to	the	percentage	of	BMMC	adhesion	in	the	absence	of	CADM1	blocking	peptide.												
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To	validate	the	results	from	the	CADM1	blocking	peptide,	I	also	performed	CADM1	knockdown	experiments	in	BMMCs	(detailed	protocol	is	in	section	2.7.2).	On	brief,	4-5×106	BMMCs	/	reaction	were	transfected	with	2μg	of	CADM1	ShRNA	or	scrambled	plasmid	using	Amaxa	Nucleofector	II	(Amaxa).	After	48	hours,	cells	were	sorted	using	FACS.		Only	the	GFP	expressing	cells	were	carried	out	for	subsequent	experiments.	The	effectiveness	of	CADM1	knockdown	was		~100%	in	GFP-sorted	BMMC,	(see	section	2.7.1).	Transfected	BMMC	were	incubated	with	DRG	cultures	for	2	hours	at	37°C	prior	to	performing	the	adhesion	assay	(	described	in	section	2.4.2).	CADM1	knockdown	significantly	reduced	the	adhesion	of	BMMC	to	neurons	from	37	±	1.3%	in	non-transfected	cells	or	33	±	0.7	%	in	scrambled	ShRNA	transfected	cells	to	11.6	±	0.8%	in	CADM1	ShRNA	transfected	BMMCs	(Figure	5.6).	This	result	confirms	the	major	role	of	CADM1	in	BMMC	adhesion	to	neurons.	
	
Figure	5.6	CADM1	knockdown	attenuates	BMMCs	adhesion	to	neurons.		BMMCs	were	transfected	with	CADM1	ShRNA	or	scrambled	control	ShRNA	and	then	their	adherence	to	neurons	tested	using	a	calcein	based	assay.	CADM1	knockdown	significantly	reduced	BMMC	adhesion.	(N=4).	Each	bar	represents	the	mean	±SEM.	One-way	ANOVA	followed	by	Turkey’s	multiple	comparison	post-test	was	performed.	***	denotes	p<	0.001	compared	to	non-transfected	BMMC	group.	
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5.2.3	CADM1	mediates	neuronal-enhancement	of	mast	cell	degranulation	Neuronal-enhancement	of	mast	cell	degranulation	is	cell-cell	contact	dependent.	Because	I	showed	that	BMMCs	adhere	to	neurons	to	a	large	extent	by	CADM1,	here	I	investigated	if	blocking	CADM1-mediated	adhesion	could	affect	neuronal-enhancement	of	mast	cell	degranulation.	2.5X105	BMMCs/	well	were	co-cultured	with	DRG	for	24	hours	in	presence	or	absence	of	10μg/ml	of	CADM1	blocking	peptide.	Next	day,	BMMCs	in	co-cultures	were	stimulated	by	DNP	for	30	minutes,	supernatants	collected	and	assayed	for	b-Hex.	The	neuronal-enhancement	of	BMMC	degranulation	was	inhibited	significantly	following	treatment	with	the	CADM1	blocking	peptide.	The	fold-change	of	Ag-independent	degranulation	following	CADM1	blocking	peptide	was	also	reduced	to	1.3	compared	to	3.3	in	the	control	group	(P=0.0143)	(Figure	5.7	A).	Moreover,	the	decrease	in	fold-change	was	even	more	striking	(P=0.0019)	following	Ag-treatment	(Figure	5.7	B),	(0.99	in	blocking	peptide	treated	cells	compared	to	2.88	in	control	group.)	Thus	adhesion	via	CADM1	is	necessary	for	neuronal-enhancement	of	BMMC	degranulation.		
	
Figure	5.7.	CADM1	blocking	peptide	reduces	neuronal	enhancement	of	BMMC	degranulation.		BMMCs	were	co-cultured	with	DRG	for	24	hours	in	the	presence	or	absence	of	10μg/ml	CADM1	blocking	peptide.	Fold	change	of	Ag-Indep	degranulation	(A)	or	Ag-activated	degranulation	(B)	were	calculated	and	compared	by	two-tailed	paired	t-test,	*	denotes	p	<	0.05,	**p	<	0.01.	Each	bar	represents	the	mean	
±SEM.	(N=4).	
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	Next,	I	transfected	BMMCs	with	CADM1	ShRNA	or	control	scramble	ShRNA.	48-hour	post-transfection,	BMMCs	from	each	group	were	GFP-sorted	by	FACS	then	co-cultured	with	DRG	for	24	hour	.	Next	day,	BMMCs	were	stimulated	with	DNP	for	30	minutes.	Supernatants	were	collected	and	assayed	for	b-Hex.	Both	the	Ag-Indep	and	Ag-activated	degranulation	were	significantly	reduced	in	co-culture	of	CADM1-knockdown	BMMCs	with	DRG	(Figure	5.8).	These	results	show	that	CADM1	not	only	promotes	structural	adhesion	between	mast	cells	and	sensory	neurons	but	also	promotes	the	functional	crosstalk.	
	 	
Figure	5.8	CADM1	knockdown	reduces	neuronal	enhancement	of	BMMC	degranulation.		WT,	CADM1-knockdown	or	scramble-transfected	BMMCs	were	co-cultured	with	DRG	for	24	hours.	Fold	change	of	Ag-Independent	degranulation	(A)	or	Ag-activated	degranulation	(B)	were	calculated	and	compared	by	one-way	ANOVA	followed	by	Turkey’s	multiple	comparison	post-test	,	***denotes	p	<	0.001	compared	to	wt	BMMC-DRG	co-culture.	Each	bar	represents	the	mean	±SEM.	(N=3).	
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5.2.4	CADM1	mediates	neuronal-enhancement	of	IgE-mediated	IL-6	
production	from	mast	cells	Co-culture	BMMCs	with	DRG	also	induces	the	enhancement	of	IgE-mediated	IL-6	secretion,	so	next	I	examined	whether	CADM1	is	also	needed	for	this	functional	effect.	To	do	so,	CADM1	ShRNA	transfected	BMMCs	were	co-cultured	with	DRG	for	24	hours,	before	being	stimulated	with	DNP	for	6	hours.	Supernatants	were	then	collected	and	assayed	for	IL-6.	IL-6	secretion	from	BMMC	monoculture,	BMMC-DRG	co-culture,	and	scram-ShRNA	transfected	BMMC	in	co-culture	were	measured	in	parallel.	Again,	knockdown	of	CADM1	in	BMMC	significantly	reduced	IL-6	production	by	62%	compare	to	control	BMMC-DRG	co-culture	(459	±	30	pg/ml	and	1209	±	93	pg/ml,	respectively)	(Figure	5.9).	Remarkably,	IL-6	levels	detected	from	CADM1	–ShRNA	transfected	BMMCs	in	co-culture	were	as	low	as	those	measured	from	BMMC	monocultures,	highlighting	the	importance	of	adhesion	in	regulating	the	signaling	pathway	leading	to	cytokine	expression	and	secretion.	This	result	further	suggests	that	CADM1	is	critical	for	neuronal-enhancement	of	Ag-activated	IL-6	production	in	mast	cells.												
	
148	
			
	
Figure	5.9	CADM1	knockdown	reduces	neuronal	enhancement	of	IL-	production	by	BMMCs.		BMMC	monoculture	and	WT,	CADM1-knockdown	or	scramble-transfected	BMMCs	were	co-cultured	with	DRG	for	24	hours.	Then,	BMMCs	were	stimulated	with	10ng/ml	DNP	for	6	hours.	IL-6	was	measured	from	supernatants	and	compared	by	one-way	ANOVA	followed	by	Turkey’s	multiple	comparison	post-test	,	*denotes	p	<	0.05	compared	to	wt	BMMC-DRG	co-culture.	Each	bar	represents	the	mean	±SEM.	(N=3).	
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5.3	Discussion	As	shown	in	chapter	4,	direct	physical	attachment	between	mast	cells	and	neurons	was	found	to	be	essential	to	activate	and	enhance	mast	cell	degranulation	and	IL-6	secretion	in	co-culture.	This	indicates	that	adhesion	molecules	may	play	a	key	role	in	mediating	the	cross	talk	between	these	two	cell	types.	Among	many	adhesion	molecules,	I	am	interested	in	CADM1	as	it	is	common	adhesion	molecule	in	neurons	(Biederer	et	al.,	2002)	and	mast	cells	(Ito	et	al.,	2003).	Indeed,	it	has	been	shown	previously	that	CADM1	mediate	attachment	of	mast	cells	to	SCG	(Furuno	et	al.,	2005).	However,	the	contribution	
of	this	adhesion	molecule	in	the	DRG	enhancement	of	mast	cell	function	has	not	been	
scientifically	explored.	Thus	I	aimed	in	this	chapter	to	study	CADM1	expression	in	BMMCs	
and	DRG,	then	to	investigate	its	contribution	in	structural	and	functional	communication	
between	the	two	types	of	cells.			First,	I	studied	the	expression	of	CADM1	in	BMMCs	and	sensory	neurons	by	western	blot.	Both	cell	types	were	found	to	express	CADM1	but	as	proteins	of	different	molecular	weights,	indicative	of	different	isoforms.	CADM1	has	four	isoforms	resulting	from	alternative	splicing	(Section	1.4.2.2).	The	difference	in	isoforms	reflects	cell-type	specific	function.	Consistent	with	previous	reports	(Ito	et	al.,	2003)	(Furuno	et	al.,	2005)	(Hagiyama	et	al.,	2011),	BMMCs	were	found	to	express	CADM1	isoform	c,	a	protein	with	molecular	weight	of	∼100	kDa.	Whereas	DRG	express	CADM1	of	∼75	kDa	protein	which	corresponds	to	the	expected	molecular	weight	of	isoform	d,	the	same	isoform	found	in	lung	(Masuda	et	al.,	2002)	(Koma	et	al.,	2008).	The	abundance	of	CADM1	in	DRG	was	~3-fold	that	found	in	BMMCs.	In	contrast	to	my	result	and	that	of	others	(Hagiyama	et	al.,	2011),	(Furuno	et	al.,	2012)	reported	that	DRG	only	weakly	express	CADM1.	However,	they	isolated	DRG	from	newborns	which	may	well	have	different	properties	than	adult	DRG	(Melli	and	Höke,	2009).		The	maturity	of	neuronal	culture	could	influence	CADM1	expression,	for	example	it	has	been	shown	previously	that	the	CADM1	isoform	type	and	expression	are	changed	during	cerebrum	maturation	(Hagiyama	et	al.,	2011).			
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Next,	I	investigated	CADM1	distribution	in	BMMCs	and	neurons	by	immunocytochemistry.	Although	both	cell	types	were	found	to	express	CADM1,	BMMCs	appeared	to	express	more	CADM1	on	their	surface	compared	to	what	appeared	to	be	largely	intracellular	expression	of	CADM1	on	neurons.	Surface	expression	of	CADM1	on	BMMC	was	confirmed	by	FACS.		Interestingly,		CADM1	was	expressed	in	only	some	neurites,	but	when	BMMCs	were	co-cultured	with	DRG,	BMMCs	were	observed	to	attach	to	those	parts	of	the	neurites	where	CADM1	was	expressed.	I	also	observed	that	very	few	BMMCs	attached	to	neuronal	soma	despite	the	high	expression	of	CADM1.	The	preference	of	BMMCs	to	attach	to	neurites	over	soma	may	be	because	CADM1	is	not	expressed	on	surface	of	the	soma.	However,	surface	expression	of	CADM1	on	neurites	can’t	be	confirmed	even	with	confocal	due	to	their	small	diameter.		Altogether,	the	data	suggest	that	not	only	the	difference	in	CADM1	isoforms	but	also	the	difference	in	CADM1	distribution	could	influence	CADM1	function	in	different	cell	types.			The	function	of	CADM1	in	neurons	has	been	studied	by	Biederer	and	coworkers.	They	showed	that	CADM1	mediates	homotypic	adhesion	between	neurons	and	helps	to	form	synapses	in	the	CNS	(Biederer	et	al.,	2002).	Although	CADM1	is	expressed	on	BMMC	surface,	in	vitro	in	monocultures	at	least	it	seems	that	it	doesn’t	mediate	homotypic	adhesion	as	the	cells	do	not	adhere	to	each	other,	consistent	with	the	view	that	trans	homotypic	binding		is	isoform	dependent(Hagiyama	et	al.,	2011).		My	data	demonstrate	that	CADM1	is	a	major	key	adhesion	molecule	that	mediates	adhesion	of	mast	cells	to	neurons.	Blocking	CADM1	on	BMMCs	before	co-culture	with	neurons	reduced	the	percentage	of	BMMCs	adhered	to	neurons.	Knockdown	CADM1	expression	from	BMMCs	also	significantly	reduced	their	adhesion	to	neurons;	although,	it	also	highlights	that	despite	the	effectiveness	of	the	ShRNA	in	ablating	expression	of	CADM1	in	BMMCs,	the	reduction	in	adhesion	achieved	is	less	than	that	obtained	with	the	blocking	peptide.	This	likely	reflects		the	non-specific	blocking	effect	of	the	peptide.	The	peptide	is	designed	against	the	whole	extracellular	domain	of	CADM1,	which	is	comprised	of	373	amino	acids	(Sun	et	al.,	2014).	Thus,	this	large	molecular	weight	
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peptide	could	interfere	with	other	adhesion	receptors	that	may	be	involved	in	mast	cell	adhesion	to	neurons	such	as	N-cadherin	(Suzuki	et	al.,	2004)	on	mast	cells	or	nectin-3	on	neurons	(Furuno	et	al.,	2012).	Another	possibility	is	that	CADM1	knockdown	leads	to	compensatory	upregulation	of	other	adhesion	molecules,	as	suggested	by	(Moiseeva	et	al.,	2014).	CADM1	knockdown	in	the	HMC-1	results	in	markedly	enhanced	integrin-dependent	adhesion	of	the	cells	to	ECM.	Nonetheless,	undoubtedly	CADM1	is	responsible	for	the	majority	of	BMMCs	net	adhesion	to	neurons.			In	contrast	to	blocking	CADM1	on	BMMCs,	incubation	of	DRGs	with	CADM1	blocking	peptide	before	co-culture	had	little	effect	on	BMMC	adhesion.	The	explanations	behind	this	could	be	one	of	the	following:	(1)	Peptide	didn’t	work	on	live	DRG	because	DRG	express	CADM1	mostly	intracellularly	(Figure	5.2B).	(2)	Higher	concentration	of	blocking	peptide	is	needed	to	block	CADM1	on	DRG	since	DRG	express	3-fold	higher	levels	of	CADM1	than	BMMCs,	as	shown	by	western	blot	(Figure	5.1).	That	could	be	the	case	because	the	highest	concentration	of	peptide	used	(30µg/ml)	in	this	experiment	showed	some	reduce	in	adhesion	although	not	significant.	(3)	DRG	express	shorter	isoform	of	CADM1(isoform	d)	than	BMMCs	(isoform	c),	that	may	have	different	affinity	and	binding	ability	to	blocking	peptide.	(4)	DRG	express	another	adhesion	molecule	which	forms	heterotypic	complexes	with	CADM1	on	BMMCs.	In	addition	to	CADM1,	Nectin-3	has	been	reported	to	be	highly	expressed	by	DRG	and	localized	at	the	attachment	point	of	CADM1	expressed	by	mast	cells	(Furuno	et	al.,	2012).	Blocking	nectin-3	on	DRG	was	reported	to	decrease	mast	cells	attachment	to	neurons.	This	suggests	the	heterotypic	binding	of	CADM1	and	nectin-3	in	BMMC-DRG	co-culture.	However,	since	they	used	embryonic	DRG	culture	which	express	low	level	of	CADM1,	they	may	underestimate	the	major	role	of	CADM1.	A	recent	transcriptome	analysis	of	adult	mouse	DRG	reveal	that	the	expression	ratio	of	nectin-3	is	very	lower	than	CADM1	(Usoskin	et	al.,	2015).	Knocking	down	the	adhesion	molecules	in	DRG	is	a	more	specific	
approach	to	precisely		identify	which	one	is	the	CADM1	partner	on	mast	cells.	Despite	all	those	explanations	and	the	possible	partner	molecule	on	DRG,	BMMCs	obviously	appear	to	attach	to	neurons	largely	via	their	surface	expression	of	CADM1.		
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I	have	shown	that	constitutive	degranulation	and	IgE-mediated	degranulation	was	significantly	greater	in	BMMC-DRG	co-culture	compared	to	BMMC	monoculture	(Figure	4.4)	and	that	this	enhancement	in	degranulation	is	cell-cell	contact	depended	(figure	4.5).	I	therefore	hypothesized	that	attenuating	mast	cells	adhesion	to	neurons	by	blocking	CADM1	would	in	parallel	attenuate	neuronal-	enhancement	of	IgE-	mediated	mast	cell	function.	To	test	this	idea,	CADM1	on	mast	cells	was	blocked	or	downregulated	before	co-culture	them	with	neurons.	The	constitutive	degranulation	and	IgE-	mediated	degranulation	for	co-culture	of	CADM1-	ShRNA	BMMCs	was	almost	comparable	to	the	amount	of	degranulation	from	BMMC	monoculture.	This	indicates	that	CADM1-dependent	adhesion	of	mast	cells	to	neurons	activates	and	enhances	mast	cells	function.			The	next	question	is	whether	CADM1-	mediated	adhesion	also	contributes	to	enhancement	of	IL-6	synthesis	pathway	in	mast	cell-	neuron	co-culture.	Again,	I	found	that	knockdown	CADM1	from	BMMCs	before	co-culture	decreased	IL-6	production	following	IgE-	mediated	mast	cell	activation.	The	interaction	between	IL-6	and	CADM1	and	its	consequence	on	mast	cell	biology	has	been	suggested	before	(Hollins	et	al.,	2008).	Blocking	of	IL-6	and	CADM1	decreased	the	effect	of	airway	smooth	muscle	on	mast	cell	proliferation	co-culture.	Because	of	their	blocking	effects	were	additive,	this	suggests	cooperative	interaction	of	IL-6	and	CADM1.	However,	further	studies	to		
investigate	mechanism	of	IL-6	and	CADM1interaction	are	required.		It	has	been	shown	that	CADM1	is	critical	for	efficient	communication	between	mast	cells	and	neurons.	Ectopic	expression	of	CADM1	in	CADM1-	negative	mast	cells	line	(IC-2)	resulted	to	increase	IC-2	cell	calcium	signals	following	scorpion	venom	-evoked	neurite	activation	(Furuno	et	al.,	2005).	Interestingly,	the	same	results	have	been	obtained	from	an	in	vivo	study	(Ito	et	al.,	2007).	BMMCs	from	CADM1-knockout	mice	were	transplanted	to	mast	cell-deficient	(KitW/KitWv)	mice.		Electrical	stimulation	of	mesenteric	nerves	didn’t	evoke	mast	cell	degranulation,	while	transfection	with		mast	cells	expressing	CADM1	normalized	the	response.	Collectively,	the	data	suggest	that	CADM1	promotes	communication	between	neurons	and	mast	cells.	Moreover,	my	work	further	indicates	a	
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functional	consequence	mediated	by	CADM1-dependent	adhesion	of	mast	cells	to	neurons	is	enhanced	IgE-	signaling.		Potential	mechanisms	that	could	be	proposed	to	explain	effect	of	CADM1	on	neuronal-enhancement	of	mast	cell	activation.	Simply,	CADM1	could	enhance	mast	cell-nerve	communication	by	mediating	efficient	attachment	between	those	two	cells.	Efficient	attachment	facilitates	chemical	mediator’s	crosstalk	such	as	subP,	tryptase,	IL-6,	PG,	ATP,	serotonin		and	other	mediators.	All	those	mediators	contribute	in	feeding	back	onto	the	activating	this	functional	unit.	This	mechanism	has	been	suggested	before	by	Biederer	(Biederer	et	al.,	2002).	They	showed	that	CADM1	mediates	machinery	necessary	for	synapse	formation	between	neurons.	More	importantly,	they	demonstrated	that	synapse	was	formed	at	contact	site	between	neurons	and	non-neuronal	cells	when	transfected	with	CADM1.	However,	previous	researches	failed	to	observe	a	synaptic	structure	formation	between	mast	cells	and	neurites	(Stead	et	al.,	1989)	(Blennerhassett	et	al.,	1991).		Another	more	complicated	mechanism	that	could	explain	the	functional	effect	of	CADM1	is	that	CADM1	extracellular	binding	could	result	in	intracellular	signaling	events	in	mast	cells.		Although	the	partner	molecules	associated	with	the	cytoplasmic	domain	of	CADM1	is	not	yet	known,	but	CADM1	has	been	reported	to	influence	mast	cell	biology	and	function	(Moiseeva	et	al.,	2012).			As	mentioned	in	introduction	(Section	1.4.2.1),	it	is	suggested	that	CADM1	in	mast	cell	is	regulated	by	microphthalmia	transcription	factor	(MITF)	(Ito	et	al.,	2003),	because	MITF	mutant	BMMCs	don’t	express	CADM1.	Interestingly,	MITF	is	critical	as	well	for	mast	cells	to	produce	many	mediators	including	cytokines	and	PGD2	(Morii	and	Oboki,	2004).	This	lets	us	speculate	that	MITF	function	may	be	affected	by	CADM1	Knockdown.	That	leads	to	decrease	the	enhancement	of	mast	cell	mediator’s	production.			
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Another	potential	mechanism	is	that	CADM1-mediated	mast	cell	neuronal	attachment	may	influence	IgE/FceRI	signaling	by	either	increasing	the	number	of	FceRI	receptors	on	mast	cells	or	contributing	in	IgE	intracellular	pathway.	However,	this	speculation	was	briefly	tested	in	next	chapter.		In	conclusion,	I	have	defined	a	novel	functional	interaction	between	mast	cells	and	neurons	that	is	mediated,	mainly,	by	cell	adhesion	molecule	CADM1.	Indeed,	I	have	shown	that	CADM1-	mediated	mast	cell-	neuron	adhesion	enhance	IgE-signaling	and	mediator	production	in	mast	cells.	This	supports	the	key	role	of	CADM1	in	regulating	mast	cell-	sensory	neuron	interaction.	Targeting	CADM1on	mast	cells	by	drugs	or	antibodies	could	be	new	therapeutic	approach	for	many	neurogenic	inflammation	disorders	in	which	atopy	plays	role.	However,	further	characterization	of	CADM1	
mechanism	in		mast	cell-	neuron	interaction	will	open	up	a	new	aspect	to	understand	
neuroimmune	system.														
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Chapter	6:	Investigating	the	mechanism	
of	CADM1-	mediated	mast	cells	–neurons	
crosstalk		
	
6.1	Introduction	The	research	I	presented	in	the	previous	chapter,	showed	that	CADM1-dependent	adhesion	of	mast	cells	to	sensory	neurons	has	functional	consequences	on	mast	cell	biology.	Here	I	present	the	results	from	studies	initiated	to	investigate	the	possible	mechanism	behind	neuronal-	enhancement	of	IgE-dependent	mast	cell	activation	in	my	co-culture	system.		My	primary	objectives	were	to	determine	whether	the	enhancement	phenomenon	is	neuron-specific	and/	or	IgE-activation	specific.	The	results	of	these	
experiments	could	shed	some	light	on	possible	neuronal-mast	cell	interactions	accruing	in	
health	and	disease.												
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6.2	Results	
6.2.1	neuronal	enhancement	is	unique	for	IgE-mediated	mast	cell	
activation.	Previously	I	showed	that	neurons	enhance	IgE-mediated	mast	cell	activation,	but	whether	this	extends	to	other	mast	cell	activators	is	unknown.	Rather	than	trawling	through	and	testing	all	possible	stimulatory	receptors	expressed	on	BMMCs,	I	instead	investigated	the	effect	of	c48/80,	a	well-known	and	much	used	pan-mast	cell	activator	(See	section	1.1.2.2).	I	stimulated	BMMC	in	DRG-BMMC	co-cultures	with	a	submaximal	concentration	of	c48/80	(30µg/ml)	for	30	minutes	and	measured	degranulation	(Method	is	in	section	2.3.1.2).	As	shown	in	Figure	6.1,	c48/80	induced	the	same	percentage	of	b-Hex	in	the	presence	and	absence	of	DRG	(26	±	2	%		and	25.3	±1	%,	respectively)(P=0.92),	demonstrating	that	neuronal	crosstalk	doesn’t	simply	make	mast	cells	hyper-responsive	in	a	non-specific	manner		but	suggests	instead	that	neuronal	enhancement	is	specific	for	IgE-	signaling.		
	
Figure.6.1	Effect	of	neurons	on	c48/80-mediated	BMMC	degranulation.		BMMCs	 were	 cultured	 alone	 or	 with	 DRG	 for	 24	 hours.	 Then,	 β-hexosaminidase	 (β-hex)	 release	 was	measured	after	stimulation	with	30µg/ml	of	c48/80.	Total	β-hex	measured	from	BMMC	lysed	with	0.5%	Triton	Xl00.	Data	shown	are	mean	±	SEM	of	N=3,	each	performed	in	duplicate.	Data	were	analyzed	using	two-tailed	paired	t-test.	
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6.2.2	Effect	of	co-culture	BMMC	with	DRG	on	FceRI	distribution	on	BMMC		To	explore	the	mechanisms	behind	neuronal	enhancement	of	IgE-mediated	mast	cell	activation,	I	investigated	FceRI	expression	and	distribution	on	BMMCs	and	co-culture,	as	a	simple	upregulation	or	stabilization	of	the	receptor	at	the	plasma	membrane	could	account	for	such	an	effect.	First,	BMMCs	cultures	were	double	stained	with	antibodies	against	CADM1	and	high-affinity	receptor	for	IgE	(FceRI).	Then,	I	used	Pearson's	r	correlation	coefficient	analysis	to	determine	the	degree	of	co-localization	of	CADM1	with	FceRI	(Method	is	in	2.5.2.4).	Signals	for	FceRI	were	well	co-localized	with	CADM1	in	merged	images	(Figure	6.2).	Notably,	this	co-localization	was	mostly	confined	to	the	cell	margin.	The	Pearson's	r	value	was	significant	(Rr=0.92	±		0.03,	n=70,	N=3)	consistent	with	a	strong	co-localization	of	FceRI	and	CADM1	on	BMMCs.				
				
Figure	6.2	A	representative	fluorescence	images	of	colocalization	of	FceRI	with	CADM1	in	BMMCs.	BMMCs	were	double	stained	against	FceRI	(red)	and	CADM1	(green).	Yellow	areas	indicate	the	colocalization	in	the	merged	image.	Scale	bar	represents	10	μm.	Colocalization	was	quantified	using	Pearson’s	correlation	coefficient	as	R	value	as	shown	in	scatter	plot	(right	panel).	Representative	examples	of	70	BMMCs	from	three	independent	experiment.			
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To	investigate	the	effect	of	BMMC	attachment	to	neurons	on	FceRI	surface	expression	and	distribution,	I	quantified	FceRI	surface	expression	in	attached	and	unattached	BMMCs	in	co-cultures	using	immunocytochemistry	(Method	is	in	2.5.2.4).	Non-permeablized	BMMC-DRG	co-cultures	were	stained	against	FceRI	to	only	label	surface	molecules.	Then,	mean	fluoresce	intensities	(MFI)	were	measured	by	Fiji	software	(Figure	6.3).	There	were	no	differences	in	MFI	of	surface	FceRI	between	unattached	and	attached	BMMCs	(15.6	±	3.2	and	16.23	±	3.6,	respectively)	(P=0.54)	suggesting	that	the	enhancement	of	IgE-	mediated	degranulation	in	BMMCs	in	co-culture	is	not	simply	caused	by	up-regulation	of	FcɛRI	expression.			
		
Figure	6.3	BMMCs	attachment	to	neurons	doesn’t	affect	on	surface	FceRI	expression.		Surface	FceRI	expression	was	evaluated	for	unattached	and	attached	BMMCs	in	co-cultures	by	immunocytochemistry.	Mean	fluorescence	intensity	(MFI)	was	calculated	from	total	of	58	unattached	BMMCs	and	74	attached	BMMCs	to	neurons	(N=3).	MFI	was	compared	by	two-tailed	paired	t-test.	
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6.2.3	IgE-mediated	BMMC	enhancement	is	unique	for	sensory	neurons	One	possible	mechanism	for	CADM1-	mediated	enhancement	of	mast	cell-neuron	interaction	is	a	simple	structural	mechanism	in	which	CADM1	binding	enhances	the	chemical	communication	between	sensory	neurons	and	mast	cells	by	bringing	the	two	cells	in	close	proximity,	and	reducing	dilution	of	actively	secreted	chemical	mediators	from	the	neurons	onto	the	apposed	mast	cells.	In	such	a	case,	the	effect	of	CADM1	would	be	dependent	on	the	type	of	cell	the	mast	cell	was	adhered	to	and	specific	for	sensory	neuron	generated	mediators.	To	test	this	hypothesis,	I	reproduced	the	same	system	as	mast	cell-DRG	co-culture	but	I	used	HEK	cells	instead	of	neurons	because	HEK	cells	express	CADM1.	First,	I	confirmed	CADM1	expression	in	HEK	cells	by	western	blotting.	GAPDH	was	used	as	a	loading	control.	Bands	were	visualized	using	Li-cor.	As	shown	in	figure	6.4,	HEK	cells	express	multiple	isoforms	of	CADM1,	viewed	as	multiple	bands	at	100,	70	and	60	kDa.	As	I	showed	previously	(Figure	5.1)	,	BMMC	express	only	one	isoform	of	CADM1	at	∼100	kDa.		
			
Figure.	6.4.	Protein	expression	of	CADM1	in	BMMC	and	HEK	cells.	Immunoblot	of	lysates	prepared	from	HEK	and	BMMC	cultures,.		The	blots	were	probed	with	anti-CADM1	and	anti-GAPDH	antibodies	to	indicate	the	total	amount	of	proteins	loaded	per	lane.	The	m.w.	scale	is	shown	to	the	right	of	the	blot.	Representative	examples	of	two	experiments	performed	on	each	cell	type.	
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Next,	I	assessed	the	intercellular	adhesion	between	mast	cells	and	HEK	cells	using	the	calcein	fluorimetric	adhesion	assay	described	previously	(Section	2.4.3).	10,000	HEK	cells/	well	were	first	seeded	on	1:5	Matrigel-coated	wells.	After	1	day,	HEK	cells	reached	>75%	confluence.	100,000	calcein-	labeled	BMMCs	were	then	added	to	the	HEK	cells	and	left	to	adhere	for	2	hours.	Non-adherent	cells	were	gently	removed	and	washed	away	by	flipping	the	plate	3	times.	To	control	for	BMMC	adherence	to	matrigel,	an	equal	number	of	calcein–labeled	BMMCs	were	cultured	on	1	day-old	Matrigel-coated	wells	in	the	same	way	as	the	ones	in	co-cultures.	To	quantify	the	adhesion	between	mast	cells	and	HEK	cells,	I	measured	the	fluorescence	from	calcein-labeled	BMMCs	before	(for	total)	and	after	washing	(for	adherent)	using	a	plate	reader.	Results	were	expressed	as	percentage	of	adherent	to	total.	Only	a	small	percentages	of	BMMCs	(6.6	± 0.35	%)	adhered	to	control	matrigel	coated	wells	(Figure	6.5).	The	presence	of	HEK	cells	significantly	increased	the	percentage	of	adherent	BMMCs	to	(17.2	±1.5	%)	(P=0.017).		
	
Figure.	6.5.	Adhesion	of	BMMC	to	HEK	cells.	BMMCs	adhesion	to	HEK	cells	was	quantified	as	percentage	of	adherent	BMMC	to	total	BMMC	before	washing.	Data	are	shown	as	mean	±	SEM	from	N=3.	Each	done	in	duplicate.	Data	were	analyzed	two-tailed	paired	t-test	*p<0.05	compared	to	BMMC	culture	alone.		
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To	examine	whether	this	adhesion	lead	to	alterations	in	antigen-stimulated	secretion,	I	investigated	the	effect	of	HEK	cells	on	BMMC	degranulation.	For	that,	I	co-cultured	IgE-sensitized	BMMCs	with	75%	confluence	HEK	cells	for	one	day.	I	then	stimulated	BMMC	with	DNP	(Ag),	and	I	measured	the	percentage	of	β-hex	release	in	Ag-independent	(Ag-Indep)	BMMC	and	Ag-activated	BMMC.	To	control	for	the	effects	of	adherence,	degranulation	assays	were	also	performed	in	parallel	with	BMMC	set	up	in	monoculture.	As	shown	in	Figure	6.6,	the	percentage	of	ag-independent	β-hex	released	from	BMMC-HEK	co-culture	(5.82	±	1.6	%)	was	almost	the	same	as	that	from	BMMC	monoculture	(6.5	±	0.74%)	(P=0.52).		Ag-activated	degranulation	was	similarly	unaffected	by	co-culture	of	BMMCs	with	HEK	cells	(17.9	±	1.8	%)	compared	with	BMMCs	kept	in	monoculture	(18.2	±	1.6		%)	(P=0.89).	HEK	cells	by	themselves	secreted	negligible	amounts	of	β-hex	(2.75	±0.56	%),	and	this	amount	didn't	change	after	Ag	stimulation	(2.75	±	0.52%).	Thus	the	data	show	that	although	HEK	cells	express	CADM1	and	mast	cells	may	adhere	to	them,	this	in	itself	is	not	sufficient	to	either		activate	BMMCs	or	modulate	IgE-mediated	degranulation.		
	
Figure.6.6	Effect	of	HEK	cell	on	IgE-mediated	BMMC	degranulation.			Presensitized	BMMCs	were	cultured	alone	or	with	HEK	cells	for	24	hours.	Then,	β-hexosaminidase	(β-hex)	release	was	measured	in	resting	condition	or	after	antigen	(Ag)	stimulation.	Total	β-hex	measured	from	BMMC	lysed	with	0.5%	Triton	Xl00.	Data	shown	are	mean	±	SEM	of	N=3,	each	performed	in	duplicate.	ns=non-significant	compared	to	BMMC	alone.	Data	were	analyzed	using	two-tailed	paired	t-test.		
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6.2.4	Silence	AP	in	neurons	doesn’t	block	IgE-mediated	mast	cell	
enhancement	in	co-culture	To	investigate	the	specific	role	of	activated	neurons	in	IgE-mediated		mast	cell	enhancement	in	co-culture,	I	silenced	the	AP	in	neurons	by		incubation	DRG	with	1µm	from	each	Tetrodotoxin	(TTX)	to	block	TTX-sensitive	sodium	channels	,	and	w–conotoxin	MVIIC	and	GVIA	to	block	calcium	channels	for	10	minutes	before		BMMC	co-culture	and	during	24-h	of	co-culture	(See	material	and	methods	section	2.6.4).		First,	I	tested	the	cytotoxicity	of	this	toxin	cocktail	(CTX)	on	BMMC.	BMMCs	were	incubated	with	CTX	for	(2,	6,	12,	24	hours).	Then,	viability	of	cells	was	determined	by	counting	the	cells	in	each	condition	and	calculated	the	%	of	viability	by	using	trypan	blue	(N=3).	I	found	that	CTX	didn’t	affect	BMMC	viability	at	each	time	point	(Figure	6.7	A).		Next,	I	examined	the	effect	of	CTX	in	inhibition	of	KCl-	induced	neuronal	calcium	signals.	I	incubated	DRG	with	CTX	for	5	min,	Then,	I	stimulated	DRG	with	KCl	in	presence	of	CTX.	My	preliminary	data	(N=1,	n=29)	demonstrated	that	the	calcium	signals	from	neurons	showed	delay	in		response	to	KCl	(around	30	sec)	compared	to	neuronal	response	to	KCl	after	washing	for	15	minutes	(less	than	10	sec)	(Figure	6.7	B).		Finally,	I	tested	the	effect	of	silence	neurons	by	CTX	on	enhancement	IgE-	mediated	BMMC	degranulation	in	co-culture.	After	24	hours	of	co-culturing	BMMC	with	DRG	in	the	presence	of	CTX,	BMMCs	were	stimulated	with	100ng/ml	DNP	for	30	minutes	and	percentage	of	degranulation	was	measured.	I	found	that	CTX	slightly	decreased,	although	not	significant,	the	spontaneous	(P=	0.26)	and	Ag-activated	BMMC	degranulation	(P=0.31)	in	co-culture	(Figure	6.7	C).	However,	CTX	didn’t	affect	BMMC	degranulation	in	monoculture	(1st	and	2nd	group	in	figure	6.7	C).						
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Figure.6.7	Silence	AP	in	neurons	doesn’t	block	IgE-mediated	mast	cell	enhancement	in	co-culture		(A)	Cytotoxicity	of	1	µm	from	each	TTX,	w–conotoxin	MVIIC	and	GVIA	(CTX	or	Tx	)	on	BMMCs	for	24	hours.	(B)	The	trace	of	change	in	calcium	signals	as	reported	by	Fura-2,	of	individual	neurons	in	response	to	62mM	KcL	for	indicated	period	(n=29).	(C)	BMMCs	were	cultured	alone	or	with	DRG	for	24	hours	in	the	presence	or	absence	of	CTX	cocktail.	Then,	β-hexosaminidase	(β-hex)	release	was	measured	after	stimulation	with	100ng/ml	of	DNP.	Total	β-hex	measured	from	BMMC	lysed	with	0.5%	Triton	Xl00.	Data	shown	are	mean	±	SEM	of	N=2,	each	performed	in	duplicate.	Data	were	analyzed	using	multiple	t-test.		
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6.3	Discussion	CADM1-mediated	attachment	of	mast	cells	to	sensory	neurons	is	essential	for	potentiating	IgE-mediated	activation.	The	mechanisms	by	which	CADM1	can	modulate	mast	cell-neuron	crosstalk	however	is	unknown.	To	determine	whether	this	crosstalk	was	specific	to	IgE-	mediated	activation	or	a	general	change	in	the	responsiveness	of	BMMCs,	I	compared	the	effects	of	co-culture	on	antigen	stimulation	with	activation	by	c48/80,	a	direct	activator	of	GPCRs	in	mast	cells	(Mousli	et	al.,	1990).	The	results	of	these	experiments	showed	that	co-culture	of	mast	cells	with	neurons	does	not	enhance	c48/80-induced	mast	cell	degranulation,	suggesting	the	effect	of	neurons	on	mast	cells	is	specific	to	the	IgE-	mediated	pathway.		To	apprehend	how	neurons	may	modulate	IgE-mediated	mast	cell	response,	it	is	essential	to	briefly	review	what	is	known	about	the	signaling	pathway	(more	details	in	introduction	section	1.1.2.1	and	Figure	1.1).	IgE	is	bound	to	mast	cells	via	high-affinity	receptor	FcɛRI.	Antigen	binding	to	IgE	and	subsequent	crosslinking	of	FcɛRI		leads	to	activation	of		a	cascade	of	tyrosine	kinases	and	phosphorylation	of	the	receptor	itself,	adaptor	proteins	and	signaling	molecules.	This	signaling	cascade	induces	an	increase	in	intracellular	calcium	and	subsequent	fusion	of	mast	cell	granules	with	the	cell	membrane.	In	addition,	IgE-	mediated	signaling	activates	a	variety	of	transcription	factors	that	ultimate	lead	to	the	upregulation	and	expression	of	multiple	genes	including	those	for	coding	for	a	plethora	of	cytokines,	chemokines	and	growth	factors	(Metcalfe	et	al.,	1997)	(Gilfillan	and	Rivera,	2009).		To	determine	at	which	step	neurons	influence	IgE-	mediated	mast	cells	response,	first,	I	investigated	FcɛRI	expression	and	distribution	on	BMMCs	and	co-culture.	I	found	that	there	is	strong	co-localization	between	CADM1	and	FcɛRI	at	the	plasma	membrane.	This	suggests	the	possibility	of	direct	interaction	between	the	two	molecules	at	the	cell	surface	although	it	doesn't	explain	the	enhancement	of	IgE-mediated	response	in	attached	BMMCs.	As	there	was	no	change	in	FcɛRI	surface	expression	between	unattached	and	attached	BMMCs,	the	data	suggest	the	interaction	is	more	likely	to	be	at	
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the	level	of	signaling	rather	than	a	result	of	stabilized	expression	of	the	receptor	at	the	surface	due	to	alterations	in	trafficking	(Rios	and	Kalesnikoff,	2015).		However,	the	methods	I	used	for	assessing	surface	expression	on	BMMCs	were	admittedly	rather	crude	as	it	was	reliant	on		antibody	staining.	Unfortunately,	the	strong	adherence	of	BMMCs	to	DRG	made	it	very	difficult	to	isolate	these	for	subsequent	more	sensitive	quantitative	methods	of	surface	expression	such	as	FACS.				Although	the	intracellular	pathway	of	FcɛRI	trafficking	is	still	not	completely	understood,	the	level	of	FcɛRI	surface	expression	is	regulated	by	dynamic	processes	including:	receptor	stabilization,	recycling	and	ligand-	induced	internalization	(Rios	and	Kalesnikoff,	2015).	FcɛRI	receptor	stabilization	is	controlled	by	intracellular	and	external	factors.	Not	much	is	known	about	the	intracellular	molecules	that	influence	FcɛRI	stability,	but	they	include	members	of	Rab	family	of	small	GTPase	(Kalesnikoff	et	al.,	2007).	The	essential	external	factor	that	influence	FcɛRI	stabilization	is	IgE	binding	(Galli	et	al.,	2005).	IgE	binding	prevents	the	losing	of	FcɛRI	from	cell	surface	since	the	unoccupied	FcɛRI	receptors	undergo	endocytosis	and	some	of	them	are	recycled	back	to	the	surface	(MacGlashan,	2007).	IgE-	bound	FcɛRI	complexes	also	undergo	endocytosis	after	cross-linking	with	Ag.	This	process	is	known	as	“Ligand-	induce	internalization”	and	is	important	as	a	feed-back	to	regulate	the	activated	receptors	(Rios	and	Kalesnikoff,	2015).	Because	it	was	shown	previously	that	co-culture	of	BMMC	with	SCG	for	a	longer	time	(3	days)	showed	that	the	expression	of	FcɛRI	when	quantified	by	ICC	was	higher	in	BMMCs	attached	to	neurites	compare	to	non-attached	BMMC	in	the	same	co-culture	(Suzuki	et	al.,	2005),	this	indicates	the	neurons	could	influence	the	FcɛRI	recycling	or	newly	receptor	synthesis.	This	theory	could	be	tested	by	using	BFA	that	blocks	recycling	
and	receptor	synthesis	(Borkowski	et	al.,	2001)	then	measure	the	surface	expression	by	
FACS	to	test	the	change	in	receptor	synthesis.	Examining	the	recycling	rate	could	be	by	
selectively	labelling	FcɛRI	with	(fab)	fragment	that	don’t	induce	receptor	aggregation,	
then	measure	the	surface	expression	by	FACS	at	different	time	points	(Rios	and	Kalesnikoff,	
2015).			
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I	have	shown	enough	evidence	that	neurons	influence	IgE-mediated	mast	cells	responses.	Neurons	don’t	only	enhance	intracellular	calcium	signals	of	IgE-	activated	mast	cells	(Section	4.2.5	Figure	4.7	A2	and	B1),	but	their	effect	is	strong	enough	to	enhance	IgE-	mediated	degranulation	(Section	4.2.3	Figure	4.4)	and	IL-6	signaling	pathway	(Section	4.2.4	Figure	4.6).	However,	there	is	a	possibility	that	neurons	influence	FcɛRI	–pathway	kinase	phosphorylation.		A	suggested	strategy	to	investigate	this	
possibility	is	by	activating	mast	cells	alone	or	in	presence	of	neurons	with	Ag.	Then,	analyze	
the	level	of	mast	cell	protein	phosphorylation	using	Western	blot.	This	would	be	an	
important	future	piece	of	work	to	pursue.		The	effect	of	neurons	on	enhancing	IgE-	mediated	mast	cell	response	could	be	linked	to	mediators	such	as	neuropeptide	(Suzuki	et	al.,	1999)	or	ATP	(Suzuki	et	al.,	2007)	secreted	from	activated	neurons.	As	mentioned	in	the	introduction	(section	1.1.2.2),	extracellular	ATP	can	enhance	IgE-mediated	degranulation	in	HLMC	but	not	ionophore-mediated	degranulation	which	is	similar	to	my	data	(Schulman	et	al.,	1999).		Moreover,	blocking	of	P2X		didn’t	affect	the	enhancement	which	suggests	that	this	enhancement	is	through	P2Y	signaling.	Because	P2Y	influences	TRPC	channels,	it	is	therefore	possible	that	ATP	enhances	IgE-	mediated	degranulation	by	synergistic	modulation	of	TRPC	downstream	signaling.	Interestingly,	ATP	is	a	small,	autocrine	or	paracrine	mediator	that	is	rapidly	degraded	in	the	extracellular	environment.	To	achieve	its	intercellular	signaling,	it	requires	exceptionally	close	contact	between	the	cells.	This	could	justify	the	dependent	of	the	efficiency	of	mast	cell-neuron	interaction	on	adhesion	molecules	such	as	CADM1.		Thus,	studying	the	role	of	ATP	and	purinergic	receptors	in	mast	cell-	neuron	
cross-talk	is	an	exciting	potential	future	project.			Another	potential	mediator	that	may	enhance	IgE-mediated	response	in	co-culture	is	SCF	(Gilfillan	et	al.,	2009).	As	discussed	in	chapter	3,	SCF	dramatically	enhances	FcεRI-mediated	mast	cell	degranulation	and	cytokine	release.	Interestingly,	SCF	is	also	reported	to	induce	IL-6	production	by	BMMC	but	not	TNFa	(Gagari	et	al.,	1997),	and	to	increase	IgE-mediated	IL-6	mRNA	expression	(Hundley	et	al.,	2004)	but	not	TNF	a	(Lin	
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and	Befus,	1997).	This	is	very	similar	to	my	data	regarding	neuronal	enhancement	of	IgE-mediated	cytokine	production	(Section	4.2.4	Figure	4.6).	As	shown	in	(Figure	3.5),	SCF	activates	MAPK/STAT	and	NFκB	pathways	that	is	important	for	IL-6	production	(Akira,	1997)	(Kalesnikoff	et	al.,	2002).	In	contrast,	c-kit	signaling	pathway	don’t	involve	activation	of	NFAT	and	that	could	explain	inability	of	c-kit		to	enhance	TNFa	production	(Klein	et	al.,	2006).	Furthermore,	my	data	displayed	that	there	is	a	strong	colocalization	of	CADM1	and	Kit	molecules	on	mast		cells(Figure	5.2),	that	may	promote	their	synergistic	functions.	Therefore,	it	would	be	interesting	in	future	to	test	whether	SCF	plays	a	role	in	neuronal	enhancement	of	mast	cell	functions.	However,	I	have	tried	to	investigate	the	role	of	SCF/c-kit	in	neuronal	enhancement	of	IgE-	mediated	mast	cell	degranulation.	Therefore,	I	incubated	mast	cells	with	antibody	against	c-kit	30	minutes	before	and	during	24-	h	co-culture.	As	expected	blocking	c-kit	on	mast	cells	by	antibody	didn’t	influence	their	adhesion	to	neurons,	but	it	gave	an	incomprehensible	results	regarding	blocking	the	enhancement	in	degranulation	in	co-culture.	Moreover,	it	surprisingly	increased	the	IgE-	dependent	degranulation	in	BMMC	monoculture	and	makes	it	difficult	to	interpret.	The	question	of	whether	SCF/c-kit	plays	a	role	in	neuronal	
enhancement	of	IgE-	mediated	mast	cell	degranulation	requires	further	study	with	other	
tools	to	minimize	the	possible	complicated	factors.		Next,	I	investigated	whether	CADM1-	mediated	enhancement	of	mast	cell	function	is	specific	for	the	crosstalk	between	mast	cells	and	sensory	neurons	or	this	enhancement	could	be	reproduced	with	other	cells	expressing	CADM1.	For	that,	I	used	HEK	cells	since	HEK	cells	express	CADM1.	Contrasting	with	the	fact	that	HEK	cells	express	multiple	isoforms	of	CADM1,	the	percentage	of	BMMCs	attached	to	HEK	cells	was	less	than	BMMCs	attached	to	neurons.	Indeed,	the	attachment	of	BMMC	to	HEK	cells	failed	to	enhance	IgE-	mediated	mast	cell	response.	The	differences	in	HEK	experiment	results	can	be	contributed	to	different	CADM1	isoforms	expressed	by	neurons	and	HEK	cells.	By	WB,	I	showed	that	neurons	express	CADM1d	isoform.	While	HEK	cells	express	multiple	CADM1	isoforms	(c,	b,	and	d).	This	results	suggested	that	CADM1d	isoform	on	neurons	binds	firmer	and	more	efficient	than	other	isoforms	to	CADM1c	isoform	on	BMMCs.	This	unique	ability	of	CADM1d	is	because	its	structural	differences	from	the	other	three	
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isoforms	(a-c)	as	discussed	by	Hagiyama	(Hagiyama	et	al.,	2011).	He	co-cultured	BMMCs	with	Neuro2a	neuroblastoma	cells	that	ectopically	expressed	different	CADM1	isoforms.	Then,	the	adhesive	strengths	were	assessed	by	femtosecond	laser-induced	impulsive	forces.	BMMCs	attached	to	Neuro2a-CADM1d	neurites	firmer	than	other	isoforms.	More	interesting,	mast	cells	attached	to	Neuro2a-CADM1d	neurites	showed	more	response	to	activated	neurons	than	the	ones	attached	to	other	isoforms.	He	referred	this	privilege	of	CADM1d	isoform	based	on	the	fact	that	the	extracellular	juxtamembrane	region	of	all	isoforms	except	CADM1d	have	O-glycosylation	site	(See	Introduction	Figure	1.6).	Although	the	role	of	O-glycosylation	in	different	CADM1	isoforms	has	not	been	studied,	it	is	suggested	that	O-glycosylation	is	important	for	determining	association	partners	for	different	CADM1	isoforms	(Biederer,	2006).	The	fact	that	HEK	cells	express	multiple	CADM1	isoforms	could	account	for	the	relatively	poor	adherence	of	BMMCs	to	HEK	cells.	Since	CADM1	acts	as	an	adhesion	molecule	by	assembling	itself	on	the	cell	membrane	as	
cis-homodimer	(Masuda	et	al.,	2002)	(See	introduction	1.4.2.2	Figure	1.5)	,	it	is	possible	that	different	isoforms	on	HEK	cells	hardly	align	their	different-in-length	extracellular	domain	to	form	functional	cis-homodimer	on	cell	surface	(Moiseeva	et	al.,	2012).	While	neurons	that	express	only	one	type	of	isoform	(CADM1d)	form	functional	CADM1	cis-homodimer	easier	and	faster.	This	could	explain	the	higher	percentage	of	BMMCs	attached	firmly	to	neurons.			Although	different	CADM1	isoforms	between	HEK	cells	and	neurons	could	explain	the	differences	in	adhesive	strength,		it	doesn't	explain	the	differences	in	IgE-	mediated	enhancement	in	mast	cells.	This	enhancement	appears	to	be	cell-	type	specific	for	neurons.	This	raises	the	possibility	of	one	of	two	scenarios:	one	possibility	is	that	the	effective	adhesion	of	mast	cells	to	neurons	results	in	exposing	the	attached	mast	cells	to	secreted	neurotransmitters	which	in	turn	synergize	with	IgE-	mediated	activation	of	mast	cells.	The	second	scenario	is	that	different	partner	molecules	associate	with	CADM1	at	BMMC-neuron	sites	of	adhesion	than	at	BMMC-HEK	cell	sites	and	that	this	in	turn	leads	to	differential	effects	on	downstream	signaling	pathways	activated	through	IGE	receptors.	In	either	case,	it	is	clear	that	the	functional	consequence	of	CADM1-mediated	BMMC	adhesion	leads	to	cell	specific	effects.		
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	Finally,	although	it	is	a	preliminary	data,	I	found	that	the	safe	concentration	of	CTX	cocktail	(composed	of	TTX	and	w-conotoxin)	on	BMMCs	that	delay	KCl-induced	neuronal	response	failed	to	inhibit	the	enhancement	of	IgE-	mediated	mast	cell	degranulation	in	co-culture.	Since	TTX	and	conotoxin	block	only	AP-derived	dependent	synaptic	release	of	neurotransmitter	(Brock	and	Cunnane,	1988),	this	data	indicate	that	neurons	may	mediate	mast	cell	enhancement	through	AP-independent	neuropeptide	release.	Neurotransmitters	can	be	released	by	alternative	pathways	of	increasing	intracellular	calcium	level	(Sharma	and	Vijayaraghavan,	2003).	A	suggested	approach	to	investigate	
this	possibility	is	by	inhibiting	the	secretory	machinery	in	neurons	by	using	toxin	such	as	
botulinum.	The	botulinum	toxin	cleaves	the	synaptosomal	associated	protein	(SNAP)	25	and	syntaxins	to	prevent	the	fusion	of	the	vesicles	with	the	neuronal	membrane	and	neurotransmitter	exocytosis	(Rossetto	et	al.,	2014).		In	the	same	context,	I	have	tried	to	silence	mast	cells	in	co-culture	to	inhibit	the	enhancement	of	IgE-mediated	degranulation.	Double-	blind	clinical	trials	have	shown	that	mast	cell	stabilizers	have	a	clinical	usefulness	in	managing	the	pain	in	IBS	and	food	allergy	(Lunardi	et	al.,	1991),	(Stefanini	et	al.,	1995).	Therefore,	it	was	interesting	to	test	the	effectiveness	of	mast	cell	stabilizers	in	inhibition	of	neuronal	enhancement	effect	on	IgE	mediated	mast	cell	degranulation.	To	do	so,	I	incubated	BMMC	with	100µM	of	sodium	cromoglycat	10	minutes	before	co-culture	and	during	24-hour	co-culture	with	DRG	.	Unexpectedly,	it	didn’t	inhibit	the	neuronal	enhancement	of	IgE-	mediated	mast	cell	degranulation.	Indeed,	it	failed	to	inhibit	IgE-mediated	BMMC	degranulation	in	monoculture.	However,	cromoglycate	shows	a	different	inhibitory	effect	depending	on	mast	cell	phenotypes	and	the	lack	of	effect	of	cromolyn	on	mouse	BMMC	degranulation	has	been	confirmed	(Oka	et	al.,	2012).	On	the	other	hand,	nedocromil	(another	cromones	anti-allergic	agent)	reported	to	inhibit	IgE-mediated	degranulation	in	mouse	BMMC	(Yazid	et	al.,	2013).	Thus,	it	worth	to	repeat	this	experiment	with	other	mast	cell	
stabilizers	as	possible	therapeutic	approach	for	neurogenic	inflammation.		
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In	conclusion,	CADM1-mediated	adhesion	promotes	the	development	of	a	microenvironment	in	which	neurons	enhance	mast	cells	response	to	Ag.	As	the	consequence	the	mast	cell-neuron	crosstalk	gets	stronger.	This	could	explain	why	incidence	of	neurogenic	disorders	such	as	IBS	is	more	in	atopic	patients	(Roussos	et	al.,	2003)	(Tobin	et	al.,	2008b).	Further	understanding	of	these	signaling	pathways	is	
necessary	as	therapeutic	approach.														
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Chapter	7:	Conclusion	and	future	
directions		
My	data	clearly	showed	that	neurons	specifically	enhance	IgE-mediated	mast	cells	degranulation	and	IL-6	production	(chapter	4).	This	enhancement	is	CADM1-	mediated	contact	dependent	(chapter	5).	My	study	demonstrated	for	the	first	time	that	blocking	and/or	knockdown	CADM1	on	mast	cells	significantly	inhibited	this	enhancement.	CADM1	mediates	efficient	attachment	of	mast	cells	to	neurons	that	facilitates	the	chemical	bidirectional	communication.	The	sensitivity	of	mast	cells	to	IgE-mediated	activation	with	the	presence	of	neurons	was	not	due	to	modulate	the	FcεRI	expression,	but	it	is	presumably	as	a	consequence	of	intracellular	signaling	(Chapter	6)	(Figure	7.1).		
	The	possibility	that	cell	adhesion	molecules	(CAM)	induce	intracellular	signaling	has	been	supported	in	the	literature	(Cavallaro	and	Dejana,	2011)	(Gibson,	2011)	(Du	et	al.,	2014).	It	has	been	reported	that	the	adhesion-	mediated	signaling	could	be	induced	by	all	classes	of	CAMs.	For	example,	homophilic	binding	of	NCAM,	a	member	of	IgSF-CAM,	recruits	and	phosphorylates	focal	adhesion	kinase	(FAK).	This	results	in	tyrosine	phosphorylation	of	several	proteins,	including	FYN/MAPK	which	results	in	the	induction	of	neurite	outgrowth	(Ditlevsen	and	Kolkova,	2010).	Another	IgSF-CAM,	Mel-CAM,	also	recruits	FYN	that	phosphorylates	FAK	in	endothelial	cells	(Anfosso	et	al.,	1998).		In	the	same	way,	integrin-mediated	mast	cell	line(RBL)	adhesion	to	fibronectin	results	in	phosphorylation	of	several	proteins,	including	FAK	and	PKC	that	lead	to	calcium	mobilization	(Hamawy	et	al.,	1993).	Cadherins	also	have	been	shown	to	modulate	cell	signaling	through	receptor	tyrosine	kinases.	E-cadherin	in	epithelial	cells	can	associate	through	its	cytoplasmic	domain	with	receptor	tyrosine	kinases	to	induce	gene	expression	through	NF-κB	(Du	et	al.,	2014)and	STAT3	(Raptis	et	al.,	2009).	Recently,	it	has	been	revealed	that	NF-κB		activation	is	impaired	in	CADM1	knockdown	human	T-cell	lines	(Pujari	et	al.,	2015).	They	suggested	that	CADM1	is	required	to	inhibit	IκB-mediated	NF-κB	negative	regulation	and,	as	a	result,	enhances	NF-κB-mediated	transcriptional	signaling.	
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Figure.	7.1	Proposed	CADM1-	mediated	signaling	pathways	in	mast	cell.	CADM1	 can	 influence	 the	 activity	 of	 tyrosine	 kinase	 such	 as	 FYN/PLC	 signaling	 pathway	 and/	 or	may	interact	 with	 other	 receptor,	 such	 as	 kit,	 to	 influence	 IgE-mediated	 mast	 cell	 activation.	 The	 Figure	 is	modified	from	Figure	3.5				More	interestingly,	CAMs	can	also	modulate	receptor	tyrosine	kinases	signaling	within	a	single	cell	and	without	mediate	cell–cell	adhesion.	This	can	be	happened	by	different	mechanisms.	It	could	be	by	interacting	and	activating	growth	factor	receptors	and	other	signalling	proteins.	The	prototypical	example	that	is	extensively	studied	is	the	interaction	between	NCAM	and	fibroblast	growth	factor	receptor	(FGFR)	(Williams	et	al.,	1994)	(Francavilla	et	al.,	2007).	NCAM	directly	binds	to	FGFR	to	produce	a	distinctive	
signaling	cascade	from	those	produced	by	binding	of	its	ligand	fibroblast	growth	factor	(Francavilla	et	al.,	2009).	Moreover,	E-cadherin	binds	to	vascular	endothelial	growth	factor	receptor	2	(VEGFR2)	to	prevent	its	internalization	(Lampugnani	et	al.,	2006).	However,	cis	clustering	of	CAMs	that	follow	the	initiation	of	trans	cell-cell	adhesion	could	amplify	other	signaling	pathways.	Clustering	is	a	lateral	homotypic	binding	of	
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CAMs	on	cell	membrane	of	the	same	cell	to	strength	the	intercellular	adhesion.	As	a	result,	signaling	membrane	receptors	come	in	close	contact	with	their	cytoplasmic	partners	including	tyrosine	kinase	and	initiate	signaling.	Overall,	the	recognition	that	CAMs	not	only	maintain	cell-cell	adhesion	but	also	can	induce	intercellular	communications	and	signaling	supports	our	proposal	that	CADM1-mediated	adhesion	of	BMMC	to	neurons	has	important	functional	consequences.	Cell	signaling	driven	by	CADM1	in	BMMC	is	likely	to	enhance	FcɛRI	signaling.	Further	studies	are	required	to	fully	
understand	this	signaling	process.			Results	of	this	study	would	contribute	to	the	available	knowledge	about	mast	cell-	neuron	crosstalk	in	health	and	diseases.	In	fact,	studying	mast	cell-	neuron	crosstalk	in	GIT	is	of	great	interest	because	GIT	is	known	to	contain	the	most	extensive	immune	system	in	the	body,	as	well	as,	it	has	a	very	rich	supply	of	sensory	nerves.	This	anatomy	promotes	opportunity	for	nerves	that	release	neuropeptides	and	other	mediators	to	activate	mast	cells	that	nearby	(Stead	et	al.,	1989)	(Barbara	et	al.,	2004).	This	bidirectional	crosstalk	plays	a	homeostatic	unit	in	maintaining	gut	physiology	(section	1.1.5.1.1),	as	well	as	pathogenesis	of	GI	disorders	such	as	IBS.			The	contribution	of	mast	cell-nerve	interaction	in	the	pathogenesis	of	IBS	is	based	on	the	following	evidence:	(1)	an	increased	number	of	mast	cells	attached	to	nerves	in	IBS	patients	compare	to	controls	(Park	et	al.,	2003)	(Barbara	et	al.,	2004).	(2)	The	severity	and	the	frequency	of	abdominal	pain	in	IBS	patients	are	significantly	correlated	to	the	number	of	degranulated	mast	cells	in	direct	contact	to	nerves	(Barbara	et	al.,	2004)	(Park	et	al.,	2006).	(3)	The	severity	and	the	frequency	of	abdominal	pain	in	IBS	patients	are	also	significantly	correlated	with	expression	of	TRPV1	receptor	on	sensory	neurons	in	GIT	(Akbar	et	al.,	2008).	These	correlations	suggest	that	as	the	disease	gets	worse,	the	mast	cell-	nerve	interaction	got	stronger.	(4)	Finally	and	most	important	clinically,	mast	cell	stabilizers	have	been	shown	to	decrease	visceral	hypersensitivity	in	patient	with	IBS	(Klooker	et	al.,	2010).			
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However,	the	incidence	of	IBS	in	atopic	patients	with	known	history	of	conditions	such	as	asthma,	eczema,	or	atopic	rhinoconjunctivitis	is	higher	than	non-atopic	(Powell	et	al.,	2007)	(Tobin	et	al.,	2008b)	(Lillestøl	et	al.,	2010)	(Walker	et	al.,	2014).	Indeed,	a	cross-sectional	study	on	IBS	patients	showed	a	significant	correlation	between	serum	IgE	levels,	that	a	biomarker	for	allergies,	and	number	of	IgE-	positive	mast	cells	in	intestinal	biopsies	(Lillestøl	et	al.,	2010).	Interestingly,	IBS	symptoms	were	positively	associated	with	elevated	serum	IgE	levels	(Vara	et	al.,	2016).	Thus,	atopic	IBS	has	been	defined	as	development	of	IBS	in	atopic	patients	(Tobin	et	al.,	2008a).			These	literatures	indicate	that	the	more	severe	atopic	disease	the	stronger	mast	cell-neuron	crosstalk.	In	the	light	of	my	data,	I	propose	an	explanation	for	these	observations.	In	atopic	patients	with	high	level	of	serum	IgE,	the	exposure	to	Ag,	likely	from	ingested	food,	activates	IgE-positive	mast	cells	in	the	gut.	The	attachment	of	mucosal	mast	cells	to	neurons,	presumably	mediated	by	CADM1,	enhances	the	IgE	–	mediated	mast	cells	mediators	release	that	induce	visceral	hypersensitivity.	Consequently,	symptoms	of	IBS	would	get	worse.			This	explanation	could	be	completely	applicable	on	all	mast	cell-	neuron	interactions	in	different	tissue.	In	fact,	it	has	been	suggested	that	allergen-induced	neuromodulation	resulted	in	hyperactivity	of	nervous	system	in	atopic	patients	(Undem	and	Taylor-Clark,	2014).	As	capsaicin	induces	strong	parasympathatic	reflex	and	sneezing	when	applied	to	nasal	mucosa	of	atopic	rhinitis	patients,	an	effect	that	is	not	seen	in	healthy	subjects	(Sarin	et	al.,	2006).		All	these	data	emphasize	the	principal	role	of	IgE-mediated	mast	cell	activation	on	neuronal	activity.	An	interesting	question	is	whether	manipulation	of	this	pathway	lead	to	a	substantial	improvement	in	neuronal-	related	symptoms.	Different	potential	agents	targeting	mast	cell	biology	has	been	proposed	(Zhang	et	al.,	2016).	Among	them,	Omalizumab.	Omalizumab	stabilizes	mast	cell	functions	by	neutralizing	soluble	IgE	as	well	as	downregulating	surface	FcɛRI	on	mast	cells.	It	is	known	for	it	is	high	efficacy	in	controlling	moderate	to	severe	asthma	(Society	and	Network,	2014).	In	addition,	it	has	shown	its	effectiveness	in	treatment	of	other	allergic	diseases	as	rhinitis	
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(Casale	et	al.,	2001),	atopic	dermatitis	(Lane	et	al.,	2006)	and	urticaria	(Maurer	et	al.,	2013).	It	was	reported	in	case	study	that	it	showed	a	promising	effect	in	complete	resolution	of	IBS	symptoms	in	patient	on	Omalizumab	for	other	atopic	diseases	(Pearson	et	al.,	2015).	Possible	future	experiments	using	co-culture	model	in	the	same	way	of	this	
thesis	could	be	used	to	test	the	effect	of	different	mast	cell-targeting	approach	on	attenuate	
mast	cell-neuron	communication.			
	
Another	interesting	avenue	for	future	investigation	would	be	detailed	exploring	the	
underling	signaling	of	CADM1-dependent	neuronal	enhancement	on	IgE-mediated	
activation	in	mast	cells.	Structurally,	CADM1	resembles	NCAM,	both	belong	to	the	immunoglobulin	superfamily.	As	I	discussed	above,	NCAM	has	been	showed	to	induce	intracellular	signaling	and	interact	with	growth	factor	receptors.	Therefore,	there	is	a	possibility	that	CADM1	share	the	same	FYN/MAPK	signaling	pathway	and	may	interact	with	other	receptor	to	enhance	IgE-mediated	mast	cell	activation.	Analysis	of	FceRI	signaling	in	co-cultures	from	CADM1	knockdown	BMMCs	could	shed	some	light	onto	potential	regulatory	mechanism	of	CADM1	in	mast	cell	activity.	A	basic	technique	to	study	the	activity	of	different	kinase	that	may	involve	in	this	signal	transduction	could	be	measured	by	kinase	assay.	In	addition,	protein-protein	interactions	within	the	pathway	could	be	studied	by	co-immunoprecipitation	technique	(Kawakami	and	Kawakami,	2015).		
	This	study	addressed	the	regulatory	role	of	CADM1	in	mast	cells	activation	in	vitro,	however,	these	results	need	to	be	verified	in	vivo	in	order	to	determine	the	role	of	CADM1	in	health	and	diseases.	To	do	so,	mast	cell-	deficient	mice	that	has	been	engrafted	with	CADM1-knockdown	BMMCs	could	be	used.	Although	mast	cell-	deficient	kitW/kitWv	and	kitW-sh/kitW-sh	mice	has	been	used	extensively	for	this	purpose,	the	kit-mutation	can	confound	the	results	from	these	mouse	models(Kakurai	et	al.,	2006).	Therefore,	a	new	mast	cell-	deficient	mouse	model	has	been	introduced.	The	mast	cell-deficient	in	these	mice	is	as	a	result	of	ablation	of	myeloid	cell	leukemia	1	(Mcl-1)	which	known	as	anti-apoptotic	factor.	Consequently,	C57BL/6-Cpa3-Cre+-Mcl-1fl/fl		mice	with	normal	kit	are	produced	which	are	called	informally	“Hello	Kitty”	mice	(Lilla	et	al.,	
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2011).	Such	models	have	been	extremely	useful	in	assessing	the	role	of	CADM1	in	mast	cell-related	disorders	in	general,	and	in	neurogenic	inflammatory	disorders	in	specific.		Furthermore,	it	can	be	useful	to	assess	whether	the	absence	of	CADM1-	mediated	mast	cell	adhesion	to	neurons	has	adverse	effects	on	the	whole	organism	health.	However,	before	translate	these	results	to	human,	it	is	important	to	compare	this	data	to	other	mast	cells	phenotype	because	of	mast	cell	heterogeneity	is	a	critical	issue	in	mast	cell	biology.		
	Another	issues	that	could	limit	my	data	and	remain	to	be	addressed	are:	(1)	Among	wide	range	of	mast	cell	cytokines,	only	IL-6	and	TNFa	were	measured.	Furthermore,	a	single	granule	component,	β-hexosaminidase	was	measured	for	assessment	of	the	level	of	degranulation.	However,	other	mast	cell	and	neuronal	mediators	such	as	neuropeptides,	ATP,	serotonin	and	PGD2	are	known	to	intimately	involved	in	the	crosstalk.	Therefore,	these	mediators	must	be	investigated	in	depth	in	order	to	final	understand	the	extend	of	mast	cell-	neuron	interactions	in	health	and	the	diseases.	(2)		Although	I	have	shown	that	neurons	express	CADM1,	future	studies	should	carry	out	to	comprehensive	investigate	CADM1	distribution	along	the	neurites	and	weather	it	is	in	random	fashion	or	its	at	particular	spots,	presumably,	in	co-localization	with	receptors	that	involve	in	crosstalk.	Moreover,	I	didn’t	test	the	contribution	of	CADM1	expressed	by	DRG	on	the	enhancement	of	mast	cell	function	in	co-culture.	The	difficulty	of	transfection	primary	neurons	is	the	major	cause.	However,	this	could	represent	the	objective	of	future	studies.	
	
In	summary,	my	data	support	the	concept	that	mast	cells	responsiveness	could	be	influenced	by	their	interaction	with	other	cells	such	as	neurons.		Cell	signaling	mediated	by	CADM1	is	a	fundamental	process	to	regulate	mast	cell-	neuron	crosstalk	that	is	believed	to	be	important	in	the	progression	of	many	disorders	related	to	neurogenic	inflammation.			
	
177	
Bibliography	
ABBRACCHIO,	M.	P.	&	BURNSTOCK,	G.	1998.	Purinergic	signalling:	pathophysiological	roles.	Jpn	J	Pharmacol,	78,	113-45.	ABRAHAM,	S.	N.	&	ST	JOHN,	A.	L.	2010.	Mast	cell-orchestrated	immunity	to	pathogens.	
Nat	Rev	Immunol,	10,	440-52.	AGIS,	H.,	WILLHEIM,	M.,	SPERR,	W.	R.,	WILFING,	A.,	KRÖMER,	E.,	KABRNA,	E.,	SPANBLÖCHL,	E.,	STROBL,	H.,	GEISSLER,	K.,	SPITTLER,	A.,	BOLTZ-NITULESCU,	G.,	MAJDIC,	O.,	LECHNER,	K.	&	VALENT,	P.	1993.	Monocytes	do	not	make	mast	cells	when	cultured	in	the	presence	of	SCF.	Characterization	of	the	circulating	mast	cell	progenitor	as	a	c-kit+,	CD34+,	Ly-,	CD14-,	CD17-,	colony-forming	cell.	J	Immunol,	151,	4221-7.	AICH,	A.,	AFRIN,	L.	B.	&	GUPTA,	K.	2015.	Mast	Cell-Mediated	Mechanisms	of	Nociception.	
Int	J	Mol	Sci,	16,	29069-92.	AKBAR,	A.,	YIANGOU,	Y.,	FACER,	P.,	WALTERS,	J.	R.,	ANAND,	P.	&	GHOSH,	S.	2008.	Increased	capsaicin	receptor	TRPV1-expressing	sensory	fibres	in	irritable	bowel	syndrome	and	their	correlation	with	abdominal	pain.	Gut,	57,	923-9.	AKERS,	I.	A.,	PARSONS,	M.,	HILL,	M.	R.,	HOLLENBERG,	M.	D.,	SANJAR,	S.,	LAURENT,	G.	J.	&	MCANULTY,	R.	J.	2000.	Mast	cell	tryptase	stimulates	human	lung	fibroblast	proliferation	via	protease-activated	receptor-2.	Am	J	Physiol	Lung	Cell	Mol	Physiol,	278,	L193-201.	AKIRA,	S.	1997.	IL-6-regulated	transcription	factors.	Int	J	Biochem	Cell	Biol,	29,	1401-18.	ALIAKBARI,	J.,	SREEDHARAN,	S.	P.,	TURCK,	C.	W.	&	GOETZL,	E.	J.	1987.	Selective	localization	of	vasoactive	intestinal	peptide	and	substance	P	in	human	eosinophils.	Biochem	Biophys	Res	Commun,	148,	1440-5.	ALVING,	K.,	SUNDSTRÖM,	C.,	MATRAN,	R.,	PANULA,	P.,	HÖKFELT,	T.	&	LUNDBERG,	J.	M.	1991.	Association	between	histamine-containing	mast	cells	and	sensory	nerves	in	the	skin	and	airways	of	control	and	capsaicin-treated	pigs.	Cell	Tissue	Res,	264,	529-38.	AMADESI,	S.,	NIE,	J.,	VERGNOLLE,	N.,	COTTRELL,	G.	S.,	GRADY,	E.	F.,	TREVISANI,	M.,	MANNI,	C.,	GEPPETTI,	P.,	MCROBERTS,	J.	A.,	ENNES,	H.,	DAVIS,	J.	B.,	MAYER,	E.	A.	&	BUNNETT,	N.	W.	2004.	Protease-activated	receptor	2	sensitizes	the	capsaicin	receptor	transient	receptor	potential	vanilloid	receptor	1	to	induce	hyperalgesia.	
J	Neurosci,	24,	4300-12.	ANFOSSO,	F.,	BARDIN,	N.,	FRANCÈS,	V.,	VIVIER,	E.,	CAMOIN-JAU,	L.,	SAMPOL,	J.	&	DIGNAT-GEORGE,	F.	1998.	Activation	of	human	endothelial	cells	via	S-endo-1	antigen	(CD146)	stimulates	the	tyrosine	phosphorylation	of	focal	adhesion	kinase	p125(FAK).	J	Biol	Chem,	273,	26852-6.	ANNAHÁZI,	A.,	GECSE,	K.,	DABEK,	M.,	AIT-BELGNAOUI,	A.,	ROSZTÓCZY,	A.,	RÓKA,	R.,	MOLNÁR,	T.,	THEODOROU,	V.,	WITTMANN,	T.,	BUENO,	L.	&	EUTAMENE,	H.	2009.	
	
178	
Fecal	proteases	from	diarrheic-IBS	and	ulcerative	colitis	patients	exert	opposite	effect	on	visceral	sensitivity	in	mice.	Pain,	144,	209-17.	AVRAAMIDES,	C.	J.,	GARMY-SUSINI,	B.	&	VARNER,	J.	A.	2008.	Integrins	in	angiogenesis	and	lymphangiogenesis.	Nat	Rev	Cancer,	8,	604-17.	BACHERT,	C.	2002.	The	role	of	histamine	in	allergic	disease:	re-appraisal	of	its	inflammatory	potential.	Allergy,	57,	287-96.	BALUK,	P.	1997.	Neurogenic	inflammation	in	skin	and	airways.	J	Investig	Dermatol	Symp	
Proc,	2,	76-81.	BARBARA,	G.,	STANGHELLINI,	V.,	DE	GIORGIO,	R.,	CREMON,	C.,	COTTRELL,	G.	S.,	SANTINI,	D.,	PASQUINELLI,	G.,	MORSELLI-LABATE,	A.	M.,	GRADY,	E.	F.,	BUNNETT,	N.	W.,	COLLINS,	S.	M.	&	CORINALDESI,	R.	2004.	Activated	mast	cells	in	proximity	to	colonic	nerves	correlate	with	abdominal	pain	in	irritable	bowel	syndrome.	
Gastroenterology,	126,	693-702.	BARBARA,	G.,	WANG,	B.,	STANGHELLINI,	V.,	DE	GIORGIO,	R.,	CREMON,	C.,	DI	NARDO,	G.,	TREVISANI,	M.,	CAMPI,	B.,	GEPPETTI,	P.,	TONINI,	M.,	BUNNETT,	N.	W.,	GRUNDY,	D.	&	CORINALDESI,	R.	2007.	Mast	cell-dependent	excitation	of	visceral-nociceptive	sensory	neurons	in	irritable	bowel	syndrome.	Gastroenterology,	132,	26-37.	BASBAUM,	A.	I.,	BAUTISTA,	D.	M.,	SCHERRER,	G.	&	JULIUS,	D.	2009.	Cellular	and	molecular	mechanisms	of	pain.	Cell,	139,	267-84.	BAUER,	O.	&	RAZIN,	E.	2000.	Mast	Cell-Nerve	Interactions.	News	Physiol	Sci,	15,	213-218.	BHATIA,	M.	2010.	Hydrogen	sulfide	and	substance	P	in	inflammation.	Antioxid	Redox	
Signal,	12,	1191-202.	BIEDERER,	T.	2006.	Bioinformatic	characterization	of	the	SynCAM	family	of	immunoglobulin-like	domain-containing	adhesion	molecules.	Genomics,	87,	139-50.	BIEDERER,	T.,	SARA,	Y.,	MOZHAYEVA,	M.,	ATASOY,	D.,	LIU,	X.,	KAVALALI,	E.	T.	&	SÜDHOF,	T.	C.	2002.	SynCAM,	a	synaptic	adhesion	molecule	that	drives	synapse	assembly.	Science,	297,	1525-31.	BISCHOFF,	S.	C.	2007.	Role	of	mast	cells	in	allergic	and	non-allergic	immune	responses:	comparison	of	human	and	murine	data.	Nat	Rev	Immunol,	7,	93-104.	BISCHOFF,	S.	C.	&	DAHINDEN,	C.	A.	1992.	c-kit	ligand:	a	unique	potentiator	of	mediator	release	by	human	lung	mast	cells.	J	Exp	Med,	175,	237-44.	BISCHOFF,	S.	C.,	SCHWENGBERG,	S.,	LORENTZ,	A.,	MANNS,	M.	P.,	BEKTAS,	H.,	SANN,	H.,	LEVI-SCHAFFER,	F.,	SHANAHAN,	F.	&	SCHEMANN,	M.	2004.	Substance	P	and	other	neuropeptides	do	not	induce	mediator	release	in	isolated	human	intestinal	mast	cells.	Neurogastroenterol	Motil,	16,	185-93.	BLACK,	P.	H.	1994.	Immune	system-central	nervous	system	interactions:	effect	and	immunomodulatory	consequences	of	immune	system	mediators	on	the	brain.	
Antimicrob	Agents	Chemother,	38,	7-12.	
	
179	
BLANCO,	I.,	BÉRITZE,	N.,	ARGÜELLES,	M.,	CÁRCABA,	V.,	FERNÁNDEZ,	F.,	JANCIAUSKIENE,	S.,	OIKONOMOPOULOU,	K.,	DE	SERRES,	F.	J.,	FERNÁNDEZ-BUSTILLO,	E.	&	HOLLENBERG,	M.	D.	2010.	Abnormal	overexpression	of	mastocytes	in	skin	biopsies	of	fibromyalgia	patients.	Clin	Rheumatol,	29,	1403-12.	BLANK,	U.,	RA,	C.,	MILLER,	L.,	WHITE,	K.,	METZGER,	H.	&	KINET,	J.	P.	1989.	Complete	structure	and	expression	in	transfected	cells	of	high	affinity	IgE	receptor.	Nature,	337,	187-9.	BLENNERHASSETT,	M.	G.	&	BIENENSTOCK,	J.	1990.	Apparent	innervation	of	rat	basophilic	leukaemia	(RBL-2H3)	cells	by	sympathetic	neurons	in	vitro.	Neurosci	
Lett,	120,	50-4.	BLENNERHASSETT,	M.	G.	&	BIENENSTOCK,	J.	1998.	Sympathetic	nerve	contact	causes	maturation	of	mast	cells	in	vitro.	J	Neurobiol,	35,	173-82.	BLENNERHASSETT,	M.	G.,	TOMIOKA,	M.	&	BIENENSTOCK,	J.	1991.	Formation	of	contacts	between	mast	cells	and	sympathetic	neurons	in	vitro.	Cell	Tissue	Res,	265,	121-8.	BORKOWSKI,	T.	A.,	JOUVIN,	M.	H.,	LIN,	S.	Y.	&	KINET,	J.	P.	2001.	Minimal	requirements	for	IgE-mediated	regulation	of	surface	Fc	epsilon	RI.	J	Immunol,	167,	1290-6.	BRADDING,	P.,	OKAYAMA,	Y.,	HOWARTH,	P.	H.,	CHURCH,	M.	K.	&	HOLGATE,	S.	T.	1995.	Heterogeneity	of	human	mast	cells	based	on	cytokine	content.	J	Immunol,	155,	297-307.	BRADDING,	P.,	WALLS,	A.	F.	&	HOLGATE,	S.	T.	2006.	The	role	of	the	mast	cell	in	the	pathophysiology	of	asthma.	J	Allergy	Clin	Immunol,	117,	1277-84.	BRAIN,	S.	D.	&	WILLIAMS,	T.	J.	1985.	Inflammatory	oedema	induced	by	synergism	between	calcitonin	gene-related	peptide	(CGRP)	and	mediators	of	increased	vascular	permeability.	Br	J	Pharmacol,	86,	855-60.	BRAIN,	S.	D.,	WILLIAMS,	T.	J.,	TIPPINS,	J.	R.,	MORRIS,	H.	R.	&	MACINTYRE,	I.	1985.	Calcitonin	gene-related	peptide	is	a	potent	vasodilator.	Nature,	313,	54-6.	BRIGHTLING,	C.	E.,	BRADDING,	P.,	SYMON,	F.	A.,	HOLGATE,	S.	T.,	WARDLAW,	A.	J.	&	PAVORD,	I.	D.	2002.	Mast-cell	infiltration	of	airway	smooth	muscle	in	asthma.	N	
Engl	J	Med,	346,	1699-705.	BROCK,	J.	A.	&	CUNNANE,	T.	C.	1988.	Electrical	activity	at	the	sympathetic	neuroeffector	junction	in	the	guinea-pig	vas	deferens.	J	Physiol,	399,	607-32.	BROWN,	J.	M.,	NEMETH,	K.,	KUSHNIR-SUKHOV,	N.	M.,	METCALFE,	D.	D.	&	MEZEY,	E.	2011.	Bone	marrow	stromal	cells	inhibit	mast	cell	function	via	a	COX2-dependent	mechanism.	Clin	Exp	Allergy,	41,	526-34.	BUHNER,	S.,	LI,	Q.,	VIGNALI,	S.,	BARBARA,	G.,	DE	GIORGIO,	R.,	STANGHELLINI,	V.,	CREMON,	C.,	ZELLER,	F.,	LANGER,	R.,	DANIEL,	H.,	MICHEL,	K.	&	SCHEMANN,	M.	2009.	Activation	of	human	enteric	neurons	by	supernatants	of	colonic	biopsy	specimens	from	patients	with	irritable	bowel	syndrome.	Gastroenterology,	137,	1425-34.	BULANOVA,	E.	&	BULFONE-PAUS,	S.	2010.	P2	receptor-mediated	signaling	in	mast	cell	biology.	Purinergic	Signal,	6,	3-17.	
	
180	
BURNSTOCK,	G.	2009.	Purinergic	receptors	and	pain.	Curr	Pharm	Des,	15,	1717-35.	BUTTERFIELD,	J.	H.,	WEILER,	D.,	DEWALD,	G.	&	GLEICH,	G.	J.	1988.	Establishment	of	an	immature	mast	cell	line	from	a	patient	with	mast	cell	leukemia.	Leuk	Res,	12,	345-55.	BYRNE,	R.	D.,	ROSIVATZ,	E.,	PARSONS,	M.,	LARIJANI,	B.,	PARKER,	P.	J.,	NG,	T.	&	WOSCHOLSKI,	R.	2007.	Differential	activation	of	the	PI	3-kinase	effectors	AKT/PKB	and	p70	S6	kinase	by	compound	48/80	is	mediated	by	PKCalpha.	Cell	
Signal,	19,	321-9.	CAMPENOT,	R.	B.	1977.	Local	control	of	neurite	development	by	nerve	growth	factor.	
Proc	Natl	Acad	Sci	U	S	A,	74,	4516-9.	CARLTON,	S.	M.	2014.	Nociceptive	primary	afferents:	they	have	a	mind	of	their	own.	J	
Physiol,	592,	3403-11.	CARROLL,	N.	G.,	MUTAVDZIC,	S.	&	JAMES,	A.	L.	2002.	Increased	mast	cells	and	neutrophils	in	submucosal	mucous	glands	and	mucus	plugging	in	patients	with	asthma.	Thorax,	57,	677-82.	CASALE,	T.	B.,	CONDEMI,	J.,	LAFORCE,	C.,	NAYAK,	A.,	ROWE,	M.,	WATROUS,	M.,	MCALARY,	M.,	FOWLER-TAYLOR,	A.,	RACINE,	A.,	GUPTA,	N.,	FICK,	R.,	DELLA	CIOPPA,	G.	&	GROUP,	O.	S.	A.	R.	T.	2001.	Effect	of	omalizumab	on	symptoms	of	seasonal	allergic	rhinitis:	a	randomized	controlled	trial.	JAMA,	286,	2956-67.	CAVALLARO,	U.	&	CHRISTOFORI,	G.	2004.	Cell	adhesion	and	signalling	by	cadherins	and	Ig-CAMs	in	cancer.	Nat	Rev	Cancer,	4,	118-32.	CAVALLARO,	U.	&	DEJANA,	E.	2011.	Adhesion	molecule	signalling:	not	always	a	sticky	business.	Nat	Rev	Mol	Cell	Biol,	12,	189-97.	CENAC,	N.,	ALTIER,	C.,	MOTTA,	J.	P.,	D'ALDEBERT,	E.,	GALEANO,	S.,	ZAMPONI,	G.	W.	&	VERGNOLLE,	N.	2010.	Potentiation	of	TRPV4	signalling	by	histamine	and	serotonin:	an	important	mechanism	for	visceral	hypersensitivity.	Gut,	59,	481-8.	CENAC,	N.,	GARCIA-VILLAR,	R.,	FERRIER,	L.,	LARAUCHE,	M.,	VERGNOLLE,	N.,	BUNNETT,	N.	W.,	COELHO,	A.	M.,	FIORAMONTI,	J.	&	BUENO,	L.	2003.	Proteinase-activated	receptor-2-induced	colonic	inflammation	in	mice:	possible	involvement	of	afferent	neurons,	nitric	oxide,	and	paracellular	permeability.	J	Immunol,	170,	4296-300.	CHEN,	C.	C.,	GRIMBALDESTON,	M.	A.,	TSAI,	M.,	WEISSMAN,	I.	L.	&	GALLI,	S.	J.	2005.	Identification	of	mast	cell	progenitors	in	adult	mice.	Proceedings	of	the	National	
Academy	of	Sciences	of	the	United	States	of	America,	102,	11408-11413.	CHEN,	W.,	MI,	R.,	HAUGHEY,	N.,	OZ,	M.	&	HÖKE,	A.	2007.	Immortalization	and	characterization	of	a	nociceptive	dorsal	root	ganglion	sensory	neuronal	line.	J	
Peripher	Nerv	Syst,	12,	121-30.	CHEN,	X.	J.	&	ENERBÄCK,	L.	1999.	Immature	peritoneal	mast	cells	in	neonatal	rats	express	the	CTMC	phenotype,	as	well	as	functional	IgE	receptors.	APMIS,	107,	957-65.	
	
181	
CHIAPPETTA,	N.	&	GRUBER,	B.	2006.	The	role	of	mast	cells	in	osteoporosis.	Semin	
Arthritis	Rheum,	36,	32-6.	COLGAN,	S.	P.,	ELTZSCHIG,	H.	K.,	ECKLE,	T.	&	THOMPSON,	L.	F.	2006.	Physiological	roles	for	ecto-5'-nucleotidase	(CD73).	Purinergic	Signal,	2,	351-60.	CRAIG,	S.	S.,	SCHECHTER,	N.	M.	&	SCHWARTZ,	L.	B.	1988.	Ultrastructural	analysis	of	human	T	and	TC	mast	cells	identified	by	immunoelectron	microscopy.	Lab	Invest,	58,	682-91.	CUESTA,	M.	C.,	QUINTERO,	L.,	PONS,	H.	&	SUAREZ-ROCA,	H.	2002.	Substance	P	and	calcitonin	gene-related	peptide	increase	IL-1	beta,	IL-6	and	TNF	alpha	secretion	from	human	peripheral	blood	mononuclear	cells.	Neurochem	Int,	40,	301-6.	CZARNETZKI,	B.	M.	&	BEHRENDT,	H.	1981.	Studies	on	the	in	vitro	development	of	rat	peritoneal	mast	cells.	Immunobiology,	159,	256-68.	DE	JONGE,	F.,	DE	LAET,	A.,	VAN	NASSAUW,	L.,	BROWN,	J.	K.,	MILLER,	H.	R.,	VAN	BOGAERT,	P.	P.,	TIMMERMANS,	J.	P.	&	KROESE,	A.	B.	2004.	In	vitro	activation	of	murine	DRG	neurons	by	CGRP-mediated	mucosal	mast	cell	degranulation.	Am	J	
Physiol	Gastrointest	Liver	Physiol,	287,	G178-91.	DENG,	P.	Y.	&	LI,	Y.	J.	2005.	Calcitonin	gene-related	peptide	and	hypertension.	Peptides,	26,	1676-85.	DI	NARDO,	G.,	BARBARA,	G.,	CUCCHIARA,	S.,	CREMON,	C.,	SHULMAN,	R.	J.,	ISOLDI,	S.,	ZECCHI,	L.,	DRAGO,	L.,	OLIVA,	S.,	SAULLE,	R.,	BARBARO,	M.	R.	&	STRONATI,	L.	2014.	Neuroimmune	interactions	at	different	intestinal	sites	are	related	to	abdominal	pain	symptoms	in	children	with	IBS.	Neurogastroenterol	Motil,	26,	196-204.	DINA,	O.	A.,	GREEN,	P.	G.	&	LEVINE,	J.	D.	2008.	Role	of	interleukin-6	in	chronic	muscle	hyperalgesic	priming.	Neuroscience,	152,	521-5.	DITLEVSEN,	D.	K.	&	KOLKOVA,	K.	2010.	Signaling	pathways	involved	in	NCAM-induced	neurite	outgrowth.	Adv	Exp	Med	Biol,	663,	151-68.	DODD,	P.	R.	2002.	Excited	to	death:	different	ways	to	lose	your	neurones.	Biogerontology,	3,	51-6.	DORAN,	C.,	CHETRIT,	J.,	HOLLEY,	M.	C.,	GRUNDY,	D.	&	NASSAR,	M.	A.	2015.	Mouse	DRG	Cell	Line	with	Properties	of	Nociceptors.	PLoS	One,	10,	e0128670.	DU,	W.,	LIU,	X.,	FAN,	G.,	ZHAO,	X.,	SUN,	Y.,	WANG,	T.,	ZHAO,	R.,	WANG,	G.,	ZHAO,	C.,	ZHU,	Y.,	YE,	F.,	JIN,	X.,	ZHANG,	F.,	ZHONG,	Z.	&	LI,	X.	2014.	From	cell	membrane	to	the	nucleus:	an	emerging	role	of	E-cadherin	in	gene	transcriptional	regulation.	J	Cell	
Mol	Med,	18,	1712-9.	DVORAK,	A.	M.,	MASSEY,	W.,	WARNER,	J.,	KISSELL,	S.,	KAGEY-SOBOTKA,	A.	&	LICHTENSTEIN,	L.	M.	1991.	IgE-mediated	anaphylactic	degranulation	of	isolated	human	skin	mast	cells.	Blood,	77,	569-78.	DVORAK,	A.	M.	&	MORGAN,	E.	S.	1997.	Diamine	oxidase-gold	enzyme-affinity	ultrastructural	demonstration	that	human	gut	mucosal	mast	cells	secrete	histamine	by	piecemeal	degranulation	in	vivo.	J	Allergy	Clin	Immunol,	99,	812-20.	
	
182	
EBBINGHAUS,	M.,	SEGOND	VON	BANCHET,	G.,	MASSIER,	J.,	GAJDA,	M.,	BRÄUER,	R.,	KRESS,	M.	&	SCHAIBLE,	H.	G.	2015.	Interleukin-6-dependent	influence	of	nociceptive	sensory	neurons	on	antigen-induced	arthritis.	Arthritis	Res	Ther,	17,	334.	EBERSBERGER,	A.,	AVERBECK,	B.,	MESSLINGER,	K.	&	REEH,	P.	W.	1999.	Release	of	substance	P,	calcitonin	gene-related	peptide	and	prostaglandin	E2	from	rat	dura	mater	encephali	following	electrical	and	chemical	stimulation	in	vitro.	
Neuroscience,	89,	901-7.	EBERTZ,	J.	M.,	HIRSHMAN,	C.	A.,	KETTELKAMP,	N.	S.,	UNO,	H.	&	HANIFIN,	J.	M.	1987.	Substance	P-induced	histamine	release	in	human	cutaneous	mast	cells.	J	Invest	
Dermatol,	88,	682-5.	ECHTENACHER,	B.,	MÄNNEL,	D.	N.	&	HÜLTNER,	L.	1996.	Critical	protective	role	of	mast	cells	in	a	model	of	acute	septic	peritonitis.	Nature,	381,	75-7.	EL-NOUR,	H.,	LUNDEBERG,	L.,	BOMAN,	A.,	BECK,	O.,	HARVIMA,	I.	T.,	THEODORSSON,	E.	&	NORDLIND,	K.	2005.	Study	of	innervation,	sensory	neuropeptides,	and	serotonin	in	murine	contact	allergic	skin.	Immunopharmacol	Immunotoxicol,	27,	67-76.	FITZGERALD,	S.	M.,	LEE,	S.	A.,	HALL,	H.	K.,	CHI,	D.	S.	&	KRISHNASWAMY,	G.	2004.	Human	lung	fibroblasts	express	interleukin-6	in	response	to	signaling	after	mast	cell	contact.	Am	J	Respir	Cell	Mol	Biol,	30,	585-93.	FORSYTHE,	P.	&	BIENENSTOCK,	J.	2012.	The	mast	cell-nerve	functional	unit:	a	key	component	of	physiologic	and	pathophysiologic	responses.	Chem	Immunol	
Allergy,	98,	196-221.	FORSYTHE,	P.,	MCGARVEY,	L.	P.,	HEANEY,	L.	G.,	MACMAHON,	J.	&	ENNIS,	M.	2000.	Sensory	neuropeptides	induce	histamine	release	from	bronchoalveolar	lavage	cells	in	both	nonasthmatic	coughers	and	cough	variant	asthmatics.	Clin	Exp	
Allergy,	30,	225-32.	FRANCAVILLA,	C.,	CATTANEO,	P.,	BEREZIN,	V.,	BOCK,	E.,	AMI,	D.,	DE	MARCO,	A.,	CHRISTOFORI,	G.	&	CAVALLARO,	U.	2009.	The	binding	of	NCAM	to	FGFR1	induces	a	specific	cellular	response	mediated	by	receptor	trafficking.	J	Cell	Biol,	187,	1101-16.	FRANCAVILLA,	C.,	LOEFFLER,	S.,	PICCINI,	D.,	KREN,	A.,	CHRISTOFORI,	G.	&	CAVALLARO,	U.	2007.	Neural	cell	adhesion	molecule	regulates	the	cellular	response	to	fibroblast	growth	factor.	J	Cell	Sci,	120,	4388-94.	FURNESS,	J.	B.,	CALLAGHAN,	B.	P.,	RIVERA,	L.	R.	&	CHO,	H.	J.	2014.	The	enteric	nervous	system	and	gastrointestinal	innervation:	integrated	local	and	central	control.	Adv	
Exp	Med	Biol,	817,	39-71.	FURUNO,	T.,	HAGIYAMA,	M.,	SEKIMURA,	M.,	OKAMOTO,	K.,	SUZUKI,	R.,	ITO,	A.,	HIRASHIMA,	N.	&	NAKANISHI,	M.	2012.	Cell	adhesion	molecule	1	(CADM1)	on	mast	cells	promotes	interaction	with	dorsal	root	ganglion	neurites	by	heterophilic	binding	to	nectin-3.	J	Neuroimmunol,	250,	50-8.	FURUNO,	T.,	ITO,	A.,	KOMA,	Y.,	WATABE,	K.,	YOKOZAKI,	H.,	BIENENSTOCK,	J.,	NAKANISHI,	M.	&	KITAMURA,	Y.	2005.	The	spermatogenic	Ig	
	
183	
superfamily/synaptic	cell	adhesion	molecule	mast-cell	adhesion	molecule	promotes	interaction	with	nerves.	J	Immunol,	174,	6934-42.	FURUNO,	T.,	MA,	D.,	VAN	DER	KLEIJ,	H.	P.,	NAKANISHI,	M.	&	BIENENSTOCK,	J.	2004.	Bone	marrow-derived	mast	cells	in	mice	respond	in	co-culture	to	scorpion	venom	activation	of	superior	cervical	ganglion	neurites	according	to	level	of	expression	of	NK-1	receptors.	Neurosci	Lett,	372,	185-9.	FURUNO,	T.	&	NAKANISHI,	M.	2011.	Analysis	of	neuroimmune	interactions	by	an	in	vitro	coculture	approach.	Methods	Mol	Biol,	789,	171-80.	GAGARI,	E.,	TSAI,	M.,	LANTZ,	C.	S.,	FOX,	L.	G.	&	GALLI,	S.	J.	1997.	Differential	release	of	mast	cell	interleukin-6	via	c-kit.	Blood,	89,	2654-63.	GALLI,	S.	J.	1990.	New	insights	into	"the	riddle	of	the	mast	cells":	microenvironmental	regulation	of	mast	cell	development	and	phenotypic	heterogeneity.	Lab	Invest,	62,	5-33.	GALLI,	S.	J.	2000.	Mast	cells	and	basophils.	Curr	Opin	Hematol,	7,	32-9.	GALLI,	S.	J.,	KALESNIKOFF,	J.,	GRIMBALDESTON,	M.	A.,	PILIPONSKY,	A.	M.,	WILLIAMS,	C.	M.	&	TSAI,	M.	2005.	Mast	cells	as	"tunable"	effector	and	immunoregulatory	cells:	recent	advances.	Annu	Rev	Immunol,	23,	749-86.	GALLI,	S.	J.	&	TSAI,	M.	2008.	Mast	cells:	versatile	regulators	of	inflammation,	tissue	remodeling,	host	defense	and	homeostasis.	J	Dermatol	Sci,	49,	7-19.	GALLI,	S.	J.,	TSAI,	M.	&	WERSHIL,	B.	K.	1993.	The	c-kit	receptor,	stem	cell	factor,	and	mast	cells.	What	each	is	teaching	us	about	the	others.	Am	J	Pathol,	142,	965-74.	GALLI,	S.	J.,	ZSEBO,	K.	M.	&	GEISSLER,	E.	N.	1994.	The	kit	ligand,	stem	cell	factor.	Adv	
Immunol,	55,	1-96.	GANESHAN,	K.	&	BRYCE,	P.	J.	2012.	Regulatory	T	cells	enhance	mast	cell	production	of	IL-6	via	surface-bound	TGF-β.	J	Immunol,	188,	594-603.	GARLAND,	E.	L.	2012.	Pain	processing	in	the	human	nervous	system:	a	selective	review	of	nociceptive	and	biobehavioral	pathways.	Prim	Care,	39,	561-71.	GAVAZZI,	I.,	KUMAR,	R.	D.,	MCMAHON,	S.	B.	&	COHEN,	J.	1999.	Growth	responses	of	different	subpopulations	of	adult	sensory	neurons	to	neurotrophic	factors	in	vitro.	Eur	J	Neurosci,	11,	3405-14.	GIBBS,	B.	F.,	WIERECKY,	J.,	WELKER,	P.,	HENZ,	B.	M.,	WOLFF,	H.	H.	&	GRABBE,	J.	2001.	Human	skin	mast	cells	rapidly	release	preformed	and	newly	generated	TNF-alpha	and	IL-8	following	stimulation	with	anti-IgE	and	other	secretagogues.	Exp	
Dermatol,	10,	312-20.	GIBSON,	N.	J.	2011.	Cell	adhesion	molecules	in	context:	CAM	function	depends	on	the	neighborhood.	Cell	Adh	Migr,	5,	48-51.	GILFILLAN,	A.	M.,	PEAVY,	R.	D.	&	METCALFE,	D.	D.	2009.	Amplification	mechanisms	for	the	enhancement	of	antigen-mediated	mast	cell	activation.	Immunol	Res,	43,	15-24.	
	
184	
GILFILLAN,	A.	M.	&	RIVERA,	J.	2009.	The	tyrosine	kinase	network	regulating	mast	cell	activation.	Immunol	Rev,	228,	149-69.	GILFILLAN,	A.	M.	&	TKACZYK,	C.	2006.	Integrated	signalling	pathways	for	mast-cell	activation.	Nat	Rev	Immunol,	6,	218-30.	GINIATULLIN,	R.,	NISTRI,	A.	&	FABBRETTI,	E.	2008.	Molecular	mechanisms	of	sensitization	of	pain-transducing	P2X3	receptors	by	the	migraine	mediators	CGRP	and	NGF.	Mol	Neurobiol,	37,	83-90.	GODA,	Y.	2002.	Cadherins	communicate	structural	plasticity	of	presynaptic	and	postsynaptic	terminals.	Neuron,	35,	1-3.	GOLDSTEIN,	M.	E.,	HOUSE,	S.	B.	&	GAINER,	H.	1991.	NF-L	and	peripherin	immunoreactivities	define	distinct	classes	of	rat	sensory	ganglion	cells.	J	Neurosci	
Res,	30,	92-104.	GORAL,	V.,	KUCUKONER,	M.	&	BUYUKBAYRAM,	H.	2010.	Mast	cells	count	and	serum	cytokine	levels	in	patients	with	irritable	bowel	syndrome.	
Hepatogastroenterology,	57,	751-4.	GOTTWALD,	T.	P.,	HEWLETT,	B.	R.,	LHOTÁK,	S.	&	STEAD,	R.	H.	1995.	Electrical	stimulation	of	the	vagus	nerve	modulates	the	histamine	content	of	mast	cells	in	the	rat	jejunal	mucosa.	Neuroreport,	7,	313-7.	GRACE,	P.	M.,	HUTCHINSON,	M.	R.,	MAIER,	S.	F.	&	WATKINS,	L.	R.	2014.	Pathological	pain	and	the	neuroimmune	interface.	Nat	Rev	Immunol,	14,	217-31.	GROSCHWITZ,	K.	R.,	AHRENS,	R.,	OSTERFELD,	H.,	GURISH,	M.	F.,	HAN,	X.,	ABRINK,	M.,	FINKELMAN,	F.	D.,	PEJLER,	G.	&	HOGAN,	S.	P.	2009.	Mast	cells	regulate	homeostatic	intestinal	epithelial	migration	and	barrier	function	by	a	chymase/Mcpt4-dependent	mechanism.	Proc	Natl	Acad	Sci	U	S	A,	106,	22381-6.	GRUBER,	B.	L.,	KEW,	R.	R.,	JELASKA,	A.,	MARCHESE,	M.	J.,	GARLICK,	J.,	REN,	S.,	SCHWARTZ,	L.	B.	&	KORN,	J.	H.	1997.	Human	mast	cells	activate	fibroblasts:	tryptase	is	a	fibrogenic	factor	stimulating	collagen	messenger	ribonucleic	acid	synthesis	and	fibroblast	chemotaxis.	J	Immunol,	158,	2310-7.	GU,	J.	G.	&	MACDERMOTT,	A.	B.	1997.	Activation	of	ATP	P2X	receptors	elicits	glutamate	release	from	sensory	neuron	synapses.	Nature,	389,	749-53.	GUILARTE,	M.,	SANTOS,	J.,	DE	TORRES,	I.,	ALONSO,	C.,	VICARIO,	M.,	RAMOS,	L.,	MARTÍNEZ,	C.,	CASELLAS,	F.,	SAPERAS,	E.	&	MALAGELADA,	J.	R.	2007.	Diarrhoea-predominant	IBS	patients	show	mast	cell	activation	and	hyperplasia	in	the	jejunum.	Gut,	56,	203-9.	GUMBINER,	B.	M.	2005.	Regulation	of	cadherin-mediated	adhesion	in	morphogenesis.	
Nat	Rev	Mol	Cell	Biol,	6,	622-34.	GUO,	W.	&	GIANCOTTI,	F.	G.	2004.	Integrin	signalling	during	tumour	progression.	Nat	
Rev	Mol	Cell	Biol,	5,	816-26.	HAGEMANN,	C.,	MEYER,	C.,	STOJIC,	J.,	EICKER,	S.,	GERNGRAS,	S.,	KÜHNEL,	S.,	ROOSEN,	K.	&	VINCE,	G.	H.	2006.	High	efficiency	transfection	of	glioma	cell	lines	and	primary	cells	for	overexpression	and	RNAi	experiments.	J	Neurosci	Methods,	156,	194-202.	
	
185	
HAGIYAMA,	M.,	FURUNO,	T.,	HOSOKAWA,	Y.,	IINO,	T.,	ITO,	T.,	INOUE,	T.,	NAKANISHI,	M.,	MURAKAMI,	Y.	&	ITO,	A.	2011.	Enhanced	nerve-mast	cell	interaction	by	a	neuronal	short	isoform	of	cell	adhesion	molecule-1.	J	Immunol,	186,	5983-92.	HAIG,	D.	M.,	HUNTLEY,	J.	F.,	MACKELLAR,	A.,	NEWLANDS,	G.	F.,	INGLIS,	L.,	SANGHA,	R.,	COHEN,	D.,	HAPEL,	A.,	GALLI,	S.	J.	&	MILLER,	H.	R.	1994.	Effects	of	stem	cell	factor	(kit-ligand)	and	interleukin-3	on	the	growth	and	serine	proteinase	expression	of	rat	bone-marrow-derived	or	serosal	mast	cells.	Blood,	83,	72-83.	HAKIMI,	J.,	SEALS,	C.,	KONDAS,	J.	A.,	PETTINE,	L.,	DANHO,	W.	&	KOCHAN,	J.	1990.	The	alpha	subunit	of	the	human	IgE	receptor	(FcERI)	is	sufficient	for	high	affinity	IgE	binding.	J	Biol	Chem,	265,	22079-81.	HAMAWY,	M.	M.,	MERGENHAGEN,	S.	E.	&	SIRAGANIAN,	R.	P.	1993.	Cell	adherence	to	fibronectin	and	the	aggregation	of	the	high	affinity	immunoglobulin	E	receptor	synergistically	regulate	tyrosine	phosphorylation	of	105-115-kDa	proteins.	J	Biol	
Chem,	268,	5227-33.	HAMAWY,	M.	M.,	MERGENHAGEN,	S.	E.	&	SIRAGANIAN,	R.	P.	1994.	Adhesion	molecules	as	regulators	of	mast-cell	and	basophil	function.	Immunol	Today,	15,	62-6.	HARA,	M.,	ONO,	K.,	HWANG,	M.	W.,	IWASAKI,	A.,	OKADA,	M.,	NAKATANI,	K.,	SASAYAMA,	S.	&	MATSUMORI,	A.	2002.	Evidence	for	a	role	of	mast	cells	in	the	evolution	to	congestive	heart	failure.	J	Exp	Med,	195,	375-81.	HARPER,	A.	A.	&	LAWSON,	S.	N.	1985a.	Conduction	velocity	is	related	to	morphological	cell	type	in	rat	dorsal	root	ganglion	neurones.	J	Physiol,	359,	31-46.	HARPER,	A.	A.	&	LAWSON,	S.	N.	1985b.	Electrical	properties	of	rat	dorsal	root	ganglion	neurones	with	different	peripheral	nerve	conduction	velocities.	J	Physiol,	359,	47-63.	HASSTEDT,	S.	J.,	BEZEMER,	I.	D.,	CALLAS,	P.	W.,	VOSSEN,	C.	Y.,	TROTMAN,	W.,	HEBBEL,	R.	P.,	DEMERS,	C.,	ROSENDAAL,	F.	R.	&	BOVILL,	E.	G.	2009.	Cell	adhesion	molecule	1:	a	novel	risk	factor	for	venous	thrombosis.	Blood,	114,	3084-91.	HENSELLEK,	S.,	BRELL,	P.,	SCHAIBLE,	H.	G.,	BRÄUER,	R.	&	SEGOND	VON	BANCHET,	G.	2007.	The	cytokine	TNFalpha	increases	the	proportion	of	DRG	neurones	expressing	the	TRPV1	receptor	via	the	TNFR1	receptor	and	ERK	activation.	Mol	
Cell	Neurosci,	36,	381-91.	HILL,	P.	B.,	MACDONALD,	A.	J.,	THORNTON,	E.	M.,	NEWLANDS,	G.	F.,	GALLI,	S.	J.	&	MILLER,	H.	R.	1996.	Stem	cell	factor	enhances	immunoglobulin	E-dependent	mediator	release	from	cultured	rat	bone	marrow-derived	mast	cells:	activation	of	previously	unresponsive	cells	demonstrated	by	a	novel	ELISPOT	assay.	
Immunology,	87,	326-33.	HODGKINSON,	C.	A.,	MOORE,	K.	J.,	NAKAYAMA,	A.,	STEINGRÍMSSON,	E.,	COPELAND,	N.	G.,	JENKINS,	N.	A.	&	ARNHEITER,	H.	1993.	Mutations	at	the	mouse	microphthalmia	locus	are	associated	with	defects	in	a	gene	encoding	a	novel	basic-helix-loop-helix-zipper	protein.	Cell,	74,	395-404.	HOERMANN,	G.,	BLATT,	K.,	GREINER,	G.,	PUTZ,	E.	M.,	BERGER,	A.,	HERRMANN,	H.,	CERNY-REITERER,	S.,	GLEIXNER,	K.	V.,	WALZ,	C.,	HOETZENECKER,	K.,	
	
186	
MÜLLAUER,	L.,	REITER,	A.,	SOTLAR,	K.,	SEXL,	V.,	VALENT,	P.	&	MAYERHOFER,	M.	2014.	CD52	is	a	molecular	target	in	advanced	systemic	mastocytosis.	FASEB	J,	28,	3540-51.	HOGABOAM,	C.,	KUNKEL,	S.	L.,	STRIETER,	R.	M.,	TAUB,	D.	D.,	LINCOLN,	P.,	STANDIFORD,	T.	J.	&	LUKACS,	N.	W.	1998.	Novel	role	of	transmembrane	SCF	for	mast	cell	activation	and	eotaxin	production	in	mast	cell-fibroblast	interactions.	J	Immunol,	160,	6166-71.	HOLLINS,	F.,	KAUR,	D.,	YANG,	W.,	CRUSE,	G.,	SAUNDERS,	R.,	SUTCLIFFE,	A.,	BERGER,	P.,	ITO,	A.,	BRIGHTLING,	C.	E.	&	BRADDING,	P.	2008.	Human	airway	smooth	muscle	promotes	human	lung	mast	cell	survival,	proliferation,	and	constitutive	activation:	cooperative	roles	for	CADM1,	stem	cell	factor,	and	IL-6.	J	Immunol,	181,	2772-80.	HOLZER,	P.	1988.	Local	effector	functions	of	capsaicin-sensitive	sensory	nerve	endings:	involvement	of	tachykinins,	calcitonin	gene-related	peptide	and	other	neuropeptides.	Neuroscience,	24,	739-68.	HONDA,	T.,	SAKISAKA,	T.,	YAMADA,	T.,	KUMAZAWA,	N.,	HOSHINO,	T.,	KAJITA,	M.,	KAYAHARA,	T.,	ISHIZAKI,	H.,	TANAKA-OKAMOTO,	M.,	MIZOGUCHI,	A.,	MANABE,	T.,	MIYOSHI,	J.	&	TAKAI,	Y.	2006.	Involvement	of	nectins	in	the	formation	of	puncta	adherentia	junctions	and	the	mossy	fiber	trajectory	in	the	mouse	hippocampus.	Mol	Cell	Neurosci,	31,	315-25.	HORIE,	H.	&	KIM,	S.	U.	1984.	Improved	survival	and	differentiation	of	newborn	and	adult	mouse	neurons	in	F12	defined	medium	by	fibronectin.	Brain	Res,	294,	178-81.	HSIEH,	F.	H.,	SHARMA,	P.,	GIBBONS,	A.,	GOGGANS,	T.,	ERZURUM,	S.	C.	&	HAQUE,	S.	J.	2005.	Human	airway	epithelial	cell	determinants	of	survival	and	functional	phenotype	for	primary	human	mast	cells.	Proc	Natl	Acad	Sci	U	S	A,	102,	14380-5.	HU,	Z.	Q.,	ZHAO,	W.	H.	&	SHIMAMURA,	T.	2007.	Regulation	of	mast	cell	development	by	inflammatory	factors.	Curr	Med	Chem,	14,	3044-50.	HUANG,	C.,	DE	SANCTIS,	G.	T.,	O'BRIEN,	P.	J.,	MIZGERD,	J.	P.,	FRIEND,	D.	S.,	DRAZEN,	J.	M.,	BRASS,	L.	F.	&	STEVENS,	R.	L.	2001.	Evaluation	of	the	substrate	specificity	of	human	mast	cell	tryptase	beta	I	and	demonstration	of	its	importance	in	bacterial	infections	of	the	lung.	J	Biol	Chem,	276,	26276-84.	HUANG,	M.,	BERRY,	J.,	KANDERE,	K.,	LYTINAS,	M.,	KARALIS,	K.	&	THEOHARIDES,	T.	C.	2002.	Mast	cell	deficient	W/W(v)	mice	lack	stress-induced	increase	in	serum	IL-6	levels,	as	well	as	in	peripheral	CRH	and	vascular	permeability,	a	model	of	rheumatoid	arthritis.	Int	J	Immunopathol	Pharmacol,	15,	249-254.	HUGHES,	P.	A.,	HARRINGTON,	A.	M.,	CASTRO,	J.,	LIEBREGTS,	T.,	ADAM,	B.,	GRASBY,	D.	J.,	ISAACS,	N.	J.,	MALDENIYA,	L.,	MARTIN,	C.	M.,	PERSSON,	J.,	ANDREWS,	J.	M.,	HOLTMANN,	G.,	BLACKSHAW,	L.	A.	&	BRIERLEY,	S.	M.	2013.	Sensory	neuro-immune	interactions	differ	between	irritable	bowel	syndrome	subtypes.	Gut,	62,	1456-65.	HUNDLEY,	T.	R.,	GILFILLAN,	A.	M.,	TKACZYK,	C.,	ANDRADE,	M.	V.,	METCALFE,	D.	D.	&	BEAVEN,	M.	A.	2004.	Kit	and	FcepsilonRI	mediate	unique	and	convergent	signals	
	
187	
for	release	of	inflammatory	mediators	from	human	mast	cells.	Blood,	104,	2410-7.	HUNT,	S.	P.	&	MANTYH,	P.	W.	2001.	The	molecular	dynamics	of	pain	control.	Nat	Rev	
Neurosci,	2,	83-91.	HYNES,	R.	O.	1992.	Integrins:	versatility,	modulation,	and	signaling	in	cell	adhesion.	Cell,	69,	11-25.	HYNES,	R.	O.	2002.	Integrins:	bidirectional,	allosteric	signaling	machines.	Cell,	110,	673-87.	HÜLTNER,	L.,	DRUEZ,	C.,	MOELLER,	J.,	UYTTENHOVE,	C.,	SCHMITT,	E.,	RÜDE,	E.,	DÖRMER,	P.	&	VAN	SNICK,	J.	1990.	Mast	cell	growth-enhancing	activity	(MEA)	is	structurally	related	and	functionally	identical	to	the	novel	mouse	T	cell	growth	factor	P40/TCGFIII	(interleukin	9).	Eur	J	Immunol,	20,	1413-6.	IBRAHIM,	M.	Z.,	REDER,	A.	T.,	LAWAND,	R.,	TAKASH,	W.	&	SALLOUH-KHATIB,	S.	1996.	The	mast	cells	of	the	multiple	sclerosis	brain.	J	Neuroimmunol,	70,	131-8.	IEMURA,	A.,	TSAI,	M.,	ANDO,	A.,	WERSHIL,	B.	K.	&	GALLI,	S.	J.	1994.	The	c-kit	ligand,	stem	cell	factor,	promotes	mast	cell	survival	by	suppressing	apoptosis.	Am	J	Pathol,	144,	321-8.	INAMURA,	N.,	MEKORI,	Y.	A.,	BHATTACHARYYA,	S.	P.,	BIANCHINE,	P.	J.	&	METCALFE,	D.	D.	1998.	Induction	and	enhancement	of	Fc(epsilon)RI-dependent	mast	cell	degranulation	following	coculture	with	activated	T	cells:	dependency	on	ICAM-1-	and	leukocyte	function-associated	antigen	(LFA)-1-mediated	heterotypic	aggregation.	J	Immunol,	160,	4026-33.	INOUE,	T.,	HAGIYAMA,	M.,	ENOKI,	E.,	SAKURAI,	M.	A.,	TAN,	A.,	WAKAYAMA,	T.,	ISEKI,	S.,	MURAKAMI,	Y.,	FUKUDA,	K.,	HAMANISHI,	C.	&	ITO,	A.	2013.	Cell	adhesion	molecule	1	is	a	new	osteoblastic	cell	adhesion	molecule	and	a	diagnostic	marker	for	osteosarcoma.	Life	Sci,	92,	91-9.	IRANI,	A.	A.,	SCHECHTER,	N.	M.,	CRAIG,	S.	S.,	DEBLOIS,	G.	&	SCHWARTZ,	L.	B.	1986.	Two	types	of	human	mast	cells	that	have	distinct	neutral	protease	compositions.	Proc	
Natl	Acad	Sci	U	S	A,	83,	4464-8.	IRANI,	A.	M.,	BRADFORD,	T.	R.,	KEPLEY,	C.	L.,	SCHECHTER,	N.	M.	&	SCHWARTZ,	L.	B.	1989.	Detection	of	MCT	and	MCTC	types	of	human	mast	cells	by	immunohistochemistry	using	new	monoclonal	anti-tryptase	and	anti-chymase	antibodies.	J	Histochem	Cytochem,	37,	1509-15.	IRANI,	A.	M.,	NILSSON,	G.,	MIETTINEN,	U.,	CRAIG,	S.	S.,	ASHMAN,	L.	K.,	ISHIZAKA,	T.,	ZSEBO,	K.	M.	&	SCHWARTZ,	L.	B.	1992.	Recombinant	human	stem	cell	factor	stimulates	differentiation	of	mast	cells	from	dispersed	human	fetal	liver	cells.	
Blood,	80,	3009-21.	ISHIZAKA,	T.,	DE	BERNARDO,	R.,	TOMIOKA,	H.,	LICHTENSTEIN,	L.	M.	&	ISHIZAKA,	K.	1972.	Identification	of	basophil	granulocytes	as	a	site	of	allergic	histamine	release.	J	Immunol,	108,	1000-8.	
	
188	
ITO,	A.	2010.	[Reviews]	Heterotypic	cell-cell	interaction	mediated	by	Cell	Adhesion	Molecule-1,	CADM1:	Physiological,	pathological	and	physical	aspects.	Acta	Medica	
Kinki	University,	35,	77-85.	ITO,	A.,	HAGIYAMA,	M.	&	OONUMA,	J.	2008.	Nerve-mast	cell	and	smooth	muscle-mast	cell	interaction	mediated	by	cell	adhesion	molecule-1,	CADM1.	J	Smooth	Muscle	
Res,	44,	83-93.	ITO,	A.,	HAGIYAMA,	M.,	OONUMA,	J.,	MURAKAMI,	Y.,	YOKOZAKI,	H.	&	TAKAKI,	M.	2007.	Involvement	of	the	SgIGSF/Necl-2	adhesion	molecule	in	degranulation	of	mesenteric	mast	cells.	J	Neuroimmunol,	184,	209-13.	ITO,	A.,	JIPPO,	T.,	WAKAYAMA,	T.,	MORII,	E.,	KOMA,	Y.,	ONDA,	H.,	NOJIMA,	H.,	ISEKI,	S.	&	KITAMURA,	Y.	2003.	SgIGSF:	a	new	mast-cell	adhesion	molecule	used	for	attachment	to	fibroblasts	and	transcriptionally	regulated	by	MITF.	Blood,	101,	2601-8.	ITO,	T.,	SMRŽ,	D.,	JUNG,	M.	Y.,	BANDARA,	G.,	DESAI,	A.,	SMRŽOVÁ,	Š.,	KUEHN,	H.	S.,	BEAVEN,	M.	A.,	METCALFE,	D.	D.	&	GILFILLAN,	A.	M.	2012.	Stem	cell	factor	programs	the	mast	cell	activation	phenotype.	J	Immunol,	188,	5428-37.	JACOBSEN,	F.,	MERTENS-RILL,	J.,	BELLER,	J.,	HIRSCH,	T.,	DAIGELER,	A.,	LANGER,	S.,	LEHNHARDT,	M.,	STEINAU,	H.	U.	&	STEINSTRAESSER,	L.	2006.	Nucleofection:	a	new	method	for	cutaneous	gene	transfer?	J	Biomed	Biotechnol,	2006,	26060.	JAFFAR,	Z.	H.	&	PEARCE,	F.	L.	1990.	Histamine	secretion	from	mast	cells	stimulated	with	ATP.	Agents	Actions,	30,	64-6.	JANISZEWSKI,	J.,	BIENENSTOCK,	J.	&	BLENNERHASSETT,	M.	G.	1990.	Activation	of	rat	peritoneal	mast	cells	in	coculture	with	sympathetic	neurons	alters	neuronal	physiology.	Brain	Behav	Immun,	4,	139-50.	JANISZEWSKI,	J.,	BIENENSTOCK,	J.	&	BLENNERHASSETT,	M.	G.	1994.	Picomolar	doses	of	substance	P	trigger	electrical	responses	in	mast	cells	without	degranulation.	Am	J	
Physiol,	267,	C138-45.	JONES,	M.	P.,	WALKER,	M.	M.,	FORD,	A.	C.	&	TALLEY,	N.	J.	2014.	The	overlap	of	atopy	and	functional	gastrointestinal	disorders	among	23,471	patients	in	primary	care.	
Aliment	Pharmacol	Ther,	40,	382-91.	KAKURAI,	M.,	MONTEFORTE,	R.,	SUTO,	H.,	TSAI,	M.,	NAKAE,	S.	&	GALLI,	S.	J.	2006.	Mast	cell-derived	tumor	necrosis	factor	can	promote	nerve	fiber	elongation	in	the	skin	during	contact	hypersensitivity	in	mice.	Am	J	Pathol,	169,	1713-21.	KALESNIKOFF,	J.,	BAUR,	N.,	LEITGES,	M.,	HUGHES,	M.	R.,	DAMEN,	J.	E.,	HUBER,	M.	&	KRYSTAL,	G.	2002.	SHIP	negatively	regulates	IgE	+	antigen-induced	IL-6	production	in	mast	cells	by	inhibiting	NF-kappa	B	activity.	J	Immunol,	168,	4737-46.	KALESNIKOFF,	J.,	RIOS,	E.	J.,	CHEN,	C.	C.,	ALEJANDRO	BARBIERI,	M.,	TSAI,	M.,	TAM,	S.	Y.	&	GALLI,	S.	J.	2007.	Roles	of	RabGEF1/Rabex-5	domains	in	regulating	Fc	epsilon	RI	surface	expression	and	Fc	epsilon	RI-dependent	responses	in	mast	cells.	Blood,	109,	5308-17.	
	
189	
KALLENBORN-GERHARDT,	W.	&	SCHMIDTKO,	A.	2011.	A	novel	signaling	pathway	that	modulates	inflammatory	pain.	J	Neurosci,	31,	798-800.	KARIMI,	K.,	REDEGELD,	F.	A.,	BLOM,	R.	&	NIJKAMP,	F.	P.	2000.	Stem	cell	factor	and	interleukin-4	increase	responsiveness	of	mast	cells	to	substance	P.	Exp	Hematol,	28,	626-34.	KATZ,	H.	R.,	RAIZMAN,	M.	B.,	GARTNER,	C.	S.,	SCOTT,	H.	C.,	BENSON,	A.	C.	&	AUSTEN,	K.	F.	1992.	Secretory	granule	mediator	release	and	generation	of	oxidative	metabolites	of	arachidonic	acid	via	Fc-IgG	receptor	bridging	in	mouse	mast	cells.	J	
Immunol,	148,	868-71.	KAWAKAMI,	Y.	&	KAWAKAMI,	T.	2015.	Basic	techniques	to	study	FcεRI	signaling	in	mast	cells.	Methods	Mol	Biol,	1220,	205-18.	KELLY,	M.,	HWANG,	J.	M.	&	KUBES,	P.	2007.	Modulating	leukocyte	recruitment	in	inflammation.	J	Allergy	Clin	Immunol,	120,	3-10.	KINASHI,	T.	&	SPRINGER,	T.	A.	1994.	Steel	factor	and	c-kit	regulate	cell-matrix	adhesion.	
Blood,	83,	1033-8.	KIRSHENBAUM,	A.	S.,	AKIN,	C.,	WU,	Y.,	ROTTEM,	M.,	GOFF,	J.	P.,	BEAVEN,	M.	A.,	RAO,	V.	K.	&	METCALFE,	D.	D.	2003.	Characterization	of	novel	stem	cell	factor	responsive	human	mast	cell	lines	LAD	1	and	2	established	from	a	patient	with	mast	cell	sarcoma/leukemia;	activation	following	aggregation	of	FcepsilonRI	or	FcgammaRI.	Leuk	Res,	27,	677-82.	KIRSHENBAUM,	A.	S.,	GOFF,	J.	P.,	KESSLER,	S.	W.,	MICAN,	J.	M.,	ZSEBO,	K.	M.	&	METCALFE,	D.	D.	1992.	Effect	of	IL-3	and	stem	cell	factor	on	the	appearance	of	human	basophils	and	mast	cells	from	CD34+	pluripotent	progenitor	cells.	J	
Immunol,	148,	772-7.	KIRSHENBAUM,	A.	S.,	KESSLER,	S.	W.,	GOFF,	J.	P.	&	METCALFE,	D.	D.	1991.	Demonstration	of	the	origin	of	human	mast	cells	from	CD34+	bone	marrow	progenitor	cells.	J	Immunol,	146,	1410-5.	KITAMURA,	Y.	1989.	Heterogeneity	of	mast	cells	and	phenotypic	change	between	subpopulations.	Annu	Rev	Immunol,	7,	59-76.	KITAMURA,	Y.	&	GO,	S.	1979.	Decreased	production	of	mast	cells	in	S1/S1d	anemic	mice.	
Blood,	53,	492-7.	KITAMURA,	Y.,	GO,	S.	&	HATANAKA,	K.	1978.	Decrease	of	mast	cells	in	W/Wv	mice	and	their	increase	by	bone	marrow	transplantation.	Blood,	52,	447-52.	KITAMURA,	Y.,	KANAKURA,	Y.,	SONODA,	S.,	ASAI,	H.	&	NAKANO,	T.	1987.	Mutual	phenotypic	changes	between	connective	tissue	type	and	mucosal	mast	cells.	Int	
Arch	Allergy	Appl	Immunol,	82,	244-8.	KLEIN,	M.,	KLEIN-HESSLING,	S.,	PALMETSHOFER,	A.,	SERFLING,	E.,	TERTILT,	C.,	BOPP,	T.,	HEIB,	V.,	BECKER,	M.,	TAUBE,	C.,	SCHILD,	H.,	SCHMITT,	E.	&	STASSEN,	M.	2006.	Specific	and	redundant	roles	for	NFAT	transcription	factors	in	the	expression	of	mast	cell-derived	cytokines.	J	Immunol,	177,	6667-74.	
	
190	
KLIMEK,	L.	&	PFAAR,	O.	2011.	[Allergic	rhinitis.	Immunological	and	neurogenic	mechanisms].	HNO,	59,	1191-7.	KLOOKER,	T.	K.,	BRAAK,	B.,	KOOPMAN,	K.	E.,	WELTING,	O.,	WOUTERS,	M.	M.,	VAN	DER	HEIDE,	S.,	SCHEMANN,	M.,	BISCHOFF,	S.	C.,	VAN	DEN	WIJNGAARD,	R.	M.	&	BOECKXSTAENS,	G.	E.	2010.	The	mast	cell	stabiliser	ketotifen	decreases	visceral	hypersensitivity	and	improves	intestinal	symptoms	in	patients	with	irritable	bowel	syndrome.	Gut,	59,	1213-21.	KNIGHT,	P.	A.,	WRIGHT,	S.	H.,	LAWRENCE,	C.	E.,	PATERSON,	Y.	Y.	&	MILLER,	H.	R.	2000.	Delayed	expulsion	of	the	nematode	Trichinella	spiralis	in	mice	lacking	the	mucosal	mast	cell-specific	granule	chymase,	mouse	mast	cell	protease-1.	J	Exp	
Med,	192,	1849-56.	KOBAYASHI,	H.,	ISHIZUKA,	T.	&	OKAYAMA,	Y.	2000.	Human	mast	cells	and	basophils	as	sources	of	cytokines.	Clin	Exp	Allergy,	30,	1205-12.	KOMA,	Y.,	FURUNO,	T.,	HAGIYAMA,	M.,	HAMAGUCHI,	K.,	NAKANISHI,	M.,	MASUDA,	M.,	HIROTA,	S.,	YOKOZAKI,	H.	&	ITO,	A.	2008.	Cell	adhesion	molecule	1	is	a	novel	pancreatic-islet	cell	adhesion	molecule	that	mediates	nerve-islet	cell	interactions.	
Gastroenterology,	134,	1544-54.	KOYASU,	S.,	NAKAUCHI,	H.,	KITAMURA,	K.,	YONEHARA,	S.,	OKUMURA,	K.,	TADA,	T.	&	YAHARA,	I.	1985.	Production	of	interleukin	3	and	gamma-interferon	by	an	antigen-specific	mouse	suppressor	T	cell	clone.	J	Immunol,	134,	3130-6.	KULKA,	M.,	SHEEN,	C.	H.,	TANCOWNY,	B.	P.,	GRAMMER,	L.	C.	&	SCHLEIMER,	R.	P.	2008.	Neuropeptides	activate	human	mast	cell	degranulation	and	chemokine	production.	Immunology,	123,	398-410.	KUSHNIR-SUKHOV,	N.	M.,	BROWN,	J.	M.,	WU,	Y.,	KIRSHENBAUM,	A.	&	METCALFE,	D.	D.	2007.	Human	mast	cells	are	capable	of	serotonin	synthesis	and	release.	J	Allergy	
Clin	Immunol,	119,	498-9.	LAIDLAW,	T.	M.,	STEINKE,	J.	W.,	TIÑANA,	A.	M.,	FENG,	C.,	XING,	W.,	LAM,	B.	K.,	PARUCHURI,	S.,	BOYCE,	J.	A.	&	BORISH,	L.	2011.	Characterization	of	a	novel	human	mast	cell	line	that	responds	to	stem	cell	factor	and	expresses	functional	FcεRI.	J	Allergy	Clin	Immunol,	127,	815-22.e1-5.	LAMPUGNANI,	M.	G.,	ORSENIGO,	F.,	GAGLIANI,	M.	C.,	TACCHETTI,	C.	&	DEJANA,	E.	2006.	Vascular	endothelial	cadherin	controls	VEGFR-2	internalization	and	signaling	from	intracellular	compartments.	J	Cell	Biol,	174,	593-604.	LANE,	J.	E.,	CHEYNEY,	J.	M.,	LANE,	T.	N.,	KENT,	D.	E.	&	COHEN,	D.	J.	2006.	Treatment	of	recalcitrant	atopic	dermatitis	with	omalizumab.	J	Am	Acad	Dermatol,	54,	68-72.	LANGLEY,	K.	E.,	BENNETT,	L.	G.,	WYPYCH,	J.,	YANCIK,	S.	A.,	LIU,	X.	D.,	WESTCOTT,	K.	R.,	CHANG,	D.	G.,	SMITH,	K.	A.	&	ZSEBO,	K.	M.	1993.	Soluble	stem	cell	factor	in	human	serum.	Blood,	81,	656-60.	LAURENZI,	M.	A.,	PERSSON,	M.	A.,	DALSGAARD,	C.	J.	&	HAEGERSTRAND,	A.	1990.	The	neuropeptide	substance	P	stimulates	production	of	interleukin	1	in	human	blood	monocytes:	activated	cells	are	preferentially	influenced	by	the	neuropeptide.	
Scand	J	Immunol,	31,	529-33.	
	
191	
LEE,	D.	M.,	FRIEND,	D.	S.,	GURISH,	M.	F.,	BENOIST,	C.,	MATHIS,	D.	&	BRENNER,	M.	B.	2002.	Mast	cells:	a	cellular	link	between	autoantibodies	and	inflammatory	arthritis.	Science,	297,	1689-92.	LEE,	H.	R.,	HO,	W.	Z.	&	DOUGLAS,	S.	D.	1994.	Substance	P	augments	tumor	necrosis	factor	release	in	human	monocyte-derived	macrophages.	Clin	Diagn	Lab	Immunol,	1,	419-23.	LEON,	A.,	BURIANI,	A.,	DAL	TOSO,	R.,	FABRIS,	M.,	ROMANELLO,	S.,	ALOE,	L.	&	LEVI-MONTALCINI,	R.	1994.	Mast	cells	synthesize,	store,	and	release	nerve	growth	factor.	Proc	Natl	Acad	Sci	U	S	A,	91,	3739-43.	LEVI-SCHAFFER,	F.,	DAYTON,	E.	T.,	AUSTEN,	K.	F.,	HEIN,	A.,	CAULFIELD,	J.	P.,	GRAVALLESE,	P.	M.,	LIU,	F.	T.	&	STEVENS,	R.	L.	1987.	Mouse	bone	marrow-derived	mast	cells	cocultured	with	fibroblasts.	Morphology	and	stimulation-induced	release	of	histamine,	leukotriene	B4,	leukotriene	C4,	and	prostaglandin	D2.	J	Immunol,	139,	3431-41.	LEVY,	D.,	BURSTEIN,	R.,	KAINZ,	V.,	JAKUBOWSKI,	M.	&	STRASSMAN,	A.	M.	2007.	Mast	cell	degranulation	activates	a	pain	pathway	underlying	migraine	headache.	Pain,	130,	166-76.	LEWIS,	R.	J.,	CHACHI,	L.,	NEWBY,	C.,	AMRANI,	Y.	&	BRADDING,	P.	2016.	Bidirectional	Counterregulation	of	Human	Lung	Mast	Cell	and	Airway	Smooth	Muscle	β2	Adrenoceptors.	J	Immunol,	196,	55-63.	LICHTENFELS,	R.,	BIDDISON,	W.	E.,	SCHULZ,	H.,	VOGT,	A.	B.	&	MARTIN,	R.	1994.	CARE-LASS	(calcein-release-assay),	an	improved	fluorescence-based	test	system	to	measure	cytotoxic	T	lymphocyte	activity.	J	Immunol	Methods,	172,	227-39.	LIEBREGTS,	T.,	ADAM,	B.,	BREDACK,	C.,	RÖTH,	A.,	HEINZEL,	S.,	LESTER,	S.,	DOWNIE-DOYLE,	S.,	SMITH,	E.,	DREW,	P.,	TALLEY,	N.	J.	&	HOLTMANN,	G.	2007.	Immune	activation	in	patients	with	irritable	bowel	syndrome.	Gastroenterology,	132,	913-20.	LILLA,	J.	N.,	CHEN,	C.	C.,	MUKAI,	K.,	BENBARAK,	M.	J.,	FRANCO,	C.	B.,	KALESNIKOFF,	J.,	YU,	M.,	TSAI,	M.,	PILIPONSKY,	A.	M.	&	GALLI,	S.	J.	2011.	Reduced	mast	cell	and	basophil	numbers	and	function	in	Cpa3-Cre;	Mcl-1fl/fl	mice.	Blood,	118,	6930-8.	LILLESTØL,	K.,	HELGELAND,	L.,	ARSLAN	LIED,	G.,	FLORVAAG,	E.,	VALEUR,	J.,	LIND,	R.	&	BERSTAD,	A.	2010.	Indications	of	'atopic	bowel'	in	patients	with	self-reported	food	hypersensitivity.	Aliment	Pharmacol	Ther,	31,	1112-22.	LIN,	C.	R.,	AMAYA,	F.,	BARRETT,	L.,	WANG,	H.,	TAKADA,	J.,	SAMAD,	T.	A.	&	WOOLF,	C.	J.	2006.	Prostaglandin	E2	receptor	EP4	contributes	to	inflammatory	pain	hypersensitivity.	J	Pharmacol	Exp	Ther,	319,	1096-103.	LIN,	T.	J.	&	BEFUS,	A.	D.	1997.	Differential	regulation	of	mast	cell	function	by	IL-10	and	stem	cell	factor.	J	Immunol,	159,	4015-23.	LINDEN,	D.	R.,	MANNING,	B.	P.,	BUNNETT,	N.	W.	&	MAWE,	G.	M.	2001.	Agonists	of	proteinase-activated	receptor	2	excite	guinea	pig	ileal	myenteric	neurons.	Eur	J	
Pharmacol,	431,	311-4.	
	
192	
LINDSAY,	R.	M.	&	HARMAR,	A.	J.	1989.	Nerve	growth	factor	regulates	expression	of	neuropeptide	genes	in	adult	sensory	neurons.	Nature,	337,	362-4.	LIU,	R.,	LIN,	G.	&	XU,	H.	2013.	An	efficient	method	for	dorsal	root	ganglia	neurons	purification	with	a	one-time	anti-mitotic	reagent	treatment.	PLoS	One,	8,	e60558.	LONGAIR,	M.	H.,	BAKER,	D.	A.	&	ARMSTRONG,	J.	D.	2011.	Simple	Neurite	Tracer:	open	source	software	for	reconstruction,	visualization	and	analysis	of	neuronal	processes.	Bioinformatics,	27,	2453-4.	LONGSTRETH,	G.	F.,	THOMPSON,	W.	G.,	CHEY,	W.	D.,	HOUGHTON,	L.	A.,	MEARIN,	F.	&	SPILLER,	R.	C.	2006.	Functional	bowel	disorders.	Gastroenterology,	130,	1480-91.	LORENTZ,	A.,	SELLGE,	G.	&	BISCHOFF,	S.	C.	2015.	Isolation	and	characterization	of	human	intestinal	mast	cells.	Methods	Mol	Biol,	1220,	163-77.	LUNARDI,	C.,	BAMBARA,	L.	M.,	BIASI,	D.,	CORTINA,	P.,	PEROLI,	P.,	NICOLIS,	F.,	FAVARI,	F.	&	PACOR,	M.	L.	1991.	Double-blind	cross-over	trial	of	oral	sodium	cromoglycate	in	patients	with	irritable	bowel	syndrome	due	to	food	intolerance.	Clin	Exp	
Allergy,	21,	569-72.	LUNDEQUIST,	A.	&	PEJLER,	G.	2011.	Biological	implications	of	preformed	mast	cell	mediators.	Cell	Mol	Life	Sci,	68,	965-75.	MA,	Y.,	HWANG,	R.	F.,	LOGSDON,	C.	D.	&	ULLRICH,	S.	E.	2013.	Dynamic	mast	cell-stromal	cell	interactions	promote	growth	of	pancreatic	cancer.	Cancer	Res,	73,	3927-37.	MACGLASHAN,	D.	2003.	Histamine:	A	mediator	of	inflammation.	J	Allergy	Clin	Immunol,	112,	S53-9.	MACGLASHAN,	D.	W.	2007.	Endocytosis,	recycling,	and	degradation	of	unoccupied	FcepsilonRI	in	human	basophils.	J	Leukoc	Biol,	82,	1003-10.	MAGGI,	C.	A.	1995.	Tachykinins	and	calcitonin	gene-related	peptide	(CGRP)	as	co-transmitters	released	from	peripheral	endings	of	sensory	nerves.	Prog	Neurobiol,	45,	1-98.	MAGGI,	C.	A.	1997.	The	effects	of	tachykinins	on	inflammatory	and	immune	cells.	Regul	
Pept,	70,	75-90.	MAGGI,	C.	A.,	GIULIANI,	S.	&	SANTICIOLI,	P.	1997.	CGRP	potentiates	excitatory	transmission	to	the	circular	muscle	of	guinea-pig	colon.	Regul	Pept,	69,	127-36.	MAGGI,	C.	A.	&	MELI,	A.	1988.	The	sensory-efferent	function	of	capsaicin-sensitive	sensory	neurons.	Gen	Pharmacol,	19,	1-43.	MALHOTRA,	R.	2016.	Understanding	migraine:	Potential	role	of	neurogenic	inflammation.	Ann	Indian	Acad	Neurol,	19,	175-82.	MANDAI,	K.,	RIKITAKE,	Y.,	MORI,	M.	&	TAKAI,	Y.	2015.	Nectins	and	nectin-like	molecules	in	development	and	disease.	Curr	Top	Dev	Biol,	112,	197-231.	MARQUARDT,	D.	L.,	GRUBER,	H.	E.	&	WASSERMAN,	S.	I.	1984.	Adenosine	release	from	stimulated	mast	cells.	Proc	Natl	Acad	Sci	U	S	A,	81,	6192-6.	
	
193	
MARSHALL,	J.	S.,	GOMI,	K.,	BLENNERHASSETT,	M.	G.	&	BIENENSTOCK,	J.	1999.	Nerve	growth	factor	modifies	the	expression	of	inflammatory	cytokines	by	mast	cells	via	a	prostanoid-dependent	mechanism.	J	Immunol,	162,	4271-6.	MASUDA,	M.,	YAGETA,	M.,	FUKUHARA,	H.,	KURAMOCHI,	M.,	MARUYAMA,	T.,	NOMOTO,	A.	&	MURAKAMI,	Y.	2002.	The	tumor	suppressor	protein	TSLC1	is	involved	in	cell-cell	adhesion.	J	Biol	Chem,	277,	31014-9.	MATSUDA,	H.,	KANNAN,	Y.,	USHIO,	H.,	KISO,	Y.,	KANEMOTO,	T.,	SUZUKI,	H.	&	KITAMURA,	Y.	1991.	Nerve	growth	factor	induces	development	of	connective	tissue-type	mast	cells	in	vitro	from	murine	bone	marrow	cells.	J	Exp	Med,	174,	7-14.	MATSUSHIMA,	H.	&	BOGENMANN,	E.	1990.	Nerve	growth	factor	(NGF)	induces	neuronal	differentiation	in	neuroblastoma	cells	transfected	with	the	NGF	receptor	cDNA.	
Mol	Cell	Biol,	10,	5015-20.	MAURER,	M.,	FISCHER,	E.,	HANDJISKI,	B.,	VON	STEBUT,	E.,	ALGERMISSEN,	B.,	BAVANDI,	A.	&	PAUS,	R.	1997.	Activated	skin	mast	cells	are	involved	in	murine	hair	follicle	regression	(catagen).	Lab	Invest,	77,	319-32.	MAURER,	M.,	LOPEZ	KOSTKA,	S.,	SIEBENHAAR,	F.,	MOELLE,	K.,	METZ,	M.,	KNOP,	J.	&	VON	STEBUT,	E.	2006.	Skin	mast	cells	control	T	cell-dependent	host	defense	in	Leishmania	major	infections.	FASEB	J,	20,	2460-7.	MAURER,	M.,	ROSÉN,	K.,	HSIEH,	H.	J.,	SAINI,	S.,	GRATTAN,	C.,	GIMENÉZ-ARNAU,	A.,	AGARWAL,	S.,	DOYLE,	R.,	CANVIN,	J.,	KAPLAN,	A.	&	CASALE,	T.	2013.	Omalizumab	for	the	treatment	of	chronic	idiopathic	or	spontaneous	urticaria.	N	Engl	J	Med,	368,	924-35.	MAYER,	E.	A.,	RAYBOULD,	H.	&	KOELBEL,	C.	1988.	Neuropeptides,	inflammation,	and	motility.	Dig	Dis	Sci,	33,	71S-77S.	MCCARY,	C.,	TANCOWNY,	B.	P.,	CATALLI,	A.,	GRAMMER,	L.	C.,	HARRIS,	K.	E.,	SCHLEIMER,	R.	P.	&	KULKA,	M.	2010.	Substance	P	downregulates	expression	of	the	high	affinity	IgE	receptor	(FcepsilonRI)	by	human	mast	cells.	J	Neuroimmunol,	220,	17-24.	MCLATCHIE,	L.	M.,	FRASER,	N.	J.,	MAIN,	M.	J.,	WISE,	A.,	BROWN,	J.,	THOMPSON,	N.,	SOLARI,	R.,	LEE,	M.	G.	&	FOORD,	S.	M.	1998.	RAMPs	regulate	the	transport	and	ligand	specificity	of	the	calcitonin-receptor-like	receptor.	Nature,	393,	333-9.	MELEMEDJIAN,	O.	K.,	ASIEDU,	M.	N.,	TILLU,	D.	V.,	PEEBLES,	K.	A.,	YAN,	J.,	ERTZ,	N.,	DUSSOR,	G.	O.	&	PRICE,	T.	J.	2010.	IL-6-	and	NGF-induced	rapid	control	of	protein	synthesis	and	nociceptive	plasticity	via	convergent	signaling	to	the	eIF4F	complex.	J	Neurosci,	30,	15113-23.	MELLI,	G.	&	HÖKE,	A.	2009.	Dorsal	Root	Ganglia	Sensory	Neuronal	Cultures:	a	tool	for	drug	discovery	for	peripheral	neuropathies.	Expert	Opin	Drug	Discov,	4,	1035-1045.	MELLI,	G.,	JACK,	C.,	LAMBRINOS,	G.	L.,	RINGKAMP,	M.	&	HÖKE,	A.	2006a.	Erythropoietin	protects	sensory	axons	against	paclitaxel-induced	distal	degeneration.	Neurobiol	
Dis,	24,	525-30.	
	
194	
MELLI,	G.,	KESWANI,	S.	C.,	FISCHER,	A.,	CHEN,	W.	&	HÖKE,	A.	2006b.	Spatially	distinct	and	functionally	independent	mechanisms	of	axonal	degeneration	in	a	model	of	HIV-associated	sensory	neuropathy.	Brain,	129,	1330-8.	MELLI,	G.,	TAIANA,	M.,	CAMOZZI,	F.,	TRIOLO,	D.,	PODINI,	P.,	QUATTRINI,	A.,	TARONI,	F.	&	LAURIA,	G.	2008.	Alpha-lipoic	acid	prevents	mitochondrial	damage	and	neurotoxicity	in	experimental	chemotherapy	neuropathy.	Exp	Neurol,	214,	276-84.	METCALFE,	D.	D.	2008.	Mast	cells	and	mastocytosis.	Blood,	112,	946-56.	METCALFE,	D.	D.,	BARAM,	D.	&	MEKORI,	Y.	A.	1997.	Mast	cells.	Physiol	Rev,	77,	1033-79.	MIERKE,	C.	T.,	BALLMAIER,	M.,	WERNER,	U.,	MANNS,	M.	P.,	WELTE,	K.	&	BISCHOFF,	S.	C.	2000.	Human	endothelial	cells	regulate	survival	and	proliferation	of	human	mast	cells.	J	Exp	Med,	192,	801-11.	MILLS,	C.	D.,	NGUYEN,	T.,	TANGA,	F.	Y.,	ZHONG,	C.,	GAUVIN,	D.	M.,	MIKUSA,	J.,	GOMEZ,	E.	J.,	SALYERS,	A.	K.	&	BANNON,	A.	W.	2013.	Characterization	of	nerve	growth	factor-induced	mechanical	and	thermal	hypersensitivity	in	rats.	Eur	J	Pain,	17,	469-79.	MITSUI,	H.,	FURITSU,	T.,	DVORAK,	A.	M.,	IRANI,	A.	M.,	SCHWARTZ,	L.	B.,	INAGAKI,	N.,	TAKEI,	M.,	ISHIZAKA,	K.,	ZSEBO,	K.	M.	&	GILLIS,	S.	1993.	Development	of	human	mast	cells	from	umbilical	cord	blood	cells	by	recombinant	human	and	murine	c-kit	ligand.	Proc	Natl	Acad	Sci	U	S	A,	90,	735-9.	MIZOGUCHI,	A.,	NAKANISHI,	H.,	KIMURA,	K.,	MATSUBARA,	K.,	OZAKI-KURODA,	K.,	KATATA,	T.,	HONDA,	T.,	KIYOHARA,	Y.,	HEO,	K.,	HIGASHI,	M.,	TSUTSUMI,	T.,	SONODA,	S.,	IDE,	C.	&	TAKAI,	Y.	2002.	Nectin:	an	adhesion	molecule	involved	in	formation	of	synapses.	J	Cell	Biol,	156,	555-65.	MOISEEVA,	E.	P.,	LEYLAND,	M.	L.	&	BRADDING,	P.	2012.	CADM1	isoforms	differentially	regulate	human	mast	cell	survival	and	homotypic	adhesion.	Cell	Mol	Life	Sci,	69,	2751-64.	MOISEEVA,	E.	P.,	LEYLAND,	M.	L.	&	BRADDING,	P.	2013a.	CADM1	is	expressed	as	multiple	alternatively	spliced	functional	and	dysfunctional	isoforms	in	human	mast	cells.	Mol	Immunol,	53,	345-54.	MOISEEVA,	E.	P.,	ROACH,	K.	M.,	LEYLAND,	M.	L.	&	BRADDING,	P.	2013b.	CADM1	is	a	key	receptor	mediating	human	mast	cell	adhesion	to	human	lung	fibroblasts	and	airway	smooth	muscle	cells.	PLoS	One,	8,	e61579.	MOISEEVA,	E.	P.,	STRAATMAN,	K.	R.,	LEYLAND,	M.	L.	&	BRADDING,	P.	2014.	CADM1	controls	actin	cytoskeleton	assembly	and	regulates	extracellular	matrix	adhesion	in	human	mast	cells.	PLoS	One,	9,	e85980.	MOLIN,	D.,	EDSTRÖM,	A.,	GLIMELIUS,	I.,	GLIMELIUS,	B.,	NILSSON,	G.,	SUNDSTRÖM,	C.	&	ENBLAD,	G.	2002.	Mast	cell	infiltration	correlates	with	poor	prognosis	in	Hodgkin's	lymphoma.	Br	J	Haematol,	119,	122-4.	
	
195	
MOON,	T.	C.,	ST	LAURENT,	C.	D.,	MORRIS,	K.	E.,	MARCET,	C.,	YOSHIMURA,	T.,	SEKAR,	Y.	&	BEFUS,	A.	D.	2010.	Advances	in	mast	cell	biology:	new	understanding	of	heterogeneity	and	function.	Mucosal	Immunol,	3,	111-28.	MORGAN,	A.	J.	&	JACOB,	R.	1994.	Ionomycin	enhances	Ca2+	influx	by	stimulating	store-regulated	cation	entry	and	not	by	a	direct	action	at	the	plasma	membrane.	
Biochem	J,	300	(	Pt	3),	665-72.	MORI,	N.,	SUZUKI,	R.,	FURUNO,	T.,	MCKAY,	D.	M.,	WADA,	M.,	TESHIMA,	R.,	BIENENSTOCK,	J.	&	NAKANISHI,	M.	2002.	Nerve-mast	cell	(RBL)	interaction:	RBL	membrane	ruffling	occurs	at	the	contact	site	with	an	activated	neurite.	Am	J	Physiol	Cell	
Physiol,	283,	C1738-44.	MORII,	E.	&	OBOKI,	K.	2004.	MITF	is	necessary	for	generation	of	prostaglandin	D2	in	mouse	mast	cells.	J	Biol	Chem,	279,	48923-9.	MORIYAMA,	T.,	IIDA,	T.,	KOBAYASHI,	K.,	HIGASHI,	T.,	FUKUOKA,	T.,	TSUMURA,	H.,	LEON,	C.,	SUZUKI,	N.,	INOUE,	K.,	GACHET,	C.,	NOGUCHI,	K.	&	TOMINAGA,	M.	2003.	Possible	involvement	of	P2Y2	metabotropic	receptors	in	ATP-induced	transient	receptor	potential	vanilloid	receptor	1-mediated	thermal	hypersensitivity.	J	
Neurosci,	23,	6058-62.	MOUSLI,	M.,	BRONNER,	C.,	BOCKAERT,	J.,	ROUOT,	B.	&	LANDRY,	Y.	1990.	Interaction	of	substance	P,	compound	48/80	and	mastoparan	with	the	alpha-subunit	C-terminus	of	G	protein.	Immunol	Lett,	25,	355-7.	MUSCH,	M.	W.	&	SIEGEL,	M.	I.	1986.	Antigen-stimulated	metabolism	of	inositol	phospholipids	in	the	cloned	murine	mast-cell	line	MC9.	Biochem	J,	234,	205-12.	NAGASAKA,	A.,	MATSUE,	H.,	MATSUSHIMA,	H.,	AOKI,	R.,	NAKAMURA,	Y.,	KAMBE,	N.,	KON,	S.,	UEDE,	T.	&	SHIMADA,	S.	2008.	Osteopontin	is	produced	by	mast	cells	and	affects	IgE-mediated	degranulation	and	migration	of	mast	cells.	Eur	J	Immunol,	38,	489-99.	NAKANISHI,	M.	&	FURUNO,	T.	2008.	Molecular	basis	of	neuroimmune	interaction	in	an	in	vitro	coculture	approach.	Cell	Mol	Immunol,	5,	249-59.	NAKANO,	T.,	ANDOH,	T.,	SASAKI,	A.,	NOJIMA,	H.	&	KURAISHI,	Y.	2008.	Different	roles	of	capsaicin-sensitive	and	H1	histamine	receptor-expressing	sensory	neurones	in	itch	of	mosquito	allergy	in	mice.	Acta	Derm	Venereol,	88,	449-54.	NECTOUX,	J.,	FICHOU,	Y.,	ROSAS-VARGAS,	H.,	CAGNARD,	N.,	BAHI-BUISSON,	N.,	NUSBAUM,	P.,	LETOURNEUR,	F.,	CHELLY,	J.	&	BIENVENU,	T.	2010.	Cell	cloning-based	transcriptome	analysis	in	Rett	patients:	relevance	to	the	pathogenesis	of	Rett	syndrome	of	new	human	MeCP2	target	genes.	J	Cell	Mol	Med,	14,	1962-74.	NIGROVIC,	P.	A.,	BINSTADT,	B.	A.,	MONACH,	P.	A.,	JOHNSEN,	A.,	GURISH,	M.,	IWAKURA,	Y.,	BENOIST,	C.,	MATHIS,	D.	&	LEE,	D.	M.	2007.	Mast	cells	contribute	to	initiation	of	autoantibody-mediated	arthritis	via	IL-1.	Proc	Natl	Acad	Sci	U	S	A,	104,	2325-30.	NILSSON,	G.,	BUTTERFIELD,	J.	H.,	NILSSON,	K.	&	SIEGBAHN,	A.	1994.	Stem	cell	factor	is	a	chemotactic	factor	for	human	mast	cells.	J	Immunol,	153,	3717-23.	
	
196	
NILSSON,	G.,	JOHNELL,	M.,	HAMMER,	C.	H.,	TIFFANY,	H.	L.,	NILSSON,	K.,	METCALFE,	D.	D.,	SIEGBAHN,	A.	&	MURPHY,	P.	M.	1996.	C3a	and	C5a	are	chemotaxins	for	human	mast	cells	and	act	through	distinct	receptors	via	a	pertussis	toxin-sensitive	signal	transduction	pathway.	J	Immunol,	157,	1693-8.	NISHIDA,	M.,	KAWAI,	K.,	TANAKA,	M.,	TEGOSHI,	T.	&	ARIZONO,	N.	2003.	Expression	of	E-cadherin	in	human	mast	cell	line	HMC-1.	APMIS,	111,	1067-74.	NISHIMOTO,	N.,	MIYASAKA,	N.,	YAMAMOTO,	K.,	KAWAI,	S.,	TAKEUCHI,	T.	&	AZUMA,	J.	2009.	Long-term	safety	and	efficacy	of	tocilizumab,	an	anti-IL-6	receptor	monoclonal	antibody,	in	monotherapy,	in	patients	with	rheumatoid	arthritis	(the	STREAM	study):	evidence	of	safety	and	efficacy	in	a	5-year	extension	study.	Ann	
Rheum	Dis,	68,	1580-4.	NOLI,	C.	&	MIOLO,	A.	2001.	The	mast	cell	in	wound	healing.	Vet	Dermatol,	12,	303-13.	NOVAK,	I.	2003.	ATP	as	a	signaling	molecule:	the	exocrine	focus.	News	Physiol	Sci,	18,	12-7.	O'MALLEY,	D.,	LISTON,	M.,	HYLAND,	N.	P.,	DINAN,	T.	G.	&	CRYAN,	J.	F.	2011.	Colonic	soluble	mediators	from	the	maternal	separation	model	of	irritable	bowel	syndrome	activate	submucosal	neurons	via	an	interleukin-6-dependent	mechanism.	Am	J	Physiol	Gastrointest	Liver	Physiol,	300,	G241-52.	O'SULLIVAN,	M.,	CLAYTON,	N.,	BRESLIN,	N.	P.,	HARMAN,	I.,	BOUNTRA,	C.,	MCLAREN,	A.	&	O'MORAIN,	C.	A.	2000.	Increased	mast	cells	in	the	irritable	bowel	syndrome.	
Neurogastroenterol	Motil,	12,	449-57.	OHMAN,	L.	&	SIMRÉN,	M.	2010.	Pathogenesis	of	IBS:	role	of	inflammation,	immunity	and	neuroimmune	interactions.	Nat	Rev	Gastroenterol	Hepatol,	7,	163-73.	OHSHIRO,	H.,	SUZUKI,	R.,	FURUNO,	T.	&	NAKANISHI,	M.	2000.	Atomic	force	microscopy	to	study	direct	neurite-mast	cell	(RBL)	communication	in	vitro.	Immunol	Lett,	74,	211-4.	OKA,	T.,	KALESNIKOFF,	J.,	STARKL,	P.,	TSAI,	M.	&	GALLI,	S.	J.	2012.	Evidence	questioning	cromolyn's	effectiveness	and	selectivity	as	a	'mast	cell	stabilizer'	in	mice.	Lab	
Invest,	92,	1472-82.	OKA,	T.,	OKA,	K.,	HOSOI,	M.	&	HORI,	T.	1995.	Intracerebroventricular	injection	of	interleukin-6	induces	thermal	hyperalgesia	in	rats.	Brain	Res,	692,	123-8.	OKABE,	N.,	SHIMIZU,	K.,	OZAKI-KURODA,	K.,	NAKANISHI,	H.,	MORIMOTO,	K.,	TAKEUCHI,	M.,	KATSUMARU,	H.,	MURAKAMI,	F.	&	TAKAI,	Y.	2004.	Contacts	between	the	commissural	axons	and	the	floor	plate	cells	are	mediated	by	nectins.	Dev	Biol,	273,	244-56.	OKABE,	T.,	HIDE,	M.,	HIRAGUN,	T.,	MORITA,	E.,	KORO,	O.	&	YAMAMOTO,	S.	2006.	Bone	marrow	derived	mast	cell	acquire	responsiveness	to	substance	P	with	Ca(2+)	signals	and	release	of	leukotriene	B(4)	via	mitogen-activated	protein	kinase.	J	
Neuroimmunol,	181,	1-12.	OKAYAMA,	Y.	&	KAWAKAMI,	T.	2006.	Development,	migration,	and	survival	of	mast	cells.	Immunol	Res,	34,	97-115.	
	
197	
OKUMURA,	N.,	TSUJI,	K.,	EBIHARA,	Y.,	TANAKA,	I.,	SAWAI,	N.,	KOIKE,	K.,	KOMIYAMA,	A.	&	NAKAHATA,	T.	1996.	Chemotactic	and	chemokinetic	activities	of	stem	cell	factor	on	murine	hematopoietic	progenitor	cells.	Blood,	87,	4100-8.	OLLERENSHAW,	S.	L.,	JARVIS,	D.,	SULLIVAN,	C.	E.	&	WOOLCOCK,	A.	J.	1991.	Substance	P	immunoreactive	nerves	in	airways	from	asthmatics	and	nonasthmatics.	Eur	
Respir	J,	4,	673-82.	OSUGA,	Y.,	KOGA,	K.,	TSUTSUMI,	O.,	IGARASHI,	T.,	OKAGAKI,	R.,	TAKAI,	Y.,	MATSUMI,	H.,	HIROI,	H.,	FUJIWARA,	T.,	MOMOEDA,	M.,	YANO,	T.	&	TAKETANI,	Y.	2000.	Stem	cell	factor	(SCF)	concentrations	in	peritoneal	fluid	of	women	with	or	without	endometriosis.	Am	J	Reprod	Immunol,	44,	231-5.	OTSU,	K.,	NAKANO,	T.,	KANAKURA,	Y.,	ASAI,	H.,	KATZ,	H.	R.,	AUSTEN,	K.	F.,	STEVENS,	R.	L.,	GALLI,	S.	J.	&	KITAMURA,	Y.	1987.	Phenotypic	changes	of	bone	marrow-derived	mast	cells	after	intraperitoneal	transfer	into	W/Wv	mice	that	are	genetically	deficient	in	mast	cells.	J	Exp	Med,	165,	615-27.	OTTOSSON,	A.	&	EDVINSSON,	L.	1997.	Release	of	histamine	from	dural	mast	cells	by	substance	P	and	calcitonin	gene-related	peptide.	Cephalalgia,	17,	166-74.	PADAWER,	J.	1974.	Editorial:	The	ins	and	outs	of	mast	cell	function.	Am	J	Anat,	141,	299-302.	PAREDES,	R.	M.,	ETZLER,	J.	C.,	WATTS,	L.	T.,	ZHENG,	W.	&	LECHLEITER,	J.	D.	2008.	Chemical	calcium	indicators.	Methods,	46,	143-51.	PARK,	C.	H.,	JOO,	Y.	E.,	CHOI,	S.	K.,	REW,	J.	S.,	KIM,	S.	J.	&	LEE,	M.	C.	2003.	Activated	mast	cells	infiltrate	in	close	proximity	to	enteric	nerves	in	diarrhea-predominant	irritable	bowel	syndrome.	J	Korean	Med	Sci,	18,	204-10.	PARK,	J.	H.,	RHEE,	P.	L.,	KIM,	H.	S.,	LEE,	J.	H.,	KIM,	Y.	H.,	KIM,	J.	J.	&	RHEE,	J.	C.	2006.	Mucosal	mast	cell	counts	correlate	with	visceral	hypersensitivity	in	patients	with	diarrhea	predominant	irritable	bowel	syndrome.	J	Gastroenterol	Hepatol,	21,	71-8.	PASCUAL,	D.	W.	&	BOST,	K.	L.	1990.	Substance	P	production	by	P388D1	macrophages:	a	possible	autocrine	function	for	this	neuropeptide.	Immunology,	71,	52-6.	PASSANTE,	E.,	EHRHARDT,	C.,	SHERIDAN,	H.	&	FRANKISH,	N.	2009.	RBL-2H3	cells	are	an	imprecise	model	for	mast	cell	mediator	release.	Inflamm	Res,	58,	611-8.	PAVLOVIC,	S.,	DANILTCHENKO,	M.,	TOBIN,	D.	J.,	HAGEN,	E.,	HUNT,	S.	P.,	KLAPP,	B.	F.,	ARCK,	P.	C.	&	PETERS,	E.	M.	2008.	Further	exploring	the	brain-skin	connection:	stress	worsens	dermatitis	via	substance	P-dependent	neurogenic	inflammation	in	mice.	J	Invest	Dermatol,	128,	434-46.	PEARCE,	F.	L.,	AL-LAITH,	M.,	BOSMAN,	L.,	BROSTOFF,	J.,	CUNNIFFE,	T.	M.,	FLINT,	K.	C.,	HUDSPITH,	B.	N.,	JAFFAR,	Z.	H.,	JOHNSON,	N.	M.	&	KASSESSINOFF,	T.	A.	1989.	Effects	of	sodium	cromoglycate	and	nedocromil	sodium	on	histamine	secretion	from	mast	cells	from	various	locations.	Drugs,	37	Suppl	1,	37-43;	discussion	69-77.	
	
198	
PEARSON,	J.	S.,	NIVEN,	R.	M.,	MENG,	J.,	ATARODI,	S.	&	WHORWELL,	P.	J.	2015.	Immunoglobulin	E	in	irritable	bowel	syndrome:	another	target	for	treatment?	A	case	report	and	literature	review.	Therap	Adv	Gastroenterol,	8,	270-7.	PETERS,	E.	M.,	KUHLMEI,	A.,	TOBIN,	D.	J.,	MÜLLER-RÖVER,	S.,	KLAPP,	B.	F.	&	ARCK,	P.	C.	2005.	Stress	exposure	modulates	peptidergic	innervation	and	degranulates	mast	cells	in	murine	skin.	Brain	Behav	Immun,	19,	252-62.	PETRENKO,	A.	B.,	YAMAKURA,	T.,	BABA,	H.	&	SHIMOJI,	K.	2003.	The	role	of	N-methyl-D-aspartate	(NMDA)	receptors	in	pain:	a	review.	Anesth	Analg,	97,	1108-16.	PETRUSKA,	J.	C.,	NAPAPORN,	J.,	JOHNSON,	R.	D.,	GU,	J.	G.	&	COOPER,	B.	Y.	2000.	Subclassified	acutely	dissociated	cells	of	rat	DRG:	histochemistry	and	patterns	of	capsaicin-,	proton-,	and	ATP-activated	currents.	J	Neurophysiol,	84,	2365-79.	PISI,	G.,	OLIVIERI,	D.	&	CHETTA,	A.	2009.	The	airway	neurogenic	inflammation:	clinical	and	pharmacological	implications.	Inflamm	Allergy	Drug	Targets,	8,	176-81.	PLETCHER,	M.	T.,	NOBUKUNI,	T.,	FUKUHARA,	H.,	KURAMOCHI,	M.,	MARUYAMA,	T.,	SEKIYA,	T.,	SUSSAN,	T.,	ISOMURA,	M.,	MURAKAMI,	Y.	&	REEVES,	R.	H.	2001.	Identification	of	tumor	suppressor	candidate	genes	by	physical	and	sequence	mapping	of	the	TSLC1	region	of	human	chromosome	11q23.	Gene,	273,	181-9.	POWELL,	N.,	HUNTLEY,	B.,	BEECH,	T.,	KNIGHT,	W.,	KNIGHT,	H.	&	CORRIGAN,	C.	J.	2007.	Increased	prevalence	of	gastrointestinal	symptoms	in	patients	with	allergic	disease.	Postgrad	Med	J,	83,	182-6.	PUJARI,	R.,	HUNTE,	R.,	THOMAS,	R.,	VAN	DER	WEYDEN,	L.,	RAUCH,	D.,	RATNER,	L.,	NYBORG,	J.	K.,	RAMOS,	J.	C.,	TAKAI,	Y.	&	SHEMBADE,	N.	2015.	Human	T-cell	leukemia	virus	type	1	(HTLV-1)	tax	requires	CADM1/TSLC1	for	inactivation	of	the	NF-κB	inhibitor	A20	and	constitutive	NF-κB	signaling.	PLoS	Pathog,	11,	e1004721.	PULLEN,	N.	A.,	FALANGA,	Y.	T.,	MORALES,	J.	K.	&	RYAN,	J.	J.	2012.	The	Fyn-STAT5	Pathway:	A	New	Frontier	in	IgE-	and	IgG-Mediated	Mast	Cell	Signaling.	Front	
Immunol,	3,	117.	PURCELL,	W.	M.,	COHEN,	D.	L.	&	HANAHOE,	T.	H.	1989.	Comparison	of	histamine	and	5-hydroxytryptamine	content	and	secretion	in	rat	mast	cells	isolated	from	different	anatomical	locations.	Int	Arch	Allergy	Appl	Immunol,	90,	382-6.	RAPTIS,	L.,	ARULANANDAM,	R.,	VULTUR,	A.,	GELETU,	M.,	CHEVALIER,	S.	&	FERACCI,	H.	2009.	Beyond	structure,	to	survival:	activation	of	Stat3	by	cadherin	engagement.	
Biochem	Cell	Biol,	87,	835-43.	RAZIN,	E.,	IHLE,	J.	N.,	SELDIN,	D.,	MENCIA-HUERTA,	J.	M.,	KATZ,	H.	R.,	LEBLANC,	P.	A.,	HEIN,	A.,	CAULFIELD,	J.	P.,	AUSTEN,	K.	F.	&	STEVENS,	R.	L.	1984.	Interleukin	3:	A	differentiation	and	growth	factor	for	the	mouse	mast	cell	that	contains	chondroitin	sulfate	E	proteoglycan.	J	Immunol,	132,	1479-86.	RAZIN,	E.,	MENCIA-HUERTA,	J.	M.,	LEWIS,	R.	A.,	COREY,	E.	J.	&	AUSTEN,	K.	F.	1982a.	Generation	of	leukotriene	C4	from	a	subclass	of	mast	cells	differentiated	in	vitro	from	mouse	bone	marrow.	Proc	Natl	Acad	Sci	U	S	A,	79,	4665-7.	
	
199	
RAZIN,	E.,	STEVENS,	R.	L.,	AKIYAMA,	F.,	SCHMID,	K.	&	AUSTEN,	K.	F.	1982b.	Culture	from	mouse	bone	marrow	of	a	subclass	of	mast	cells	possessing	a	distinct	chondroitin	sulfate	proteoglycan	with	glycosaminoglycans	rich	in	N-acetylgalactosamine-4,6-disulfate.	J	Biol	Chem,	257,	7229-36.	RENNICK,	D.,	HUNTE,	B.,	HOLLAND,	G.	&	THOMPSON-SNIPES,	L.	1995.	Cofactors	are	essential	for	stem	cell	factor-dependent	growth	and	maturation	of	mast	cell	progenitors:	comparative	effects	of	interleukin-3	(IL-3),	IL-4,	IL-10,	and	fibroblasts.	Blood,	85,	57-65.	RENZI,	D.,	PELLEGRINI,	B.,	TONELLI,	F.,	SURRENTI,	C.	&	CALABRÒ,	A.	2000.	Substance	P	(neurokinin-1)	and	neurokinin	A	(neurokinin-2)	receptor	gene	and	protein	expression	in	the	healthy	and	inflamed	human	intestine.	Am	J	Pathol,	157,	1511-22.	RICHARDSON,	F.,	YOUNG,	G.	D.,	SENNELLO,	R.,	WOLF,	J.,	ARGAST,	G.	M.,	MERCADO,	P.,	DAVIES,	A.,	EPSTEIN,	D.	M.	&	WACKER,	B.	2012.	The	evaluation	of	E-Cadherin	and	vimentin	as	biomarkers	of	clinical	outcomes	among	patients	with	non-small	cell	lung	cancer	treated	with	erlotinib	as	second-	or	third-line	therapy.	Anticancer	
Res,	32,	537-52.	RILEY,	J.	F.	&	WEST,	G.	B.	1952.	Histamine	in	tissue	mast	cells.	J	Physiol,	117,	72P-73P.	RIOS,	E.	J.	&	KALESNIKOFF,	J.	2015.	FcεRI	expression	and	dynamics	on	mast	cells.	
Methods	Mol	Biol,	1220,	239-55.	RIVERA,	J.	&	OLIVERA,	A.	2007.	Src	family	kinases	and	lipid	mediators	in	control	of	allergic	inflammation.	Immunol	Rev,	217,	255-68.	ROSSETTO,	O.,	PIRAZZINI,	M.	&	MONTECUCCO,	C.	2014.	Botulinum	neurotoxins:	genetic,	structural	and	mechanistic	insights.	Nat	Rev	Microbiol,	12,	535-49.	ROTTEM,	M.,	OKADA,	T.,	GOFF,	J.	P.	&	METCALFE,	D.	D.	1994.	Mast	cells	cultured	from	the	peripheral	blood	of	normal	donors	and	patients	with	mastocytosis	originate	from	a	CD34+/Fc	epsilon	RI-	cell	population.	Blood,	84,	2489-96.	ROUSSOS,	A.,	KOURSARAKOS,	P.,	PATSOPOULOS,	D.,	GEROGIANNI,	I.	&	PHILIPPOU,	N.	2003.	Increased	prevalence	of	irritable	bowel	syndrome	in	patients	with	bronchial	asthma.	Respir	Med,	97,	75-9.	ROZNIECKI,	J.	J.,	DIMITRIADOU,	V.,	LAMBRACHT-HALL,	M.,	PANG,	X.	&	THEOHARIDES,	T.	C.	1999.	Morphological	and	functional	demonstration	of	rat	dura	mater	mast	cell-neuron	interactions	in	vitro	and	in	vivo.	Brain	Res,	849,	1-15.	RUAN,	H.	Z.	&	BURNSTOCK,	G.	2003.	Localisation	of	P2Y1	and	P2Y4	receptors	in	dorsal	root,	nodose	and	trigeminal	ganglia	of	the	rat.	Histochem	Cell	Biol,	120,	415-26.	RUKWIED,	R.,	MAYER,	A.,	KLUSCHINA,	O.,	OBREJA,	O.,	SCHLEY,	M.	&	SCHMELZ,	M.	2010.	NGF	induces	non-inflammatory	localized	and	lasting	mechanical	and	thermal	hypersensitivity	in	human	skin.	Pain,	148,	407-13.	RYCHTER,	J.	W.,	VAN	NASSAUW,	L.,	TIMMERMANS,	J.	P.,	AKKERMANS,	L.	M.,	WESTERINK,	R.	H.	&	KROESE,	A.	B.	2011.	CGRP1	receptor	activation	induces	
	
200	
piecemeal	release	of	protease-1	from	mouse	bone	marrow-derived	mucosal	mast	cells.	Neurogastroenterol	Motil,	23,	e57-68.	SAITO,	H.,	EBISAWA,	M.,	SAKAGUCHI,	N.,	ONDA,	T.,	IIKURA,	Y.,	YANAGIDA,	M.,	UZUMAKI,	H.	&	NAKAHATA,	T.	1995.	Characterization	of	cord-blood-derived	human	mast	cells	cultured	in	the	presence	of	Steel	factor	and	interleukin-6.	Int	Arch	Allergy	
Immunol,	107,	63-5.	SAND,	E.,	THEMNER-PERSSON,	A.	&	EKBLAD,	E.	2009.	Mast	cells	reduce	survival	of	myenteric	neurons	in	culture.	Neuropharmacology,	56,	522-30.	SANDIG,	H.	&	BULFONE-PAUS,	S.	2012.	TLR	signaling	in	mast	cells:	common	and	unique	features.	Front	Immunol,	3,	185.	SANMUGALINGAM,	D.,	WARDLAW,	A.	J.	&	BRADDING,	P.	2000.	Adhesion	of	human	lung	mast	cells	to	bronchial	epithelium:	evidence	for	a	novel	carbohydrate-mediated	mechanism.	J	Leukoc	Biol,	68,	38-46.	SARIN,	S.,	UNDEM,	B.,	SANICO,	A.	&	TOGIAS,	A.	2006.	The	role	of	the	nervous	system	in	rhinitis.	J	Allergy	Clin	Immunol,	118,	999-1016.	SASAKI,	Y.,	YOSHIMOTO,	T.,	MARUYAMA,	H.,	TEGOSHI,	T.,	OHTA,	N.,	ARIZONO,	N.	&	NAKANISHI,	K.	2005.	IL-18	with	IL-2	protects	against	Strongyloides	venezuelensis	infection	by	activating	mucosal	mast	cell-dependent	type	2	innate	immunity.	J	Exp	Med,	202,	607-16.	SAWADA,	J.,	ITAKURA,	A.,	TANAKA,	A.,	FURUSAKA,	T.	&	MATSUDA,	H.	2000.	Nerve	growth	factor	functions	as	a	chemoattractant	for	mast	cells	through	both	mitogen-activated	protein	kinase	and	phosphatidylinositol	3-kinase	signaling	pathways.	Blood,	95,	2052-8.	SCHMELZ,	M.	&	PETERSEN,	L.	J.	2001.	Neurogenic	inflammation	in	human	and	rodent	skin.	News	Physiol	Sci,	16,	33-7.	SCHMITT,	E.,	FASSBENDER,	B.,	BEYREUTHER,	K.,	SPAETH,	E.,	SCHWARZKOPF,	R.	&	RÜDE,	E.	1987.	Characterization	of	a	T	cell-derived	lymphokine	that	acts	synergistically	with	IL	3	on	the	growth	of	murine	mast	cells	and	is	identical	with	IL	4.	Immunobiology,	174,	406-19.	SCHNEIDER,	C.	A.,	RASBAND,	W.	S.	&	ELICEIRI,	K.	W.	2012.	NIH	Image	to	ImageJ:	25	years	of	image	analysis.	Nat	Methods,	9,	671-5.	SCHULMAN,	E.	S.,	GLAUM,	M.	C.,	POST,	T.,	WANG,	Y.,	RAIBLE,	D.	G.,	MOHANTY,	J.,	BUTTERFIELD,	J.	H.	&	PELLEG,	A.	1999.	ATP	modulates	anti-IgE-induced	release	of	histamine	from	human	lung	mast	cells.	Am	J	Respir	Cell	Mol	Biol,	20,	530-7.	SCHULMAN,	E.	S.,	MACGLASHAN,	D.	W.,	PETERS,	S.	P.,	SCHLEIMER,	R.	P.,	NEWBALL,	H.	H.	&	LICHTENSTEIN,	L.	M.	1982.	Human	lung	mast	cells:	purification	and	characterization.	J	Immunol,	129,	2662-7.	SCHWIEGER,	J.,	ESSER,	K.	H.,	LENARZ,	T.	&	SCHEPER,	V.	2016.	Establishment	of	a	long-term	spiral	ganglion	neuron	culture	with	reduced	glial	cell	number:	Effects	of	AraC	on	cell	composition	and	neurons.	J	Neurosci	Methods,	268,	106-16.	
	
201	
SCOTT,	B.	S.	1977.	Adult	mouse	dorsal	root	ganglia	neurons	in	cell	culture.	J	Neurobiol,	8,	417-27.	SCROGGS,	R.	S.	&	FOX,	A.	P.	1992.	Calcium	current	variation	between	acutely	isolated	adult	rat	dorsal	root	ganglion	neurons	of	different	size.	J	Physiol,	445,	639-58.	SELLGE,	G.,	LORENTZ,	A.,	GEBHARDT,	T.,	LEVI-SCHAFFER,	F.,	BEKTAS,	H.,	MANNS,	M.	P.,	SCHUPPAN,	D.	&	BISCHOFF,	S.	C.	2004.	Human	intestinal	fibroblasts	prevent	apoptosis	in	human	intestinal	mast	cells	by	a	mechanism	independent	of	stem	cell	factor,	IL-3,	IL-4,	and	nerve	growth	factor.	J	Immunol,	172,	260-7.	SESTINI,	P.,	DOLOVICH,	M.,	VANCHERI,	C.,	STEAD,	R.	H.,	MARSHALL,	J.	S.,	PERDUE,	M.,	GAULDIE,	J.	&	BIENENSTOCK,	J.	1989.	Antigen-induced	lung	solute	clearance	in	rats	is	dependent	on	capsaicin-sensitive	nerves.	Am	Rev	Respir	Dis,	139,	401-6.	SEVERINI,	C.,	IMPROTA,	G.,	FALCONIERI-ERSPAMER,	G.,	SALVADORI,	S.	&	ERSPAMER,	V.	2002.	The	tachykinin	peptide	family.	Pharmacol	Rev,	54,	285-322.	SHARMA,	G.	&	VIJAYARAGHAVAN,	S.	2003.	Modulation	of	presynaptic	store	calcium	induces	release	of	glutamate	and	postsynaptic	firing.	Neuron,	38,	929-39.	SHEFLER,	I.,	SEGER,	R.	&	SAGI-EISENBERG,	R.	1999.	Gi-mediated	activation	of	mitogen-activated	protein	kinase	(MAPK)	pathway	by	receptor	mimetic	basic	secretagogues	of	connective	tissue-type	mast	cells:	bifurcation	of	arachidonic	acid-induced	release	upstream	of	MAPK.	J	Pharmacol	Exp	Ther,	289,	1654-61.	SHINGAI,	T.,	IKEDA,	W.,	KAKUNAGA,	S.,	MORIMOTO,	K.,	TAKEKUNI,	K.,	ITOH,	S.,	SATOH,	K.,	TAKEUCHI,	M.,	IMAI,	T.,	MONDEN,	M.	&	TAKAI,	Y.	2003.	Implications	of	nectin-like	molecule-2/IGSF4/RA175/SgIGSF/TSLC1/SynCAM1	in	cell-cell	adhesion	and	transmembrane	protein	localization	in	epithelial	cells.	J	Biol	Chem,	278,	35421-7.	SILBERSTEIN,	R.,	MELNICK,	M.,	GREENBERG,	G.	&	MINKIN,	C.	1991.	Bone	remodeling	in	W/Wv	mast	cell	deficient	mice.	Bone,	12,	227-36.	SLEIGH,	J.	N.,	WEIR,	G.	A.	&	SCHIAVO,	G.	2016.	A	simple,	step-by-step	dissection	protocol	for	the	rapid	isolation	of	mouse	dorsal	root	ganglia.	BMC	Res	Notes,	9,	82.	SOCIETY,	B.	T.	&	NETWORK,	S.	I.	G.	2014.	British	guideline	on	the	management	of	asthma.	Thorax,	69	Suppl	1,	1-192.	SOFRONIEW,	M.	V.,	HOWE,	C.	L.	&	MOBLEY,	W.	C.	2001.	Nerve	growth	factor	signaling,	neuroprotection,	and	neural	repair.	Annu	Rev	Neurosci,	24,	1217-81.	SPANOS,	C.,	PANG,	X.,	LIGRIS,	K.,	LETOURNEAU,	R.,	ALFERES,	L.,	ALEXACOS,	N.,	SANT,	G.	R.	&	THEOHARIDES,	T.	C.	1997.	Stress-induced	bladder	mast	cell	activation:	implications	for	interstitial	cystitis.	J	Urol,	157,	669-72.	SPERR,	W.	R.,	AGIS,	H.,	CZERWENKA,	K.,	KLEPETKO,	W.,	KUBISTA,	E.,	BOLTZ-NITULESCU,	G.,	LECHNER,	K.	&	VALENT,	P.	1992.	Differential	expression	of	cell	surface	integrins	on	human	mast	cells	and	human	basophils.	Ann	Hematol,	65,	10-6.	SPIERINGS,	E.	L.	2003.	Pathogenesis	of	the	migraine	attack.	Clin	J	Pain,	19,	255-62.	
	
202	
ST	HILL,	C.	A.	2011.	Interactions	between	endothelial	selectins	and	cancer	cells	regulate	metastasis.	Front	Biosci	(Landmark	Ed),	16,	3233-51.	STANISOR,	O.	I.,	VAN	DIEST,	S.	A.,	YU,	Z.,	WELTING,	O.,	BEKKALI,	N.,	SHI,	J.,	DE	JONGE,	W.	J.,	BOECKXSTAENS,	G.	E.	&	VAN	DEN	WIJNGAARD,	R.	M.	2013.	Stress-induced	visceral	hypersensitivity	in	maternally	separated	rats	can	be	reversed	by	peripherally	restricted	histamine-1-receptor	antagonists.	PLoS	One,	8,	e66884.	STANKO,	J.	P.,	EASTERLING,	M.	R.	&	FENTON,	S.	E.	2015.	Application	of	Sholl	analysis	to	quantify	changes	in	growth	and	development	in	rat	mammary	gland	whole	mounts.	Reprod	Toxicol,	54,	129-35.	STEAD,	R.	H.,	DIXON,	M.	F.,	BRAMWELL,	N.	H.,	RIDDELL,	R.	H.	&	BIENENSTOCK,	J.	1989.	Mast	cells	are	closely	apposed	to	nerves	in	the	human	gastrointestinal	mucosa.	
Gastroenterology,	97,	575-85.	STEAD,	R.	H.,	TOMIOKA,	M.,	QUINONEZ,	G.,	SIMON,	G.	T.,	FELTEN,	S.	Y.	&	BIENENSTOCK,	J.	1987.	Intestinal	mucosal	mast	cells	in	normal	and	nematode-infected	rat	intestines	are	in	intimate	contact	with	peptidergic	nerves.	Proc	Natl	Acad	Sci	U	S	
A,	84,	2975-9.	STEFANINI,	G.	F.,	SAGGIORO,	A.,	ALVISI,	V.,	ANGELINI,	G.,	CAPURSO,	L.,	DI	LORENZO,	G.,	DOBRILLA,	G.,	DODERO,	M.,	GALIMBERTI,	M.	&	GASBARRINI,	G.	1995.	Oral	cromolyn	sodium	in	comparison	with	elimination	diet	in	the	irritable	bowel	syndrome,	diarrheic	type.	Multicenter	study	of	428	patients.	Scand	J	
Gastroenterol,	30,	535-41.	STEMPELJ,	M.,	CARMAN-KRZAN,	M.	&	FERJAN,	I.	2003.	Regulatory	role	of	extracellular	Na+	and	Ca2+	ions	in	nerve	growth	factor	induced	histamine	secretion	from	rat	mast	cells.	Inflamm	Res,	52,	74-8.	SUN,	Z.,	MENG,	C.,	WANG,	S.,	ZHOU,	N.,	GUAN,	M.,	BAI,	C.,	LU,	S.,	HAN,	Q.	&	ZHAO,	R.	C.	2014.	MicroRNA-1246	enhances	migration	and	invasion	through	CADM1	in	hepatocellular	carcinoma.	BMC	Cancer,	14,	616.	SUZUKI,	A.,	SUZUKI,	R.,	FURUNO,	T.,	TESHIMA,	R.	&	NAKANISHI,	M.	2004.	N-cadherin	plays	a	role	in	the	synapse-like	structures	between	mast	cells	and	neurites.	Biol	
Pharm	Bull,	27,	1891-4.	SUZUKI,	A.,	SUZUKI,	R.,	FURUNO,	T.,	TESHIMA,	R.	&	NAKANISHI,	M.	2005.	Calcium	response	and	FcepsilonRI	expression	in	bone	marrow-derived	mast	cells	co-cultured	with	SCG	neurites.	Biol	Pharm	Bull,	28,	1963-5.	SUZUKI,	R.,	FURUNO,	T.,	MCKAY,	D.	M.,	WOLVERS,	D.,	TESHIMA,	R.,	NAKANISHI,	M.	&	BIENENSTOCK,	J.	1999.	Direct	neurite-mast	cell	communication	in	vitro	occurs	via	the	neuropeptide	substance	P.	J	Immunol,	163,	2410-5.	SUZUKI,	R.,	FURUNO,	T.,	OKAMOTO,	K.,	TESHIMA,	R.	&	NAKANISHI,	M.	2007.	ATP	plays	a	role	in	neurite	stimulation	with	activated	mast	cells.	J	Neuroimmunol,	192,	49-56.	SUZUKI,	R.,	FURUNO,	T.,	TESHIMA,	R.	&	NAKANISHI,	M.	2001.	Bi-directional	relationship	of	in	vitro	mast	cell-nerve	communication	observed	by	confocal	laser	scanning	microscopy.	Biol	Pharm	Bull,	24,	291-4.	
	
203	
TAIANA,	M.	M.,	LOMBARDI,	R.,	PORRETTA-SERAPIGLIA,	C.,	CIUSANI,	E.,	OGGIONI,	N.,	SASSONE,	J.,	BIANCHI,	R.	&	LAURIA,	G.	2014.	Neutralization	of	schwann	cell-secreted	VEGF	is	protective	to	in	vitro	and	in	vivo	experimental	diabetic	neuropathy.	PLoS	One,	9,	e108403.	TAKANO,	H.,	NAKAZAWA,	S.,	OKUNO,	Y.,	SHIRATA,	N.,	TSUCHIYA,	S.,	KAINOH,	T.,	TAKAMATSU,	S.,	FURUTA,	K.,	TAKETOMI,	Y.,	NAITO,	Y.,	TAKEMATSU,	H.,	KOZUTSUMI,	Y.,	TSUJIMOTO,	G.,	MURAKAMI,	M.,	KUDO,	I.,	ICHIKAWA,	A.,	NAKAYAMA,	K.,	SUGIMOTO,	Y.	&	TANAKA,	S.	2008.	Establishment	of	the	culture	model	system	that	reflects	the	process	of	terminal	differentiation	of	connective	tissue-type	mast	cells.	FEBS	Lett,	582,	1444-50.	TAKEICHI,	M.	1995.	Morphogenetic	roles	of	classic	cadherins.	Curr	Opin	Cell	Biol,	7,	619-27.	TAM,	S.	Y.,	TSAI,	M.,	YAMAGUCHI,	M.,	YANO,	K.,	BUTTERFIELD,	J.	H.	&	GALLI,	S.	J.	1997.	Expression	of	functional	TrkA	receptor	tyrosine	kinase	in	the	HMC-1	human	mast	cell	line	and	in	human	mast	cells.	Blood,	90,	1807-20.	TEPASS,	U.,	GODT,	D.	&	WINKLBAUER,	R.	2002.	Cell	sorting	in	animal	development:	signalling	and	adhesive	mechanisms	in	the	formation	of	tissue	boundaries.	Curr	
Opin	Genet	Dev,	12,	572-82.	TERADA,	T.	&	MATSUNAGA,	Y.	2000.	Increased	mast	cells	in	hepatocellular	carcinoma	and	intrahepatic	cholangiocarcinoma.	J	Hepatol,	33,	961-6.	TETLOW,	L.	C.	&	WOOLLEY,	D.	E.	1995.	Distribution,	activation	and	tryptase/chymase	phenotype	of	mast	cells	in	the	rheumatoid	lesion.	Ann	Rheum	Dis,	54,	549-55.	THEOHARIDES,	T.	C.	2002.	Mast	cells	and	stress--a	psychoneuroimmunological	perspective.	J	Clin	Psychopharmacol,	22,	103-8.	THEOHARIDES,	T.	C.,	DONELAN,	J.,	KANDERE-GRZYBOWSKA,	K.	&	KONSTANTINIDOU,	A.	2005.	The	role	of	mast	cells	in	migraine	pathophysiology.	Brain	Res	Brain	Res	Rev,	49,	65-76.	TKACZYK,	C.,	HOREJSI,	V.,	IWAKI,	S.,	DRABER,	P.,	SAMELSON,	L.	E.,	SATTERTHWAITE,	A.	B.,	NAHM,	D.	H.,	METCALFE,	D.	D.	&	GILFILLAN,	A.	M.	2004.	NTAL	phosphorylation	is	a	pivotal	link	between	the	signaling	cascades	leading	to	human	mast	cell	degranulation	following	Kit	activation	and	Fc	epsilon	RI	aggregation.	Blood,	104,	207-14.	TOBIN,	M.	C.,	KESHAVAZIAN,	A.	&	FARHARDI,	A.	2008a.	Atopic	irritable	bowel	syndrome:	same	old	hat	or	a	new	entity?	Expert	Rev	Gastroenterol	Hepatol,	2,	457-9.	TOBIN,	M.	C.,	MOPARTY,	B.,	FARHADI,	A.,	DEMEO,	M.	T.,	BANSAL,	P.	J.	&	KESHAVARZIAN,	A.	2008b.	Atopic	irritable	bowel	syndrome:	a	novel	subgroup	of	irritable	bowel	syndrome	with	allergic	manifestations.	Ann	Allergy	Asthma	Immunol,	100,	49-53.	TORU,	H.,	KINASHI,	T.,	RA,	C.,	NONOYAMA,	S.,	YATA,	J.	&	NAKAHATA,	T.	1997.	Interleukin-4	induces	homotypic	aggregation	of	human	mast	cells	by	promoting	LFA-1/ICAM-1	adhesion	molecules.	Blood,	89,	3296-302.	
	
204	
TRAUTMANN,	A.,	FEUERSTEIN,	B.,	ERNST,	N.,	BRÖCKER,	E.	B.	&	KLEIN,	C.	E.	1997.	Heterotypic	cell-cell	adhesion	of	human	mast	cells	to	fibroblasts.	Arch	Dermatol	
Res,	289,	194-203.	TSAI,	M.,	TAKEISHI,	T.,	THOMPSON,	H.,	LANGLEY,	K.	E.,	ZSEBO,	K.	M.,	METCALFE,	D.	D.,	GEISSLER,	E.	N.	&	GALLI,	S.	J.	1991.	Induction	of	mast	cell	proliferation,	maturation,	and	heparin	synthesis	by	the	rat	c-kit	ligand,	stem	cell	factor.	Proc	
Natl	Acad	Sci	U	S	A,	88,	6382-6.	UNDEM,	B.	J.	&	TAYLOR-CLARK,	T.	2014.	Mechanisms	underlying	the	neuronal-based	symptoms	of	allergy.	J	Allergy	Clin	Immunol,	133,	1521-34.	UNSAIN,	N.,	HEARD,	K.	N.,	HIGGINS,	J.	M.	&	BARKER,	P.	A.	2014.	Production	and	isolation	of	axons	from	sensory	neurons	for	biochemical	analysis	using	porous	filters.	J	Vis	
Exp.	USOSKIN,	D.,	FURLAN,	A.,	ISLAM,	S.,	ABDO,	H.,	LÖNNERBERG,	P.,	LOU,	D.,	HJERLING-LEFFLER,	J.,	HAEGGSTRÖM,	J.,	KHARCHENKO,	O.,	KHARCHENKO,	P.	V.,	LINNARSSON,	S.	&	ERNFORS,	P.	2015.	Unbiased	classification	of	sensory	neuron	types	by	large-scale	single-cell	RNA	sequencing.	Nat	Neurosci,	18,	145-53.	VAN	DER	KLEIJ,	H.	P.,	MA,	D.,	REDEGELD,	F.	A.,	KRANEVELD,	A.	D.,	NIJKAMP,	F.	P.	&	BIENENSTOCK,	J.	2003.	Functional	expression	of	neurokinin	1	receptors	on	mast	cells	induced	by	IL-4	and	stem	cell	factor.	J	Immunol,	171,	2074-9.	VAN	DER	WEYDEN,	L.,	ARENDS,	M.	J.,	RUST,	A.	G.,	POULOGIANNIS,	G.,	MCINTYRE,	R.	E.	&	ADAMS,	D.	J.	2012.	Increased	tumorigenesis	associated	with	loss	of	the	tumor	suppressor	gene	Cadm1.	Mol	Cancer,	11,	29.	VAN	DIEST,	S.	A.,	STANISOR,	O.	I.,	BOECKXSTAENS,	G.	E.,	DE	JONGE,	W.	J.	&	VAN	DEN	WIJNGAARD,	R.	M.	2012.	Relevance	of	mast	cell-nerve	interactions	in	intestinal	nociception.	Biochim	Biophys	Acta,	1822,	74-84.	VAN	HOUWELINGEN,	A.	H.,	KOOL,	M.,	DE	JAGER,	S.	C.,	REDEGELD,	F.	A.,	VAN	HEUVEN-NOLSEN,	D.,	KRANEVELD,	A.	D.	&	NIJKAMP,	F.	P.	2002.	Mast	cell-derived	TNF-alpha	primes	sensory	nerve	endings	in	a	pulmonary	hypersensitivity	reaction.	J	
Immunol,	168,	5297-302.	VAN	STEENWINCKEL,	J.,	NOGHERO,	A.,	THIBAULT,	K.,	BRISORGUEIL,	M.	J.,	FISCHER,	J.	&	CONRATH,	M.	2009.	The	5-HT2A	receptor	is	mainly	expressed	in	nociceptive	sensory	neurons	in	rat	lumbar	dorsal	root	ganglia.	Neuroscience,	161,	838-46.	VARA,	E.	J.,	SVANES,	C.,	SKORGE,	T.	D.,	BERSTAD,	A.,	FLORVAAG,	E.,	JARVIS,	D.,	OMENAAS,	E.,	WAATEVIK,	M.,	JOHANNESSEN,	A.	&	LIED,	G.	A.	2016.	Functional	Gastrointestinal	Symptoms	Are	Associated	with	Higher	Serum	Total	IgE	Levels,	but	Less	Atopic	Sensitization.	Dig	Dis	Sci,	61,	189-97.	VARADARADJALOU,	S.,	FÉGER,	F.,	THIEBLEMONT,	N.,	HAMOUDA,	N.	B.,	PLEAU,	J.	M.,	DY,	M.	&	AROCK,	M.	2003.	Toll-like	receptor	2	(TLR2)	and	TLR4	differentially	activate	human	mast	cells.	Eur	J	Immunol,	33,	899-906.	VENKATESHA,	R.	T.,	BERLA	THANGAM,	E.,	ZAIDI,	A.	K.	&	ALI,	H.	2005.	Distinct	regulation	of	C3a-induced	MCP-1/CCL2	and	RANTES/CCL5	production	in	human	mast	cells	by	extracellular	signal	regulated	kinase	and	PI3	kinase.	Mol	Immunol,	42,	581-7.	
	
205	
VINCENT,	A.	M.,	RUSSELL,	J.	W.,	SULLIVAN,	K.	A.,	BACKUS,	C.,	HAYES,	J.	M.,	MCLEAN,	L.	L.	&	FELDMAN,	E.	L.	2007.	SOD2	protects	neurons	from	injury	in	cell	culture	and	animal	models	of	diabetic	neuropathy.	Exp	Neurol,	208,	216-27.	VON	KÖCKRITZ-BLICKWEDE,	M.,	GOLDMANN,	O.,	THULIN,	P.,	HEINEMANN,	K.,	NORRBY-TEGLUND,	A.,	ROHDE,	M.	&	MEDINA,	E.	2008.	Phagocytosis-independent	antimicrobial	activity	of	mast	cells	by	means	of	extracellular	trap	formation.	
Blood,	111,	3070-80.	WAKAYAMA,	T.,	OHASHI,	K.,	MIZUNO,	K.	&	ISEKI,	S.	2001.	Cloning	and	characterization	of	a	novel	mouse	immunoglobulin	superfamily	gene	expressed	in	early	spermatogenic	cells.	Mol	Reprod	Dev,	60,	158-64.	WALKER,	M.	M.,	POWELL,	N.	&	TALLEY,	N.	J.	2014.	Atopy	and	the	gastrointestinal	tract--a	review	of	a	common	association	in	unexplained	gastrointestinal	disease.	Expert	
Rev	Gastroenterol	Hepatol,	8,	289-99.	WANG,	S.	H.,	DONG,	L.,	LUO,	J.	Y.,	GONG,	J.,	LI,	L.,	LU,	X.	L.	&	HAN,	S.	P.	2007.	Decreased	expression	of	serotonin	in	the	jejunum	and	increased	numbers	of	mast	cells	in	the	terminal	ileum	in	patients	with	irritable	bowel	syndrome.	World	J	
Gastroenterol,	13,	6041-7.	WATABE,	K.,	ITO,	A.,	KOMA,	Y.	I.	&	KITAMURA,	Y.	2003.	IGSF4:	a	new	intercellular	adhesion	molecule	that	is	called	by	three	names,	TSLC1,	SgIGSF	and	SynCAM,	by	virtue	of	its	diverse	function.	Histol	Histopathol,	18,	1321-9.	WELLER,	C.	L.,	COLLINGTON,	S.	J.,	WILLIAMS,	T.	&	LAMB,	J.	R.	2011.	Mast	cells	in	health	and	disease.	Clin	Sci	(Lond),	120,	473-84.	WENDELER,	M.	&	SANDHOFF,	K.	2009.	Hexosaminidase	assays.	Glycoconj	J,	26,	945-52.	WENG,	H.	R.	&	DOUGHERTY,	P.	M.	2005.	Response	properties	of	dorsal	root	reflexes	in	cutaneous	C	fibers	before	and	after	intradermal	capsaicin	injection	in	rats.	
Neuroscience,	132,	823-31.	WERSHIL,	B.	K.	2000.	IX.	Mast	cell-deficient	mice	and	intestinal	biology.	Am	J	Physiol	
Gastrointest	Liver	Physiol,	278,	G343-8.	WESTON,	A.	P.,	BIDDLE,	W.	L.,	BHATIA,	P.	S.	&	MINER,	P.	B.	1993.	Terminal	ileal	mucosal	mast	cells	in	irritable	bowel	syndrome.	Dig	Dis	Sci,	38,	1590-5.	WILLIAMS,	E.	J.,	FURNESS,	J.,	WALSH,	F.	S.	&	DOHERTY,	P.	1994.	Activation	of	the	FGF	receptor	underlies	neurite	outgrowth	stimulated	by	L1,	N-CAM,	and	N-cadherin.	
Neuron,	13,	583-94.	WINSTON,	J.,	TOMA,	H.,	SHENOY,	M.	&	PASRICHA,	P.	J.	2001.	Nerve	growth	factor	regulates	VR-1	mRNA	levels	in	cultures	of	adult	dorsal	root	ganglion	neurons.	
Pain,	89,	181-6.	WOOLF,	C.	J.	&	MA,	Q.	2007.	Nociceptors--noxious	stimulus	detectors.	Neuron,	55,	353-64.	WOUTERS,	M.	M.,	VICARIO,	M.	&	SANTOS,	J.	2016.	The	role	of	mast	cells	in	functional	GI	disorders.	Gut,	65,	155-68.	
	
206	
WU,	L.	C.	2011.	Immunoglobulin	E	receptor	signaling	and	asthma.	J	Biol	Chem,	286,	32891-7.	XIA,	Y.,	HU,	H.	Z.,	LIU,	S.,	REN,	J.,	ZAFIROV,	D.	H.	&	WOOD,	J.	D.	1999.	IL-1beta	and	IL-6	excite	neurons	and	suppress	nicotinic	and	noradrenergic	neurotransmission	in	guinea	pig	enteric	nervous	system.	J	Clin	Invest,	103,	1309-16.	XIANG,	Z.,	BLOCK,	M.,	LÖFMAN,	C.	&	NILSSON,	G.	2001.	IgE-mediated	mast	cell	degranulation	and	recovery	monitored	by	time-lapse	photography.	J	Allergy	Clin	
Immunol,	108,	116-21.	XING,	W.,	AUSTEN,	K.	F.,	GURISH,	M.	F.	&	JONES,	T.	G.	2011.	Protease	phenotype	of	constitutive	connective	tissue	and	of	induced	mucosal	mast	cells	in	mice	is	regulated	by	the	tissue.	Proc	Natl	Acad	Sci	U	S	A,	108,	14210-5.	XU,	X.,	ZHANG,	D.,	LYUBYNSKA,	N.,	WOLTERS,	P.	J.,	KILLEEN,	N.	P.,	BALUK,	P.,	MCDONALD,	D.	M.,	HAWGOOD,	S.	&	CAUGHEY,	G.	H.	2006.	Mast	cells	protect	mice	from	Mycoplasma	pneumonia.	Am	J	Respir	Crit	Care	Med,	173,	219-25.	YAMAGUCHI,	M.,	SAYAMA,	K.,	YANO,	K.,	LANTZ,	C.	S.,	NOBEN-TRAUTH,	N.,	RA,	C.,	COSTA,	J.	J.	&	GALLI,	S.	J.	1999.	IgE	enhances	Fc	epsilon	receptor	I	expression	and	IgE-dependent	release	of	histamine	and	lipid	mediators	from	human	umbilical	cord	blood-derived	mast	cells:	synergistic	effect	of	IL-4	and	IgE	on	human	mast	cell	Fc	epsilon	receptor	I	expression	and	mediator	release.	J	Immunol,	162,	5455-65.	YANG,	W.,	KAUR,	D.,	OKAYAMA,	Y.,	ITO,	A.,	WARDLAW,	A.	J.,	BRIGHTLING,	C.	E.	&	BRADDING,	P.	2006.	Human	lung	mast	cells	adhere	to	human	airway	smooth	muscle,	in	part,	via	tumor	suppressor	in	lung	cancer-1.	J	Immunol,	176,	1238-43.	YAZID,	S.,	SINNIAH,	A.,	SOLITO,	E.,	CALDER,	V.	&	FLOWER,	R.	J.	2013.	Anti-allergic	cromones	inhibit	histamine	and	eicosanoid	release	from	activated	human	and	murine	mast	cells	by	releasing	Annexin	A1.	PLoS	One,	8,	e58963.	YOSHIDA,	S.	&	MATSUDA,	Y.	1979.	Studies	on	sensory	neurons	of	the	mouse	with	intracellular-recording	and	horseradish	peroxidase-injection	techniques.	J	
Neurophysiol,	42,	1134-45.	YU,	M.,	TSAI,	M.,	TAM,	S.	Y.,	JONES,	C.,	ZEHNDER,	J.	&	GALLI,	S.	J.	2006.	Mast	cells	can	promote	the	development	of	multiple	features	of	chronic	asthma	in	mice.	J	Clin	
Invest,	116,	1633-41.	ZHANG,	J.,	NING,	J.,	GENG,	J.,	CUI,	B.	&	DONG,	X.	2012.	Down-regulation	of	tumor	suppressor	in	lung	cancer	1	(TSLC1)	expression	correlates	with	poor	prognosis	in	patients	with	colon	cancer.	J	Mol	Histol,	43,	715-21.	ZHANG,	L.,	SONG,	J.	&	HOU,	X.	2016.	Mast	Cells	and	Irritable	Bowel	Syndrome:	From	the	Bench	to	the	Bedside.	J	Neurogastroenterol	Motil,	22,	181-92.	ZHILING,	Y.,	FUJITA,	E.,	TANABE,	Y.,	YAMAGATA,	T.,	MOMOI,	T.	&	MOMOI,	M.	Y.	2008.	Mutations	in	the	gene	encoding	CADM1	are	associated	with	autism	spectrum	disorder.	Biochem	Biophys	Res	Commun,	377,	926-9.		
